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ABSTRACT 
Autosomal dominant polycystic kidney disease (ADPKD) is one of the most common 
genetic disorders (Gabow, 1993), with an estimated prevalence of 1 in 400 to I in 1000 
(Dalgaard, 1957; Gabow, 1993). The disease is the fourth leading cause ofrenal failure 
with more than 10 million people affected worldwide (Grantham, 1997). Mutations in 
at least two genes (PKDJ, PKD2) can lead to the disease (European PKO Consortium, 
1994; Mochizuki, et al. 1996). This project deals with autosomal dominant PKO, 
caused by mutations in the PKDJ gene, which account for 85% of reported cases. 
Mutation detection in the PKDJ gene is difficult as the gene is relatively !arge (46 exons 
over 52kb of genomic DNA), it has a high GC content, and is duplicated in numerous 
homologues of unknown function. Mutations detected to date are usually private and 
many neutral polymorphisms have also been detected. Co-amplification of PKDJ 
homologous genes, which correspond to at least 75% of its mRNA, poses the largest 
obstacle fot PKDJ mutation detection studies. 
In this study, novel strategies for mutation screening in the duplicated region of PKDJ 
have been developed. In the process of the work further characterisation of the PKDJ 
homologous genes has been achieved, and the results suggest that at least two of the 
homologues are non-functionmg (i.e. not translated) pseudogenes. 
Subjects from three countries were screened for mutations in the PKDJ gene in order to 
detect mutations and to attempt genotype-phenotype correlations in a disorder which 
exhibits a high degree of inter· and intra·fumilial phenotypic heterogeneity. Seventy· 
four sequence variations were detected, of which twenty·four are believed to be 
pathogenic. 
In the Australian cohort, DNA was screened over 95% of the coding region aT1d a 
mutation detection rate of74% was achieved. This result is favourable wh�n compared 
to other studies. Findings from the study and others in the literature suggest that PKDI 
gennline mutations do not indicate a simple genotype·phenotype correlation, and future 
studies will need to incorporate many other biological and environmental variables in 
order to establish how the genotype influences the complex phenotype of the disease. 
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I. Introduction 
I. Introduction 
I. 1. Introduction 
1.1.i. Autosomal Dominant Polycystic Kidney Disease 
Autosomal dominant polycystic kidney disease (ADPKD) is one of the most common 
genetic disorders (Gabow, 1993), with an estimated prevalence of 1 in 400 to I in 1000 
(Dalgaard, 1957; Gabow, 1993 ). The disease is the fourth leading cause of renal failure 
with more than 10 million people affected worldwide (Grantham, 1997). 
Although most cases of the disease present in adulthood, hence the synonym adult 
polycystic kidney disease, it is in fact a systemic hereditary disorder which can occur at any 
time of life, including in utero (Zerres et al., 1985). The mode of inheritance in ADPKD 
was defined over 40 years ago and the disease exhibits complete penetrance with respect to 
the occurrence of renal cysts (Dalgaard, 1957), although it does not always progress to 
chronic or end-stage renal failure (Churchill, et al., 1984). Mutations in at least two genes 
(PKDJ, PKD2) can lead to the disease (European PKD Consortium, 1994; Mochizuki, et 
al. 1996). This project deals with autosomal dominant PKD, caused by mutations in the 
PKDJ gene. 
1.1. ii. The P KD 1 Gene 
Tr.e first gene for polycystic kidney disease (PKDJ) is located on human chromosome 
16pl3.3 (The European PKD Consortium, 1994). The gene produces a 14 kb transcript 
2 
which has been detected in many tissue-specific cell lines (The European PKD Consortium, 
1994). The highest PKDJ gene expression levels were found in kidney- and liver-derived 
cell lines {The European PKD Consortium, 1994). The PKDJ gene spans 52 kb of 
genomic DNA, and includes 46 exons. A 14 kb mRNA transcript is produced and encodes 
a novel protein, polycystin-1, which is 4302 amino acids in length (The International PKD 
Consortium, 1995). PKDJ is duplicated at least 3 times on human chromosome 16p13.l. 
The PKDJ homologous genes (HGs) are up to 97% homologous with the PKDJ gene over 
two-thirds of its length (The European PKD Consortium, 1994). It is not known if the HG 
transcripts produce functional proteins (Hughes et al., 1995). Due to their co-amplification 
with PKDJ, they represent a major obstacle for mutation detection studies in the PKDJ 
gene (Peral et al., 1997). 
I. I.iii. The ADPKD Phenotype 
Both inter- and intra-familial phenotypic variation have been observed in autosomal 
dominant polycystic kidney disease. Some affected individuals do not progress to end­
stage renal failure (ESRF), and those that do exhibit a wide variation in age at onset of 
ESRF (Milutinovic et al., 1984; Parfrey et al., 1990; Gabow, 1993; Gn1nfeld, 1998). In 
addition to renal disease, ADPKD has been associated with a number of extra-renal 
symptoms, these also vary both between and within affected families (Gabow, 1993). 
3 
1.2 Strategy of the Study 
I.2.i. Study Aims & Expected Outcomes 
The aim of this study is to design and implement screening techniques for mutations in the 
P KD 1 gene. Mutations identified will be assessed in order to detennine if significant 
genotype/phenotype correlations exist in ADPKD. To date, no common pathogenic 
mutations have been detected in PKDJ (Krawczak & Cooper, 1997). Since private 
mutations in the PKDJ gene are usual, and the size of the population in the present study is 
relatively small, it is not anticipated that a definitive answer to the genotype/phenotype 
question will be achieved. However, novel sequence variations discovered here in both the 
unique and duplicated regions ofthePKDJ gene will add to the growing numbers of PKDI 
mutations and polymorphisms. As greater numbers of mutations are discovered, it will be 
possible to assess if there is a pre-disposition to particular types of mutation in the gene and 
if clustering of mutations exist. If mutational clustering does exist, it will be of interest to 
assess in which functional domains of polycystin-1 it occurs. In addition to improved data 
on the PKDI gene, the detection of familial mutations will also allow diagnostic 
laboratories to offer molecular diagnosis to pre-symptomatic family members. 
III.2.ii. Study Plan 
The investigation of mutations in the P KD 1 gene in this study will be divided into three 
parts. The first wiH involve screening of the unique region of the gene by single strand 
confinnation polymorphism analysis (SSCP) in 48 PKDJ-linked unrelated individuals from 
Australia, Bulgaria and Poland. When sequence variations are indicated by SSCP, manual 
4 
DNA sequencing will be perfonned. Manual sequencing was chosen because of its 
availability. It also has the advantage that heterozygotes are easily detected without the 
ambiguity often associated with other methods. This will be followed by an assessment of 
mutation detection efficiency using SSCP compared to direct automated sequencing 
analysis. The second part of the study will address one of the major problems associated 
with mutation detection screening of the PKDJ gene. It will involve the determination of 
appropriate methods to investigate the duplicated region of the gene without the co­
amplification of PKDI homologous genes. It will also include investigation of the PKDI 
HGs, to provide inf'orrnation on their functional significance. The final part of the study 
will be the implementation of these mutation-screening techniques in the duplicated region 
of the PKDI gene. This screening will be performed on the DNA of PKDI-linked ADPK.D 
individuals from Australia 
5 
II. Review of Literature 
II, Literature Reyje»;: 
II. I, General Literature 
11.1.i. Clinical Course and Heterogeneity of ADPKD 
The first major study on ADPKD was based on 284 Danish patients and their families 
(Dalgaard, 1957). Apart from reporting the prevalence of ADPKD, this study and 
others since (Churchill et al., 1984; Gabow et al., 1992; Ravine et al., 1992; Coto et al., 
1995) have shown marked phenotypic heterogeneity. Differences have also been noted 
in the prevalence of ADPKD (Yersin et al .. 1997; Kirubakaran, 1998). ADPKD 
appears to be less common in people of African descent than in Caucasians (Yersin et 
al., 1997). Approximately 65% of the population of the Seychelles are of African 
descent and 30% are of Caucasian or mixed descent. Of 42 families with ADPKD 
studied in the Seychelles over a three-year period, only three families were of African 
descent (Yersin er al., 1997). A low incidence (2/423 renal patients) of ADPKD has 
also been noted amongst Central Australian Aborigines (Kirubakaran, 1998). 
As stated, there is wide variation in age at onset of end-stage renal failure (ESRF) 
(Milutinovic et al., 1984; Parfrey et al., 1990; Gabow, 1993; Grilnfeld, 1998). Most 
affected individuals reach ESRF between the ages of 45-70 years, and approximately 
30-50% never progress to ESRF (Parfrey et al., 1990). Mutations in the PKDJ gene 
generally lead to an earlier age at onset and a faster rate of progression towards ESRF 
than mutations at the PKD2 locus (Ravine et al., 1992; Hateboer et al .. 1999b ). A small 
proportion of affected individuals who show linkage to PKDJ exhibit very early onset 
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(Zerres, er al., 1993). Such patients can present in utero and, if they survive the first 12 
months, ESRF can occur as early as 3 years of age (MacDennot et al., 1998). 
Hypertension is the most common complication associated with ADPKD, occurring in 
approximately 30% of children and 60% of adults prior to the onset of chronic renal 
failure (CRF) (Gabow, 1993). Hypertension in ADPKD appears to result in an earlier 
age at onset and an increased rate of progression of renal disease (Milutinovic, et al., 
1984; Chapmen & Schrier, 1991; Gabow er al., 1992). A multi-centre study (Geberth et 
al .. 1995b) has shown that ADPKD families with a concomitant genetic predisposition 
to essential hypertension show earlier onset of terminal renal failure. Left ventricular 
hypertrophy has been shown to occur at a relatively early age in ADPKD hypertensive 
individuals by comparison with non·ADPKD patients with essential hypertension 
(Chapman & Schrier. 1991). 
Extra-renal manifestations of ADPKD include hepatic, ovarian, seminal vesicular, 
pancreatic, pulmonary, oesophageal and splenic cysts (Danaci, et al., 1998). Hepatic 
cysts a.e the most common and, although not usually pre'>ent in ADPKD patients at an 
early age, they are detected in approximately 75-80% of affected individuals aged 60-70 
years (Dalgaard, 1957; Milutinovic, et al., 1980; Grunfeld et al., 1985). Cysts in other 
organs appear to be less common, with little information on their incidence (Gabow, 
1993; Danaci, et al., 1998). 
lntracranial aneurysms (ICAs) are another well-<iocumented symptom associated with 
ADPKD, with an estimat�d incidence of 4-11% (Kaehny & Everson. 1991; Lozano & 
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Leblanc. 1992; Chapmen er al., 1992; Schievink, er al .. 1992; van Dijk et al., 1995; Fick 
et al., 1995). These figures may be under-estimates, since a prospective Japanese study 
on 41 ADPKD patients identified ICAs in 17 patients i.e. 41% (Wakabayashi et al., 
1983). ADPKD has been associated with a higher incidence of several other diseases 
compared to the incidence found in the general population. These include heart disease, 
particularly mitral and tricuspid valve prolapse (Hossack et al., 1988), and colonic 
diverticuli (Starnes et al., 1985; Gabow 1990). ADPKD patients show increased rates 
of colonic perforation compared to other renal patients (Scheff et al., 1980). 
ADPKD co-occurs most commonly with tuberous sclerosis (TSC), an autosomal 
dominant disorder that results in benign tumours (hamartoma), usually in the brain, skin 
and kidney. The TSC2 gene, mutations in which account for approximately 50% of 
cases of tuberous sclerosis, is located adjacent to PKDJ in a tail-to-tail orientation on 
chromosome 16 (Harris, 1997). A gross deletion involving both TSC2 and PKDJ was 
instnunental in mapping the PKDJ gene (Wunderle et al., 1994 ), (see section 11.2.i). 
Other conditions reported to co-occur less commonly with ADPKD are summarised in 
Table 11.1. No genetic cause of co-occurrence has been established between ADPKD 
and any of these conditions. 
The co-existence of cystic fibrosis (CF) and ADPKD may prove te> bt one of the most 
interesting associations. Cystic fibrosis, the most common autosomal recessive disease 
in Caucasians, has a reported incidence in Australia of l :3,000 births and is 
characterised by intestinal and pulmonary obstruction (Massie et al., 2000). The 
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presence of both disorders seems to have an effect on the phenotype of ADPKD 
(O'Sullivan el al., 1998). In a large family, adult members affected by both ADPKD 
and CF (but not the CF carriers) displayed less severe polycystic kidney and liver 
disease (O'Sullivan, et al., 1998). 
In vitro experiments on monolayer cell cultures from ADPKD renal cystic epithelia, 
suggest that the CF protein, cystic fibrosis transmembrane conductance regulator 
(CFfR), is responsible for active chloride ion (Cl-) and fluid secretion in the cysts 
(Brill et al., 1996; Davidow et al., 1996; Hanaoka et al., 1996). In pulmonary cells, the 
CFfR controls the net movement of Cl- across the apical membrane (Bear et al., 1991) 
and may also be involved in modulating vesicle transportation, organelle function and 
P�eudomonas binding (Bradbwy 1999). Mutations in the CFTR gene lead to a decrease 
in fluid secretion and an increase in fluid absorption (Grantham et al., 1995). It has 
been proposed that in contrast to CF, where too little Cl- and fluid are secreted, in 
ADPKD patients too much Cl- and fluid are secreted by cyst epithelia (O'Sullivan et 
al., 1998). This finding has been supported by other studies (Devuyst et al., 1999; 
Hanaoka & Guggino, 2000), although the change in expected phenotype may be 
dependent on the specific CF mutations (Persu et al., 2000). A decline in ADPKD 
phenotype severity, associated with co-occurring ADPKD and CF, suggests that the 
modulation of epithelial Cl- secretion may have therapeutic benefit (Cotton & Avner, 
1998), but this hypothesis has yet to be tested in vivo. 
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Table 11.1. Diseases Reported to Co-occur with ADPKD 
Disorder Description Number of References 
families 
Caroli's disease Cystic dilations of the intrahepatic biliary ducts 4 Jordan et al. ( 1989): Mousson et al. 
(1997); Torra et al. (1997) 
Adenoma of the Causes biliary obstruction 2 Norton el al. ( 1995 ); Serafini & 
ampulla of vater Carey ( 1999) 
General overlap Aortic root dilation & aneurysm, aortic valve incompetence, 4 Somlo et al. (1993); Kaplan et al. 
connective pectus abnonnalities. joint laxity, arachnodactyly. scoliosis, ( 1997) 
tissue disorder dolichostenomella, and high arched palate 
Marfan syndrome A connective tissue disorder affecting the skeletal and At least 5 DiMatteo et al., ( 1965); Selgas et al., 
cardiovascular systems and the eyes ( 1981 ); Ortino et al., ( 1988); 
Biermann et al., ( 1992); Hateboer el 
al., (2000) 
Oral-facial- Oral and digital anomalies with facial dysmorphism Numerous Harrod et al. ( 1976 ); Donnai et al. 
digital syndrome ( 1987); Connacher er al. ( J 987); 
(type I) Feather et al. (1997) 
Skeletal One case with polydactyly and PKD I Turco el al. (1993) 
malformations 
II. I .ii. The Pathogenesis of ADPKD 
Altered growth in the kidney epithelial cells of ADPKD patients has been observed 
under electron microscopy, with cyst wall epithelial cell hyperplasia and micropolyp 
fonnation within the cyst observed (Evan et al., 1979). The formation of cysts is not 
simply caused by an increase in the size of the renal tubules due to the stretching of 
cells, but results from cell proliferation (Grantham et al., 1987). It has been suggested 
that, by precipitating renal ischaemia and an increase in renin release, cyst expansion 
can contribute to the early development of hypertension in ADPKD and thus further 
accelerate progression to ESRF (Chapman et al 1990). 
Apoptotic DNA fragmentation has been detected in the poJycystic kidneys of J 6 
patients, 10 of whom had ADPKD and renal failure, 5 had ADPKD but no renal failure, 
and one was from a one day-old infant with a terminal recessive form of PKD (Woo, 
1995). Apoptosis was not observed in the kidneys of 12 normal controls or in the 
kidneys of 25 renal patients who did not have polycystic disease (Woo, 1995}. The 
results suggest that apoptotic loss of renal tissue may contribute to the progressive 
deterioration of renal function in PKD (Woo, 1995). Since the gene products of PKDJ 
and PKD2 are believed to be involved in cell-matrix and cell-cell interactions, their 
deficiency or altered function may play a role in the development of apoptosis seen in 
ADPKD kidneys (Zhou & Kukes, 1998). 
There is evidence that fewer than I% of renal tubules become cystic and lead to loss of 
renal function (Grantham, 1997). As cyst numbers increase, kidney function 
concomitantly deteriorates and serum creatinine levels rise, ultimately leading to ESRF 
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in 50% of affected individuals by 59 years of age (Parfrey et al., 1990). Kidney cysts 
have the following characteristic features: (a) they all originate from renal tubular 
epithelium; (b) as cysts expand, there is a differential increase in the number of 
epithelial ceJls found in kidney tubules compared to the number of cells in nonnal 
tubules; ( c) fluid derived from the glomerular filtrate and net trans-epithelial secretion 
of solute accumulates in the cyst cavity; and (d) cysts become enlarged in association 
with matrix re-modelling (Grantham, 1997). Since there is substantial intra· and inter­
familial variance in the rate of kidney enlargement, it has been postulated that 
epigenetic factors play a role in the modulation of renal cyst growth (Grantham, 1997). 
Evidence of a neutral lipid, which has the capacity to advance the progression of 
ADPKD, has been reported (Grantham, 1997). This lipid, or family of lipids, acts as a 
secretory agonist (secretagogue) and has been detected in the cyst fluids removed from 
patients with advanced ADPKD and in the cyst fluid of mice with PKD (pcylpcy) 
(Grantham, 1997). These cyst fluids have also been shown to stimulate the proliferation 
of MOCK (Madin-Darby canine kidney) renal epithelial cells in culture (Yamaguchi et 
al., 1995). The secretagogue, referred to as cyst-activating factor (CAF), may stimulate 
progression of the disease in two ways; (a) by increasing cellular proliferation and fluid 
secretion, and (b) by increasing interstitial inflammation and fibrosis (Grantham, 1997). 
The glycoprotein laminin present in human serum and urine, is a.'lother factor that may 
play a role in cyst proliferation (Slade et al., 1998). Laminin is one of the major 
intrinsic macromolecules of the tubular basement membrane. In a study by Slade et al. 
( 1998), undiluted cyst fluid contained no intact laminin but laminin fragments were 
present. Fragments of this type, isolated from human placenta, have previously been 
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shown to increase proliferation of cultured epithelial cells, both nonnal and ADPKD 
(Slade et al., 1996). It is believed that contact between laminin fragments and the 
epithelial cells lining renel tubular cysts could contribute to increased epithelial 
proliferation in ADPKD (Slade et al., 1998). 
The effect of transforming growth factor-alpha (TGF-a.) and epidennal growth factor 
(EGF), have also been investigated in terms of their effect on ADPKD cell proliferation 
(Lee et al., 1998). Both of these agents are known mitogens expressed in the kidney, 
and bind to the same epidermal growth factor receptor (EGFR) (Lee et al., 1998). A 
study employing immuno-staining showed that renal cystic epithelia exhibit increased 
expression of both the growth factor TGF-a and its receptor (EGFR) mRNA (Lee et al., 
1998). Intense cytoplasmic staining of the tubular epithelia for TGF-a and EGFR 
proteins has been shown at all stages of cyst development in ADPKD kidney tissues 
compared to normal human controls (Lee et al., t 998). These elevated levels of TGF-cx. 
and EGFR expression were not detected in the surrounding tissues, suggesting that 
TGF-a and EGFR signalling may be a common mechanism in cystic epithelial 
proliferation (Lee et al., 1998). 
Cysts require a net influx of fluid to prevent collapse of the cell walls (Murcia et al., 
1999). Therefore the transition of nonnal absorptive epithelium into cystic secretory 
epithelium is necessary for cyst pathophysiology (Murcia et al., 1999). This transition 
is not irreversible, as cystic epithelia have been shown to revert to wild-type absorptive 
behaviour in the absence of the stimulating endogenous secretagogues found in cyst 
fluid. such as fOiSkolin, an adenylate cyclase activator (Grantham et al., 1995). 
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Monolayer human ADPKD patient-derived cell cultures embedded in type- I collagen 
have been shown to fonn cysts in the presence of forskolin or epidermal growth factor 
(Woo et al., 1994). This cyst formation does not occur when nonnal kidney cells are 
treated in the same manner, indicating that mutant ADPKD cells have an intrinsic 
ability which differs from that of normal kidney epithelial cells (Woo et al., 1994). Cyst 
formation has been reversibly inhibited in vitro by ouabain and amiloride (both are 
diuretics used as anti-hypertensive drugs), plus colchicine, vinhlastine and taxol (these 
compounds interrupt the cell cycle during mitosis and have been used as anti-cancer 
drugs) (Woo et al., 1994). Experiments using colchicine, vinblastine and taxol have 
been conducted in vivo on cpk mice, a murine model of autosomal recessive PKD (Woo 
et al., 1994 ). Both colchicine and vinblastine proved lethal in the mice, however taxol 
administered on a weekly basis decreased cyst enlargement, resulted in minimal loss of 
renal function, and prolonged life from 25-28 postnatal days in untreated mice up to 200 
days in taxol-treated mice (Woo et al., 1994). These findings imply that, when the key 
processes of renal cyst formation and proliferation are understood, dietary and 
pharmacological treatments may help to delay the proliferation of cysts and the onset of 
ESRF in ADPKD (Grantham, 1997). 
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Il.2. The Genetic Basis of ADPKD 
11.2.i. Locus Heterogeneity in ADPKD 
The first major breakthrough in the localisation of the ADPKD genes occurred when 
close linkage to the a.-globin locus on the short arm of chromosome 16 was observed 
(Reeders et al., 1985). This was achieved using a highly polymorphic DNA marker (the 
3' HVR-hypervariable region) approximately 8 kb beyond the 3' end of the a-globin 
gene. The marker was analysed in four British and five Dutch families totalling 183 
members, and gave a maximwn combined lod score of 25.85 at 8 = 0.05 (99% 
confidence interval 2-11 cM) (Reeders et al., 1985). Each of the nine families displayed 
linkage to this locus, now known to be the PKDI gene. The families presented with the 
most typical clinical form of the disease, ESRF occWTed at a mean age of 48 years and, 
in the effective absence of phenotypic variation, genetic heterogeneity was deemed 
improbable (Reeders et al., 1985). A subsequent study in South Wales of 12 ADPKD 
kindreds gave a maximum combined lod score of 24.187 (8 = 0.03) using the a.-globin 
and 3' HVR probes (Lazarou et al., 1987). 
Refined linkage mapping became possible shortly afterwards with the marker 24-1, 
which flanks the PKDJ gene on the side opposite to the a.-globin gene (Breuning et al., 
1987). Ajoint study analysing 27 Northern European ADPKD families failed to detect 
evidence of linkage heterogeneity (Reeders et al., 1987). A not: 1l)' Kimberling and 
Gabow added to this paper in proof, suggested possible locus heterogeneity in families 
with more diverse ethnic origins. The first example was an ADPKD family of Sicilian 
origin which did not show linkage to the a.-globin gene on chromosome l 6p 
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(Kimberling et al., 1988). An average of 85% of all Caucasian families with ADPKD 
show linkage to PKDJ (Peters & Sandkuijl, 1992). For that reason this is the major 
gene selected for investigation in this thesis. 
The position and order of the many markers isolated around the PKDJ region was 
initially determined using a panel of somatic cell hybrids and extensive linkage analysis 
in normal and PKDJ families (Breuning et al .• 1990; Reeders et al., 1988; Germino et 
al., 1990). Further work creating a long-range restriction map localised the PKDJ 
region to an area spanning approximately 750-500 kb (Harris et al., 1990; Gennino et 
al., 1993), flanked by the markers GGG I and SM7 (Hanis et al., 1991; Somlo et al., 
1992). The region has a high CpG content and could contain as many as 20 genes. This 
large nwnber of candidate genes hindered the subsequent fine localisation of the P KD 1 
gene (Gennino et al., 1993). 
Linkage disequilibrium studies were undertaken using additional markers: VK.5B in a 
Scottish study (Pound et al., 1992), and BLu 24 with a Spanish population (Peral et al., 
1994). These studies showed evidence of a common ancestor in a proportion (approx. 
40%) of each population, but the degree of linkage disequilibrium was too weak to 
position the PKDJ locus with precision. 
As previously noted, the first ADPKD family which did not display linkage to the 
alpha-haemoglobin complex on chromosome 16p was of Sicilian origin (Kimberling et 
al., 1988), and was clinically indistinguishable from families in which ADPKD was 
linked to chromosome 16 (Kimberling et al., 1988). Numerous families were 
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subsequently reported in the literature to have a form of ADPKD that did not co­
segregate with genetic markers on chromosome 16p (Elles et al., 1990; Bachner et al., 
1990; Coto et al., 1992; Bear et al., 1992). As more non-PKDJ-linked families were 
identified it was noted that ADPKD in these families appeared to exhibit a milder 
clinical phenotype (Bear et al., 1992; Ravine et al., 1992). 
The second .-;;JPKD gene, PKD2, was mapped in the original Sicilian kindred to a 9-
cM segment flanked by the markers� D4S23 l and D4S4 l 4 on the long arm of 
chromosome 4 (Kimberling et al .. 1993). The highest lod scores in this two-point 
lin�age analysis were obtained between ADPKD and D4$395 (Z = 9.83, 8 = 0.07) and 
AOPKD and D4S4l4 (Z = 10.13, 8 = 0.06). Peters et al. (1993) independently mapped 
the PKD2 gene to chromosome 4q, in a study of eight families where ADPKD did not 
co-segregate with markers on chromosome 16p. This chromosome had previously been 
studied for Huntington disease (Gusella et al., 1983) and facioscapulohumeral 
dystrophy (Wijmenga et al., 1991), so markers closely linked to PKD2 were readily 
available for predictive diagnostic purposes (Peters et al., 1993). 
The question of further locus heterogeneity in ADPKD remains open, since at least five 
families show linkage to neither PKDJ nor PKD2 (Daoust et al., 1995; Bogdanova et 
al., 1995; de Almeida et al., 1995; Turco et al., 1997; Ariz.a et al., 1997). A possible 
positive lod-score to markers linked to chromosome 7 has been reported for "PKD3" 
(de Almeida et lll .. 1999). Pbenotypic variation has been found between the five 
families, which may result from modifying or environmental factors, as suggested in 
PKD1 and PKD2 (Hateboer, et al., 1999a). Alternatively, there may be more than three 
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genes responsible for the ADPKD phenotype, although the existence of even a iliird 
locus for ADPKD has been questioned since mnny confounders can lead to false 
exclusion of linkage (Paterson & Pei, 1998). 
It was suggested that bilineal transmission of two independent PKD mutations within 
the same family might lead to false exclusion of linkage when only one disease locus is 
considered at a time (Paterson & Pei, 1998). This could arise either through mutations 
involving both copies of PKDJ or PKD2 segregating within the same family. In such 
cases, individuals carrying two identical mutations are referred to as homozygotes, 
whereas those with two different mutant alleles are tennec! compound heterozygotes. 
Alternately, one PKDJ and one PKD2 mutation could segregate within the same family. 
In such cases, some affected individuals would have digenic mutations (i.e. in both 
ADPKD genes) and others would have only PKDJ or PKD2 mutations. Predictably 
these events would be rare. However, only five ADPKD families have failed to show 
linkage to either the PKDJ or PKD2 genes (Paterson & Pei, 1998). In 2001 the first 
family with bilineal ADPKD was reported (Pei et al., 2001). Family members had 
either germline mutations in PKDJ or PKD2, and a smaller, more severely affected 
subset were shown to have both mutations. 
A novel PKD2-like gene (PKDL} has been reported (Nomura et al., 1998) which 
displays 50% amino acid (aa) sequence identity and 71% homology to PKD2. The 
structure of the gene is suggestive of a role as a sub-unit of an ion channel, but there is 
no evidence of linkage to suggest that it could be associated with ADPKD in humans 
(Nomura et al., 1998). PKD2L2 is a third gene with significant homology to PKD2 and 
19 
PKDL. It has been recently mapped to human chromosome 5q31. and the gene product 
(polycystin-L-2) h1ls 48% identity with polycystin-2 and 47% identity with polycystin- L 
(Guo et al., 2000). 
11.2.ii. Ethnic Heterogeneity of ADPKD 
Two Southern European groups have reported a lower incidence of linkage to th� PKDJ 
gene than had previously been reported. A Bulgarian study of 22 families showed 
approximately 68% of patients with linkage to PKDJ (Bogdanova et al., 1995). and a 
smaller study of seven Greek-Cypriot families showed linkage to PKDJ in only four 
families, the others were linked to PKD2 (Constantinou-Deltas et al., 1995). Due to the 
small numbers in each study, it is not possible to detennine if locus heterogeneity is 
significantly different when compared to the larger study populations previously 
conducted in Northern Europeans (Peters & Sandlruijl. 1992). A more recent study on 
48 ADPKD families of Korean descent found that 79% of individuals had ADPKD 
linked to PKDJ, and 21% were linked to PKD2 (Lee et al., 2001 ). 
Il.2.iii, Molecular Cloning of the PKD Genes 
Cloning of the PKDJ gene was facilitated by the identification of a family with two 
genetic disorders, both due to mutations in genes located on chromosome 16 p l3.3 
(Wunderle et al., 1994). Affected members in a Portuguese kindred had two distinct 
phenotypes, either typical autosomal dominant polycystic kidney disease (PKDJ) or 
type-2 tuberous sclerosis (TSC2). The mother and daughter in this family bad balanced 
translocations, 46:XX t(l6;22)(p l3.3;q l 1 .21) and displayed ADPKD but not TSC2. In 
contrast, the son had an unbalanced translocation 45XY/-16-22+der(l6) 
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(16qter�l6p13.3::22q l l .21� 22qter) and displayed the clinical features of 1SC2 but 
not ADPKD. It was therefore concluded that the unbalanced translocation most 
probably resulted in a deletion at the 1SC2 locus, whereas the balanced translocation 
was investigated to see if it disrupted the PKDJ locus (The European PKO Consortium, 
1994 ). Investigation of the family using polymorphic markers refined the P KD J locus 
to 60 kb and enabled the construction of a cosmid contig covering the breakpoint 
region. Hence the polycystic breakpoint (PBP) gene was listed as the most likely 
candidate gene for PKD/ (The European PKO Consortium, 1994). 
More recently in humans the polycystic kidney disease and receptor for egg jelly related 
gene (PKDREJ) was localised close to the same region of chromosome 22 (Hughes et 
al., 1999). The PK.DREG protein is expressed exclusively in the testis of humans 
coincident with sperm maturation, suggesting a role in the fertilisation process (Hughes 
et al., 1999). 
The PKD2 gene was cloned by the construction of a cosmid- and Pl-based contig 
extending over 680 kb on chromosome 4q. Northern blot hybridisation revealed a 5.4 
kb transcript (cTM-4) expressed in most fetal and adult tissues, including kidney, ovary, 
testis, small and large intestine and fetal lung (Mochizuki et al., 1996 ), which showed 
homology at the amino acid level with the PKDI gene product. Mutation screening in 
the cTM-4 transcript in three unrelated affected individuals revealed three nonsense 
mutations that segregated with the disease phenotype in their families, and on that basis 
cTM-4 was deemed to be the PKD2 gene (Mochizuki et al., 1996). 
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ll.2.iv. Structure of the PKDJ Gene 
As previously stated, the PKDJ gene comprises 46 exons spanning 52 kb, and produces 
a 14.5 kb mRNA transcript which encodes a 4302 aa protein with novel domain 
architecture (The International PKO Consortium 1995). The PKDJ gene contains 3 
long polypyrimidine tracts in introns I , 21 and 22 (Van Raay et al., 1996) the longest 
of which (depicted in Fig ll.l) is located in IVS 21 and spans 2.5 kb. 
Duplicated e,on Jt · ..f6 Unique Pl([)J region 
____________________ ....., ________________ ____ 
e on 1. 33 
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Polypyrimidine Repeat 
11111111111 1 3• 
Figure Ill. The PKDJ Gene. (Adapted from Hughes et al. , 1995). 
U.2.v. The PKDl Protein 
Polycystin-1 , the predicted PKDl protein, is a glycoprotein which consists of an 
extracellular 5' N-terminus of over 2500 aa, multiple transmembrane domains, and a 
cytoplasmic 3' C-terminus (Fig II.2) (The International PKD Consortiwn, 1995; Hughes 
et al. , 1995). 
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Figure 11.2. Polycystin-1. 
The basic defect in ADPKD is believed to be tubular dysmorphogenesis. The principal 
features include altered structure and function of the Golgi complex altered structure 
and composition of the matrix, and abnormal cell differentiation, resulting in faulty 
matrix-cell communication (Carone et al. , 1995). It has therefore been proposed that 
polycystin-1 is either involved in the mediation of cell-cell or cell-matrix interactions, 
or that it could be an intrinsic component of the extracellular matrix (The International 
PKD Consortium, 1995). 
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The domain architecture of polycystin-1 has been predicted by several groups, with only 
slight suggested variations (The International PKD Consortium, 1995; Hughes et al., 
1995). The presence of two leucine-rich repeat regions (LRRs) is probably one of the 
most striking features (The International PKD Consortium, 1995; Hughes et al., 1995). 
Proteins which contain this domain are believed to be involved in protein-protein 
interactions, such as cell recognition, binding to components of the extracellular matrix 
or signal transduction (Hughes et al., 1995). The LRRs in PKDJ are very close to the 5' 
terminus, in exons 2 and 3, and are flanked by two cysteine-rich domains (The 
International PKD Consortium, 1995). This combination of 2 LRRs flanked by the 
cysteine-rich domains is a feature of a number of proteins involved in protein-protein 
interactions (Hughes el al., 1995). Examples of these LRR-containing proteins include 
the von Willebrand factor receptor (Lopez et aL, 1987) and the Drosophila proteins 
chaoptin, involved in cell adhesion (Reinke, et al., 1988), toll, involved in dorsal-ventral 
polarity (Hashimoto et al., 1988), and slit, involved in morphogenesis (Rothberg et al., 
1990). Homology has also been observed between the PKDI exon 4 encoded domain 
and the trk gene (Hughes et al., 1995), a proto-oncogene known to encode a membrane­
spanning tyrosine kinase expressed in neural tissues (Martin-Zanca et al., 1986). 
The next functional domain in PKDJ is a C-type lectin domain. The usual function of 
the domain, associated with cell adhesion and recognition, is to bitid specific 
carbohydrates in the presence of calcium ions. In most proteins, this domain is encoded 
by either one or three exons (Drickamer, 1989), e.g. the human LOX-I gene (Aoyama et 
al., 1999) and the C-type lectin superfamily cartilage derived gene, CLECSF I (Nearne 
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et al., 1999), both of which have three exons for this domain. In PKDI the domain is 
not typical, as it is encoded by a novel number of exons ( exons 6 and 7), in association 
with a previously unreported combination of protein domains (Hughes et al., 1995). 
The most numerous of the PKDI domains is a novel lg-like repeat, dubbed the PKO 
domain (The International Consortium, 1995). According to this source, the lg-like 
domain is repeated 14 times, once in exon S, once in exon 13, once in exon 14 and 11 
times in exon 15 (aa 1031-2142). The lg-like repeat was detected 16 times by Hughes 
et al. ( 1995), who placed the first repeat in exon 5 and the remaining 15 repeats in exons 
11-15. Both groups state that the repeat motif consists of about 80-90 aa and, although 
the function of the lg-like repeats has not been established, they too are in an 
extracellular position. The area covered by these repeats represents approximately 30% 
of the PKDI gene. The current opinion is that there are 16 copies of the repeat (van 
Adelsberg, 1999). The lg-like repeats have been shown to have a Greek key 13-
sandwich topology (Bycroft et al., 1999), also known as the immunoglobulin (lg)-like 
fold (Bork et al., 1994 ). It is built from two (3-sheets, one with three strands (labelled A, 
B, and E) and the other with four strands (labelled G, F, C, and C'), packed face to face. 
The structure of the lg-like repeat found in PKDI is similar to the lg-like fold found in 
other cell surface proteins, however it is not identical to any known protein· and 
therefore represents a novel protein family (Bycroft et al.. 1999). 
Repeat number ten is believed to be of particular functional significance, as all of its 
surface residues are conserved on one (3-sheet in the Fugu genome (Bycroft et al., 
1999). Comparative analysis of the human and Fugu genomes for PKDI has 
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demonstrated PKDJ repeat number 10 to be in an evolutionarily conserved synteny 
group, suggesting that it may play an important role in normal cellular physiology 
(Sandford et al., 1997). The 40% sequence identity between human and Fugu 
polycystin-1 suggests that it is the tertiary structure of this protein, rather than sequence 
identity, which is necessary for normal function (Sandford et al., 1997). 
The next domain, FN-III, shows extensive homology to the sea urchin receptor for egg 
jelly (REJ) protein (Moy et al., 1996). REJ, a 210-kD sperm membrane glycoprotein, 
has been shown to function as an ion channel regulator and is believed to trigger the sea 
urchin sperm acrosome 1 e :.ction (Moy et al., 1996 ). The REJ protein is modular in 
design and consists of one EGF module (containing the 7 diagnostic Cys residues), two 
C-type lectin carbohydrate recognition modules and a novel module, ·the REJ module', 
which shares homology with the human PKDJ protein. The REJ module comprises 
50% of the REJ protein (residues 480-1187) and 17%. of polycystin-1 (residues 2146-
2882). The two modules (Altschul et al., 1990; Pearson & Lipman, 1988) are 20% 
identical (Moy et al., 1996). The evolutionary homology between the REJ of sea urchin 
and human PKDJ suggests that PKDJ may also be involved in ion channel regulation 
(V acquier & Moy, 1997). 
There is some inconsistency in the literature concerning the other domains of the PKDJ 
gene. The International PKO Consortium (1995) reported a low-density lipoprotein 
type-A (LDL-A) domain in exon IO. Due to its hydrophobic nature, the domain was 
predicted to have a receptor-related role as a ligand-binding region. Hughes et al. 
(1995) failed to mention such a domain but they did predict the presence of four 
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fibronectin type Ill (FN-III) repeats, situated beyond the lg-like repeats toward the 3' C­
tenninal region of polycystin-1. These domains are found in extracellular matrix 
proteins, and in extracellular locations of receptor and cell adhesion molecules (Hughes 
et al .. 1995). 
Each of the groups studying polycystin-1 also indicated the presence of several (most 
probably 11) transmembrane domains (Hughes et al., 1995; The International PKD 
Consortium. 1995). The region around the transmembrane (TM) domains (numbers 
TMl-6 and TMI 1) has recently been subjected to further analysis (Bateman & 
Sandford, 1999). This investigation was undertaken using the PSI-BLAST sequence 
comparison program, on the premise that there is a high degree of sequence 
conservation between human and Fugu polycystin-1. This sequence region was found 
to have matches to 67 other sequences in SWISS-PROT version 37 and TrEMBL 
version 9 (Bairoch & Apweiler, 1999), namely mammalian lipoxygenases, 
triacyglycerol lipase and lipoprotein lipase. Following this work, a new protein domain, 
the PLAT domain (after polycystin-1, lipoxygenase and alpha toxin) has been described 
(Bateman & Sandford, 1999). The PLAT domain is found in the first intracellular 
region of the PKDJ gene between TMI-TM2, corresponding to exons 26-29 (Bateman 
& Sandford, 1999). The domain is associated with protein-protein and protein-lipid 
interactions in other proteins, suggesting that the first cytoplasmic loop of polycystin-1 
may be important in mediating interactions with other membrane protein{s) involved in 
polycystin-l function- (Bateman & Sandford, 1999). All of the polycystin-1 domains 
predicted to date indicate a role in protein:protein signalling (Harris, 1999). 
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11,2.vi. PKDI Homologous Transcripts 
In addition to the PKDJ gene, three other homologous genes (HGs) have been identified 
by Northern blotting (The International PKD Consortium, 1995; Hughes et al., 1995; 
The European PKD Consortiwn, 1994). These genes, named HG-A., HG-B, and HG-C, 
produce transcripts of approximately 21 kb, 17 kb and 8.5 kb respectively (Hughes et 
al., 1995). As noted previously, the HGs are up to 97% homologous with the PKDJ 
gene over two-thirds of its length and it has not been detennined if the HG transcripts 
produce functional proteins (Hughes et al., 1995). The origins of these HGs could be 
explained in two ways: either they are alternatively spliced forms of the PBP (PKDJ) 
gene or they are separate genes co-located in 16p l3.l. All three of the identified HGs 
map to chromosome 16pl3. l proximal to the PKDJ region (The European Polycystic 
Kidney Disease Consortiwn, 1994 ). 
II.2.vii. Polycystic Kidney Disease in Animals 
The ADPKD murine gene (Pied/) has been mapped to mouse chromosome 17 (Olsson 
et al., 19%). Like its human counterpart, it lies tail to tail with the murine Tsc2 but is 
not duplicated elsewhere on the murine genome, and does not include the 
polypyrmidine tracts in intrans 21 and 22, suggesting that these changes are recent 
evolutionary events (Piontek & Germino, 1999). The expression of Pkdl has been 
observed from the morola embryonic stage up to adulthood (Guillaume et al., 1999). 
High levels of pkdl protein expression in the embryo suggest a role in development 
(Guillaume et al., 1999). Phenotypic variation had been observed between two reported 
Pkdl murine models (Lu et al., 1997; Kim, et al., 2000a). The first Pkdl model (PKDJ 
�34) involves a frameshift mutation {Lu et al., 1997), which produces a less severe 
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phenotype than that observed in the L3946* mutant polycystin 1 model, where the 
mouse polycystin-1 is expected to terminate after amino acid L3946 (equivalent to 
polycystin-1 L3955 in humans) (Kim, et al., 2000a). Other animal models which may 
be useful for the study of ADPKD are the Persian cat (Felclhahn, 1995; Biller et al., 
1996) and the bull terrier dog (O'Leary et al., 1999). 
11.2.viii. The Structure of the PKD2 Gene 
PKD2 has been shown to consist of at least 15 exons (Hayashi et al., 1997), and its 
architecture includes six membrane-spanning domains and intracellular amino- and 
carboxy- termini (Mochizuki et al., 1996). There is approximately 25% identity 
between the putative 968 aa PKD2 gene product, polycystin-2, and almost 450 aa of 
polycystin-1 (Mochizuki et al., 1996). This homology corresponds to transmembrane 
domains 1-6 of PKD2 and covers four transmembrane domains of PKDJ. The PKD2 
gene is not duplicated on chromosome 4q as PKDJ is on chromosome 16. The domains 
that are found in PKD2 share homology with a family of Ca2+ (and Na2) channels, 
mostly with the L-type voltage-activated Ca2+ channel etrn (V ACC am) (Mochizuki et 
al., 1996). 
The murine Pkd2 gene has been reported by two independent groups (Wu et al., 1997; 
Pennekamp et al .. 1998). Pkd2 is located on mouse chromosome 5 spanning at least 35 
kb and, like its human homologue, consists of 15 exons (Pennekamp et al., 1998). The 
peptide shows 95% homology to human polycystin-2, with well-conserved functional 
domains (Pennekarnp et al., 1998). 
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The most interesting aspect of the PKD2 gene structure relates to its apparent 
interaction with PKDJ. A coiled-coii domain in the C-terminus of the PKDI gene has 
been described which binds specifically to the C-tenninus of the PKD2 gene product 
(Qian et al., 1997}. This heterodimeric interaction suggests that PK.DJ and PKD2 may 
interact in vivo in a signalling pathway for normal tubular morphogenesis. Mutations in 
either gene could then lead to the identical pathology observed in ADPKD (Qian et al., 
1997). The interaction of PKDJ and PKD2 results in the up-regulation of PKDJ 
expression, suggesting that PKDJ may require PKD2 for the maintenance of normal 
expression levels (Tsiokas er al., 1997). Inactivation of the heterodimeric-signalling 
pathway may impair terminal differentiation and lead to cysts (Arnould et al., 1999). 
Given evidence of the five known polycystin-type prcteins, it is possible that more than 
two polycysrin proteins interact in such signalling pathways (Nomura et al., 1998). 
Il.2.ix. Expression Patterns of Polycystin-1 and Polycystin-2 
Polycystin-1 is expressed in a number of tissues, including the thymus, thyroid, adrenal 
glands, tonsils, duodenum, stomach, liver, spleen, heart, lungs, testes, brain and kidney 
(Ward er al., 1996), and it is present from fetal to adult life (Peters et al., 1996). 
Polycystin-1 has been detected at higher concentrations in cystic kidneys than in normal 
controls (Ward et al., 1996). In both normal and cystic kidneys, polycystin-1 
expression is localised to the epithelium of all tubular structures and the glomerular 
parietal and visceral epithelium (podocytes) (Peters et al., 1996). Fetal expression of 
polycystin-1 is higher than the normal adult level (Griffin et al., 1996; Wilson, 1997; 
Huan & van Adelsberg, 1999; Weston et al., 1997). Some cultured kidney cyst-lining 
epithelial cells have shown strong staining for polycystin-1 at the site of inter-cell 
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interaction, adding evidence to the hypothesis that polycystin-1 is involved in cell:cell 
interactions (Veldhuisen et al., 1999). More recent studies by the same group have 
shown that polycystin-1 expression is not confined to epithelial cells but is also present 
in endocrine cells involved in the secretion or transport of molecules. Much stronger 
staining for polycystin-1 was detected in cardiac muscle compared to skeletal muscle. 
Cardiac muscle fibres communicate via gap junctions, and the high expression of 
polycystin-l may correlate with the munber of interactions between these cells (Peters 
et al., 1999). 
With the exception of Ibraghimov-Beskrovnaya et al. (1997), all studies (Ward et al., 
1996; Griffin et al., 1996; Palsson et al., 1996; Peters el al., 19%; Geng et al., 1996; 
Wilson, 1997; Huan & van Adelsberg, 1999; Weston et al., 1997; van Adelsberg et al., 
1997), have reported that polycystin-1 is expressed at higher levels in the cystic kidney 
epithelia of adult ADPKD individuals than in normal adult kidneys (van Adelsberg et 
al., 1999). This contrasts with what one would expect due to the haploinsufficiency 
associated with an autosomal dominant disorder, or indeed with the two-hit model of 
cystogenesis (see section II.3.i.). A higher level of expression in affected individuals 
may be the result of an accumulation of non-functional protein caused by truncating or 
rnissense mutations in the PKDJ gene. Such increased levels of protein exp1ession have 
been associated with mutations in the NEMJ and TPM3 genes linked to nemaline 
myopathy (Tan et al., 1999). 
Polycystin-2 presents with a similar pattern of expression to polycystin-1 in the distal 
tubule and collecting duct kidney epithelia, but with more marked vascular endothelial 
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cell staining (Foggensteiner et al., 2000). Co-localisation of the two polycystins was 
demonstrated by dual colour immunofluorescence (Ong et al., 1999). A 34 aa region of 
polycystin-2 (Glu 787-Ser 820) had been localised to the endoplasmic reticulwn of 
endothelial cells (HEK.293) in culture, where it was the site of specific interaction with 
an as yet unidentified protein (Cai et al., 1999). The localisation of full-length 
polycystin-2 to intracellular membranes suggested that this protein may be a sub-unit of 
intracellular channel complexes (Cai et al., 1999). 
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11.3. The Mutations and Polymmphisms Associated with ADPKD 
11.3.i. Mutational Mechanisms of ADPKD 
In ADPKD, it is important not only to understand how cystic proliferation occurs, but 
also to appreciate the underlying genetic mechanisms and the factors causing their 
initiation. A two-hit model has been proposed to explain cyst formation (Qian el al., 
1996), involving the hereditary germline mutation (first hit) and a somatic mutation of 
the normal allele (second hit) which results in the loss of heterozygosity (LOH) of the 
normal PKD gene product (Qian et al., 1996). The two-hit model was first proposed to 
explain the genetic origin of retinoblastoma (Knudson, 1971 ), a form of cancer affecting 
the light-sensitive retinal ce11s. Unilateral and segmentally localised forms of PKD give 
credence to the two-hit hypothesis of ADPKD ( Gouldesbrough & Fleming, 1998). 
Individuals with the disorder have segmental cystic abnormalities in one kidney that are 
morphologically identical to ADPKD, however they have no family history of the 
disease and simple surgical resection is curative (Gouldesbrough & Fleming, 1998). If 
the two-hit model explains cyst formation in ADPKD, it could be postulated that two 
somatic mutations could lead to the rare disease phenotype in unilateral and segmentally 
localised PKD (Gouldesbrough & Fleming, 1998). 
A number of additional studies have shown that LOH is associated with ADPKD in 
individual renal cysts (Brasier & Henske, 1997; Koptides et al., 1998; Torra et al., 
1999). Three different somatic mutations, along with a missense germline mutation in 
exon 31 of PKDJ, were detected in 3 of 17 renal cysts removed from an ADPKD 
patient during transplantation surgery (Koptides et al., 1998). As previously stated, 
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accwnulation of non-functional protein may occur in these cells and could account for 
the over-expression of polycystin-1 often associated with ADPKD. Renal cysts 
associated with a germline mutation in the PKD2 gene (Koptides et al., 1999; Torra et 
al., 1999), and hepatic cysts of ADPKD individuals (Watnick et al., 1998b) have also 
been shown to involve somatic mutations, extending the two-hit hypothesis of cyst 
formation to the PKD2 gene and to other organs apart from the kidney. This 
homozygous loss of normal PKDJ or PKD2 function preswnably alters the ability of 
epithelial cells to retain tissue organisation, resulting in proliferation and cyst formation 
(Wu & Somlo, 2000). In a murine model (WS25) carrying an unstable allele, which 
introduced an in-frame stop codon nine codons downstream of the 5' cloning junction, 
there was a cessation in Pkd2 protein expression in renal epithelial cells after cyst 
formation (Wu et al., 1998). A true null allele mouse model (WS183) was also 
observed, and in this model Pkd2-I- mice were not viable (Wu et al., 1998). 
A paper on polycystin-2 expression confinned the positive staining for polycystin-2 in 
individual kidney cysts from PKD2-linked individuals, thus questioning the two-hit 
hypothesis as the pathological factor in cyst formation (Ong et al., 1999). It was argued 
that if the staining is positive for a mutant protein inactivated by a missense mutation, 
then the two-hit hypothesis is plausible (Ong et al., 1999). Alternatively, the detection 
of polycystin-2 in cystic epithelia may indicate that cyst initiation can occur without 
loss of the normal protein or possibly through somatic mutations at other loci (such as 
PKDI), affecting proteins which may be part of the polycystin complex (Ong t:t al., 
1999). 
34 
A dominant negative effect of the mutated allele has been proposed (Roelfsema et al., 
1997). This occurs when the mutated protein interacts with the wild-type gene product 
and adversely affects the normal function of that protein. It is suggested that the model 
applies to a nwnber of autosomaI dominant diseases, including generalised resistance to 
thyroid hormone (GRTH) (Yen et al., 1992), Marfan syndrome (Aoyama et al., 1993), 
Diabetes-insulin receptor mutation (Levy-Toledano et al., 1994), and growth honnone 
deficiency (Hayashi et al., 1999). This form of mutational mechanism has also been 
shown to be associated with a variable phenotypic effect. Differing mutations in the c­
erbA-beta-J-thyroid-hormone receptor have divergent effects on dimerization activity, 
and appear to influence the level of dominant negative activity in humans (Hao et al., 
1994). 
Gene conversion may be a mutational mechanism in ADPKD. One group proposed that 
the HGs of PKDJ might represent reservoirs for mutation generation in ADPKD via 
gene conversion (Watnick et al .. 1998a). Gene conversion was first studied ili yeast and 
bas been defined as the non-reciprocal exchange of genetic information (Murti et al., 
1994). It has been postulated that gene conversion and recombination may be related 
processes that involve pairing of homologous sequences, although in gene conversion 
genetic information is transferred from the donor gene to the recipient without the donor 
undergoing concomitant modification (Murti et al., 1994). 
The role of gene conversion as a mutational mechanism has been linked to other human 
genes and their pseudogenes, e.g., with congenital adrenal hyperplasia (CYP21 gene) 
(Collier et al., 1993), neurofibromatosis (Hulsebos et al., 1996), and the von Willebrand 
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factor gene (Eikenboom et al., 1994). CYP21 is somewhat similar to PKDJ: both genes 
are duplicated on the same chromosome and share greater than ()5% sequence identity 
across many thousands of base pairs with their respective homologue(s) (Collier et al., 
1994; Tusie-LWla & White, 1995). In the PKDJ gene, gene conversion is proposed as a 
likely cause of the cluster ofmissense mutations in exon 23 (Watnick at al., 1998a). It 
is yet to be detennined if this mutational mechanism is responsible for germline 
mutations in other duplicated parts of the gene, or for somatic mutations. C-iven the fact 
that the HGs extend over approximately 70% of PKDJ, gene conversion could well be a 
major mechanism of mutation (Watnick et al .. 1998a). 
Another possible source of mutation in the PKDJ gene is the polypyrimidine tract in 
IVS 21 (Van Raay et al., 1996), because of its many triple helices (Watnick et al., 
1998a). The tract (-2.5 kb) contains a nwnber of repeat elements that are predicted to 
form H-DNA structures. These structures form a triple helix and have been shown to 
promote mutagenesis in cultured cells (Wang et al., 1996a). Triplex formation by a 
poly(dG)-poly(dC) tract separating two homologous sequences in a bacterial system 
was shown to promote recombination when transcription of the downstream gene was 
activated (Wang et al., 1996a; Kohwi & Panchenko, 1993). Since recombination and 
gene conversion are related processes, it might be expected that the polypyrimidine 
tracts in PKDJ increase the rate of rnutagenesis (Watnick et al., 1998a). Preliminary 
evidence supporting this theory comes from the potential clustering of missense 
mutations in exons 23 and 25 of PKDJ (Watnick et al., 1997; Peral et al., 1997), around 
the polypyrimidine tracts in introns 21 and 22. 
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ll.3.ii. Mutations Found in PKDI 
As of February 2002 there have been 185 mutations reported in the gene (Table l l.2}. 
Table 11.2. PK/JI Mutations by Type and Region 
Mutation Type Total 3' Unique 5' Repeated 
Number R�ion Re2ion 
Nucleotide Substitutions 
missense 53 15 39 
nonsense 45 19 26 
splicing 15 6 9 
Deletions. Insertions and Duplications 
Small deletions 43 12 32 
Small insertions 16 10 7 
Large deletions 9 4 5 
Large duplication I l 0 
TOTAL 185 67 118 
(Krawcz.ak & Cooper. 1997; Afaal et al., 2000; Aguiari et al., 2000; Kim. el al .. 2000b; 
Koptides et al .. 2000; Perrichot et al., 2000 a & b; Phakdeekitcharoen el al., 2000 & 
200 I: Rossetti et al., 200 I; Mizoguchi et al., 200 I: Bouba et al., 200 l; Tsuchiya et al .. 
200 I; Ding et al.. 2002 ). 
1I.3.1ii. Tvpes of Mutations in PKDI 
Approximately 80% of all mutations in the 3' region and 67% of mutations in the 5' 
region are truncating. This figure is probably biased as PTI was used by two groups to 
screen for mutations (Peral et al .. 1997; Roelfsema et al., 1997). Mutations have been 
detected in cxons I to cxon 46. although few !,>Toups have screened the entire region 
(Rossetti et al .. 200 I; Phakdeekitcharoen et al., 200 I), and a bias exists for mutation 
screening in exons 15. 23 and 25 (Table 11.3 ). As more studies screen the entire 5' 
region ( exons 1 to 33) for both truncating and non-truncating mutations, a true 
indication of the specific types of mutation involved will be established for the l'KD 1 
gene 
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Il.3.iv. Location of PKDI Mutations 
A comprehensive list of mutations published in the PKDI gene are given in Table 11.3, 
and their locations are depicted in Figure 11.3. More than half of the studies (19/30) 
show a bias for mutation detection in the non-duplicated 3' region of the gene. Thirty­
six percent (67/185) of all reported mutations are clustered in the unique region, which 
accounts for only -2.Skb of the gene product (International PKD Consortium, 1995). 
Only 6-7% of individuals with ADPKD Jinked to the PKDJ gene have detectable 
mutations in the unique region of the gene (see Table II.3), this region represents 
approximately 18% of polycystin-1. 
Mutations have been detected in each exon of the 3' region of PKDJ. A non-disease­
causing VNTR is located in IVS 42 (Peral et al., 1996b). The seven alleles detected at 
this site range from 410 bp to 215 bp, representing an intron size variation of 325-130 
bp. The intron is a complex structure and includes a 34 bp repeat that was present five 
times in the analysed clone (Peral et al., 1996b). The variation may interfere with 
amplification by changing the primer binding sites, or result in an amplicon too large for 
the chosen mutation screening technique to be effective. Physical difficulties associated 
with amplification could perhaps explain why so few variants have been detected in 
exon 42 and IVS 42 of the gene. 
Mutation screening results infer that the majority of gcrmline mutations are located in 
the duplicated region (82%) of polycystin-1. As of February 2002, 118 mutations have 
been reported in the duplicated region from approximately 600 individuals analysed 
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(see Table 11.3). A true mutation detection rate cannot be estimated, as most studies 
have failed to screen the entire gene, however a relative rate of detection can be 
observed by comparing the number of patients screened with the percentage of the gene 
covered (Table VII. I). 
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11.3.v. Recurrent Mutations in PKDJ 
There have been no reports on any common recurring pathogenic mutations in PKDJ 
and no mutational hot-spots are apparent in the gene. As indicated in Table ll.5 the 
nonsense mutation, Q4041 X, in exon 44 has been reported in four families (Turco et al., 
1995; Daniells et al., 1998b; Torra et al., 1998). Comparisons of polymorphic 
haplotypes of the Q4041X-bearing chromosomes in families with this mutation revealed 
no identity by descent (Torra et al., 1998). A slipped-mispairing model has been 
proposed to explain the recurrence of the mutation (Daniells et al., 1998b). Whatever 
the mechanism of origin, the most common PKDI mutation known to date, Q4041X, 
accounts for only 4 of approximately 950 disease alleles. 
Other possible recurring mutations that have been found include: a small deletion in 
exon 15 (5224del2) in three families (Watnick et al., 1999); a nonsense mutation in 
exon 46, R4227X in two families (Peral et al .. 1996b &1997); and a missense mutation, 
R4275W in exon 46 (Badenas et al., 1999) in a further two families. Most mutation 
detection studies so far conducted for ADPKD have involved multi-generational 
families. Spontaneous (de novo) mutations are estimated to account for 10% or less of 
all reported ADPKD cases (Gabow, 1993 & 1996; Koptides et al., 2000). 
11.3.vi. Mutational Effects on Protein 
The majority of PKDI mutations detected result in a truncated protein that lacks a part 
of or possibly the entire C-tenninus of polycystip-1, suggesting that this region has an 
important function (Li et al., 1999). A nonsense mutation (R4227X) towards the 3' end 
of the gene results in the loss of a phosphorylation site in the polycystin-1 C-terminal 
41 
domain at serine residue 4251. It is proposed that this serine is the site of 
phosphorylation by a cAMP-dependent protein kinase in normal human renal collecting 
tubule cells and may be necessary for normal kidney function (Li et al., 1999). 
Until more ADPKD genotypes (including both tnutcating and non-tnutcating mutations) 
can be related to the function of PKDJ and PKD2 gene products, and their interactions 
or pathways, it will not be possible to predict the severity of particular mutations. 
Hence the importance of gathering phenotypic information, and using it in the 
correlation of mutations resulting from truncated proteins and missense changes in 
particular protein domains. No significant clustering of mutations, either truncating or 
in-frame, in any particular region of the gene have been reported in PKDJ, however, 
trends such as the number of missense mutations in exons 23 and 25 (Watnick et 
al., 1997) are emerging. The occurrence of missense mutations in these exons, and other 
patterns, will be discussed in Chapter VII together with the results of mutations detected 
in this study. 
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Table 11.3. Mutations Detected in PKDJ 
Mutation Tvoe Reference 
Total deletion of the Large deletion European PKD Consortium, ( 1994 ). 
PKDJ gene ( entire gene) 
c.224del l 3  Small deletion Rossetti et al., (200 l )  
Frameshift 
exon 1 
LI3Q Missense Rossetti et al, (2001) 
exon 1 
g.18177del 3 kb Large deletion Thomas et al., (1999) 
IVS 1-exon 5 Frameshift 
S75F Missense Rossetti et al., (20u 1) 
exon 2 
W139C Missense Rossetti et al., (2001) 
exon 4 
S225X Nonsense Rossetti et al., (2001) 
exon 5 
Q227X Nonsense Rossetti et al., (2001) 
exon 5 
R324L Missense Thomas et al., ( 1999) 
exon 5 
IVS7+1G>A Splicing mutation Rossetti et al .. (2001) 
Frameshift 
IVS9+1G>T Splicing mutation Rossetti et al., (200 I ) 
Framesluft 
c.2296delC Small deletion Rossetti et al., (2001) 
Frameshift 
exon 10 
c.2296insC Small insertion Rossetti et al., (2001) 
Frameshift 
exon 10 
Q705X Nonsense Rossetti et al., (2001) 
exon 11 
S745 Nonsense Rossetti et al., (2001) 
exon 11 
L845S Missense Thomas et al., (1999) 
exon 11 
W967R Missense Phakdeekitcharoen et al., (2001) 
exon 12 
c.3220del4 Small deletion Watnick et al., (1999) 
Frameshift 
exon 13 
c.3336delG Small deletion Phakdeekitcharoen et al., (2000) 
Frameshift 
exon 13 
IVS13-2A>T Splicing mutation Thommoppakhun et al., (2000) 
IVS 14-1 G>A Splicing mutation Thomas et al., (1999) 
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Gl I66S Missense Phakdeek itcharoen et al .. (2000) 
exon 15 
c.3804del7 Small deletion Watnick et al., (1999) 
Frameshift 
exon 15 
c.3866delT Small deletion Roelfsema et al., ( 1997) 
exon 15 
c.4036/4 2del2 Small deletion Roelfsema et al., ( 1997) 
exon 15 
c.413 7 delCT Small deletion Rossetti et al., (200 l) 
Frarneshift 
exon 15 
c.429IdelG Small deletion Rossetti et al., (2001) 
Frameshift 
exon 15 
c.4787delG Small deletion Rossetti et al., (2001) 
Frarneshift 
exon 15 
El537X Nonsense Rossetti et al., (200 I) 
exon 15 
c.4898 insT Small insertion Thomas et al., ( 1999) 
Frameshift 
exon 15 
c.50I4de1A Small deletion Roelfsema et al., ( 1997) 
exon 15 
Ql653X Nonsense Phakdeekitcharoen et al., (2000) 
exon 15 
c.5224del2 Small deletion Watnick et al., (1999) 
Frameshift 
exon 15 
W l826X Nonsense Watnick et al., (1999) 
exon 15 (Fl826X in paper!) 
c.5782dell Small deletion Watnick et al., (1999b) 
Frameshift 
exon 15 
W l874X Nonsense Roelfsema et al., ( 1997) 
exon 15 
c.5870dell4 Small deletion Rossetti et al., (2001) 
Frameshift 
exon 15 
Q1922X Nonsense Thomas et al., (1999) 
exon 15 
c.6187delC Small deletion Rossetti et al., (2001) 
In-frame 
exon 15 
Vl956E Missense Phakdeek itcharoen et al., (2000}) 
exon 15 
Q1960X Nonsense Phakdeekitcharoen el al., (2000) 
exon 15 
Q2039X Nonsense Phakdeekitcharoen et al., (2000) 
exon 15 
c.6434del 28 Large deletion Thomas et al., ( 1999) 
exon 15 
c.6574del7 Small deletion Roelfsema et al., ( 1997) 
exon 15 
R2163X Nonsense Rossetti et al., (2001 ) 
exon 15 
c.6868del 15 Small deletion Rossetti et al., (200 I) 
In-frame 
exon 15 
c.6937delAC Small deletion Rossetti et al., (200 I) 
Frameshift 
exon 15 
Q2243X Nonsense Rossetti et al., (200 I) 
exon 15 
C2229X Nonsense Rossetti et al., (2001) 
exon 15 
T2250M Missense Penichot et al., (2000b) 
exon 15 
IVS15 +2 T>G Splicin� mutation Penichot et al., (2000b) 
c. 7 I 74/7 l 79del 14 Small deletion Bouba et al., (2001) 
Frameshift 
exon 16 
R2329W Missense Perrichot et al., (2000b) 
exon 16 
c.7205del7 Small deletion Phakdeekitcharoen et al., (2000) 
Frameshift 
exon 16 
c.721 l ins7 Small insertion Rossetti et al., (2001) 
Frameshift 
exon 16 
Y2336D Missense Rossetti et al., (20G l) 
exon 16 
Y2336X Nonsense Penichot et al., (2000b) 
exon 16 
7277-3 C>G Splicing mutation Watnick et al., (1999) 
IVS 16/exon 17 Frameshift 
C2370X Nonsense Rossetti et al., (2001) 
exon 17 
c. 7324delGT Small deleti:.m Rossetti et al., (200 I) 
Frameshift 
exon 17 
c.7397insl l Small insertion Watnick et al., (1999) 
Frameshift exon 17 
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R2402X Nonsense Phakdeekitcharoen et al., (2000) 
exon 17 
R2408C Missense Phakdeekitcharoen et al., (2000) 
exon 18 
R2430X Nonsense Phakdeekitcharoen et al., (2000) 
exon 18 
c.7535ins3 Small insertion Phakdeekitcharoen et al., (2000) 
In-frame 
exon 18 
P247IL Missense Bouba et al., (2001) 
exon 18 
Q2519L Missense Bouba et al., (2001) 
exon 19 
Q2558X Nonsense Phakdeekitcharoen et al .. (2000) 
exon 19 
c.7946del3 Small deietion Bouba et al., (200 l )  
In-frame 
exon 20 
c.8030del5 Small deletion Perrichot et al., (2000b) 
Frameshift 
exon 20 
c.8047del3 Small deletion Bouba et al., (200 I) 
In-frame 
exon 20 
R2639X Nonsense Perrichot et al., (2000b) 
exon 21 
c.8126ins20 Small insertion Rossetti et al., (2001) 
Frameshift 
exon 21 
T2649I Missense Bouba et al., (2001) 
exon21 
c.8159delCT Small deletion Phakdeekitcharoen et al., (2000) 
Frameshift 
exon 21 
c.8I83del8 Small deletion Bouba et al., (2001) 
Frameshift 
exon 21 
IVS2 l -2delAG Splicing mutation Rossetti et al., (2001) 
L2696R Missense Phakdeekitcharoen et al., (2001) 
exon 22 
A2752D Missense Rossetti et al., (200 l )  
exon 23 
M2760T Missense Watnick et al., ( 1997) 
exon23 
R2761P Missense Watnick et al., ( 1997) 
exon 23 
L2763V Missense exon 23 Watnick et al., (1997) 
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M2764T Missense Watnick et al., {1997) 
exon23 
c.8507 ins l2 Small insertion Rossetti et al., (2001) 
In-frame 
exon23 
V2768M Missense Rossetti et al., (2001) 
exon 23 
E2771K Missense Rossetti et al., (2001) 
exon 23 
R2791Q Missense Watnick et al., ( I 997) 
exon 23 
L2816P Missense Rossetti et al., (2001) 
exon 23 
12826T Missense Watnick et al., ( 1997) 
exon23 
c.8657delC Small deletion Peral et al., (1997) 
Frameshift 
exon23 
G2858S Missense Rossetti et al., (2001) 
exon 23 
Q2900X Nonsense Roelfsema et al., ( 1997) 
exon 23 
H2921P Missense Koptides et al., (2000) 
exon 23 
c.9 I 42/9 I 43del3 Small deletion Bouba et al., (2001) 
In-frame 
exon 24 
E2966D Missense Afzal et al., (2000) 
exon 25 
R2985G Missense Phakdeek itcharoen et al., (2001) 
exon 25 
L2993P Missense Peral et al., ( 1997) 
exon25 
W3001X Nonsense Phakdeek itcharoen et al., (200 I) 
exon25 
V3008L Missense Watnick et al., (1997) 
exon 25 
c.9245dell8 s�_1al l deletion Rossetti et al .. (2001) 
In-frame 
exon 25 
Q30I6R Missense Peral et al., (1997) 
exon 25 
E3020X Nonsense Peral et al., (1997) 
exon 25 
R3039 C Misscnse Phakdeek itcharoen et al., (2001) 
exon 25 
F3064L Missense exon 25 Watnick et al., ( 1997) 
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c.9299delC Small deletion Peral et al., (1997) 
Frameshift 
exon 25 
IVS25-16G>A Splicing mutation Rossetti er al., (2001) 
Frameshift 
W3180X Nonsense Rossetti et al., (2001) 
exon 27 
c.9867delT Small deletion Perrichot et al., (2000b) 
Frameshift 
exon 28 
Q3206X Nonsense Perrichot et al., (2000b) 
exon 28 
R3247H Missense Afzal et al., (2000) 
exon 29 
V32851 Missense Phakdeekitcharoen et al., (200 I) 
exon 29 
c.10135-2A>T Splicing mutation Afzal et al., (2000) 
IVS29 
V3375M Missense Koptides et al., ( 1998) 
exon 31 
T3382M Missense Afzal et al., (2000) 
exon 31 
Deletion of2 kb Large deletion European PKD Consortium, ( 1994) 
exon 31-exon 34 Frameshift 
c.10378 + 25del 19 Small deletion Peral et al., (1997) 
IVS31 Frameshift 
Q3394X Nonsense Rossetti et al., (2001) 
exon 32 
Deletion of 5.5 kb of Large deletion European PKD Consortium, ( 1994) 
genomic DNA exon 34- 3 'UTR 
Q3474X Nonsense Perrichot et al., (1999) 
exon 34 
T3509M* Missense Mizoguchi et al., (2001) 
exon 35 
L3510V Missense Peral et al., (1997) 
exon 35 
Q3513X Nonsense Peral et al., (1997) 
exon 35 
G3559R Missense Tsuchiya et al., (2001) 
exon 36 
c. l 0946insT Small insertion Peral e I al., ( 1996b) 
exon 36 
E3631D Missense Peral et al., ( 1996b) 
exon 37 
P3648L Missense Ding et al., (2002) 
exon 37 
M3677T Missense exon 38 Turco et al., ( 1997) 
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C3693X Nonsense M izoguchi et al., (2001) 
exon 38 
R3718Q Missense Aguiari et al .. (2000) 
exon 38 
c.l l 284 insT Small insertion Perrichot et al., ( 1999) 
Frameshift 
exon 38 
c.1 l 285 insC Small insertion Perrichot et al., (1999) 
Frameshift 
exon 38 
c.l 1307del61 Large deletion Tsuchiya et al., (200 I) 
exon 38 
l 1449del l5 Small deletion Afzal et al .• ( 1999) 
( cDNA level) exon 39 
c.l 1453dell5 Small deletion Peral et al .. (1996b) 
in-frame exon 39 
R3752W M issense Kim et al., (2000b) 
exon39 
I39E40-25 to 139E40+47 Large deletion Peral e I al.. (1996b) 
72bp deletion 
IVS39+1 G>C Splicing mutation Peral et al., ( 1997) 
c. l 1549ins10 Small insertion Turco et al .. (1997) 
IO b p  duplication Frameshift 
exon 40 
c. l l 548del8 Small deletion Kim et al., (2000b) 
Frameshift 
exon40 
C. l l 674 insG Small insertion Kim et al., (2000b) 
Frameshift 
exon41 
Y3818X Nonsense Peral et al., (1996 a) 
exon41 
Q3820X Nonsense Perrichot et al., (2000 a) 
exon41 
Q3837X Nonsense Peral et al., ( 1996b) 
exon 41 
D3814N Missense Kim et al., (2000b) 
exon41 
IVS41 +2 ins3 ** Splicing mutation Perrichot et al., (2000 a) 
L3851P M issense Aguiari et al., (2000) 
exon42 
c.12187ins9 Small insertion Perrichot et al., (1999) 
exon43 
c.12714ins23 Large insertion Perrichot et al., (1999) 
duplication 
exon 43 
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18 bp deletion Small Deletion Peral et al., (1995) 
E43IVS43 +15/16 Splicing 
20 bp deletion Small Deletion Peral et al., (1995) 
E43IVS43 + 5-13 Splicing 
15 bp del in 75 bp intron Splicing mutation Tighe et al., (1998) 
Paper states IVS 47! Prob ab ly IVS 43? 
Q4010X Nonsense Dani ells et al., ( 1998b) 
exon44 
W4011X Nonsense Roelfsema et al., (1997) 
exon44 
R4020X Nonsense Rossetti et al., (1996) 
exon44 
E4024X Nonsense Daniells et al., (1998b) 
exon44 
G4031D Missense Daniells et al., ( 1998b) 
exon44 
Y4039X Nonsense Rossetti et al., (200 I) 
exon44 
Q4041X Nonsense Turco et al., (1995) 
exon44 
c.12252del2 Small deletion Afzal et al., (1999) 
Frameshift 
exon44 
c. l 2262delA T Small deletion Daniells et al., (1998b) 
Frameshift 
exon44 
c. l 2290 insG Small insertion Afzal et al., (1999) 
Frameshift 
exon 44 
IVS 44 + I G>C Splicing mutation E uropean PKO C onsortium, (1994) 
In-frame 
IVS44-l G>C S plicing mutation Badenas et al., ( 1999) 
IVS 44 
Q4059X Nonsense Daniells et al., (1998a) 
exon 45 
C4086X Nonsense Neophytou et al., (1996) 
exon45 
Q4124X Nonsense Daniells et al., (1998a) 
exon 45 
Y4126X Nonsense Turco et al., (1997) 
exon45 
R4135 G Missense Perrichot et al., (1999) 
exon 45 
W4139X Nonsense Perrichot et al., (1999) 
exon 45 
c.12412 ins20 Small insertion Daniells et al., (1998a) 
Frameshift exon 45 
50 
c. I 7 4 70insA Small insertion Ding el al., (2002) 
Frameshift 
exon 45 
c. l 2506insG Small insertion Daniells el al., ( 1998a) 
Frameshift 
exon 45 
c. l 2593delA Small deletion Ding et al., (2002) 
Frameshift 
exon 45 
c.12601 del3 Small deletion Afzal et al., (1999) 
In frame 
exon 45 
c.12617delC Small deletion Rossetti et al., (2001) 
Frameshift 
exon 45 
1YS45+55del25 Large deletion Aguiari er al .. (2000) 
intron 45 
IVS 45-1 G>A Splicing mutation Badenas et al.. (1999) 
R4153C Missense Perrichot et al., ( 1999) 
exon 46 
Q4224P Missense Badenas et al., (1999) 
exon 46 
R4227X Nonsense Peral et al., (1996b) 
exon 46 
Y4236X Nonsense Perrichot et al., (2000a) 
exon 46 
12722delT Small deletion Kim et al., (2000b) 
(cDNA level) Frameshift 
exon 46 
c. l 2739delA Small deletion Peral er al., (1997) 
Frameshift 
exon 46 
c.1280 I del28 Large deletion Torra et al .. (1997) 
exon 46 
R4275W Missense Badenas er al.. (1999) 
exon 46 
•T3509M Mizoguchi er al .. (200 I) list this change as disease-causing, Peral er al., 
( 1997) and the present study propose that the same variation is neutral. 
00 IVS41 +2ins3 Penichot er al., (2000a) list this change as disease-causing, Koptides 
et al., (2000) cite the same variation as neutral although no RNA work was performed. 
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11.3.vii. Neutral Polymorphisms in the Human Genome 
Single nucleotide polymorphisms (SNPs) represent the most frequent type of variation 
in the human genome. It was originally estimated that they occur at about I per I 000 bp 
in a population (Wang et al.. 1998), but more recent estimates from the International 
SNP Map Working Group are l SNP per 1.9kb, with a higher SNP occurrence within 
genes (Sachidanandam et al .. 2001). The genetic diversity created by SNPs could 
contribute to the basis of heritable variation in disease susceptibility and supply 
information on human migrations (Wang et al.. 1998). There has been increased 
appreciation that large collections of SNPs could provide a useful tool for studies into 
the genetic basis of complex human diseases (Risch & Merikangas, 1996 ). For whole­
genome association studies, it has been calculated that useful levels of linkage 
disequilibrium are unlikely to extend beyond a distance of 3 kb in the general 
population, and so for screening to be informative approximately 500,000 appropriately 
spaced SNPs are required (Kruglyak, 1999). 
In practice, one SNP for a particular gene may be informative and associated with a 
disease gene, whilst another in the same gene may well be informative as a genetic 
marker, however, not be associated with disease susceptibility. For example, there are 
tens of polymorphisms found in the beta-globin gene but only one single nucleotide 
polymorphism in this gene is associated with sickle-cell disease (Roses, 1997). Two 
particular SNPs within the sequence of apolipoprotein E are phenotype-associated; one 
is responsible for the transition from APOE4 to APOE3, and the other from APOE3 to 
APOE2. APOE4 is associated with an increased risk and lower age al onset of 
Alzheimer's disease, whereas APOE2 is associated with decreased risk and older age at 
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onset of Alzheimer's disease (Roses, 1997). When choosing SNPs for genome 
screening, it wilJ be necessruy not only to monitor how they are spaced as infonnative 
genetic markers, but also to consider their biological relevance to the disease (Roses, 
1997). 
Obviously it is not only work specific to SNP discovery which will record 
polymorphisms in the genome. All mutation detection screening studies, including the 
present investigation, have the potential to uncover disease-causing and neutral 
polymorphisms. The HGBASE database, Human Genie Bi-Allelic Sequences database 
(Uppsala University & lnteractiva Biotechnologie GmbH. http://hgbase.interactiva.de/) 
has the capacity to list known polymorphisms within particular human genes (Brookes 
et al., 2000). As of February 2002 only 11 SNPs have been listed in HGBASE for the 
PKDJ gene, although many more are reported in the literature (Tables Il.4(a) & II.4(b)). 
11.3.viii. Neutral Polymorphisms in PKDJ 
Of the 132 neutral polymorphisms detected from exons 2 to the 3' UTR in the PKDJ 
gene, 126 are SNPs, the remaining six consist of three small deletions and three small 
insertions (Table ll.4.b). A r,Jmber of studies have focused on exons 5 to 15� exons 17 
to 21; and exon 23 to the 3' UTR, equivalent to an overall genomic area of 27,073 bp. 
This indicates a frequency in that portion of PKDJ of l SNP per 237 bp ( 114 in all). a 
figure that is in accordance with currently reported frequencies for the rest of the 
genome (htt_p;/&gbase,cgr.ki.se/). If the proposed pathogenic SNPs of PKDJ are added 
(92 in all, not nonnally defined as SNPs because they are disease-causing), this figure is 
1 nucleotide variant per 131 bp in PKDI. confirming the high mntability of the gene. 
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The non-disease-causing polymorphisms so far recorded in the P KD I gene are listed in 
Tables ll.4.a & II.4.b. Mapping and understanding this high level of polymorphism in 
the PKDI gene (and in the PKD2 gene), could lead to a better comprehension of the 
mutation rates and mutational mechanisms associated with ADPKD. The presence or 
absence of particular non-disease-causing polymorphisms may also correlate with 
clinical heterogeneity in ADPKD (Watnick et al., 1999). Some neutral polymorphisms 
may associate with particular disease-causing mutations displaying a similar phenotype, 
or they may influence phenotypic heterogeneity between family members with identical 
gennline mutations. Although for diagnostic purposes it is the detection of disease­
causing mutations that is of primary concern, all neutral polymorphisms should be noted 
for future consideration with regard to clinical heterogeneity and association with 
particular disease-causing mutations. 
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Table II.4(a). N on-disease C au sing M issense C hanges D etected in PKDJ 
Neutral Missense Chanf!e Location Reference 
4406T/A- W/RI399 Exon IS Thomas et al., (1999) 
4406T/C- W/R1399 Exon IS Watnick et al., (1999) 
S568Cff - PILI 786 Exon 15 T homas et al., (1999) 
6I95G/A- R/HI995 Exon 15 Phakdeekitcharoen et al., (2000) 
7347 A/G - Y/C2379 Exon 17 Perrichot et al., (2000b) 
7386G/C - R/P2392 Exon 17 Watnick et al., (1999) ## 
7479C/T - S/F2423 Exon 18 Watnick et al., (1999) ## 
7853G/C - E/02548 Exon 19 Watnick et al., (1999) 
7956C/T -T/M2582 Exon20 Bouba et al., (2001) 
8021G/A-D/N2604 Exon 20 Phakdeekitcharoen et al., (2000) 
8124A/G- H/R2638 Exon 21 Watnick et al., ( I 999) 
8231C/T- P/S2674 Exon 22 Rossetti et al., (2001) 
8334C/T-T/M2708 Exon 22 Rossetti et al., {2001) 
841 lC/A- P/T2734 Exon 23 Rossetti et al., (200 I) 
8415A!T- Q/L2735 Exon 23 Rossetti et al., {2001) 
8S04C/T -R/C2765 Exon 23 Rossetti et al., (2001) 
85S6G/A- V/M2782 Exon 23 Rossetti et al., (2001) 
8651G/A- G/R2814 Exon 23 Rossetti et al., (200 I) 
8873C/G -R/G2888 Exon23 Rossetti et al., (200 I) 
89240/ A -V /12905 Exon23 Rossetti et al., (200 l) 
90190/C - E/D2966 Exon 24 Rossetti et al., {2001) 
912SG/A-D/N2972 Exon 24 Bouba et al., (200 I) 
9235G/ A - V /M3008 Exon 25 M izosru chi et al., {200 I} 
9406GT/CC- F/L3066 Exon 25 Peral et al., (1997) 
9407T/C - F/L3066 Exon 25 Perrichot et al., (2000b) 
9627G/T- G/V3139 Exon 27 Perrichot et al., (2000b) 
9789C/T - P/L3 l 93 Exon28 Perrichot et al., (2000b) 
10737C/T - T/M3S09 Exon 35 Peral et al., ( 1997). 
I 0743C/T - A/V35 l l Exon 35 Peral et al., ( 1997). 
10893G/A- S/N3S61 Exon 36 Perrichot et al., (1999) 
12168C/G - A/G398S Exon 43 Badenas et al., (1999) 
12341 A/G - I/V4044 Exon 44 Rossetti et al., (1996) 
I2384C/T - AIV4058 Exon45 C onstantinides et al., ( 1997) 
12777C/T- S/F4189 Exon46 Peral et al., (1997) 
## Watnick et al., (1999). Onl y found in affected members with aneurysm ( may be a 
pol ymorphism associated with disease phenotype). 
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Table H.4(b). Neutra l Po lymorph isms Detected in PKDJ 
Polvmorohism Location Reference 
487G/A-A92 Exon2 Rossetti et al., (2001) 
1023Cff ( l 234Cff) - A34 l * Exon5 Thomas et al., ( 1999) 
1330T/C - L373 Exon5 Rossetti et al., (2001) 
1420C/T-H403 Exon6 Rossett i et al., (200 I) 
1921Cff- H570 Exon 7 Rossetti et al., (200 I) 
2694A/C (2905A/C)- A898* Exon I I Thomas et al., ( 1999) 
27000/ A (2911 G/ A) - P900* Exon 11 Thomas et al., ( 1999) 
2730Cff (2941Cff)- D910* Exon 11 Thomas et al., ( 1999) 
291 lG/A - P900 Exon 11 Watnick et al., ( 1999) 
2941Cff- D910 Exon 11 Watnick et al., (1999) 
g.25134Cff IVS 11 Thomas et al., ( 1999) 
2972T/G (3 l 83T/G) - V991 * Exon 12 Thomas et al., (1999) 
3274T/C - 01021 Exonl3 Watnick et al., (1999) 
3111A/G (3322A/G) - L l037* Exonl3 Thomas et al., (1999). 
3372Cff (3583Cff) - Al 124* Exon 15 Thomas et al., ( 1999) 
3375Cff (3586Cff) - SI 125* Exon 15 Thomas et al., ( 1999) 
3864C/T (4075Cff) - H1288* Exon 15 Thomas et al., ( 1999) 
46350/A (48460/A)- Kl545* Exon 15 Thomas et al., ( 1999) 
4876A/C - AI555 Exon 15 Watnick et al., (1999) 
4885G/A-Tl558 Exon 15 Watnick et al., (1999) 
5383Cff - TI 724 Exon 15 Watnick et al., (1999) 
5359C/T (5570Cff)- L1787* Exon 15 Thomas et al., (1999) 
5485Crr (5696Cff) - LI829* Exon 15 Thomas et al., ( 1999) 
57630/A (59740/A) - L l921 * Exon 15 Thomas et al., (1999) 
6058Cff - S 1949 Exon 15 Phakdeekitcharoen et al., (2000) 
7 l 38Cff - 02309 Exon 16 Perrichot et al., (2000b) 
71470/A-A2312 Exon 16 Rossetti et al., (200 I) 
IVS 16-9 GIA IVS 16 Perrichot et al., {2000b) 
73450/f - V2378 Exon 17 Watnick et al., (1999) ## 
7376TIC- L2389 Exonl7 Watnick et al., (1999) 
IVS 17 -27 CIA IVS 17 Perr ichot et al., (2000b) 
IVS 17 - 10 CIA IVS 17 Perrichot et al., (2000b) 
7652Cff - L2472 u Exon 18 Watnick et al., (1999) 
7652Cff - L248 l Exon 18 Perrichot et al., (2000b) 
7696Cff - C2495 Exon 18 Phakdeekitcharoen et al., (2000) 
7919T IC - L2570 Exon 20 Watnick et al., (1999) 
8002A/G - P2597 Exon 20 Bouba et al., (2001) 
8446T/G - S2745 Exon 23 Watnick et al., ( 1997) 
8650C/f -S2813 Exon 23 Rossetti et al., (2001) 
8890C/G - S2893 Exon 23 Rossetti et al., (2001) 
9124T/C- A.2971 Exon 24 Watnick et al., (1997) 
9159 + 14A/G IVS 24 Watnick et al., (1997) 
IVS 24 - 17 A/G IVS 24 Perr ichot er al., (2000b) 
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91750/A - A2988 Exon 25 Perrichot et al., (2000b) 
g.38997C/A-L2995 Exon 25 Mizoauchi et al., (2001) 
94060/e - V306S Exon 25 Watnick er al .• (1997) 
9481 err - v3090 Exon 26 Perrichot et al .• (2000b) 
9541T/e- P31 l0 Exon 26 Peral et al., (1997) 
98800/ A - T3223 Exon 28 Peral et al., ( 1997) 
IVS 31 +7 NG IVS 31 Perrichot et al., (2000b) 
IVS 34 +20 GIA IVS 34 Perrichot et al., (2000b) 
948 I err - v3090 Exon 36 Koptides et al., (2000) 
1076Serr- L3589* Exon 36 Aguiari et al., (2000) 
(10976err) 
10976C/A - L3589 *** Exon 36 Perrichot et al., ( 1999) 
is this L3589M 
or I0976err L3589 
�.47848err IVS 36 Mizoauchi et al., (2001) 
g.47853dele IVS 36 Mizoszuchi et al., (2001) 
108690/A P3623* Exon 37 Aguiari et al., (2000) 
(110800/A) 
g.48085err IVS 37 Mizoszuchi et al., (2001) 
g.48205e/G IVS 37 Mizoauchi et al., (2001) 
11364+ 13 G> A IVS 38 Perrichotetal, (1999) 
11477 +17de114 IVS 39 Badenas et al., (1999) 
115210/A-A337I Exon 40 Rossetti et al., (200 I) 
g.485090/ A -L3674 Exon 38 Mizoauchi et al., (2001) 
L3753 Exon 39 Tsuchiya et al., {200 l) 
115840/e - S3791 Exon 40 Peral et al., ( 1996b) 
g.496370/A IVS 40 Mizoauchi et al., (200 I) 
IVS41 +2ins3 °0 IVS 41 Koptides et al., (2000) 
IVS4 l +8ins3 IVS 41 Aszuiari et al., (2000) 
g.49833err IVS 41 Mizoro.ichi et al., (2001) 
g.49942T/G IVS 41 Mizoszuchi et al., (2001) 
g.49942T/G IVS 41 Mizoauchietal, (2001) 
g,50075G/A-E3871 Exon 42 Mizoauchi et al., (200 I) 
g.50493C/A-A3910 Exon 43 Mizoauchi et al., (2001) 
I2124Crr- R3971 Exon 43 Perrichot et al., (1999) 
I2184C/G - A399I Exon 43 Badenas et al., (1999) 
123070/C - L4032 Exon 43 Badenas et al., (1999) 
12212 - 34C/A IVS 43 Daniells et al., (1998b} 
12211 + 37ins5 IVS 43 Badenas et al., ( 1999) 
12346 +19de1G IVS 44 Daniells et al., (1998b) 
12485C/G - A4091 *** Exon 45 Perrichot et al., (1999) 
(L4092V) 
or l2483C/G-A409IG 
12271A>T/G/C-A4091 * Exon 45 Aguiari et al., (2000) 
( 12484A>T/G/C) 
12617Crr - L4136 Exon 45 Badenas et al., (1999) 
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12652+ 34 G>T IVS 45 Perrichot et al., (1999) 
12838TiC - P4209 Exon 46 Peral et al., ( 1997) 
g.51659C/T-D4234 Exon 46 Mizoiruchi et al., (200 I) 
12444C/T- P4254* Exon 46 Aguiari et al., (2000) 
(12655Cfr) 
12973Cfr - P4254 Exon 46 Peral el al., (1996b) 
13133G>A 3'UTR Perrichot el al., ( 1999) 
131350/A 3'UTR Badenas et al., ( J 999). 
13233A/G 3'UTR Badenas et al., ( 1999) 
13357T/C 3'UTR Badenas et al., (J 999) 
13364Cfr 3'UTR Badenas el al., ( 1999) 
133700/A 3'UTR Badenas et al., ( 1999) 
*Both Thomas et al., ( 1999) and Aguiari et al., (2000) published nucleottde positions 
(in bold) that do not correspond to the c.DNA sequence (Acc. L33243), the nucleotide 
positions that do correspond toL33243 are given in brackets. 
** Watnick et al., ( 1999). If 7652C/T is correct then amino acid sf,.,u)d read L248 I. If 
not the c.DNA position maybe 7625C/T. 
0• Perrichot et al., (1999) published 2 polymorphisms 10976C/A and 12485C/G where 
the corresponding amino acid change is unclear. 
uu Koptides el al., (2000) list IVS41 +2ins3 as neutral, Perrichot et al., (2000a), cite 
the same variation as disease-causing, no RNA work was performed. 
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Jl.4. Genotype-Phenotype Correlation in Single-Gene Disorders 
11.4.i. Phenotypic Variation 
A topic of particular interest is why some families, or individuals within families, are 
severely affected by a monogenic inherited disease whilst others are not. It is important 
to understand what is happening at the molecular level in order to ascertain if any 
prediction of disease outcome is possible and, if so, how to establish a course of 
treatment which may prevent, delay or minimise the onset of particular symptoms. 
Understanding the mode of action of specific mutations will also contribute towards a 
more coherent picture of gene structure and protein function (Waters el al., 1998). The 
prevalence of ADPKD in the general Japanese population has been estimated at I in 
4,000, approximately one quarter of that in Caucasians (Higashihara el al., 1998), 
whereas the prevalence diagnosed at autopsy in Japan is about 1 in 400 (Higashihara el 
al., 1998). This discrepancy suggests that a large proportion of ADPKD individuals do 
not progress to ESRF during their lifetimes (Higashihara et al., 1998). The less severe 
clinical phenotype does not correspond to fewer families Jinked to PKDJ (Wang et al., 
1995), so there must be other mechanisms, apart from locus heterogeneity, which 
control phenotypic variation in this population. In addition to the genotype associated 
with a disease gene, other modifying factors, both genetic and environmental, must be 
considered when comparing disease phenotypes (Dipple & McCabe, 2000). 
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11.4.ii. Genotype-Phenotype Correlation Studies 
Genotype-phenotype correlations have been investigated in many Mendelian diseases. 
Examples include phenylketonuria (PKU) (Ledley, 1991; Scriver et al., 1996; Waters et 
al., 1998); cystic fibrosis (The Cystic Fibrosis Genotype-Phenotype Consortium, 1993; 
Zielenski & Tsui, 1995; Ferrari & Cremonesi, 1996); adrenoleukodystrophy (Dodd et 
al., 1997; Smith et al., 1999); spinal muscular atrophies (Brahe & Bertini, 1996 ); 
inherited peripheral neuropathies (Nelis et al., 1999); breast cancers associated with 
mutations in the BRCAJ and BRCA2 genes (Weber, 1998; Presneau et al., 1998), and 
Marfan Syndrome (Ramirez et al., 1999). Genotype-phenotype correlations have not 
yet been reported for PKDJ. Any significant trends in phenotype variation, associated 
with particular types of mutations and located in regions of the gene corresponding to 
various protein domains, will be discussed in Chapter VII. Possible genetic factors 
contributing to phenotypic expression include locus heterogeneity, mutation 
heterogeneity (including complexities such as compound heterozygosity, the presence 
of double mutant alleles and neutral variants), and the genotypes of modifying genes. 
Examples of how each of these factors may affect the disease phenotype are outlined 
below. 
II.4.ii.(a). Locus Heterogeneity 
There are numerous conditions that are classified clinically as one disorder but which 
are in fact caused by mutations in different genes. A few examples of such conditions 
and their associated genes are tuberous sclerosis (TSC/ or TSC2), inherited breast 
cancer (BRCAJ or BRCA2), and hereditary non-polyposis colorectal cancer (hMSH6, 
PMS2, hMLHJ, hMSH2 or TGFBR2). One condition displaying a particularly high 
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level of locus heterogeneity is retinitis pigmentosa, with 14 loci so far associated with 
the clinical phenotype (http://www.ncbi.nlm.nih.gov/Omiml). 
As previously stated, PKD2 is generally associated with a milder phenotype than PKDJ. 
Ravine er al. (1992), found that non-PKDJ patients lived longer than PKDJ patients, 
had a lower risk of hypertension and progression to ESRF, and had fewer renal cysts at 
the time of diagnosis. A more recent multi-centre study reviewed the differences 
between the two phenotypes by comparing 333 people with ADPKD linked to the 
PKDJ gene (33 families) and 291 people with the PKD2-linked disease (31 families) 
with 398 matched controls (Hateboer et al., 1999b ). It found that the median age at 
death or at ESRF was 53 years in PKDJ-affected individuals, 69 years in PKD2-
affected individuals and 78 years in normal controls (Hateboer et al., 1999b ). 
Il.4.ii.(b}. Mutation Heterogeneity 
The position and type of mutation within a gene may be used to predict its effect on 
gene expression. A missense variation that is not predicted to alter protein structure 
would not be expected to be associat�d with a severe phenotype, whereas a large 
deletion or early truncation resulting in loss of function could have severe 
consequences. For example, the first mutation detected in ADPKD was a deletion of 
most, if not all, of the PKDJ gene (European PKD Consortium, 1994). This type of 
deletiora is associated with very early onset ADPKD and a particularly severe phenotype 
(Brook-Carter et al., 1994; Longa et al., 1997; Harris, 1997). The HPA 
(hyperphenylalaninaemia) gene has a large number of mutations similar to PKDJ. 
More than 300 mutations have been identified in HP A and the associated phenotype 
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ranges from classical PKU, with impaired cognitive development, to non-PKU HP A, 
with a low risk of mental retardation (Waters et al., l 998). 
Complex genotype-phenotype correlations exist m cystic fibrosis, with over 900 
mutations found in the CFFR gene (http://www.genet.sickkids.on.ca/cftr/). While there 
is no obvious correlation between the genotype and the severity of most CF symptoms 
(The CF Genotype-Phenotype Consortium, 1993), there is a general correlation with 
respect to long-term pancreatic sufficiency involving a group of mutations (The CF 
Genotype-Phenotype Consortium, 1993). The CFFR model was first proposed by 
Riordan et al, ( 1989) and consists of two portions each with similar nucleotide binding 
folds (NBD1 & 2) that connect via a regulatory domain, plus a membrane-spanning 
domain which forms a channel pore. CF patients who display pancreatic sufficiency 
generally have mutati, .s which are found outside the NBDl domain, whereas the most 
severe phenotypes are often associated with a cluster of mutations in the NBD1 domain 
(Nousia-Arvanitakis, 1999). 
The emerging mutational pattern in ADPKD is that of a large number of private 
mutations confined to individual families, thus complicating the identification of 
molecular defects and the study of genotype-phenotype correlations. An additional 
factor that will impact on the feasibility of genotype-phenotype correlations is the lack 
of clinical detail in many published mutation studies (Daniells et al., 1998a & 1998b; 
Roelfsema et al., 1997; Thomas et al., 1999; Afzal et al., 1999; Thongnoppakhun et al., 
1999 & 2000; Rossetti et al., 2001), and in the mutation database (Ki·awczak & Cooper, 
1997). 
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No specific mutation has been associated with a particular phenotype, however, large 
deletions of the PKDJ gene with involvement of the TSC2 gene have shown a pattern of 
severe early onset renal disease (Hanis, 1997). Another example of pbenotypic severity 
associated with a particular mutation has been reported in three unrelated families with 
the same deletion (c.5224del2) in exon 15 of PKDI (Watnick et al., 1999). The three 
families formed part of a group of 35 families who were chosen for the study because 
they each had some individuals with either very early onset of disease symptoms or 
cerebral aneurysms. The biased selection of the study group does not allow the 
conclusion that c.5224del2 in PKDI is invariably associated with a phenotype 
associated with early disease onset or cerebral involvement. 
The most frequently occurring mutation in the PKDI gene is a nonsense mutation in 
exon 44 (Q4041 X), which has been detected in four families to date (Turco et al., 1995; 
Torra et al., 1998; Daniells et al., I998b). The number of affected people in the 
families are, however, too small to permit a significant genotype-phenotype 
comparison. The phenotype details associated with Q4041X are outlined in Table II.5. 
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Table 11.5. Phenotype associated with Q4041X 
Reference Family Ethnicity Sex and Age at Other 
details age CRF/ESRF/ symptoms 
death 
Turco ct al .. ( 1995). VR4001 Italian #I female ESRF 56 Hepatic cysts 
deceased Death 68 
5 affected 
members #2 male CRF39 Hypertension 
39 years 
#3 female ESRF 70 Hcpallc cysts 
72 years 
#4 male ESRF 42 Hepatic cysts 
48 years Transplant 45 
#5 female Normal renal Hepatic cysts, 
34 years function hypertension 
Torra et al .• ( 1998) PR43 Spanish #1 malr CRF (n/a) Hepatic cysts, 
(This includes Ox 1433 39 years hypertension 
detected by Peral ct al .. 3 a1Tccred 
1997). members #2 male ESRF (n/a) (n/a) 
deceased death age 42 
#3 female CRF (n/a) (n/a) 
42 years 
Ox 1433 British Maie age CRF (n/a) Hypertension 
(I member 60 years 
adopted, 
no 
children) 
Daniells ct al .. ( 1998b) Family69 Caucasian (n/a) {n/a) (n/a) 
No details (Welsh) 
Rossetti et al.. (200 I) I cnta) (n/a) (n/a) (n/a) (n/a) 
(n/a - no details available. age at death given is due to ESRF). 
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11.4.ij,(c). Compound Heterozygotes and Double Mutant Alleles 
Many individuals affected by single-gene disorders carry two different mutations, one 
on each homologous chromosome. Such individuals are tenned compound 
heterozygotes. It has not been possible to make genotype-phenotype correlations for 
PKU compound heterozygotes, as the phenotype variation is too complex (Scriver, 
1995). 
A further complication can occur when a double mutant allele is present, with two 
mutations on the same chromosome. This can lead to three (or theoretically even four) 
different mutations in the same gene in one individual contributing to the phenotype in 
conjunction with other modifying factors. A number of examples have been shown, 
including cystic fibrosis (Savov er al., 1995; Steffann et al., 1998; Fanen et al .. 1999), 
homocystinuria ( de Franchis et al., 1999), and Marfan syndrome (Wang et al., 1996b ). 
As ADPKD is inherited in a dominant manner, it seems improbable that a large number 
of compound heterozygotcs could exist. Mutation detection of cystic epithelial cells 
has, however, revealed somatic as well as gennline mutations present in both the PKDJ 
and PKD2 genes. The mutational mechanism associated with this is the "two-hit 
model" (Knudson, 1971) (see section Il.3.i). The phenotypic variability in ADPKD 
could be partially attributable to the two-hit model of mutation, with a combination of a 
germline muta:ion and variable somatic mutations. This is more complex than the 
phenotypic variability associated with different compound heterozygotes for PKU 
mutations (Scriver, 1995) as variable somatic mutations are found in the same 
individual. 
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11.4.ii.Cd}. Neutral Variants 
Neutral variants are non-disease-causing polymorphisms which occur in the disease 
gene of interest. Whilst they alone do not appear to cause the disease, it is not yet 
known how or if different combinations of variants could affect phenotypic severity. It 
should be remembered that many genes harbour an array of polymorphisms. The P AH 
(Phenylalanine hydroxylase) locus (100 kb) associated with PKU has at least 18 single 
nucleotide polymorphisms (SNPs), eight bi-allelic restriction fragment length 
polymorphisms (RFLPs), and two multi-allelic sites (Scriver & Waters, 1999). The 
individual polymorphisms and their corresponding haplotype structures, along with 
allelic variation in the 5' untranslated region of the gene, may influence gene 
transcription and expression (Scriver & Waters, I 999). 
No conclusion has been reached as to how neutral variation may (or may not) influence 
the phenotype of ADPKD. However, a paper by Watnick et al. ( 1999) proposed that the 
combined effect of a number of apparently "neutral" missense substitutions could result 
in a pathogenic "hypennorphic" allele. For example, mutations in the SOD] gene are 
usually associated with the autosomal dominant condition familial amyotrophic lateral 
sclerosis (F ALS). There is a polymorphism in this gene (090A) which, in the 
heterozygous state, produces no clinical effect, but homozygmes for the change display 
the clinical phenotype (Andersen el al., 1995). It will be important to record all 
polymorphisms detected in the PKDJ gene in a designated database in order to test this 
hypothesis in the future. Even if the hypermorphic allele is not disease-causing, the 
polymorphic variation may act as a modifying factor. Thus it would be advantageous 
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for future studies if such a database contained detailed phenotypic information along 
with specific genotype, i.e. both the mutations and the non-disease causing 
polymorphisms found in the PKDJ gene. 
II.4.ii.(e). Modifying Genes 
The specific genotype of a disease gene is not the only factor which influences gene 
expression and phenotype severity. Gene interactions can be expected to have a 
functional effect. For example, phenotypic severity in CF has been difficult to correlate 
with the CFfR genotype. In a CFfR murine model (cftr°11Hsc/cftr°11Hsc), little lwig 
involvement is displayed but an intestinal obstruction similar to the meconium ileus 
observed in human infants with CF is present (Rozmahel et al., 1996). A possible 
modifying gene has been reported in these mice, localised close to the centromere on 
mouse chromosome 7, where several genes are possible candidates for the modulation 
of disease severity (Rozmahel et al., 1996). A region of synteny exists between this 
region and human chromosome 19qI3 (Rozmahel et al., 1996), which was 
demonstrated to harbour a similar hwnan CF modifier gene (Zielenski et al., 1999}. 
Several possible modifying genes involved in ADPKD have been examined, including 
the genes fowid in the renin-angiotensinogen-aldosterone system (RAS) proposed as the 
widerlying cause of hypertension in ADPKD (Chapman et al., 1990). A modifying 
factor of particular interest is the insertion/deletion polymorphism at the locus for the 
angiotensin I-converting enzyme (ACE) polymorphism, associated with cardiac 
pathology such as myocardial infarction and angina (Behn et al., 1993; Caulfield et al., 
1994; Nakai et al., 1994), and left ventricular hypertrophy (Schunkert et al., 1994; 
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Prasad el al., 1994 ). The deletion allele of this polymorphism has been implicated in an 
earlier age at onset of ESRF for individuals with diabetic nephropathy (both IDDM and 
NIDDM), lgA nephropathy (Doria et al., 1994; Yoshhida et al., 1995), and 
nephroangiosclerosis (Mallamaci et al., 2000). Three independent studies on the ACE 
polymorphism and ADPKD have suggested that individuals homozygous for the 
deletion allele (0/0) are at increased risk of early onset of ESRF compared to their I/0 
counterparts (Baboolal et al., 1997; Perez-Oller et al., I999;Van Dijk et al., 1999). The 
poor prognosis was not invariably associated with a higher tendency towards the 
development of hypertension, however, an association between the 0/0 genotype and 
the occurrence of microalbuminuria has been reported (Van Dijk el al., 1999). A recent 
study on ADPKD individuals from Australia, Bulgaria and Poland found no relationship 
between ADPKD severity and ACE in terms of plasma enzyme activity and 1/0 
genotypes (Schiavello et al., 2001}. 
II.4.iii. Environmental Factors 
Environmental factors need to be considered when assessing the genetic contribution to 
the phenotype. For example, in the PiZZ form of a-1 antitrypsin deficiency some of the 
phenotypic variation with respect to lung involvement reflects smoking behaviour 
(Scriver & Waters, 1999). Another major environmental modifying factor to be 
considered is diet. In some diseases, such as PKU or hypergalactosemia, the exclusion 
of certain foods (containing phenylalanine or galactose respectively) from the diet 
prevents the onset of clinical symptoms. As illustrated in a-1 antitrypsin deficiency, 
life style choices and exposure to toxins and carcinogens can also contribute to 
phenotype. In the case of Gorlin's syndrome, a hereditary predisposition to nevoid 
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basal cell carcinomas (Gorlin, 1995), levels of UV radiation due to sun exposure may 
impact on the severity of the skin cancer phenotype. 
The effect of dietruy intake of protein on the rate of decJine of glomerular filtration rate 
was investigated in a study population of 200 participants with ADPKD (Klahr et al., 
1995). Specifically, protein was restricted in the diet and blood pressure was controlled 
with the use of anti-hypertensive medication. Lower protein intake, but not prescription 
of a keto acid-amino acid supplement, was marginally associated with a slower 
progression of renal disease (Klahr et al., 1995). ADPKD patients often consider a low­
protein diet to delay the onset of renal failure (Maroni, 1998; Zarazaga et al., 2001 ), 
however, this is not mandatory and depends on advice from clinicians. A recent study 
by Davis et al. (200 I), suggests that the use c,f tyrosine kinase inhibitors combined with 
future gene therapy techniques may prove more effective than low protein diets and 
traditional anti-hypertensive medication. 
11.4.vii. The importance of Genotype-Phenotype Studies for ADPKD 
Genotype-phenotype correlations for ADPKD will not be possible with any degree of 
accuracy until many mutations have been detected. All new mutations, along with the 
respective phenotypes, give further information as to how truncating mutations and 
missense changes relate to protein function and subsequent pathogenesis. Where intra­
familial variation is observed, the study of modifying factors will lead to a better 
understanding of how the PKD genes interact with other genes in the same pathway in 
the control of normal epithelial cell function, and how environmental factors can 
influence cystic proliferation. If genotype-phenotype correlations are established, it will 
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be possible to more reliably predict disease outcome and perhaps to establish if a certain 
course of treatment could delay the onset of particular symptoms for some patients, i.e. 
getting the right drugs to the right people. 
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III. Methodology 
Ill. Methodology (Part I) 
Ill. l Literature Review of Methodology 
Many screening techniques are available for mutation detection and all rely on the basic 
premise that they should be simple, accurate, time-efficient, economical and sensitive. 
The choice of mutation detection method depends on a number of factors. The 
necessary equipment must be available and many techniques require a high degree of 
laboratory skill to yield maximal detection rates. In addition, the nature of the gene 
screened must also be considered. If mutations in the gene of interest are 
predominantly truncating, as seen in the dystrophin gene (Krawczak & Cooper, 1997), a 
method such as the protein truncation test (PIT) would be suitable. In contrast, if a 
significant proportion of the mutations are missense, as found in CFfR (Krawczak & 
Cooper, 1997), the conventional PIT would then not be applicable. The size of the 
template and its relative GC content must also be taken into account. Single-strand 
conformation polymorphism (SSCP) analysis as a mutation screening method has been 
shown to be cheap and efficient but only when PCR fragments are of optimal length 
(200 to 400 bp) (Orita et al., 1989; Savov er al., 1992). 
Mo�eover, the quality and specificity of template influences the efficiency of all 
mutation detection screening techniques and sequencing methods. Jn the case of PKDJ 
this is particularly important when trying to screen for mutations in the 5' duplicated 
region of the gene. 
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Ill, Li. Pre-Screening Methods 
Prior to screening, most techniques require the amplification of gene products using the 
polymerase chain reaction (PCR) (Saiki er al., 1986). The nature of the PKDI gene 
makes it technically challenging to amplify because of a high G-C content and the co­
amplification of homologous gene transcripts. Strategies employed to produce a PKDJ­
specific template for mutation detection of the duplicated region are discussed here and 
novel strategies are presented in section 111.5. 
General techniques to improve the specificity of PCR include the addition '.'r' PCR 
enhancers (Kramer & Donald, 1999). In addition to the basic PC..t<. mix, enzyme­
stabilising proteins including BSA (bovine serum albwnin) or gelatine, and enzyme­
stabilising solvents e.g. glycerol, are routinely included (Kramer & Donald, 1999). 
Enzyme-stabilising solutes e.g. betaine, and solvents such as dimethyl sulphoxide 
(DMSO) have been shown to dramatically reduce non-specific priming events by 
decreasing inter- and intra-strand reannealing (Winship, I 989). Tetramethylammonium 
chloride (TMAC) has also been used as a PCR enhancer (Hung et al., 1990). 
Commercially available PCR additives such as Q-solution (QIAGEN) and the 
Advantage-GC™ PCR Kit (Clontech) can increase reaction specificity. 
III. I.ii. DNA Screening Techniques. 
111.1.ii.{a). Single-Strand Conformation Polymorphism Analysis 
Single-strand conformation polymorphism (SSCP) analysis detects single base 
substitutions. It relies on the assumption that changes in nucleotide sequence affect the 
confonnation of PCR product when it has been convened into its single-strand forms by 
heating and then snap-chilling the PCR products in fonnamide- or DMSO- based 
73 
loading buffers. The single-strand DNA is fractionated through a polyacrylamide gel 
under non-denaturing conditions, hence its altered electrophoretic mobility (Orita et al., 
1989). 
This is one of the techniques most commonly used for mutation screening since it is a 
relatively simple procedure and gives rapid results. The length of PCR fragments that 
can be analysed by SSCP does, however, restrict the usefulness of the method. It was 
initially believed that SSCP was limited to testing PCR products of less than 200 bp 
(Orita et al., 1989). Subsequently, it has been reported that, by increasing the 
percentage of the acrylamide gel, SSCP can screen PCR products greater than 400 bp in 
length (Savov et al., 1992). Even with this increased length, the technique can be 
restrictive when large genes are involved, due to the numerous products that need to be 
analysed. The sensitivity of the method in detecting mutations must also be considered; 
in a blind trial on the CITR gene it has been estimated to be as high as 84% (Jordanova 
et al., 1997). Methods to improve the sensitivity of SSCP include using a variety of 
cross-linking ratios, by altering the acrylamide:bisacrylamide ratio of the gel. In 
addition to conventional polyacrylamide gel, a number of commercial gels (such as the 
MOE gel solution, BMA, Rockland, ME) are also available. The use of 5-10% glycerol 
in the running buffer has also helped to increase SSCP sensitivity. The theory behind 
this modification was explained by Kukita et al. (1997), who found that TBE buffer 
with glycerol maintained a relatively low pH (8.1 or less) with improved separation of 
mutant fragments of up to 800 base pairs. 
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In addition to the electrophoretic conditions of SSCP, the gel visualisation technique 
can also influence the sensitivity of the method and detection rates. Radiolabelling of 
DNA, by end-labelling one of the PCR primers, has traditionally been used to allow 
visualisation by autoradiography (Nataraj et al., 1999). For simplicity and ease of 
handling silver-staining is often the method of choice, although it is not always as 
sensitive as radiolabelling (Budowle et al .• 1991). When a high throughput of samples 
is required, SSCP using fluorescently-labelled primers on automated capillary 
sequencers can be used (Larsen et al., 1999). Running times on conventional gels can 
be improved using fluorescent scanners with dyes/stains such as SYBR Gold 
(Molecular Probes) (Tuma et al., 1999). 
111.1.ii.{b). HDA, CSGE, DGGE and DHPLC. 
Other electrophoretic gel-based screening techniques, akin to SSCP in their simplicity 
and dependence upon confonnational change, include heteroduplex analysis (HOA) 
(Nagamine, et al., 1989; White et al., 1992), conformation sensitive gel electrophoresis 
(CSGE) (Ganguly et al., 1993), and denaturing gradient gel electrophoresis (DGGE) 
(Fischer & Lennan, 1979). HOA works on the principle that mismatched DNA 
duplexes, i.e. heteroduplexes, have an altered electrophoretic mobility compared to 
homoduplexes (White et al., 1992). Heteroduplexes form when PCR products from a 
heterozygote template re-anneal and can be distinguished from homoduplexes by 
electrophoresis. The conformation changes which result from single base pair 
alterations (a bubble-type) can be much more difficult to detect by this method than a 
small deletion or insertion (bulge-type) (Battacharyyu & Lilley, 1989). HDA has been 
used to detect mutations in the unique and duplicated regions of PKDJ (Table Vil. I, 
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p252). Mutation detection rates can improve when a combination of HOA and SSCP 
are used, e.g. with the neurofibromatosis type 1 gene (NFJ) (Abernathy, et al., 1997). 
CSGE is a modification of HOA with 15% fonnamide and 10% ethylene glycol used to 
emphasise confonnational differences (Gangtily et al., 1993). 
DOGE works on the principle of partial melting of double-stranded DNA in 
polyacrylamide gels (Fischer & Lennann, 1979). In the presence of urea and 
fonnamide gradient, DNA which is A:T-rich denatures more readily than G:C-rich 
reg;(ms, thus altering the electrophoretic mobility of the DNA (Fischer & Lermann, 
1979). If the sample is heterozygous, the four possible homoduplex and heteroduplex 
species formed during PCR amplification melt at different rates to produce four bands 
on the polyacxylamide gel, compared to the one band seen in the wild-type control 
(Cotton, 1997). If, however, the DNA is homozygous for a particular sequence 
variation it produces only one band, which is different to that seen in the wild-type 
homozygous specimen. Mutations in PKDJ have been detected using DOGE, although 
the method generally requires significant optimisation and can be difficult to use 
because of the high GC content of the gene (Perrichot et al., 1999). 
Denaturing high performance liquid chromatography (DHPLC) involves the liquid 
chromatography of PCR products through a column containing alkylated nonporous 
particles (Hayward-Lester et al., 1996; Liu et al., 1998a). Due to a lower binding 
capacity, heteroduplexes display reduced column retention time relative to 
homoduplexes. DHPLC is highly sensitive for fragments between 220 to 445 bp 
(Arnold et al., 2000). A disadvantage of the technique is that relatively expensive 
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equipment is required for DHPLC and mobile phase temperatures must be calculated 
with regard to GC content for all PCR fragments screened (Liu et al., 1998a). 
111. l .ii.(c}. Dideoxyfinget:printing 
This method is a hybrid of SSCP and Sanger dideoxyfingerprinting (Sarkar et al., 
1992). Sanger sequencing reactions, performed in forward and reverse directions using 
only one dideoxy terminator, are subjected to non-denaturing gel electrophoresis. 
Mutations present in the sequencing reaction can be detected in the dideoxy component 
of the reaction because of a gain or loss of a dideoxy tennination segment. Since this 
gain or loss could be masked by the normal allele, the method is further enhanced by 
the inclusion of a SSCP gel fractionation reaction, which can detect a shift in mobility 
of at least one of the termination segments that follow the mutation (Blaszyk et al., 
1995). The strength of this assay is therefore in the ability to generate a spectrum of 
fragments for modified SSCP analysis, thus increasing the sensitivity of SSCP. 
Improvements to the technique have been made by increasing the length of fragment 
screened from about 250 bp up to 500 bp, through Bi-directional dideoxy fingerprinting 
(Bi-ddF). Two simultaneous cycle sequencing termination reactions are performed in 
the down- and upstream. directions, using only one dideoxy tenninator and two labelled 
primers (Haavik et al., 1996; Liu et al., 1996). The most recent update to the protocol, 
denaturation fingerprinting (dnF2R), is suitable for screening regions with a high GC 
content and utilises DOGE and Bi-ddF with two dideoxy tenninators (Liu, et al., 
1998b ). During the course of the Human Genome Project, relative direct sequencing 
costs have fallen. Sequencing is now the first choice of many researchers. 
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III.1.ii.(d). Mismatch Cleavage Methods 
Enzymatic mismatch cleavage (EMC) is another mutation detection screening test 
which, as its name suggests, utilises the properties of specific enzymes to cleave 
double-strand heteroduplex DNA at sites of mismatch (Kleff & Kemper, 1988). A T4 
Endo VII-based mutation detection kit, the PASSPORT Mutation Scanning Kit 
(Amersham, Pharmacia Biotech), is now commercially available ( lnganas et al., 2000). 
In EMC, heteroduplex DNA is formed when an excess of mutant DNA is mixed in the 
same tube with wild-type DNA, melted, and then allowed to re-anneal. The technique 
has been shown to detect all 4 possible types of mismatched bases with up to 95% 
efficiency (Youil et al., 1995). As it can screen in excess of I kb (Forrest et al., 1995), 
it may be preferable to SSCP in terms of the number of reactions required to screen 
large genes. 
A similar technique to EMC is referred to as chemical mismatch cleavage (CMC),which 
was developed as a modification of the Maxam-Gilbert DNA sequencing method 
(Cotton et al., 1988). Mismatched thiamines are susceptible to modification by osmium 
tetroxide and mismatched cytosines by hydroxylamine. The modified bases are then 
cleaved by piperidine treatment. Unfortunately, osmium tetroxide is a noxious 
chemical, and for this reason the use of CMC has been somewhat limited (Taylor & 
Deeble, 1999). 
Ill. 1.ii.(e). DNA Sequencing 
In addition to its capacity in characterising sequence variations indicated by other 
screening techniques, DNA sequencing can also be used as a direct screening technique. 
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Sequencing can be perfonned using traditional single-strand manucl dideoxy 
sequencing and radio-labelling (Sanger et al., 1977 & 1980; Gyllensten & Erlich, 1988), 
or thennal cycle sequencing (Murray, 1989). 
The first approach can be undertaken in two ways. The traditional Sanger sequencing 
method used the Kienow fragment (large subunit of DNA polymerase I} to synthesise a 
short complementary copy from specifically primed DNA template (Sanger et al., 
1977). This was performed with radiolabelled dATP and then transferred into four 
separate reaction tubes, each containing all four dNTPs and a specific ddNTP. This 
approach failed to sequence the first 50 or so bases from the primer. Alternatively, a 
labelling/tennination method could be perfonned (Tabor & Richardson, l 987), where 
asymmetric PCR products are used as template for the sequencing reactions. Primers 
are annealed to the template and radiolabelled dNTPs are incorporated into the 
sequencing reactions using T7 polymerase. For both methods, sequencing reactions are 
denahtred then loaded in adjacent lanes of denaturing polyacrylamide gels. Thermal 
cycle sequencing is less cwnbersome to perform, as fluorescent primers can be used and 
only one reaction tube per sample is necessary (Murray, I 989). 
A dideoxy cycle sequencing reaction is performed when template, primer, dNTPs, 
ddNTPs and a thermostable polymerase are subjected to repeated rounds of 
denaturation, annealing and synthesis. Most commercially available sequencing kits for 
automated sequencing now use fluorescently labelled dideoxynucleotide terminators, 
relying on fluorescence imaging systems for detection. For example, the Applied 
Biosystems Incorporated (ABI) Prism Dye terminator chemistry provides a robust non-
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isotopic method of sequencing on an automated sequencer (Kwok et al., 1994). DNA 
sequencing technologies have improved rapidly during the course of the Genome 
Projects. Advancements and modifications include the invention of high-throughput 
sequencers, the use of dideoxy-terminators labelled with energy transfer dyes (BigDyes) 
(AB1), and combination of the annealing and extension steps of sequencing reactions. 
The new chemistry has increased peak heights and allowed greater sequencing accuracy 
(Wen, 2001). 
III. I .iii. RNA Screening Technigues. 
Another cle.;vage-bascd method of mutation screening is non-isotopic RN Ase cleavage 
(NIRCA) (Goldrick et al., 1996 ), developed as a modification to ribonuclease cleavage 
(Myers et al., 1985). NIRCA works on the principle that duplex RNA targets, up to I 
kb in length, are cleaved by RN Ase at their site of base pair mismatch (Goldrick et al., 
1996 ). The mismatched substrates are generated by ir. vitro transcription, and PCR or 
RT-PCR (Reverse Transcription-Polymerase Chain Reaction) amplification is 
performed using primers with bacteriophage RNA polymerase promoters ro 
subsequently generate large quantities of RNA from both strands (Goldrick et al., 
1996 ). Complementary wild-type and mutant transcripts are hybridised and incubated 
with RN Ase. Cleavage products are subjected to electrophoresis and geis are visualised 
by ethidium bromide staining (Goldrick e1 al., 1996). Mutations in PKDJ have been 
detected using this method (Peral et al .. 1997). 
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Ill, J .iv. Protein Screening Techniques. 
TI1e protein truncation test (PTT) is usually based on a combination of RT-PCR coupled 
to in vitro transcription and translation, and is used to selectively detect translation­
terminating mutations (Roest et al., 1993), it can also be perfonned on DNA from 
within large exons. PTT is an appropriate mutation screening method for disorders 
where the majority of mutations result in premature translation termination. The PTT 
comprises 4 main steps: (i). RNA is isolated from peripheral blood lymphocytes or 
other tissue, with the assumption that it is processed in an identical manner to the target 
tissue; (ii). it is then reverse transcribed tc c.DNA; (iii). c.DNA (or DNA if used) is 
amplified by PCR; (iv). the PCR product is used as template in a 'nested PCR', 
performed with an inner primer containing a T7-promoter and a eukaryotic translation 
initiation sequence at the 5' end. This extra sequence allows a single tube in vitro 
transcription and translation of the PCR products. The coupled T7 RNA polymerase 
transcription and rabbit reticulocyte lysate system (Promega ™) results in the 
incorporation of [35S] methionine or other radio-labelled amino acids into the nascent 
peptides. The translation products are then fractionated by polyacrylamide gel 
electrophoresis (SDS-PAGE), and visualised by autoradiography (Roest et al., 1993). 
Truncated protein products resulting from premature termination are shorter than the 
normal protein product and migrate more quickly through the gel. Size markers are 
used to estimate the length of a truncated protein and automated sequencing can then be 
performed in the region where a mutation is expected. Although this method can only 
be used when the disease gene is prone to translation-terminating mutations, it is 
particularly useful if the gene is large and has many exons. PTT has been successfully 
81 
used to detect mutations in products varying in length from 971 to 5,131 bp (Roest et 
al .• 1993), including PKDI (Roelfsema et al., 1997; Peral et al., 1997). There is a 
limitation associated with this technique, as it can fail to detect mutations in the 
presence of nonsense-mediated mRNA decay. This limitation can be reduced by 
combining the RT-PCR/PTT protocol with the preincubation of cells in cyclohexamide 
to stabilise the mutant RNA (Bateman er al., 1999). 
III. I. v. Comparison of Mutation Detection Methods. 
A recent study by Yuan et al. (1999) using the Marfan syndrome FBNJ gene (encoding 
a 2,871-aa protein) and the hepatocellular carcinoma P53 gene (encoding a 393-aa 
protein) compared SSCP/HDA, EMC and direct sequencing in tenns of cost and 
efficiency. When labour and reagents were taken into account SSCP/HDA was the 
cheapest method with a cost of US$865.84 per patient, compared to US$1585.82 per 
patient for EMC. and US$l 74 l .02 per patient for direct sequence analysis. 
The detection efficiency of the three methods varied. Although SSCP/HDA was the 
cheapest method of mutation screening, four of the twenty control mutations tested 
remained undetected (80% detection rate); three of these mutations were contained in 
PCR fragments greater than 400 bp in size (Yuan et al., 1999). When the direct 
sequencing method was performed with primers in only one direction two mutations in 
FBN I were missed, this represents a 90% detection rate. Missed mutations were 
claimed to be due to fluorescent background interference (Yuan et al .• 1999). When the 
samples were re-amplified and directly sequenced in both directions, the mutations were 
duly detected, the sequencing chemistry used was not described (Yuan et al., 1999). All 
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20 mutations were detected by EMC. A criticism made by the authors rc:garc!ing EMC 
was that considerable time and effort were needed for initial optimisation. Pre­
diagnostic optimisation would increase the cost of the analysis when compared to other 
more widely practised methods (Yuan et al., 1999). 
Tnere is a lack of literature on cost and efficiency analyses of different screening 
methods, although individual studies provide approximate rates of efficiency/detection 
with various genes. A detection rate of almost I 00% has been reported using DGGE 
after the design of specific primers and the addition of GC clamps (Lerman & 
Silverstein, 1987; Theophilus et al., 1989; Fodde & Losekoot, 1994). NIRCA has beeu 
estimated to have a detection rate of 80-90% (Taylor & Deeble, 1999). A 100% 
detection rate was achieved using ddF to on the hwnan factor IX gene (Sarkar et al., 
1992) and the P53 gene (Blaszyk et al., 1995). It is difficult to estimate the overall 
efficiency of mutation detection with PIT as it can only be used to detect truncating 
errors. The PTT detection rate in NF/ (nueurofibromatosis gene) has been reported at 
47.l % (40/85) (Fahsold et al., 2000). As 80% of mutations in the NFJ gene are 
estimated to be truncating, if this is considered, the relative detection rate of PIT for 
truncating mutations increases to 58.8% (40/68) (Fahsold et al., 2000). 
It can be assumed that the choice of screening technique for any particular mutation 
detection study must be the one that is expected to achieve a high detection rate and is 
available within a given budget. Since no screening technique can offer 100% 
accuracy, and sequencing costs are becoming lower, many researchers are choosing 
direct sequencing rather than preliminary screening techniques. 
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III.1.vi. Amplification of PKDI without Homologous Gene (HG) contamination 
Methods to prevent the co-amplification of the HGs when screening for mutations in the 
duplicated region of PKDJ are swnmarised in Table lll.2. They include: (l ) 
"anchored" primers in the unique region of the gene for long-range amplification into 
the duplicated area (Watnick et al., 1997; Peral et al., 1997; Kopndes et al., 1998; 
Thongnoppakhun et al., 1999); (2) the PIT method (Roelfsema et al., 1997); or (3) 
design of PKDI specific primers (Watnick et al., 1999; Thomas et al., 1999). 
Amplifications from primers anchored in the unique sequences of PKDJ into the 
duplicated region of the gene have been successful from exon 34 to primers located 
upstream of exon 23. It was not considered possible to perform long-range 
amplification of genomic DNA from exon 34 further 5' of ex.on 23 as IVS22 contains 
the longest polypyrimidine tract (approx. 2.5 kb) found in any human gene (Van Raay 
et al., 1996). Most researchers have fowtd it impossible to amplify across the tract to 
include exons upstream of exon 23. 
The design of PKD/-specific primers for use in the duplicated region has been difficult 
due to a lack of sequence information on the HGs. Although some sequence 
information has been produced, the Human Genome Project has not completed 
characterisation of the entire chromosome 16 region where the HGs lie. To solve this 
problem, sequences in the 5' region of PKDJ unique to that gene were sought, so that 
appropriate primers could be designed. It has been shown that the HG identity with 
PKDJ does not span the entire 5' region (Watnick er al., 1997). BAC (bacterial 
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artificial chromosome) libraries can be screened by PCR to locate clones (or "pools" of 
clones) containing DNA inserts that amplify with the primers of interest. 
BACs can be used for cloning large inserts of DNA ranging from 100 to 300 kb 
(Monaco & Larin, 1994 ). Clones consist of a bacterial vector with a stretch of foreign 
insert DNA (Shizuya el al., 1992). There is little chimaerism associated with BACs, so 
insert DNA is expected to originate from a single source of continuous DNA (Monaco 
& Larin, 1994 ). This implies that when the clones in a BAC library are screened for 
PKDI sequences, some may correspond to the PKDI gene and others to one or more of 
the HGs. No single BAC clone could contain both PKDJ and the HGs, as these 
sequences are physically too far apart on chromosome 16. 
BAC libraries are arranged in 96-well microtitre plates and correspond to particular 
chromosomes. The super-pool plates have DNA from eight individual clones pooled 
together per well. A detectable product indicates that one or more of the clones in the 
super-pool plate contain the specific insert of interest, so corresponding pool plates can 
then be screened to determine which clones are of interest. Clones are then obtained as 
glycerol stocks, cultured, and the DNA is extracted. This DNA originating from PKDJ 
or the HGs (but not both) is sequenced, and variations in DNA sequence can be used to 
design PKDJ specific primers. 
III. I .vii. Methodology specific to ADPKD 
Most studies of mutations in the PKDJ gene have screened only the 3' unique region 
(Table III.I). The groups that report mutations in the duplicated region (Table III.2) 
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have used slightly different strategies to prevent co-amplification of the HGs and detect 
mutations in PKDJ . 
Table Ill.I. Mutation Screemng of DNA in Exons 34 to 46 of the PKDJ Gene. 
Screening Method Reference Mutations detected/ ADPKD 
SSCP 
HDA 
HDA&SSCP 
DHPLC&SSCP 
DGGE 
PTT & Direct Sequencing 
RT-PCR&PTT 
Grand Total 
Peral et al., (1996b) 
Peral et al., (1996a) 
Neophytou et al., (1996) 
Torra et al., (1997) 
Daniells et al.. ( l 998b) 
Badenas et al., (1999) 
Afzal et al., (1999) 
Kim et al. , (2000b) 
Peral et al. , (1995) 
Turco et al. , (1995) 
Rossetti et al. , (1996) 
Aguiari et al., (2000) 
Turco et al. , (1997) 
Mizoguchi et al. , (2001) 
Perrichot et al. , ( 1999) 
Perrichot et al., (2000a) 
Rossetti et al. , (2001) 
Roelfsema et al., (1997) 
Individuals tested 
2/45-6/ 150 
l family only 
1/14 
1 family only 
5/147 
7/175 
4/90 
6/91 
Total = 31/669 
2/ 130 
1/20 
1/67 
3/40 
Total = 8/257 
3/60 
Total= 3/60 
4/176 
Total = 4/176 
8/146 
additional 3/ 146 
Total = 11/146 
6/ 131 
Total = 6/131 
1/20 
Total= 1/20 
Grand Total== 64/1459 
(4.4%) 
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Table 111.2. Mutations Detected in the Duplicated Region of the PKDJ gene. 
Screening Reference Mutations Exons Screened 
Method** Detected/Tested in Duplicated 
(& Template) Individuals PKDJ Region 
SSCP Koptides et al., (1998) 1 patient only Ex23-34 
(DNA) Watnick et al., (1999) 8/35 Exll-21 
Afzal et al., (2000) 3/90 Ex 23-34 
Koptides et al., (2000) 1 patient only Ex 23-34 
Bouba et al., (2001) 8/53 Ex 16-34 
Phakdeekitcharoen et al., 19/54 Ex 1-34 
(2000 & 200 I) 
Total= 40/234 
HDA Watnick et al., (1997) 8/80 Ex 23-34 
(DNA) 
Total= 8/80 
DGGE Perrichot et al., (2000b) 8/146 Ex 15-21 & 23-34 
(DNA) 
Total= 8/146 
PTT Roelfsema et al., (1997) 6/135 Ex 15 &23 
(in vitro 
translated) Total= 6/135 
PTT &NIRCA Peral et al., (1997) 6/95 Ex 22-46 
(RT-PCR) 
Total= 6/95 
PTT &Direct Rossetti et al., (2001) 51/131 Ex 1-34 
Sequencing 
Total= 51/131 
Direct Sequencing 
DNA Thomas et al., (1999) 7/24, Ex2-15 
RNA Thongnoppakhun et al., 1 patient only Full length RNA 
(2000) 
Total= 8/25 
Grand Total Grand Total= 
127/846 (15.0%) 
**Screening was usually performed on dilute XL-PCR PKDJ-spec1fic template, from pnmers 
anchored in the unique region of the gene or by using sequences in the duplicated region 
specific to PKDJ. 
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The European PKO Consortium ( I 994) first reported mutations in the duplicated region 
of PKDJ, although they did not specifically screen for 5' mutations. Rather, they were 
able to confirm that the PBP (Polycystic Break Point) gene was the PKDJ gene 
following the discovery of a total deletion in a Portuguese family. Three additional 
aberrant transcripts were then detected in PKDJ, namely a 2 kb deletion between exons 
31-34, a 5.5 kb deletion from exon 32 to the 3'UTR, and a splicing mutation in IVS 44. 
The first study to specifically screen for mutations in the 5' region used PTI' to detect 
six truncating mutations in P KD I exons 15 and 23 (Roelfsema el al., 1997). On the 
assumption that the HGs were transcribed but not translated (European PKD 
Consortium, 1994), only the PKDJ protein product was screened by PTI and the HGs 
were not translated (Roelfsema el al.. 1997). The approach was somewhat limited 
because amplification required exonic primers, and only the larger exons of PKDJ, e.g. 
15 and 23, could be screened using genomic DNA as template. In addition, missense 
mutations, which may account for approximately 30% of mutations in the duplicated 
region of PKD (see Chapter II). would not be detected by PIT (Roelfsema et al., 1997). 
Peral et al. ( 1997) also used a combination of PIT and NIRCA to detect six mutations 
in cDNA templates amplified by RT-PCR. The 2.4 kb template was amplified with a 
PKDJ-specific primer in the unique region of the gene (exon 34) and a forward primer 
in the duplicated region (exon 22). 
Most groups have used genomic ON A as template for mutation screening. Anchored 
PKDJ-specific primers in the unique 3' region were used with primers which extend 
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into the repeat region of the gene for Jong range amplification (XL-PCR), followed by 
various screening methods (Watnick et al., 1997; Peral et al., 1997; Koptides et al., 
1998 & 2000� Perrichot ei al., 2000b; Afzal ei al., 2000; Phakdeekitcharoen et al., 2000 
& 2001; Bouba et al., 2001). The PKDJ-specific XL-PCR amplified product was 
diluted {> 1: 10-4) prior �u re-amplification, with nested primers to overcome the 
problem of any residual genomic contamination by HGs from the initial PCR 
amplification (Watnick et al., 1997). 
The first two groups to detect PKDJ mutations between exons 2 to 5 and 11 to 21 of the 
PKDI gene used XL-PCR from PKDJ-specific primer sites in IVSl and exon 15 
(Thomas er al., 1999; Watnick et al., 1999). Long-range PCR products were then 
diluted and used as template for the amplification of individual exons. Specific PKDJ 
primers were designed by comparing the known PKDJ sequence to a BAC clone 
(GenBank AC002039) that contained 2 copies of the HGs (Loftus et al., 1999). 
More recently two groups (Rossetti et al., 200 I; Phakdeekitcharoen et al., 2001 ), 
reported screening the entire duplicated region of the PKDJ gene. In the Rossetti study, 
51 mutations were detected between exons 1 to 34 from 13 i individuals tested with a 
combination of the PTT and direct sequence analysis. Phakdeekitcharoen et al. (2001) 
compared the PKDJ sequence to the published sequence of HGs 1 & 2 (Loftus et al., 
1999), in order to design PKDJ-specific primers sites. From these results they were 
able to amplify exons I to 34 as eight XL-PCR fragments. Exon 22 was amplified as a 
separate exon to avoid amplification across its surrounding polypyrimidine tracts. XL-
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PCR fragments were then diluted (> I: IO"") and used as template in nested-PCR 
followed by SSCP analysis. 
One group has reported the first long-range RT-PCR of the entire coding sequence of 
the PKDI gene (Thongnoppakhun et al., 1999), with the XL-PCR cDNA template 
diluted I 000-fold prior to nested PCR to avoid HG contamination. This lead to the 
discovery of a splice-acceptor site mutation, in IVS 13 of PKDI, by direct manual 
sequencing (Thongnoppakhun et al., 2000). 
Afzal & Jeffery (2001), recently reported the XL-PCR amplification ofa 13.S kb PKDI 
fragment between exon 34 and IVS2 J. An amplification of this type from genomic 
DNA was previously believed to be impossible, due to difficulties involved in 
extending amplification over the 2.5 kb polypyrimidine tract in IVS 22 (Van Raay et 
al., 1996). The present study was not able to replicate the results for this amplification. 
If this XL-PCR amplification could be performed routinely, it would allow full 
screening of the PKDI gene between exons 22 and 34 without HG i'.lterference. 
PJtematively, other strategies could be developed which permit the amplification of 
PK.DI without co-amplification of the homologous genes. Either way, it would mean 
that more mutations could be detected throughout the gene and a significant genotype­
phenotype correlation study would be possible. Outcomes of this type of research 
would lead to a greater understanding of the mechanisms of mutation in ADPKD, the 
function of polycystin-1, its possible pathways and interactions, the disease 
pathogenesis, and the wide-ranging phenotypic variability found in ADPKD. 
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Ill. Methodology (Psrt II) 
m.2-7, Subjects and Methods 
111.2, Additional Protocols 
Additional methods used in this project may be found in Appendix A. Details of 
protocols relevant to the thesis, accompanied by the various solutions used, are 
presented in that section. 
IIJ,3 Subjects 
111.3.i, Sample Collection and Preparation Prior to Analysis 
Researchers other than this candidate undertook the preliminary set-up of the �•,,dy, 
phenotypic data and clinical samples were collected. genomic DNA from peripheral 
blood was extracted, and linkage analysis studies were performed. Results of this work 
were made available to this candidate. Except where specifically indicated, the author 
conducted all further practical work and statistical analyses. 
Genomic DNA or blood spots from patients tested as part of this project were obtained 
from three collaborative studies. Australian, Bulgarian and Polish families were 
recruited for a multi-centre study investigating the genetic and environmental factors 
involved in ADPKD. Families were ascertained through the patient regisuy at the 
Department of Nephrology, Royal Perth Hospital (RPH), Perth, Western Australia; the 
haemodialysis centres at the Departments of Nephrology in Plovdiv and Pleven, 
Bulgaria; and the Depdrtment ofNephrology, Jagiellonian University, Krakow, Poland. 
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The diagnosis of ADPKD followed standard u!trasonographic criteria first describ.:d by 
Bear er al. ( ! 984 ). then further refined by Ravine et al. ( J 994 ). The same diagnostic 
protocol was used in all three countries. When patients gave informed consent to 
participate in the study. they were invited for interview at the various centres and 
familial and clinicai histories were established. Infonnation on the nnture and pattern of 
inheritance of the disease was provided to patients with prdimimuy genetic counselling, 
additional counselling was available if requested. A pedigree was constructed for each 
patient and questionnaires on genetic, clinical, dietary and lifestyle factors were 
administered. The results of these questionnaires, in combination with clinical tests, 
provided the basis of the phenotypic information made available to this candidate. All 
index patients were requested to invil� family members to participate in the study, and 
most families responded positively with affected and unaffected (or unknown status) 
individuals agreeing to join the study. The information gathered from patients included 
general questions, such as date and place of birth, ethnic origin, number and disease 
status of family members. This was followed by specific clinical questions on diagnosis 
and reason for examination, first symptom (and what that symptom was), onset of 
hypertension, CRF, and ESRF, details of kidney transplantation, occurrence of extra­
renal cysts and other extra-renal symptoms. The ages at which these events occurred 
were a1so noted. 
To ensure confidentiality, a numbering system, rather than family name was used to 
identify all participant data and biological samples in the study. Clmical data y.,ere a1so 
obtained from medical records with patients consent. These data included ultra:.ound 
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findings, blood pressure values, and biochemical analyses including serum creatinine 
levels, plus the type and severity of symptoms at diagnosis and at subsequent visits. 
Linkage analysis was performed when possible by Ms Tina Schiavello (Centre for 
Human Genetics, Edith Cowan University, Perth, Australia), Prof Joachim Hallmayer 
(University of Western Australia, Perth, WA) and Dr Nadja Bogdanova (Institute of 
Human Genetics, Westfiilische Wilhelms-Universitiit (WWU), Munster, Germany), 
results of their work were made available to this candidate. Using this information, it 
was possible to screen those families who had ADPKD most probably linked to the 
PKDJ gene on chromosome 16, thus increasing the chance of mutation detection. 
Observed minimum and maximum LOD scores in those "positively" PKDJ-linked 
families ranged from 0.3-1.8 and all families had a probability of linkage to PKDI of 
0. 9 or greater using the methods described by Hateboer et al. ( 1999b ). 
The study populations consisted of 26 families from Bulgaria, 19 from Australia and 7 
from Poland. In addition to the 19 Australian families, 31 Australian ADPKD index 
patients of unknown linkage status were included for direct sequence analysis of exons 
44-46 of the PKDJ gene. 
Genomic DNA samples were either extracted from peripheral whole blood or blood 
spots, or made available as a blood spot on filter paper. The DNA extractions of whole 
blood were performed by Dr Bogdanova and Ms Schiavello using a salt precipitation 
method (Miller et al., 1988), and DNA from blood spots was extracted using a 
phenoVchloroform method (Sambrook et al., 1989). 
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l11e extracted genomic DNA was measured by UV-light spectrophotometry at 260run to 
detennine its concentration and to assess DNA purity. Stock solutions were stored at 
-70°C, and working DNA solutions were prepared at concentrations of 50ng/µJ and 
lOng/µI and stored at 4°C. 
It was possibie to directly PCR amplify fragments of 200-400 hp in length of genomic 
DNA from blood spot filter papers without prior extraction. A blood spot 
(approximately 3 mm in diameter) was cut from th1: filter paper and placed into the PCR 
reaction tube. An extra 5µ1 of ddH20 was added to the 25µ1 total reaction volume to 
replace the 5µ1 volume of DNA typically used. This type of PCR was only perfonned 
on some family members who were unable to provide whole blood samples for analysis. 
All index patients in the study donated whole blood for DNA extraction. 
lil.4. Mutation Detection of PKDJ - 3' Unique Region 
The region spanning exons 34 to the 3'- UTR of PKDJ is unique to the gene, therefore 
co-amplification of homologous genes was not a problem. However, PKDJ is GC-rich 
and some exons required a high degree of optimisation prior to successful amplification, 
after which mutation screening was perfonned using SSCP analysis. Any variations 
detected in SSCP banding patterns were further investigated by direct sequencing. 
Where possible, suspected disease-causing sequence variants were tested for familial 
segregation. 
Mutations not resulting in premature truncation, i.e. missense variants and in-frame 
deletions and insertions, were subjected to secondary protein structure programs such as 
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the PHDsec algorithm (Rost et al., 1994) or nnPredict (BCM HTfP address) in order to 
predict their likely effect on protein structure. Evolutionary conservation of DNA 
sequence variations was assessed with BLAST (http://www,ncbi.nlm.nih,gov/BLASTD 
or Pfam (http://www.sanger.ac.uk/Software/Pfam/). Phenotypic data for recurrent 
mutations and mutations in identical protein domains were compared between and 
within families. 
III.4.i. Polymerase Chain Reaction 
PCR was used to amplify genomic DNA for the individual exons in the unique region 
of the PKDI gene. The basic amplification reagents are detailed below (Table 111.3) 
and specific primers and conditions to each amplification reaction arr .i sted in Table 
III.5. 
Table 111.3 PCR Amplification Reagents. 
PCR Reaction Mix (xl volume) 
Reagent {cone.) 
Template genomic DNA ( lOnglµl) 
IOX Buffer 
MgCh(SOmM) 
1.25mM each dNTPs 
Forward Primer (60nglul) 
Reverse Primer (60nglul) 
Taq Polymerase (5.5U/µl)* 
ddH20 up to 25 µI 
Total Volume 
Volume 
5.0µ1 
2.5µ1 
0.8µ1 
4.0µ1 
0.5µ1 
0.5µ1 
0.2µ1 
11.5µ1 
25µ1 
Final Cone. 
2nglµl 
xi 
l.6mM 
200µ.M each/rxn 
l.2ng/µI 
l.2nglµl 
0.044U/µl 
(*Unless stated standard Taq DNA Polymerase and accompanying IOX Reaction Buffer 
for PCR were purchased from Life Technologies-Gibco BRL or QIAGEN). 
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Examples of the thermocycling conditions for PCR are given below (Table III.4), exon 
specific conditions are listed in Table Ill.5. Unless othenvise stated, all PCR reactions 
have three cycling steps (denaturation, annealing and extension). A two-step PCR 
indicates the same temperature for both the annealing and extension steps. 
Table 111.4. PCR Cycling Steps 
30 cycles at 65°C (3-step_) 
95°C for 3 mins xi 
65°C for l mins 
72°C for 2 mins }x30 
95°C for 0.5 mins } 
65°C for I min x l  
72°C for 7 mins xi 
35 cycles at 68°C (2-step} 
95°C for 3 mins XI 
68°C for 2 mins } 
95°C for 0.5 mins }x35 
68°C for 7 mins x l  
Despite repeated attempts to PCR amplify exon 42, a specific product for this region 
could not be generated. The various primers used are listed in Table III.6. In addition 
to the routine PCR reaction mix, additives such as DMSO, BSA plus gelatine, betaine, 
Q-solution (QIAGEN) and Perfect-Match PCR enhancer (Stratagene), and altered 
cycling conditions with annealing temperatures ranging from 55°C to 68°C were also 
evaluated. A series of buffer solutions (A-0 see Appendix A) with differing MgCh 
concentrations were also unsuccessful in generating the expected amplification product. 
Attempts to amplify a product of 82lbp across exon 42 (from exon 41 to exon 43) was 
also unsuccessful, even after employing nested PCR 
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T bl III 5 PCR f P KD 1 U . a e . . 0 mque reg :10n 
Exon Primers Annealing Size (bp) Genomic 
Temperature & of Product Position 
Special Conditions (L39891) 
34 F 5' gtgagctggggtgagaggag 3' 65°C (X 30) 240 44276-295 
R 5 · acggctgcctggcctgagtc 3 · (BSA & Gelatine) 44496-515 
35 F 5' ctgcaactgcctcctggagg 3 ' 68°C (X 35) 219 47330-349 
R 5' agctcacagggaggggctag 3 · 2-step 47530-549 
36 F 5 · ctgtgagctgcctctcacag 3 ' 63°C (X 30) 286 47541-560 
R 5' cccgtgatggaggcctgtag 3' 47807-826 
37 F 5' ggtaggctacaggcctccat 3 · 68°C (X 35) 299 47801-820 
R 5' ggagacaagagacggaggtg 3 ' 2-step 48080-099 
38 F 5' caaagccctgctgtcactgt 3 ' 64°C (X 30) 272 48439-458 
R 5' cctagggtctggctggacta 3 · 48691-710 
39 F 5' gtctctggtggccgctcact 3 ' 68°C (X 35) 259 48929-948 
R 5' agagctccgctaaaggctgc 3 · 2-step 49167-187 
40 F 5' gagctggccagcaggaaaca 3 · 68°C (X 35) 264 49330-349 
R 5' ctcccttgtccttggcgtaga 3 · 2-step 49573-593 
41 F 5 · cgtctacgccaaggacaagg 3 ' 68°C (X 35) 355 49571-590 
R 5' tggctgaggggctgtggaag 3' 2-step 49906-925 
42 Failed to amplify despite 
repeated attempts 
43 F 5 · cagcgtccctcccgccctcctga 3 · 60°C (X 40) 383 50381-403 
R 5'gcttgcagccctggggtgtgcgc 3 · 4%DMSO 50741-763 
& 10% SM Betaine 
44 F 5 · caccccagggctgcaagcag 3 · 68°C (X 35) 292 50746-765 
R 5 · acgctccagagggagtccac 3 ' 2-step 51018-037 
(3A3 C2 EPKDC, 1994)* 
45 F 5 · cgtcttagctcagctcagct 3 ' 65°C (X 30) 396 50946-965 
R 5' gtgtccctctcccccccact 3 ' 51322-341 
46 F 5 · gtgcagccggactgactgag 3 ' 68°C (X 35) 318 51361-380 
(a) R 5 · gctgctccagctggtagacg 3 · 2-step with TMAC 51659-678 
46 F 5' gaccgactcaaccaggccac 3 ' 66°C (X 35) 336 51633-652 
(b) R 5' cgtgcagccattctgcctg 3 ' 51950-968 
(PTI4, Peral 1997)** 
• Previous reference for exon 44 primer (3A3 C2) European Polycyst1c Kidney Disease Consortium, 
(1994). 
•• Previous reference for exon 46 primer (PTI -4 reverse) Peral et al. (1997). 
97 
Table IIL6. Exon 42 Amplification Primers 
Primer Description Primer Sequence Genomic Size of 
Position Product 
Initial Exon 42 Forward 5' cttccacagcccctgagcca 3' 49906-925 358 bp 
Reverse 5' ctgcgaggggtgagacgctg 3' 50244-263 
Exon 41- Exon 43 Forward 5' agctgcacaactggctggac 3' 49789-808 821 bp 
(Peral et al., I 996b) 
Reverse 5' cgcacgaaacgggtccac 3' 50592-609 (Peral et al., l 996b) 
Nested Exon 42 Forward 5' ctgagccacgcctgcactgc 3' 49918-937 346 bp 
Reverse 5' ctgcgaggggtgagacgctg 3' 50244-263 
III.4.ii. Agarose Gel Electrophoresis 
To confirm successful PCR amplification and the absence of primer-dimer 
contamination, 5µ1 aliquots of all PCR products in Ficoll loading buffer were loaded on 
a 2% agarose gel containing Ethidium Bromide (0.5µg/ml). Electrophoresis was 
performed in wide Mini-Sub™ cells (BIO-RAD), with gels (15 x 10 x 0.7cm; 2 x 20 
wells) run in 1 x TAE buffer at a constant 80V for 40 to 60 mins. A suitable size 
marker (eg. lOObp DNA ladder, Gibco BRL) was also loaded on to the gel to ensure 
that the amplified products were of the expected size. After electrophoresis, the gels 
were visualised on a bench-top UV -transilluminator (Mighty Bright UV -
transilluminator, Hoefer Instruments), and a polaroid photograph or digital image was 
taken as a permanent record. 
fll.4.iii. Single Strand Confonnation Polymorphism Analysis 
Single strand conformation polymorphism analysis (SSCP) was chosen as the method 
for mutation screening of the unique region of PKDJ. After testing different cross-
linking ratios, it was determined, that a 12% Polyacrylamide gel (acrylan1ide cross-
linked with bis-acrylamide at a ratio of 29: 1) was the most suitable for SSCP as 
previously reported (Savov et al., 1992). Gels were poured between vertical BIO-RAD 
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glass plates (using the BIO-RAD gel pouring stand) to produce a gel size of 16cm x 
16cm x 0.5cm, with a 16-well comb. When polymerised, gels were assembled on the 
PROTEANT"' II xi Vertical Electrophoresis Cell apparatus (BIO-RAD). The running 
buffers were IXTAE or IXTBE (with 5% glycerol to prevent an increase in the pH of 
TBE over 7. 7) (Kukita et al., 1997). 
PCR products (2µ1 aliquots) were prepared for SSCP analysis by the addition of equal 
volumes of fonnamide loading buffer and made up to a final volwne of 61,11 with 
ddH20. Samples were denatured in a water bath at 95°C for two minutes and then 
placed immediately on ice prior to loading. Gels were electrophoresed at various 
temperatures between 4°C and 25°C. It was determined that gels run at 25°C gave the 
best resolution. 1be gels were run in the Protean™ apparatus for varying lengths of 
rime at different constant voltages (see Table Ill.5 for exon-specific conditions) using a 
BIO-RAD power supply (PowerPac 1000). The voltage and time were considered to be 
optimal when a clear gel image was obtained by silver staining, and a good separation 
of bands had been achieved. 
The use of positive PKDJ mutation/polymorphism controls for SSCP optimisation was 
not possible, as prior to analysis we had no known sequence variants for any of the 
fragments screened. All fragments were electrophoresed in both IXT AE and IXTBE 
{+ 5% glycerol) as the sensitivity of these buffers occasionally seemed to vary between 
PCR fragments. In most exons, both buffers were equally useful (as listed in Table 
III.7), however screening results of the 263 bp fragment containing exon 40 indicated 
that different conformational changes were detected when the two buffers were 
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compared. Thus choice of running buffer should be considered when establishing 
SSCP running conditions for any fragment. 
The efficiency of the initial SSCP optimisation was later tested by comparing SSCP 
results with automated direct sequence analysis of the 3' unique region (see 
methodology III.4.viii). It was found that all disease-segregating mutations in the re-
screened sub-group detected by direct sequence analysis had been indicated in the initial 
SSCP screen (See Chapter V). However, a neutral polymorphism in a relatively large 
PCR fragment (396bp) was not detected by SSCP (See Chapter VI). 
Table 111.7. Exon-Specific SSCP Conditions 
Exon 12% PAG and Preferred Buffer Running Running 
Time Volta2e 
34 1 X TBE + 5% glycerol 8 hours 300V 
35 1 X T AE or 1 X TBE +5% glycerol 8 hours 300V 
36 1 X T AE or 1 X TBE +5% glycerol 14 hours 150V 
37 1 X T AE or 1 X TBE +5% glycerol 8 hours 300V 
38 1 X T AE or 1 X TBE +5% glycerol 6 hours 300V 
39 1 X TBE + 5% glycerol 8 hours 300V 
40 1 X T AE & 1 X TBE +5% glycerol 7 hours 300V 
41 1 X TBE + 5% glycerol 14 hours 150 V 
43 I X T AE or 1 X TBE +5% glycerol 15 hours 200V 
44 I X T AE or 1 X TBE +5% glycerol 7 hours 300V 
45 1 X T AE or l X TBE +5% glycerol 15 hours 200V 
46 (a)"' l X TAE + 0.1% SDS 7 hours 300V 
46 (b)"' 1 X T AE or I X TBE +5% glycerol 14 hours 200V 
Exon 46 is relatively long (- 1.5 kb) and was only amplified as 2 fragments that spanned the 
start of the exon to the start of the 3'-UTR (a & b). 
III.4.iv. Silver Staining 
After electrophoresis the SSCP pattern was visualised by a silver-staining procedure 
(modified from Budowle el al. , 1991) as detailed below. 
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Silver staining protocol 
I. The gel was placed in 10% Ethanol (EtOH) and gently agitated for 5 minutes before 
the EtOH was removed. 
2. The gel was then covered in I% nii.ric acid oxidising solution and agitated for 3 
minutes before rinsing in distilled water. 
3. The gel was placed in 0.1 % silver nitrate and agitated for 20 minutes. AgN03(aq) 
was then removed and the gel rinsed 3 times in distilled water for 2 minutes. 
4. A small amount of developer was added (sodium carbonate anhydrous 0.56M and 
0.04524% formaldehyde) until it just covered the gel. The gel was agitated and 
when the developer began to turn brown it was replaced with fresh developer and 
further agitated until an adequate signal appeared. 
5. When the staining was sufficiently intense to see the marker and SSCP bands, the 
gel was quickly rinsed in distilled water, drained and immediately covered in 10% 
glacial acetic acid for at least 10 minutes to stop further development of the signal 
and fix the silver stain. 
6. Acetic acid was drained and the gel covered in distilled water. 
Gels could be stored for one to two days in distilled water containing 5% glycerol, or 
dried overnight in cellulose film using the Gel Drying Kit™ from Promega. 
III.4.v. Single Strand DNA Ampiification 
When conformation changes were observed by SSCP, sequencing was performed to 
characterise the precise variation from the published sequence (GenBank Acc. L3989I). 
Manual isotopic sequencing was chosen as the sequencing method in the frrst instance, 
IOI 
as heterozygotes are easily characterised for autosomal dominant diseases such as 
ADPKD and, at the time of analysis, it was a readily available method. In later 
experiments when SSCP efficiency was evaluated, automated sequencing was 
performed. 
Prior to manual isotopic sequencing, a single-stranded DNA (ssDNA) template was 
prepared from double-stranded PCR product template by asymmetric amplification 
(Gyllensten & Erlich, 1988). The remaining PCR product, initially amplified for SSCP 
analysis, was purified to remove any excess primer or non-specific product prior to this 
procedure. QIAquick PCR purification kit (QIAGEN) was used as per the 
manufacturer's reconunendations and the clean dsDNA was eluted in 30µ1 of pure 
water (Appendix A). 
The primers used for this ssDNA amplification were the same as those already listed in 
Table III.5. The cycling conditions for each exon were retained for both the for.vard 
and reverse reactions, however the nwnber of cycles was increased to 40. The detailed 
protocol for ssDNA amplification (Table III.8) is an example of the forward reaction; 
reverse product was obtained with an excess of reverse primer. 
After amplification the product was concentrated and excess oligonucleotides were 
removed using Centricon™ centrifugal filter columns (Millipore, Centricon-30) as per 
manufacturer's recommendations (See Appendix A). 
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Table 111.S. Asymmetric PCR Amplification Reagents. 
Asymmetric PCR Reaction Mix (xi volume) 
Reagent (cone.) Volume 
Template DNA 1.0µ1 
10 x Buffer (with MgCh) 10.0µ1 
l .2 5mM dNTPs 1 6.0µ l 
Forward Primer (60ng/ul) 10.0µ1 
Reverse Primer (6ng/ul) 1.0µ1 
Taq Polymerase (5.SU/µl)• 0.5µ1 
ddH20 up to 100µ1 61.5µ1 
Total Volume 100µ] 
(The IO X Buffer and Taq polymerase were from Gibco BRL). 
Ill.4.vi. Isotopic Seguencing Reaction 
Final Cone. 
xi (l.SmM) 
200µ M each 
600ng 
6ng 
2.75U 
When SSCP analysis indicated a confonnational variation, fragments were directly 
sequenced in both forward and reverse directions using the oligonucleotide internal 
primers listed in Table.III. IO. 
Samples were rac:!iolabelled with [a-35S]-d ATP (Amersbam) for sequencing. This 
isotope was chosen in preference to [a-32P]-dATP, as its low energy .8 emissions result 
in relatively sharper autoradiographic bands. Although increased exposur� times are 
needed for autoracliography with 35S than 32P, its longer half-life means that sequencing 
products labelled with 35S can be stored for longer periods prior to electrophoresis, 
compared to those labelled with 32P. Users of 35S also are exposed to a lower dose of 
radiation than with 32P (Ausubel & Albright, Current Protocols in Molecular Biology 
Chp 7 suppl 26, 1994). The protocol for this method of sequencing is outlined in Table 
III.9. 
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Table 111.9. Isotopic Labelling Reaction. 
In microcentrifuge tube mix the following: 
ssDNA 10µ1 
2µ1 
2µ1 
Annealing buffer 
Sequencing primer (6ng/µI) 
Totai volume 14µ1 [Incubate at 80°C for 5 minutes and 
allow to cool to room temperature] 
A "master-mix" was prepared in a designated radioisotope laboratory in compliance 
with standard safety procedures. Use of a "master-mix" reduces the handling of 
radioisotope and minimises error from small volume pipetting. The volume of each 
reagent in the master-mix was equal to the volume for one sample multiplied by (n + I )  
where n was the number of samples. 
Preparation Qf_an Isotope Master Mix for LabeJJing 
Labelling Mix• ( 1 :5) 
ddH20 
[a-35S]-dATP ( lOµCi/µI) 
Total volume 
(X l volume) 
3.0µ1 
0.5µ1 
92.ul 
1.QiJl 
Add 4.0µ1 of isotope mix to the template mix and then add T7 DNA polymerase 
Template mix 14µ1 
Isotope mix 4.0µ1 
T7 Polymerase {l U/µ1) 2.0ul 
Total volume 20.0µJ 
Stand at room temperature for 5 minutes prior to sequencing reaction. 
* Labelling Mix* ( I :5) (Epicentre Technologies, Madiosn, WI, USA) 
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Table 111.10. Sequencing of P KD I Unique region 
Exon Primers (Forward and Reverse) Genomic Position (l,39891) 
34 5 ' caggctgctgagcaggtccg 3 ' R (reverse) 44428-44447 
(use with forward primed ssPCR product) 44299-44318 
5 ' gctctgaagctcacccttgc 3 ' F (forward) 
(use with reverse primed ssPCR product) 
35 5' gctacgcaagcacacctgtc 3 ' R 47498-47517 
5 · cgggatgaattcacagccta 3 ' F 4 7351-47370 
36 5' ccctggcagccccctcacct 3 ' R 4 7563-4 7582 
5 · ctgtctctgcttccccagga 3 ' F 4 7782-4 7801 
38 5' gtgcagctcctgcttgatgg 3 ' R 48595-48614 
5 ' accagagcctcctggtgtac 3 ' F 48496-458] 5 
39 5 · cacgccctgccagctca 3 ' R 49116-49132 
5 · gtgtgactgatgctgtggca 3 ' F 48981-48990 
40 5' cgtccccgagccattgtg 3' * * (FFR) R 49501-49518 
5 ' gggctctgtgtgtttcagca 3 ' F 49388-49407 
41 5 ' cctgttgtccagccagttgtg 3 · * * (NNR) R 49794-49814 
5 · gagtagttctccaggagtgc 3 ' F 49591-49610 
5 ' cacgccacccctctccggca 3 ' F 49667-49686 
44 5' ccgcgcagtcacctacca 3 ' R 50918-50935 
5 ' cagatttctcgtccgcaggct 3 ' F 50767-50787 
45 5 ' gggccgtacccacctcctt 3 ' R or 51303-51321 
5 'aggaacaactccaccatctcgtag 3 '* * (HHR) R 51242-51265 
5 'cagctcgtgtcttcctgtgt 3 ' F or 51000-51019 
5' ggctgggggctgttattctc 3 '* * (MMF) F or 51163-51182 
5' tctaccctgtgtcctgccgag 3 '* * (HHF) F 51078-51098 
46 (a) 5 ' gggagggctcaggctcacac 3 '* * (JJR) R 51575-51594 
5' gttccgccacaaagtccgct 3 ' F or 51398-51417 
5 ' tccgctttgaagggatggag 3 '* * (JJF) F 51412-51431 
46 (b) 5 ' ggactaagtgctgctggggt 3 ' R or 51850-51896 
5' caaggcggctgggcagtg 3 '** (KKR) 51760-51777 
** Previous reference (with primer name) from Peral et al. (1996b). 
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IHA,vii. Direct Seauence Analysis (Isotopic) 
111.4,vji.(a). Seguencins Reaction 
After radiolabelling of the ssPCR product, sequencing reactiofis were performed with 
termination mixes prepared as directed by the manufacturer (Boehringer Mannheim 
GmbH) for each of the 4 nucleotide-mixes (Table Ill. I I). 
Table IILl 1. Termination Mixes for Sequencing 
Reaeent A mix Cmix Gmix Tmix 
dATP 150umol/L lSOumol/L 150umol/L I501-1mol/L 
dCTP ISOµmol/L I50µmol/L I50umol/L 150umol/L 
(7-deaza) dGTP 150umol/L 150umol/L I SOumol/L I50umol/L 
dTIP I50µmol/L 150urnol/L lSOµmol/L 150wnol/L 
ddATP l Sumol/L 
ddCTP 15umol/L 
ddGTP ISumol/L 
ddTIP ISumoVL 
M�Ch IOmmol/L IOmmol/L lOmmol/L IOmrnol/L 
Tris-HCL pH 7.5 40mmol/L 40mmol/L 40mmol/L 40mmol/L 
NaCl 50mmol/L 50mmol/L SOmmo!/L SOmmol/L 
For each sample, four ( 1.5ml) microcentrifuge tubes were labelled (A, C, G or T) and 
3.5 µI of e!\ch respective termination mix were pipetted into the tube. These tubes were 
then placed in a heat block at 37°C and allowed to equilibrate for several minutes and 
4.Sµl of isotopically labelled sequencing mix was added. The reactions were allowed to 
undergo annealing and extension for five minutes at 37°C. The reaction was then 
stopped by the addition of 5µ1 of 95% (vol/vol) formamide/20 mM EDTA buffer. 
When all reactions had been stopped, tubes were stored at 4°C prior to gel 
electrophoresis (or at -20°C if electrophoresis did not occur within 24 hours). Reactions 
were run on 6% denaturing ( 6M urea. 1 x TBE) polyacrylamide gels within 48 hours of 
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sequencmg. Prior to electrophoresis, the sequencing reactions were heat denatured at 
95°C for five minutes and immediately placed on ice before being loaded on to the gel. 
III.4.vii.(b). Polyacrylamide Gel Electrophoresis for Manual Sequencing 
Electrophoresis was perfonned using a vertical gel apparatus system {Hoefer™ Poker 
Face II). Two clean glass plates, a 37x43cm back plate, and a Sigmacote™ treated 
(chlorinated organo;,olysiloxane in heptane, Sigma) 33x4 l cm top plate were assembled 
with a bottom spacer and side-spacers (0.4mm) and clamped together to prevent gel 
leakage prior to polymerisation. 
A denaturing 6M urea 6% polyacrylamide {19: l acrylamide:bis-acrylamide) gel 
solution {80ml) was prepared with 80 µI of TEMED {Sigma) and 800µ1 of 10% APS 
{ammonium persulphate, Sigma). The gel mix was poured between the plates, an 
inverted sharks-tooth comb was inserted and secured with clamps. The gel was allowed 
to polymerise for between forty minutes to two hours at room temperature. The clamps, 
bottom spacer and comb were then removed and the excess gel solution was wiped from 
the glass. The plates were assembled in the electrophoresis apparatus (Hoefer) with 
IXTBE buffer and the gel was pre-wanned at 68W constant power for 30 minutes. 
Prior to gel loading, excess urea was displaced from the well with buffer and the sharks­
tooth comb {64-wells) was ir,serted to fonn the loading slots. 
Denatured sequencing reactions (2.5µ1) were fractionated on 6% denaturing gels at 
68W constant power (BIO-RAD PowerPac 3000) for 2-3 hours at 45°C. Bands were 
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detected by autoradiography after the gel had been fixed and dried on Whatmann paper 
(3MM). 
III,4 .vii.(c). Autoradiography of Sequencing Gels, 
Dry gels were placed in autoradiographic cassettes and a sheet of X-OMAT 
autoradiographic paper (Kodak) was layed over the gel. The gels were exposed 
overnight at room temperature to X-OMAT films (or longer if the isotopic signal was 
weak) and developed through an automatic X-ray developing machine (Kodak). When 
developed, the films were examined over a standard white light box and a comparison 
was made between the resultant and the published sequence (see Fig III.I). 
Wild-type Mutant 
AC GT AC GT 
Arrow depicts a deletion of 
base G in the mutant 
sequence on the left. 
The autoradiograph above 
this position demonstrates 
the sequence frameshift after 
the deletion. 
Fig 111.1. Autoradiograph showing wild-type and mutant sequences 
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III.4.viii. Direct Automated DNA Sequencing. 
To evaluate the relative efficiency of SSCP, the amplified genomic DNA for PKDJ 
exons 44 and 45 from approximately 50 Australian ADPKD patients was screened by 
direct automated sequencing. Fifteen of these patients had been screened previously by 
SSCP and the sequence and SSCP results were directly compared. The same previously 
listed oligonucleotide primers and conditions (Table IIl.5) were used to prepare 
templates for sequencing and SSCP analysis. These primers were then used in forward 
and reverse dideoxy sequencing reactions. Sequencing was performed using the Big­
Dye ready reaction terminator cycle sequencing kit (Applied Biosystems Inc. Prism) for 
electrophoresis on the 377 Sequencer (Applied Biosystems Inc.). The recommended 
protocol was modified to a total volume of 1 Oµl. Approximately 20ng of clean double­
stranded template were used per reaction (Table 111.12 ). 
Table IIL12. Automated Sequencing Protocol. 
Sequencing Protocol Using Big-Dye Kit (ABI Prism) 
4.5µ1 
1.0µ1 
20ng 
Terminator mix 
Primer (20ng/µl) 
Template (dsDNA) 
dd.H20 to a final volume of 10µ1 
The reaction was then cycle-sequenced using the following conditions: 
1. 95°C 5 sec X 1 
2. 95°C 10 sec} 
50°C 5 sec } X 25 
3. 
60°C 4 min} 
4°C Hold at this temperature W1ril purified. 
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The sequencing reactions were ethanol-salt precipitated as recommended by 
manufacturer to remove fluorescently labelled dNTPs and cL-ied to :zero volume (see 
Appendix A for details). 
Sequencing reactions were mixed with 4 µI of formamide EDT A loading buffer, 
denatured and electrophoresed in a denaturing (6M urea) 4% polyacrylamide gel (19:1 
FMC) on an ABI 377 DNA Sequencer (as per manufacturers recommendation). The 
sequencing results were analysed using Sequence-Navigator™, a software package by 
ABI (Perkin-Elmer), or Sequencher 1995 (Gene Codes Inc). 
III.4.ix. Characterisation of Sequence Variants. 
It was necessary to establish whether detected variants were pathogenic or neutral. 
When a sequence change was detected its genomic position was noted, and if exonic or 
in the splice-site region, the effects on the mRNA and amino acid sequences were 
determined. RNA was not available in this study and therefore it was not possible to 
perform RT-PCR, which means that splice-site mutations could not be fully 
characterised. Some intronic polymorphisms located in exon recognition sequences can 
lead to exon skipping, and this type of mutation would remain undetected without RT­
PCR. 
All sequence variations were analysed using DNAsis (Hitachi Software) or 
WEBCUTTER (http://bio.lundberg.gu.se/cutter2D. These programs also indicate 
restriction enzyme sites within a given sequence of DNA. When the variant sequence is 
compared to the published "wild-type" sequence, differences in restriction sites may be 
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found. The results of these comparisons were used to locate suitable restriction 
enzymes for family segregation analyses. Restriction digest analyses were also 
performed on individuals for some common polymorphic changes indicated by SSCP. 
The use of such restriction digests not only confirms sequence variation results but also 
negates the need for extra sequencing. The specific restriction enzymes suitable for 
particular sequence variations are listed in Chapters V & VI. All restriction digests 
were performed as recommended by the manufacturer. 
Digested DNA fragments were run on 4% agarose gels or 10% non-denaturing 
polyacrylamide gels ( 19: l) using the Multiphor II Electrophoresis unit (Phannacia 
Biotech), which allows rapid separation of fragments. The gels were electrophoresed at 
a constant temperature of 10°C. 
When polymerised, the gels were placed cellophane-side down on the ceramic back­
plate of the Multiphor apparatus. Agarose gel buffer strips were prepared (3% agarose 
pre-soaked in I xTBE with a few drops of bromophenol blue added), and placed at the 
upper and lower edges of the gel. The acrylamide gel was then loaded with 2-3 µI of 
the restriction digest mix. The gels were run at a constant power output of 3 W for 
between 40 to 60 nunutes at 10°C, and then silver stained as previously described 
(Section IIl.4.iv). The gels were dried under vacuum on Whatmann paper (3 MM). 
If no change in the restriction site was detected, SSCP analysis or sequencing was used 
for family studies. In addition to family segregation analysis, all missense changes 
were compared to the wild-type sequence using the secondaiy structure protein 
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prediction algorithms PHDsec (Rost et al., 1994) and nnPredict 
(hm,:/ldot.imgen.bcm.tmc.edu 
:9331/seq-search/struc-predict.html). The wild type and variant sequences were 
submitted separately and the predicted protein structures were obtained for comparison. 
III.4.x. Characterisation of Insertions or Deletions. 
When sequence analysis indicated an insertion or deletion, a second PCR was carried 
out on the sample under investigation and the product was cloned using the TOPO TA 
cloning kit (lnvitrogen). The vector with insert was then transformed into TOPIO one 
shot competent cells. After heat shock at 42°C, the cells were cultured in SOC medium 
at 37°C, spread on to 50µg/ml ampicillin plates with X-gal and IPTG and incubated 
overnight at 37°C. On the next day, 8 to 10 white colonies were picked from each plate 
and grown as separate cultures (4ml of LB medium, 50µg/ml ampicillin) at 37°C 
overnight. Plasmid DNA was isolated using the QIAGEN Plasmid Mini Kit and then 
sequenced with Ml3 Forward (-20) and MI3 Reverse primers using the Big-Dye 
sequencing kit (Applied Biosystems) and a 377 DNA sequencer/genetic analyser. 
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lll.5. Mutation Detection in the 5' Duplicated Region. 
III.5.i, Amplification of PKDJ-specific template in the 5' Duplicated Regi..Q!! 
The difficulty associated with amplification of a PKDJ-unique template in the 
duplicated region of this gene poses a substantial problem to any mutation screening 
study. The various methods that were attempted to achieve this specificity are reviewed 
here. They focus on the long-range a.-nplification of six PKDJ-specific templates 
(Table 111.15) that in twn are used as template in nested amplification reactions (Tables 
llI.16-21). 
A reverse primer in exon 34 similar to those previously described (Watnick et al., 1997; 
Peral et al., 1997) was designed to act as a PKDJ-specific anchor for the amplification 
of exons 23 to 33. Known PKDJ-specific primer sites in exon 15 (Watnick et al .. 1999) 
and IVS I (Thomas et al.. 1999) were used to amplify PKD 1 template for exons 15 to 
21 and exons 2 to 5. Primer design was based on sequence variations between PKDJ 
and a BAC clone (AC002039) containing HGI and HG2 (Loftus et al., 1999). A 
comparison between AC002039 and PKDJ was performed to generate PKD-1 specific 
primer sites around exon 1. Exon 22 of PKDJ was not screened. It lies between two 
polypyrimidine tracts in introns 21 and 22, and as previously reported (Watnick et al., 
1997), it is exceedingly difficult to amplify across these tracts in either direction. 
BAC and PAC libraries were screened and two clones found to contain HG inserts were 
partially sequenced. The resulting sequence variations were used to generate specific 
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oligonucleotide primer sites in IVS11, and XL-template was amplified from that PKD/­
specific primer site in both forward and reverse directions to include �xons 6 to 14. 
III.5.ii. Screening ofBAC and PAC DNA Pools for PKDI and the HGs 
A PCR screen of two human DNA libraries was undertaken (Human BAC DNA pools, 
Release II, Research Genetics and Human PAC DNA pools, Genome Systems). PAC 
libraries are similar to BAC libraries and were developed from PI-derived artificial 
chromosomes which have an average insert size of 130-150 kb (Ioannou et al., 1994). 
PCR amplifications were performed with primers in both the duplicated and unique 
regions of the PKDJ gene, as listed in Table III.13. This experiment aimed to identify 
clones containing one or more of the homologous genes or the PKDI gene. When such 
clones were detected, the duplicated region was sequenced and analysed to locate 
differences that could be utilised for PKDI unique primer design. 
III.5.ii(a). Screening BAC and PAC Pools 
Both libraries were supplied as "super-pool" and "pool" plates (Research Genetics and 
Genome Systems) in a 96-well microtitre format. The covering foil or plastic on each 
plate was removed when frozen (and wiped with 100% ethanol) to prevent cross­
contamination between wells, and the microtitre plate contents thawed at room 
temperature. The PCR screen was first performed on the superpool plate and the 
addresses of any clones that were successfully PCR amplified using primers for PKDJ 
were recorded. The corresponding pool plate and its row and column plates were then 
amplified with the same primers to identify which individual clones in the superpool 
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well were positive for the PKDJ primer sequence. Amplification reactions of 25µ1 total 
volume used 1 µl of superpool plate DNA as template and 2µ1 for all other plates. 
Initial superpool screening was performed with primers for exons 2 to 3, exon 35 and 
exon 45 . A more detailed screen of the clones was then undertaken using primers for 
exons 5, 13, 15 and 31-33. The primers, their genomic location, amplification 
conditions and product size are listed in Table III.13. Cycling conditions include the 
nwnber of cycles and annealing temperature (the times listed indicate the duration of 
each repeated step, eg. l '/2 '12 ' represents 1 minute denaturation, 2 minutes annealing 
and 2 minutes extension of primers). 
Table III.13. Primers for DNA Pool Screening 
Exons Primer Sequence Cycling Genomic Product 
Conditions Position size (hp) 
2-3 1810 5' ggaaggcctctggcctacta 3 ' 55°C (X30) 19848-864 387 
1811 3 ' ggagggcagaagggatattg 3' (l '/2'/2') 20215-234 
5 5AF 5' tggagccaggaggagcagaac 3 ' 65°C (X25) 20771-791 595 
5BR 5' cagggcggcaggtgccgctt 3 ' (0.5'/0.5'/1.5 ' ) 21347-366 
13 13F 5' tcacctgccacctgggctcac 3 ' 65°C (X25) 26279-299 261 
13R 3' gacaagagcctggtgcccacc 3' (0.5'/0.5'/l .5') 26519-539 
15 3134 5' gtgctggtcaccagcatcaa 3' 55°C (X30) 28507-526 1341 
313 5 5' cagccagcaggatctgaaaat 5' (1 '/2'/2 ') 29826-847 
31-33 3 8 5 3 5 ' ggactcgtccgtgctggac 3 ' 68°C (X35) 43672-690 591 
2930 3 'ggatttggcaggcgagtaggggct 5' 2-step (0.5'/2 ' ) 44239-262 
35 3651 5'ctgcaactgcctcctggagg 3' 68°C (X35) 47330-349 220 
3652 5' ggatttggcaggcgagtaggggct 3' 2-step (0 .5'/2 ' ) 47530-549 
45 3686 5' cgtcttagctcagctcagct 3 ' 68°C (X35) 50946-965 396 
3687 5' gtgtccctctcccccccact 3 ' 2-step (0.5' /2 ') 51322-341 
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111.5.ii.(b). Culture and Isolation of BAC and PAC DNA 
When a BAC or PAC product was identified as positive for PKDI, or its HGs, a 
glycerol stock solution for the specific clone was ordered from Research Genetics or 
Genome Systems respectively. Stocks were streaked on LB (Luria Bertani) Agar-plates 
(containing chloramphenicol 12.Sµg/ml) using aseptic technique and incubated at 37°C 
overnight. To obtain sufficient working volumes of the clonal DNA for PCR 
optimisation and sequencing, a single colony from these plates was picked to inoculate 
a bacterial culture. Purification of the culture was performed using a modification of 
the QIAGEN Plasmid Mtdi Kit protocol (personal communication Dr. Arseni Markoff, 
Munster) as detailed in Appendix A 
IH.5.ii.{c). Amplification and Sequencing of BAC and PAC DNA. 
The PKDI and HG isolated DNA was then amplified with the primers listed in Table 
111.14. 
T bl Ill 14 P 
. 
ft BAC d PAC DNA A l"fi ll e . . nmers or an mp 1 1cat1on. 
Exons Primer Sequence Cycling Genomic Product 
Conditions Position size (bp) 
2-5 1810 5 · ggaaggcctctggcctacta 3 • 68°C (X 5) 19848-864 999 
1807 5 'tcagggaggcagg.cgacata 3 · J 2-step (05'/2') 20837-846 
7-9 4102 5 · cagctacgtctgcgagctgc 3 · I 68°C (X 5) 22420-439 791 
4103 5 · ggtgnggaaggcttcacggc 5 · l 2-step (0 5'/2') 23191-210 
9-10 41 04 5 · gcaggtgtaccggctcctca 3 · ' 68°C (X 5) 23261-270 454 
4105 5 · cagctgggtcctgttgtccg 3 · 2-step (0 5'/2') 23695-714 
11-12 4 I 06 5 • g<l<'gaccatgtccgagccgg 3 · 68°C (X 5) 25086-105 945 
4107 5 • gaagaccatgtccgagccgg 3 • 2-step (05'/2') 26011-030 
12-14 4108 5 · cgcggcggtcltcaagctctg 3 • 68°C (X 0) 26099-119 945 
4140 5 • gagggctgttggggaggaagg 3 · 2-step (0 5'/2') 27023-043 
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After the PCR amplification of each clonal DNA with these primers, the products were 
electrophoresed in a 1% agarose gel (a total PCR volume of 25µ1 was loaded into wells 
formed with a wide tooth comb). Bands were excised from the gel and purified using 
the QIAquick Gel Extraction Kit as recommended by the manufacturer (QIAGEN). 
The concentration of DNA after cleaning was estimated against DNA of known 
concentration on an agarose gel. Approximately 30ng of DNA were then sequenced in 
both the forward and reverse directions for each amplicon using the individual primers 
listed in Table IIl.14. 
Sequencing was perfonned using the ready reaction tenninator cycle sequencing kit, as 
recommended by the manufacturer (Applied Biosystems Inc. Prism). Clean pellets 
were air-dried and then sent to the Inst'tute of Physiology, WWU, Munster, Germany 
where samples were electrophoresed on an ABI 373 sequencer by the designated 
operator (Appendix A). 
III.5.ii.(d). PKD/·Specific Sequence in the Duplicated Region of the Gene. 
Comparisons between the resultant BAC and PAC sequences and the published 
sequence of PKDJ (GenBank Acc. L39891) were made by Dr. Arseni Markoff using 
the GeneStream global alignment tool (http://www2.igh.cnrs.fr/home.eng.htrnl). PKDJ 
introns 3, 4, 8, 9, 12, 13 and 14 were assessed for areas specific to PKDJ. On the basis 
of these results {Chapter IV), PKDJ specific primers were designed in IVSI I to amplify 
PKDJ exons 6 to 11 and 12 to 14. These are listed in Table III. IS with the other PKDJ 
primers used for Xl,·PCR amplification. 
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T bl 11115 P . f; XL T a e . . nmers or - emp ate A l'fi mp. t tcatton. 
Exons Primer Sequence Cycling Genomic Product 
Conditions Position size (hp) 
Ex2-5 IVS I F 5' cccagcgtctcatctgtctgg 3' 68 °C (X40) 17049-69 4.542 
IVS5 R 5' ggtgggaacgagggtgtcaac 3' 2 -step 21579-90 
(0.5'/5') 
Ex 6-11 2927 5' gccgcctacagcatcgtggccc 3 • 68 °C (X40) 21447-470 4,198 
I I R 5 • cagtgaggggaggcacctacact 3 • 2-step 25622-644 
(0.5'/4') 
Ex 12-14 I 2F 5' cagtgtaggtgcctcccctcactg 3' 68 °C (X40) 25621-644 1810 
3130 5' ccagcacggtcaggaggtact 3' 2-step 27410-430 
(0.5'/2 ') 
Exl5 IVS I 3 F 5' ctgtcccggttcactcactgc 3 • 68 °C (X40) 26769-89 3861 
ExlSXLR 5' caacgtgggcctccaagtagttg 3' 2-step 30607-29 
(0.5'/4') 
Ex 15-21 Exl5XLF 5'gcaactacttggaggcccacg 3' 68 °C (X40) 30606-26 3375 
IVS2 IR 5 'gcagggtgagcaggtggggccatc 3 • 2-step 33957-80 
(0.5'/4') 
23-34 TWFI • 5' ctgcactgacctcacgcatgt 3' 68 °C (X40) 37674-694 6,749 
Ex34 R 5 • atgtgggtgtcttgggtagg 3' 2-step 44403-422 
(0.5'/6') 
l11e amplification reactions were perfonned using long-range amplification enzyme 
with a hot-start (XL- rTth Applied Biosystems). 
To ensure that diluted long-range PCR products were PKD/-specific, a senes of 
dilutions (1:10·2, 1:10·3 and 1:10·5) were made prior to re- amplification and used to 
amplify exon 8 of PKDJ. A dilution factor of?:'.: I: I0-1 of PCR product had previously 
been shown to produce PKD/-specific amplification when used as template (Watnick et 
al., 1999). Diluted PCR products were then purified from an excised agarose gel slice 
using the QIAquick PCR Purification Kit as per the manufacturer' s reconunendations 
(QIAGEN). The purified products were sequenced using the SequiThenn EXCEL II 
DNA Cycle Sequencing Kit, as described by the manufacturer (Epicentre 
Technologies), and products were isotopically labelled with [ a-nP)-dA TP ( Hartmann 
Analytics). l11e detailed protocol is listed in Appendix A. 
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Prior to elec\rophoresis, the products of the sequencing reactions were denatured at 
95°C for 3 minutes and immediately placed .:,il ice. Denaturing PAG electrophoresis 
and autoradiography was performed as previously described (Section III.S.vii). The 
sequencing results (Chapter IV) indicate that a dilution of 1: 10·5 produced specific 
amplification of the P KD J gene, whereas dilutions of l : 10-2 and I : 10·3 gave rise to the 
co-amplification of homologous genes. 
III.6, Mutation Detection Screen of PKDI Exons 2 to 33 
III.6,i. PCR Amplification of individual PKD! Exons 
Genomic DNA was amplified with XL primers (Table III.15), and the products were 
diluted l: l 0·5. The diluted products ( I µI in total reaction volwne of 25 µl) acted as 
template for the nested PCR amplification of individual exons contained within the 
respective XL-PCR products (IIl.6.i.a-g). Each PCR reaction included 200µM of each 
dNTP, l .SmM MgCh, 30ng of forward and reverse primer, I X Buffer, I U of Taq 
polymerase and Sµl ofQ-solution (QIAGEN). 
Despite repeated attempts at the optimisation of reaction conditions we were unable to 
produce a PCR product of suitable quality for mutational analysis of the PKDJ gene 
surrounding exon l. The high GC content of the region surrounding exon 1 prevented 
the specific amplification for screening purposes. Other groups have reported the 
difficulty of trying to screen for mutations in exon I of the PK.DJ gene (Rossetti er al., 
2001; Phakdeekitcharoen et al., 2001). Both groups were only able to screen the region 
after performing long-range amplifications, followed by nested amplifications using 
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high annealing temperatures and PCR enhancing additives (DMSO buffer with Taq 
extender and Advantage-GC genomic polymerase and GC melt respectively). 
Ill.6.i.(a) Amolification of exons 2 to 5 
T bl 11116 P . f'; h PCR A. l'fi a C . . nmers or t e • mp 1 cation o fPKDIE 
Exons Primer Sequence Cycling 
Conditions 
Ex 2 Ex2F 5' ggaaggcctctggcctacta 3' 64°C (X35) 
Ex2R 5' ggggattcggcaaagctgat 3' (0.5'/0.S'/1') 
l:.x 3 Ex3F 5' ctcagctgtgggggattcca 3 · 58°C (X35) 
Ex3R S' ggcagaagggatattggggg 3' (0.5'/I '/I') 
Ex4 Ex4F S' ggctggcatagacccttc�c J' 64°C (X35) 
Ex4R 5' cctggctgggaaggacagag 3' (0.5'/0.5'/I ') 
Ex 5(a) Ex5aF 5 · gtggagccaggaggagca 3' 58°C (X35) 
ExSaR 5' gggaagacgtgctggagg 3' (0.5'/1'/l ') 
Ex S(b) Ex5bF 5' cctccagcacgtcttccc 3' 64°C (X35) 
Ex5b R 5' ccgcttccacctgcacg1 3' (0.5'/0.5'/I') 
Ex S(c) ExScF 5' ctcagccctgctggggacaga 3' 64°C (X35) 
IVSS R 5' ggtgggaacgagggtgtcaac 3' (O.S'i0.5'/1 ') 
xons 2 5 -
Genomic 
Position 
19845-64 
20064-74 
20045-64 
20211-30 
20378-97 
20630-50 
20770-87 
21081-98 
21081-98 
21335-52 
21315-35 
21579-89 
Product 
size (bo) 
230 
186 
273 
329 
. . 
272 
275 
120 
IIl,6.i.{b) Amplification of exons 6 to 11 
T bl II I I 7 P . ti th PCR Am J"fi ,a e . . nm�rs or e 1p I cation o f l'KDJ E xons 6 11 -
Exons Primer Sequence Cycling Genomic Product 
Conditions Position size (bp) 
6 4349 5' gtgagtgtctgctgccca 3' 58°C (X30) 21491-508 396 
4350 5' cctccttcctcctgagact 3' ( I '/I' /I') 21868-886 
1 4 3 51 5' ggctctgagcctcagttt 3' 58°C (X30) 22104-121 391 
4 3 5 2 5' taaccacagccagcgtct 3 • (I '/l '/1 ') 22476-493 
8 4353 5' gtctgttcgtcctggtgt 3' 58°C (XJO) 22575-592 306 
4354 5 · ccatcttcactgggcaca 3 · (I' /l'/1 ') 22863-880 
9 4345 5'gttcgggtagggggagtct 3' 60°C (X 35) 23090-108 271 
4346 5 'gtgaaagctcagagaggcca 3 • (0.8'/0.8'/0.8') 23341-360 
10 4 34 7 5 ' gg tggcctgtgggcaaatca 3 ' 61°C (X30) 23608-627 340 
4348 5' gcctgaggagatgcaggga 3' ()'/]'/}') 23929-947 
I I-I la 11 AF 5' gggtccacgggccatgaccgt 3' 66°C (X25) 24300-320 331 
I I AR 5 'cgcagtccagggttgggcctc 3' (0.5'/1 '/I') 24610-630 
11-1 lb 11 BF 5' acggaacagctcaccgtgct 3 ' 66°C (X25) 24581-600 320 
11 BR 5 • aaggtggccaccagggcaggg 3 • (0.5' /I' /I') 24880-900 
I I-I Jc I I CF 5' gcagtgtcagcgcccgctttg 3 · 66°C (X25) 24849-869 321 
I I CR 5' agcaccctgtctgcaggcacc 3' (0.5'/1 '/I') 25150-170 
Exon 11 was amplified as three fragments (a, b & c) due to its size (756bp). 
111.6.i.(c) Amplification of exons 12 to 14 
T bl Ul 18 P. fi I PCR A J"fi a e . . nmers or t 1e mp 1 1cat1on o fPKDJE xons 1 2  14 -
Exons Primer Sequence Cycling Genomic Product 
Conditions Position size (bp) 
12 4355 5' ccaggaggcgacaggcta 3' 61°C (X30) 25923-940 352 
5135 5' cctggccctgattggcgtc 3' (0 8'/0.8'/0.8') 26256-74 
l3 5228 5 · tcacctgccacctgggctcac 3' 68°C (X35) 26279•299 320 
5136 5' ccgaggctcagaa.aagca 3 • 2-step (0.5'12') 26581-598 
14 5002 5 • ctgtcccggttcactcactgc 3' 68°C (X35) 26769-789 275 
4140 5' gagggctgttggggaggaagg 3' 2·step (0.5 '/2 ') 27023-043 
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m.6.i.(d) Amplification of exon 15 
T bl 1111 fi I' fi a e • 9. Pnmers or the PCR Amo 1 1cation o fP I KD Exon 15 
Exon 15 Primer Sequence Cycling Gi?nomic Product 
Fra2. Conditions Position size (bn) 
16 16F s· cgggtggggagcaggtgg 3' 68°C (X35) 27351-67 280 
I 6R 5 · gctctgggtcaggacagggga 3' 2-step (0.5'/2') 27610-30 
15 I SF 5' cgcctgggggtgttcttt 3' 53°C (X30) 27569-86 270 
15 R 5' acgtgatgttgtcgcccg 3' (0.5'/0.5'/I') 27821-38 
14 14 F 5' gcccccgtggtggtcagc 3 ' 68°C (X35) 27790-807 250 
I 4R 5' caggctgcgtggggatgc 3 • 2-step (0.5'/2') 28022-39 
13 13 F 5 • ctggaggtgctgcgcgtt 3 · 67°C (X30) 27991-008 259 
13 R 5 • ctggctccacgcagatgc 3' (0.5'/0.5'/I ') 28229-46 
12 12F 5' cgtgaacagggcgcatta 3' 58°C (X30) 28203-20 270 
I 2R 5' gcagcagagatgttgttggac 3' (0.5'/0.5'/I ') 28452-72 
11 I I F 5 · ccaggctcctatcttgtgaca 3' 62°C (X30) 28433-53 249 
I I R 5 · tgaagtcacctgtgctgttgt 3 ' {0.5'/0.5 '/I') 28661-81 
10 I OF 5 • ctacctgtgggatctgggg 3' 65°C (X30) 28602-20 217 
I OR 5 · tgctgaagctcacgctcc 3' (0.5'/0.5'/I ') 28801-18 
9 9F 5' gggctcgtcgtcaatgcaag 3 · 66°C (X30) 28758-77 277 
9R 5' caccacctgcagcccctcta 5' (05'/0.5'/I ') 29005-34 
8 SF 5' ccgcccaggacagcatcttc 3' 66°C (X30) 28966-85 260 
8R 5' cgctgcccagcatgttgg 3' (0.5'/0.5'/I ') 29208-25 
7 7 F 5' cggcaaaggcttctcgctc 3' 63°C (X30) 29147-65 287 
7R 5' ccgggtgtggggaagctatg 3' (0.5'/0.5'/I ') 29414-33 
6 6F 5' cgagccatttaccacccatag 3' 1 s8°C (X30) 29398-418 231 
6R 5' gcccagcaccagctcacat 3' (0.5'/0.5'/I ') 29610-28 
5 SF 5' ccacgggcaccaatgtgag 3' 66°C (XJO) 29598-616 251 
5 R 5' ggcagccagcaggatctgaa 3' 
1 
<os10.5·11·> 29829-48 
4 4 F 5' cagcagcaaggtggtggc 3' 63°C (X30) 29791-808 333 
4R 5 · gcgtaggcgacccgagag 3' (0.5'/0 5'/1 ') 30106-23 
3 JF 5' acgggcactgagaggaacttc 3' 66°C (X30) 30065-85 206 
3 R 5 · accagcgtgcggttctcact 3' (0.5 '/0.5 '/I') 30251-70 
2 2F 5' gccgcgacgtcacctagac 3' 66°C (X30) 30177-95 265 
2R 5 · tcggccctgggctcatct 3 • (0.5'/0.5'/I ') 30424-41 
t I F 5 • ctgggactttggggatgggt 3 • 63°C (X30) 30388-407 242 
XL I 5R 5'ca<>cgtgggcctc�aagtagttg 3' (0.5'/0.5'/I ') 30607-29 
Primers first described by Watnick el al.. 1999. 
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111.6.i,<e) Amplification of exons 15 to 21 
T bl 11120 P . ti h PCR Am l'fi fPKDJE 15 21 a e . . nmers or t e 1p 1 1cat1on o xons -
Exons Primer Sequence Cycling Genomic Product 
Conditions Position size Ibo) 
15(a) Ex I 5 XLF 5 'gcaactacttggaggcccacg 3' 66°C (X35) 30606-26 287 
Ex 15aR 5' ctcaatgatgggcaccaggcg 3' (0.5'/0.5'/1 ') 30872-92 
15{b) Ex l 5bF S' catccaggccaatgtgacggt 3' 64°C (X35) 30841-61 266 
Ex I 5bR 5' cctggtggcaagctgggtgtt 3' (0.5'/0.5'/I '} 31086-106 
16 Ex I 6F 5 • ctggalggggctctcagg 3' 56°C (X30) 31197-214 289 
Eid 6R 5' cctggtggcaagctgggtgtt 3' (0.5'/0.5'/l '} 31468-85 
17 Ex 17F 5' gggtcccccagtccttccag 3' 66°C (X35) 32262-81 247 
Ex J 7R 5 · ccatccccagcccgcccaca 3' (0.5'/0.5'/1 ') 32489-508 
18 Ex I 8 F 5 · gccccctcaccaccccttct 3' 66°C (X35) 32571-90 344 
Ex 18 R 5' gatcccgctgcctcccccca 3' (0.5'/0.5'/I') 32895-914 
19 Ex I 9F 5 • gtgatgccgtggggaccgtc 3 • I 66°C (X35) 32946-65 287 
Exl9R 5' gtgagcaggtggcagtctcg 3' (0.5'/0.5 '/I') 332! 3-32 
20 Ex20F 5' ctgctcaccaccccctctg 3' 64°C (X35) 33225-43 239 
Ex20R 5' ggtcccaagcacgcatgca 3' (0.5'/0.5'/l') 33445-63 
21 Ex2 l F 5 · cgctgctgacagcttgctgtgccc 3' 66°C (X30) 33763-86 218 
I VS2 I RS' gcagggtgagcaggtggggccatc 3' (0.5'/0.5'/1 ') 33957-80 
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III.6.i.{f) Amplification of exons 23 to 33 
T bl III 21 P . fi h PCR Am rfi a e . . nmers or t e 1p 1 1catlon o fPKDJE xons 
Exons Primer Sequence Cycling 
Conditions 
23(a) TWFl * 5' ctgcactgacctcacgcatgt 3' 58°C (X30) 
23a-R 5' caccagaaagatgggctgcac 3' (0.5'/0.5'/1') 
23(b) 23bF 5' ggggccctggcc.aacctcag 3' 68°C (X35) 
23bR 5' cgtgtgccccacccgctgca 3' 2-step (0.5'/2') 
' 
24 24F 5' tgtgacctgcgcgttc!g 3' 68°C (X35) 
24 R 5 • ccaggctggcccgcagag 3 • 2-step (0.5 '/2 ') 
25 25 F 5' ctgggctcacgtccgctacc 3' 68°C (X35) 
25 R 5' cctcgactctgcagaggctc 3 • 2-step (0.5'/2') 
26 26F 5' cggctctatcctgagaaggc 3' 68°C (X35) 
26R 5' cagcacagccagtgagagca 3' 2-step (OS/2') 
27 2 7F 5' cctcccacccctccctcttg 3' 6fl°C (X35) 
27R 5' cagagcttggcagggtccgc 3' 2-step (0.5'/2') 
28 28F 5' cgagcctgacctccctcctg 3' 58°C (X30) 
28R 5' cggagtgggaccatggaacg 3' (0.5'/0.5'/I ') 
29 29F 5 · cgtgg<.:ctcctgcagtgcgg 3' 68°C (X35) 
29R 5' ggcaggaagaggctgccccg 3' 2-step (0.5'/2') 
30 30F 5' cacctgtgtggcctcctctc 3' 68°C (X35) 
30R 5' ggctccattcccagtactcc 3' 2-step (0.5'/2') 
31 31 F 5' gctgaccactgccctcgtc 3' 68°C (X35) 
3 I R 5' agtccaagctgcgccaagg 3 ' 2-step (0.5'/2') 
32 32F 5' ttggcgcagcttggactc 3' 58°C (X30) 
32R 5' cagggctcgaggtttctc 3 • I (0.5'/0.5'/I') 
33 33F 5' taccttgctgacccgcgc 3' 68°C (X35) 
3 3 R 5' ggtgagcttcagagcccc 3' 2-step (0.5 • /2 ') 
Exon 23 was ampltfied a'> two fragments (a & b) due to its size (630bp). 
* Previous reference Watnick et al., I 997. 
23 34 . 
Genomic Product 
Position size lbol 
37674-694 353 
38006.026 
37979-998 377 
38336-355 
38600-617 204 
38786-803 
38927-946 329 
39236-255 
39272-291 315 
39567-586 
41000.019 225 
41205-224 
41254-273 204 
41438-457 
41486-505 285 
41751-770 
41794-813 199 
41973-992 
43585-603 207 
43773-791 
43775-792 123 
43879-896 
44064-081 250 
44296-313 
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Ill.6.ii. Purification and Sequencing of Nested PCR Product§ 
5µ1 aliquots of the 25µ1 nested PCRs were electrophoresed on 1% agarose gels in IX 
TBE at l 00 V for 40-60 minutes, stained with ethidium bromide and photographed 
under UV-transillwnination as previously described (Section III.4.ii). When amplicons 
resulted in a clearly detectable PCR product, the remaining 20µ1 were purified through 
QIAquick PCR spin columns (QJAGEN), and eluted in 20µ1 of ddH20. This is a lower 
elution volume than recommended by the manufacturer, however, sufficient template 
was recovered to proceed with direct automated sequencing reactions. 
IIJ.7. Investigation of PKDJ Homologous Gene Seguences 
In addition to specific mutation detection of PKDJ in the duplicated region sequence, 
information on the BAC and PAC clones was also used to investigate the possible 
functions of the homologous genes. This work was undertaken as a direct result of the 
present study by Dr. Nadja Bogdanova and Dr. Arseni Markoff (Institute for Human 
Genetics, Munster, Germany) using the following methodology. 
III.7.i. Reverse Transcription and PCR (RT-PCR) 
Total RNA was isolated from confluent astrocytoma T98G human ceil cultures using 
the Trizol™ reagent (Gibco BRL) according to the manufacturer's protocol. This 
reagent is based on the single-step phenol/guanidine isothiocyanate isolation protocol 
originally described by Chomczynski and Sacchi ( 1987). The RNA was subjected to 
reverse transcription, primed with random hexamers and either PKDJ- or PKDJ 
homologue- specific primer as detailed below. 
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Total RNA Isolation Protocol 
1. 1 ml of astrocytoma cell suspension was divided bet ween two 1. 5ml microcentrifuge 
tubes and centrifuged at 6,000 rpm for 5 minutes at 4°C. 
2. The supernatant was discarded and the pellet was resuspended in 750µ1 of Trizol 
reagent (2ml of reagent per I ;c 106 cells). The tubes were shaken to homogenise 
cells. 
3. RNA was isolated in an aqueous phase from DNA and organic compowtds by the 
addition of 0.2 volumes of chloroform to the homogenate. The tubes were shaken 
for 15 seconds and incubated at room temperature for 2-3 minutes. 
4. The homogenate was then centrifuged at 12,000g for 15 minutes at 4°C. 
5. The RNA-containing upper-phase was removed into clean tubes and equal volumes 
of isopropanol used to precipitate the RNA 
6. The tubes were then incubated at -20°C for IO minutes and centrifuged for a further 
10 minutes at 4 °C to pellet the RNA 
7. The supernatant was removed, the RNA pellets were washed with 500µ1 of 75% 
ice-cold ethanol and the tubes centrifuged at 7,500 rpm for 5 minutes at 4 °C. 
8. The ethanol was removed and the pellets air-dried for 15-20 minutes. A paper 
tissue was placed over tubes to prevent air-born contamination from entering the 
tubes. 
9. The pellets were resuspended in 30µ1 ofRNase-free ddH20 at 55°C for 10 minutes. 
10. The quality of RNA and the possibility of DNA or RNase contamination was 
assessed by the electrophoresis of a 5 µ1 aliquot sample on a 2% Agnrose gel stained, 
with ethidium bromide. 
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Translationally active RN A was prepared from the polysomal fraction (membrane­
bound polysomes) as previously described (Mechler, 1987). The microsomal fraction 
was obtained through sucrose gradient centrifugation of a T98G cytoplasmic extract and 
mRNA was separated and purified from the bound polysomes. When the RNA was 
considered to be of sufficient quality, cDNA was produced by reverse transcription 
using Superscript II reverse trnnscriptase (Gibco BRL Life Technologies) as detailed 
below. 
Reverse TrnnscriP.tion 
Total RNA and mRNA (0.5 - 3µg) were primed with random hexamer (IOOpM) and 3' 
oligonucleotide primer ( lOpM) (5' GCCATCCCCGAAGGTCCAGTCGAA 3'), which 
was common to PKDJ and the homologous genes. RNase-free water was then added to 
a total volume of 12.5µ1. The mix was incubated at 65°C for 10 minutes and 
immediately placed on ice. An enzyme mix was prepared from l �t.l of Superscript II 
reverse transcriptase (Gibco BRL Life Technologies), 5µ1 of 5 x RT 151 strand buffer, 
2.5µ1 ofDIT (O.lM), 3µ1 of IOmM dNTPs (Gibco BRL Life Teclmologies), and lµl of 
RNase in}tjbitor (Gibco BRL Life Technologies), in a final volume of 12.5µ1. The RNA 
and enzyme preparations were mixed and incubated at the following temperatures, 25°C 
for 10 minutes, 42°C for 60 minutes, 50°C fer 30 minutes and 70°C for 10 minutes. 
The first round of PCR amplification was performed on 1 µI aliquots of the reverse 
transcribed products with primers listed in Table III.22. The PCR product of this first 
reaction (lµl) was then used as template in a second amplification using PKDJ and HG 
specific primers (see Table III.22). Agarose gel electrophoresis (Section III.4.ii) of 
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cDNA was then performed to assess if the homologous genes produced iranslationally 
active mRNA after specific amplification (see Chapter IV). 
Table 111.22. Primers for Amplificat1on of PKDI and Homo ogous Genes 
Exon Primer Sequence Cycling Genomic cDNA 
5 
15 
11 
13 
11 
13 
Forward outer primer 
5' gtgtgcccgtcctcm,rtgcaga 3 · 
Reverse outer primer 
5' ccgaagtcccacgtgtaaagaa 3' 
Forward PKDI nested p:-imer 
5' cttgaggcccaaccctggact 3 • 
Reverse PKDI nested primer 
5' ccggcactgtggagacctgcaga 3 · 
Forward HG nested primer 
5 • cstgaggcc:aaccctgg,gct 3 · 
Reverse HG nested primer 
5 · c!ggcactl-,rt!gagaccggcagg 3 · 
Conditions Position product 
40 cycles of 
94°C 45sec 
55°C I min 
72°C 4 mins 
40 cycles of 
94°( 45sec 
68°C I min 
72°C I min 
40 cycles of 
94°C 45sec 
size 
21373-94 2,387 bp 
27581-602 
24607-27 7 I 5bp 
26395-417 
j 68°C I min 
24607-27 (approx) 
715bp 
I 72°C I min 26395-417 
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IV. Results: 
Specific Amplification of the Duplicated Region of PKDJ 
IV. Results: Specific Amplification of the Duplicated Region of PKDI 
IV. I . Introduction 
The existence of ger1es highly homologous to PKDI raises interesting biological 
questions related to their physiological role, and at the same time presents a major 
obstacle to the specific amplification of the PKDJ gene and hence to the study of the 
molecular defects leading to ADPKD. During the course of this study, the genomic 
sequence of two of the homologues, HGl and HG2, contained in a single BAC clone 
(Accession# AC002039) became publicly available (Loftus et al., 1999). However, 
earlier studies aimed at the cloning of PKDJ (The European PKO Consortium, 1994; 
The International PKO Consortium, 1995; Hughes et al., 1995), had demonstrated the 
existence of three homologous transcripts, suggesting that at least one additional 
homologous gene remained to be characterised. To address the questions of the 
sequence characteristics of the homologues, their role, and the selection of PKO I­
specific amplification primers, a collaboration as indicated below was conducted. 
The genomic sequences of human genomic clones containing P KD 1 homologues, or 
the PKDI gene itself, were compared and their expression was examined. 
The work on the characterisation of the PK.DJ homologous genes was undertaken in 
collaboration with Dr. Nadja Bogdanova and Dr. Arseni Markoff at the Institute for 
Human Genetics, Westfiilische-Wilhelm's University, Munster, Germany. The 
candidate acknowledges their contribution and presents the joint results with their full 
knowledge and approval. 
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IV.2. Identification of human genomic clones containing PKDJ and its homologous 
genes 
As described in Chapter III (Section III.5.ii), two human genomic libraries, Human 
BAC DNA Pools (Release II, Research Genetics Inc.) and Human PAC DNA Pools 
(Genome Systems), were screened by PCR analysis for clones containing inserts of 
the duplicated and unique regions of PKDJ. Two initial PCR amplifications were­
performed with primers for PKDJ. The first experiment amplified exons 2 and 3 in 
the duplicated region of the gene. This amplification aimed to detect clones 
containing PKDI, and clones containing PKDJ homologous genes. The second 
amplification was performed "With primers for exon 45 in the unique region of the 
PKDI gene; this experiment was performed to distinguish between PKDJ-containing 
and HG-containing clones. 
Screening of the BAC library super-pool identified two wells that contained clones 
with inserts corresponding to the duplicated region of PK.DI. Subsequent pool plate 
screening confirmed the presence of two clones wit'1 unique addresses (plate 
addresses 204-o-15 and 267-d-9), that were PCR-pos1tive for exons 2-3, 5, 13, 15, and 
31-33 of PKDI. Attempts to amplify the unique region (exons 35 or 45) of PKDI in 
these clones were unsuccessful, indicating that the inserts corresponded to 
homologous genes, rather than to PKDI. Partial sequence analysis of the homt'logous 
genes contained in these clones revealed that they were not identical to other 
identified PKDI homologues, HG I and HG2 (Loftus et al., 1999) see Chapter VII, 
and they were named HG3 and HG4. 
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Screening of the PAC library identified two clones (80-1-8 and 136-M-14), which 
were PCR positive for exons 2 and 3 located in the duplicated region and exon 45 in 
the unique region of P KD I. These results indicated that the two PAC clones 
contained the PKDI gene (see Figure IV.I). 
2 3 4 M 1234567M 
A B 
12 M 345 12345M67891011 
c D 
Key to Figure 
A Lanes 1 & 2 HG 3&4 BACS with 
primer for exon 45. Lanes 3 & 4 as 
above with primers for exons 2-3. 
B. Lanes 1-3 PKDJ PACS with 
primer for exon 45. Lanes 4-7 as 
above with primers for exons 2-3. 
C. Lanes 1-2 HG 3&4 BACS with 
primer for exon 5. Lane 3 genomic 
control. Lanes 4-5 HG 3&4 BACS 
with primer for exon 13. 
D. Lanes 1-5, genomic control, 
PKDJ PAC, HG3 & 4 BAC and 
negative control for exon 15. Lane 6 
negative control, Lanes 7-9 genomic 
controls, lane 10-11 HG 3&4 BACS 
with primer for exons 31-33. 
M - Size standard marker 
Fig. IV.I. Amplification results ofBAC and PAC clones. 
The glycerol stocks of the PKDI- and HG-containing clones were purchased from the 
manufacturers, propagated and BAC and PAC DNA were extracted and purified for 
sequence analysis. 
IV.3. Sequence analysis of PKDI and the homologous genes 
To identify P KD I-specific primers and amplify specific templates for mutation 
detection analysis, the two clones containing the homologous genes and the P KD 1-
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containing clone were sequenced and compared. This study attempted to characterise 
a region of PKDJ that had not been screened previously. Early studies had screened 
PKDJ-specific templates in the duplicated region by amplifying from exon 34 in the 
unique region up to exon 23 (Peral et al., 1997; Watnick et al., 1997). Two 
subsequent studies reported screening for mutations in exons 15 to 21 (Watnick et al., 
1999b; Thomas et al., 1999). For that reason, t.'ie present study focused on the 
sequence 5' ofexon 15 of PKDJ. 
The region from exon 2 to IVS14 (nucleotide positions 19,866 to 27,595 of the PKDJ 
genomic sequence Accession# L3989l) was amplified, using as templates DNA from 
the two BAC clones (204-o-15 anc� 2l7-d-9) that cont��n the HGs, and from one of 
the PAC clones (136-M-14) representing PKDJ. The region was covered by five 
PCR fragments. These PCR products were analysed by automated direct sequencing 
as described in chapter 111. 
The resulting sequences have been deposited in GenBank under Accession numbers 
AF320593 and AF320594 (Bogdanova et al., 200 l ). 
Sequence alignment, performed by Dr. Markoff with the GENESTREAM alignment 
tool (http://www.2.igh.cnrs.fr/bome.eng.html), showed that the two sequences derived 
from BAC clones 204-o-15 and 267-d-9 differed from each other, as well as from the 
previously published HG l and HG2 (Lo� et al. 1999). Compared to PKDJ, the 
sequence of the newly identified homologous genes, HG3 and HG4, contained small 
deletions or insertions (5 to 21 base pairs), and nucleotide substitutions. The 
133 
sequence identity for this 7.7kb region was found to be 96.4% between PKDJ and 
HG3 and 96.5% between PKDJ and HG4. 
Further analysis of GenBank, using the BLAST homo]ogy search tool at NCBI 
(http://www.ncbi.nlm.nih.gov/BLAST/}, revealed two additional recent entries 
(Accession numbers AC010488 and AC040I58) which are highly homologous to 
P KD 1 and to its homologous genes. These findings point to the existence of a greater 
nwnber of homologous genes, at least six, than suggested in early publications (The 
European PKD Consortium, 1994; The International PKO Consortium, 1995; Hughes 
el al., 1995). 
IV.4. Functional characteristics of the homologous genes 
The functional importance of the PKDI homologous genes was investigated in the 
glioblastoma cell line T98G by RT-PCR. The presence of PKDJ, HG3, and HG4 
transcripts was examined in total T98G RNA, and in translationally active RNA 
prepared from a polysomal cell fraction. RT-PCR for exon 12, located in the 
duplicated region and thus present in all three genes, was pertbnned with primers 
specific to PKDJ or to HG3 and HG4. Total RNA yielded a product for exon i2 with 
botll PKD 1 and the homologous gene primers. By contrast, in the trans1ntionally 
active RNA, only a PKDJ-specific product was detected (see Appendix, Bogdanova 
et al., 2001). This experiment indicates that whilst the HGs are transcribed. they are 
not found in the translationally active polysomal fraction and therefore are unlikely to 
be translated. These findings are supported by the sequence analysis of the coding 
regions ofHG3 and HG4. The sequence was found to contain a number of premature 
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stop codons, suggesting that even if the HGs were translated they would generate 
short, and most probably non-functional, peptides (Bogdanova et al .. 2001). 
On the basis of these results, it was concluded that the PKDJ homologous genes HG3 
and HG4 are highly likely to be pseudogenes. We have proposed to refer to these 
genes as PKDJ pseudogenes 3 and 4, PKDJP3 and PKDJP4 (Bogdanova et al. 2001). 
IV.5. Design of PKD1-Specific Oligonucleotides 
We have attempted to improve the specificity of PCR amplification and diagnostic 
sequence analysis of PKDJ by selecting primers for long-range amplification (XL­
PCR) that are specific to PKDJ in the duplicated region of the gene (exons 2 to 14), 
when compared to all its known homologous genes. 
All XL-PCR primers used (Fig IV.2), are specific to PKDJ relative to the PKDJPJ 
(HGl) and PKDJP2 (HG2) sequences published in a previous study (Loftus e, 
1999). We have also compared the PKDJ sequence between exons 2 to 14 to that of 
PKDJPJ, PKD1P4 and PKDJP5 (Bogdanova et al., 2001). PKDJP6 was not 
included in this analysis, since its sequence homology to PKD 1 in this region extends 
over only 2530 bp of the PKDI gene, corresponding to PKD l exon 2 to exon 7. 
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PK.DJ XL·PCR Templates 
IVSJ-JVSS contoins exons 2, 3, 4 & 5 (- 4.5 kb product) 
IV:SS-IVSl I contains exons 6-11 (--4.2 kb) 
TVS! 1-IVSl4 contains cxons 12-14 (-1 8kb) 
--
IVS14 · E. on 15 (-3.8 kb product) ~qut.'IlCcd in 16 PCR fragments 
1 
l 
I 
Exon IS. IVS21 (-3.4 kb product) contains exons 15 to 21 
sequenced m 8 fragments 
IVS23 • TVSJ3 (-6.8 kb product) ren."fs.: 
primer anchored in PKDl unique region exons 
23 - 33 sequ1."Ilccd in 12 fragments 
s I \\ 11 11 1111 11 111 - I IIIII 11111 11111 111 II 111111111 1 3' 
Duplicated reg:iou PK.DJ unique region 
Fig IV.2. XL-PCR primers used for the amplification of PKDJ (Exons 2-33) 
To amplify a PKDJ-specific product we chose a novel primer site in IVS 11 that was 
specific to PKDJ when compared to the sequence of the homologous gene. The site 
was specific to PKDl compared with PKDJPJ, PKDJP2, PKDJPJ and PKDJP5. 
The fourth homologue, however, was found to be identical to the PKDJ gene in this 
primer site region. The primer site in intron 11 was utilised in the design of forward 
(12F) and reverse (llR) primers as shown in Figure IV.3 . Primer 6F in IVS 5 was 
used in an XL-PCR amplification reaction with primer l lR to amplify a region of 4.2 
kb, containing exons 6 to 11 (Fig IV.2), using a long-range polymerase enzyme (XL-
rTth enzyme, Applied Biosystems). Forward primer 12F with a primer in IVS 14 
(14R) (Fig IV.2) was used to produce a 1.8 kb PKDJ-specifc template, including 
exons 12 to 14. 
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The fourth homologue was found to be identical to the PKDI gene in the 6F and l IR 
primer sites. therefore XL-PCR products ( exons 6 to l I) sre not specific to P KD l 
when compared v.-ith PKDJP4. However, the nested primers used in subsequent 
amplifications of exons 6, 9, IO and the first of three fragments of exon 11 ( 11 A) are 
specific to PKDI when compared to PKDIP4. Only one sequence variation detected 
in this study, Q563X in exon 8 (Chapter V, Truncating Mutations), is possibly a HG 
variation due to the co-amr' ification of P KD IP 4. P KD IP 4 was not identical to the 
PKDJ sequence for the reverse primer for exons 12 to 14 (14R), and so this fragment 
is PKDJ-spccific when compared to all of the known homologues in the region. 
PK.DI sequence (L39891). 
PK.Di Primer I2F 
AC002039 PKD1Pl 
AC002039 PKO I P2 
AF320593 PKD1P3 
AF320594 PKDIP4 
ACOI0488 PKD1P5 
AC040158 PKDIP6 
PKO I Primer 11 R 
5' -CAGTGT AGGTGCCTCCCCTCACTG 3' (g.25621-44) 
5' CAGTGTAGGTGCTGTCCCTGTGAG 3' (g.27954-78) 
5' CAGTGTAGGTGCTGT(;CCTGTGAG 3' (g.67648-71) 
5' CAGTGT AGGTGCTGTCCCTGT�AG 3' (g.5762-5787) 
5' CAGTGT AGGTGCCTCCCCTCAC1 G 3' (g.5786-5809) 
5' TGAGGCCCGTGCCTCCCCTCACTG 3' (g.59954-78) 
5' Not present in this region 
5'CAGTGAGGGGAGGCACCT ACACT 3' (g.25622-44) 
Reverse Primer I IR is positioned at the same primer site as 12F, so it shares the same 
homology as depicted above. 
Fig IV.3. Alignment of PKDJ and HG Sequences in the IVS 11 Primer Region 
Exons 2 to 5 were amplified using a previously published PKDJ-specific forward 
primer site in JVSI (Thomas et al., 1999), and a reverse primer in exon 6. 
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IV.6. Specificity of the PCR amplification 
To confinn the specificity of the nested PCR technique with our newly designed 
primers, the nested PCR products amplified from the XL-PCR template were 
sequenced. The initial XL-PCR amplification of exons 6 to 11 was chosen as the test 
fragment, this was followed by the nested amplification of exon 8, where the template 
was used at various dilutions (1:10-4. 1:10-3 and 1:10-2). The resulting sequences were 
compared for co-amplification of PKDJ and its homologous genes (Figure IV.5). The 
experiments showed that a dilution factor greater than 1: 10-4 was necessary to produce 
a PKDJ-specific template from long-range PCR amplified product. 
Arrow indicates co-
amplified sequence. 
PCR amplification 
becomes more 
~ specific to P KD 1 at a 
dilution of 1: 10-4 or 
greater. 
Fig IV .4. Co-amplification of PKD 1 & HGs in nested PCR. 
As indicated in Chapter Ill (Section III.6), we used a previously reported primer site 
in exon 15 (Watnick et al. , 1999), specific to PKDJ when compared to HGl and HG2 
138 
(Loftus et al., 1999), to amplify two long-range fragments. The first fragment 
included most of exon 15 (IVS14F & 15R), and the second amplified the rest of exon 
15 to exon 21 {l5F & IVS2IR). The sequence of PKDP3, PKDP4 and PKDP5 has 
yet to be determined for this region, and therefore a comparison between these 
homologues and the PKDJ sequence was not possible. An anchored primer in the 
unique region of PKDJ with a forward primer in the duplicated region was used to 
amplify exons 23 to 33, as described previously (Watnick et al., 1997). 
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V. Results - Mutations 
Chapter V. Introduction 
The mutation analysis of PKDJ spanned 94% of the coding sequence, namely exons 2-
21 and 23-33 in the duplicated region, and exons 34-41 and 43-46 in the unique part of 
the gene. The duplicated region was investigated using PKDJ-specific primers, 
previously published or designed in this study as a result of the findings described in 
Chapter IV. These primers were used for the long-range PCR amplification of P KD 1 
fragments ranging in size from 1,810 bp to 6,749 bp, followed by nested PCR 
amplification and direct sequencing of the resulting products. This analysis was 
performed on 17 unrelated patients from Australian ADPKD families showing 
"positive" linkage to the PKDJ region on chromosome 16 (see p.93). 
IVSI-5 (4.5kb) 
MNCP P 
IVS5-11 (4.2kb) 
P NCM 
IVSI 1-14 (1.8kb) 
p M 
PM PPM MPP 
IVSI4-Exl5 (3.8kb) Exl5-IVS2l (3.4kb) IVS23-33 (6.8kb) 
M 
p 
NC 
Marker 
XL-PCR 
product 
Negative 
Control 
Fig V.1 Results of XL-template amplification in the duplicated region of PKDJ 
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The study of the unique 3' region of PKDJ was performed in two stages: a) screening 
by SSCP analysis, which detects conformational changes and electrophoretic mobility 
shifts resulting from sequence variation; b) specifying the nature of the sequence 
variants by direct sequencing analysis. The mutation analysis of the unique P KD 1 
region was performed in 48 unrelated individuals from ADPKD families: 15 Australian, 
26 Bulgarian and 7 Polish all showing "positive" linkage to the P KD 1 region on 
chromosome 16 (as described p.93). 
Initial PCR amplification and subsequent SSCP analysis were optimised for each of the 
13 individual fragments used to screen the unique region of the gene. The most 
appropriate PCR amplification, SSCP gel composition, and electrophoretic conditions 
are detailed in Chapter III (Section III.4 ). The gel conditions were optimised using PCR 
templates for each fragment as can be seen below (Fig V.2). Variable SSCP conditions 
markedly alter the efficiency of the technique. 
2 1 4 
Gel A: 
Ex35 run in 
TBE with 
gly~erol 
ilitlJt 
Same 
conditions 
minus glycerol 
Lane 1-3 
Wild-type 
Lane4 
Mutant 
Fig V.2. SSCP optimisation for mutation screening 
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The efficiency of the SSCP screening was assessed in the 1: Australian ADPKD 
patients by re-analysing part of the unique region, namely exons 44 and 45, and 
fragment A of exon 46. These exons were selected on the basis of the different size of 
the PCR fragments, which is a factor known to affect SSCP sensitivity (Orita, 1989), as 
well as on the basis of the large number of disease-causing mutations detected by other 
groups in this region of PKDJ (Turco et al., 1995 & 1997; Neophytou et al., 1996; 
Rossetti et al., 1996 & 2001; Roelfsema et al., 1997;· Daniells et al., 1998a & b; Afzal et 
al., 1999; Perrichot et al., 1999). 
The direct sequencing approach was also applied to 4 additional Australian patients 
from PKDJ-linked families that had joined the study at a later stage, as well as to 31 
affected individuals where linkage analysis had not been possible due to small family 
size. 
The criteria for assigning a sequence variant to the group of pathogenic mutations 
followed, as much as possible, the guidelines proposed by Cotton and Scriver ( 1998). 
The following criteria were met: (I) the same sequence variant was detected upon 
repeated analysis starting from PCR amplification; (2) the change caused a direct 
truncation of the protein either through a nucleotide substitution generating a premature 
stop codon or through a shift in the reading frame leading to a premature stop codon; 
(3) if the nucleotide change(s) resulted in an amino acid substitution or in-frame 
insertion or deletion, the altered residue was conserved in evolution and computer 
analysis of secondary protein structure suggested conformation changes; (4) a family 
study (performed whenever possible) indicated that the sequence variant segregated 
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with the disease phenotype. In some cases, family members had provided fingerprick 
blood samples r.ollected on to a filter paper card rather than whole blood. Due to the 
amount of genomic template required for long-range PCR amplification, segregation 
analysis in those few families could not be perfonned. 
The analysis resulted in the detection of a total of 74 sequence variants, of which 24 
were classified as probable disease-causing mutations (Table V.l). Twenty-one of the 
proposed disease-causing mutations, including all 12 mutations in the duplicated region 
of the gene, have been discovered as a result of this study. 
The mutation analysis included a total of 19 Australian patients wiih evidence of 
linkage to chromosome 16. The probable pathogenic mutation was identified in 14 out 
of 19, giving a 74% overall mutation detection rate for this group. 
Mutation detection in the PK.DJ gene is technically and financially demanding and is 
therefore most efficient when preceded by linkage analysis. This pre-condition was met 
for the core group of 19 Australian patients where PKDI was systematically screened. 
Nonetheless, a Jess demanding analysis of part of the unique region of the gene was 
conducted in 31 affected subjects with unknown linkage status. This part of the study 
was productive, with three mutations identified in this additional group of patients. 
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Table V.l. Summary of probable disease-causing mutations in the PKDJ gene. 
Exon or Affected Sequence Predicted effect Possible 
IVS Family ID Variation Confirmatory Assay 
Ex 5 A9 c.l352G>T Missense G381C Sac II abolished 
g.2I430G>T 
Ex 8 A4 c.1898C>T Nonsense Q563X none 
g.22716C>T 
IVS i4 A22 IVS14+1G>C Splicing Variant Alu I created 
g.26942G>C 
Ex 15 A52 c.5105-5106del Frame-shift Ode I created 
(AT) g.29004de1AT deletion 2b p 
I I 632fsX 1656 
Ex 15 A36 c.5159del G Frame-shift Afl III created 
g.29058delG deletion I b p  
V 1650fsXl721 
Ex 15 A61 c.6764T>G Missense Ava II created 
g.30662T>G Y2185D 
Ex 15 AIS c.7017C>G Nonsense S2269X Bsm AI created 
g.30915C>G 
IVS 16 AS IVS16+1G>T Splicing Variant Mae II created 
g.31394G>T 
Ex 18 A46 c.7472-74del (ACC) In-frame deletion none 
g.32650-52del 2421del T 
Ex 23 A6 c.8565G>A Missense none 
g.37893G>A G2785D . 
Ex25 A42 C. 9289-93 27 de! In-Frame deletion Visible on 3% 
g.39090del 39 3027del 13 aa agarose gel with 
ethidium bromide 
Ex 28 AJO c.9847del C  Frame-shift Bsl I created 
g.4 I352de1C deletion I b p  
F3213fsX3315 
Ex 34 B 22 c. l 0635del 23 Frame-shift Ava II abolished 
g.44374del 23 P3475fsX36 l 7 
IVS 37 857 c.IVS37-10 Splicing mutation Bsr I created 
C>Ag.48491C>A fsX3684 
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Ex40 B77 c.11587delG Frame-shift None 
g.4951 SdelG deletion I bp 
R3793fsX3824 
Ex40 PIOl c.l 1520C>A Nonsense S3770X Eag I abolished 
g.49448C>A 
Ex41 B25 c.l 1669-l I674de1 In-frame deletion Alu I abolished 
g.49737-49742del 3820-3821 del QE 
Ex44 Al8.l & c.12218C>T Nonsense Mae I (or Bfa I) 
A41.l g.5079IC>T Q4003X created 
Ex44* A72 c.12239 C>T Nonsense Q4010X Mae I created 
g.50812C>T 
Ex44° A64.1 c.12269C>T Nonsense Blp I created 
g.50842C>T R4020X 
Ex44*** A3 c.12332 C>T Nonsense Q4041X Mae I created 
g.50905C>T 
Ex45 A54 c.12347C>A Missense Bbvl abolished 
g.51003C>A IA046F 
Ex46 A38 c.12891 G>C Missense R4227P None 
g.5l637G>C 
Ex46 B41 c. l 3069ins39 In-frame insertion None 
g.5 l815ins39 aa4286ins13 
*Previous reference Damells et al., I 998b. **Previous reference Rossetti et al., 1996. 
*"'*Previous reference Turco et al., 1995. 
Tne remainder of this chapter deals with the individual disease-causing mutations in 
PKDI. The results are classified according to the type of molecular change: protein 
truncating, splice-site variation, missensc and non-truncating insertions and deletions. 
As previously noted, some mutations may not be verified as pathogenic due to lack of 
RNA for RT-PCR Mutations are named according to the recommendations of Cotton 
& Scriver ( 1998), however we have used traditional numbering for the nucleotide 
position in the gene (i.e. the first encoded nucleotide of the cDNA is at position 212 
[L33243] and position 3648 [L39891] of the genomic DNA). 
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TRUNCATING MUTATIONS 
Mutation - QS63X 
Novel 
Patient 
Ethnic Origin 
Nucleotide Change 
Position 
Gene Location 
Method of detection 
Predicted Effect 
Protein Domain 
c.DNA 
g.DNA 
Supporting Evidence: 
Family Segregation Analysis 
Confirmatory assay 
Yes 
A4.l 
Australian, British descent 
C>T transition 
1898 
22716 
Exon 8, duplicated region 
Direct sequencing 
NB. This mutation was detected iu a PCR 
fragment which may be co-amplified with 
PKD1P4 (see Chapter IV). 
Truncates polycystin-1 by 3,739 aa 
Extracellular region, downstream of C-type lectin 
domain 
Segregates with disease in 2 affected (A4.1, A4.4) 
and absent in 3 unaffected (A4.IO, 4.15 and 4.17) 
family members 
Repeat sequencing {no restriction enzyme assay 
possible) 
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Pedigree: 
A4.10 
Electrophoretogram: 
A4.4 
C>T 
~ 
A4.1 
0 
A4.15 
A4.17 
A4.15 
A4.4 
A4.17 
A4.1 
A4.10 
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Mutation - S2269X 
Novel 
Patient 
Ethnic Origin 
Nucleotide Change 
Position 
Gene Locsrion 
Method of detection 
Predicted Effec! 
Protein Domain 
c.DNA 
g.DNA 
Suppo!l"ting Evidenc;:e -
Family Segregation Analysis 
Confirmatory assay 
Yes 
Al5. l 
South African, British descent 
C>G transversion 
7017 
30915 
Exon 15, duplicated region 
Direct sequencing 
Truncates polycystin-1 by 2,033 na 
PKD domun in extracellular region 
Segregates with disease m 3 affected (Al 5.1, 
Al5.3, Al5.5) and absent m 2 unaffected (Al5.2, 
AlS.6) family members 
Sequencing (possible enzyme assay - Bsrn Al site 
created) 
149 
Pedigree: Q 
Al5 . l Al5 .2 
Al5 .3 AJ5.4 
Al5.5 Al5 .6 
Electrophoretogram: 
A15 .2 
A15.l 
c c G CG T GT G Gr • AG AC AC RC 
a a o a ~ R ~ ~ J a J J T ~ T ~ A15.5 
i ~ ~ ~ ~ f1 
~ ~ J v ll v A~) r " .,.i .A I ~ 1/ ) 
25•PKD1-1SBR- S.6 "'75 of 24 
c c G C GTGTGGT AGACACAC 
a a f ~ t ~ f r J T El T ~ T i 
fl ft ~ n n ~ l .... .) J l.t:' 1/ I 1~ 1 ..... ~ 
·-
l/ ... (/ j 
Al5 .6 
c c 
• 23•PKD1 15BR115.3., 75 of 2'45 • GCGTGTGGT AGACACAC 
~ a a r J, ZI " ~ 11 a I J T il ~ T E 
v 
n ~ 
~ n 
~ , 
I ~ I/ \ .. J .I , jl j - j 
Al5.3 
150 
Mutation S3770X 
Novel 
Patient 
Ethnic Origin 
Nucleotide Change 
Position 
Gene Location 
Method of detection 
Predicted Effect 
Protein Domain 
c.DNA 
g.DNA 
Sunporting Evidence -
Family Segregation Analysis 
Confirmatory assay 
Yes 
PIOI.l 
Polish 
C> A transversion 
11520 
49448 
Exon 40, unique region 
SSCP and sequencing 
Truncates polycystin-1 by 533 aa 
61h trans-membrane (TM) domain 
Segregates with disease in 4 affected ( t O 1.1, 
101.2, 101.3 and 101.6) and absent in 3 unaffected 
(101.5, 101.4 and 101.7) family members 
Eag I restriction enzyme assay - restriction site 
abolished (264 bp in mutant allele and 145bp + 
1 l 9bp in wild-type) 
151 
Pedigree: 
101.4 101.6 
101.2 101.7 
SSCP 2el: Shows SSCP analysis of DNA from family PlOI Exon 40 
IOI.I 101.2 101.3 101.4 101.5 101.6 101.7 
. ;--- ,~ ~. ~· ~~-..:. ·-··-> ,,.:_ _ _ :-;i 
t .~~-1 l ·~ ~ 
152 
Restriction digest of Exon 40 for Family Ptol with Eagl 
.# ff: 
'· ~.· ~ · 
.>'"' 
Sequencing Gel S3770X 
Normal PlOl.1 
TGCA TGCA 
~ 264bp 
::: 145bp & l 19bp 
Arrow indicates C> A 
153 
Mutation 04003X 
Novel 
Patients 
Ethnic Origin 
Nucleotide Change 
Position-
Gene Location 
Method of detection 
Predicted Effect 
Protein Domain 
c.DNA 
g.DNA 
Supporting Evidence -
Family Segregation Analysis 
Confirmatory assay 
Yes 
AI8.l & A41.l 
Both Australian of Macedonian descent 
C>T transition 
12218 
50791 
Exon 44, unique region 
Sequencing 
Truncates polycystin-1 by 299 aa 
Extracellular loop 
Not possible 
Direct sequencing (Possible confirmatory assay -
Mae I restriction site created) 
154 
Electrophoretogram: 
Upper Row A41. l, middle row A64.l (wild-type), lower row Al8.1 
C>T l 
155 
Mutation - 04010X 
Novel 
Patient 
Ethnic Origin 
Nucleotide Change -
Position-
Gene Location 
Method of detection 
Predicted Effect 
Protein Domain 
c.DNA 
g.DNA 
Supporting Evidence -
Family Segregation Analysis 
Confirmatory assay 
No: Daniells et al., 1998b & Kim et al., 2000b. 
A72.1 
Australian, British descent 
C>T transition 
12239 
50812 
Exon 44, unique region 
SSCP and direct sequencing 
Truncates polycystin-1 by 293 aa 
Between gth and 9th TM domains 
Not possible 
Mae I restriction enzyme assay (restriction site 
created - 226 hp + 66 bp in mutant allele and 292 
hp in wild-type) 
156 
Restriction Assay Mae I 
Lane I A72.l 
2 Lane 2 normal control 
'-1..- 292bp 
+- 226bp 
157 
Sequencing Gel 
Al8.1 (wild-type) 
A44.l (wild-type) 
A72. l (C>T Q4010X) 
158 
Mutation - R4020X 
Novel 
Patient 
Ethnic Origin 
Nucleotide Change -
Position-
Gene Location 
Method of detection 
Predicted E.:fect 
Protein Location 
c.DNA 
g.DNA 
Supporting Evidence -
Family Segregation Analysis 
Confirmatory assay 
No: Rossetti et al.. 1996 
A64.1 
Australian, British descent 
C>T transition 
12269 
50842 
Exon 44, unique region 
SSCP and direct sequencing 
Truncates polycystin-1 by 282 aa 
Between 8th and 9th TM domains 
Not possible 
Direct sequencing (possible restriction enzyme 
assay - Blp I site created) 
159 
Electrophoretogram: 
Upper row normal control; lower row A64. l 
C>T 
i 
160 
Mutation - 0404IX 
Novel 
Patient 
Ethnic Origin 
Nucleotide Change -
Position-
Gene Location 
Method of detection 
Predicted Effect 
Protein Domain 
c.DNA 
g.DNA 
Supporting Evidence -
Family Segregation Analysis 
Confirmatory assay 
No: Turco et al., 1995; Daniells et al.. 1998b 
Torra et al., 1998; Rossetti et al., 2001. 
A3.l 
Australian, British descent 
C>T transition 
12332 
50905 
Exon 44, unique region 
SSCP and direct sequencing 
Truncates polycystin-1 by 262 aa 
9"'lTM domain 
Segregates in S affected (A3.l, A3.l l, A3.13, 
A3.l 8, A3.19), not found in 1 wiaffected (A3.12) 
family members. 
Mae I restriction enzyme assay (restriction site 
created - 159 bp + 133 bp in mutant allele and 292 
bp in wild-type) 
161 
Pedieree 
? 3.11 3.12 ~ 3.1 
3.13 3.18 3.19 
Restriction Assay: Mae I 
Lanes: 
1 A3.l 
2 A3.ll 
3 A3.12 
4 A3.13 
5 A3.18 
6 A3.19 
7. normal control 
8. size standard I OObp ladder (Gibco BRL) - no well shown on gel. 
12345678 
+--- 292bp 
+--- 159bp 
+--- 133bp 
162 
SSCP & Sequencing gels 
1 2 3 4 
Lanes 1, 3, 4 - Wild-type controls 
Lane 2 - A3.l , C>T (Q4041X) 
CC T A C G CCC A G C T G G 
2 
CC T A C G CCC A G C T G G 
163 
Mutation - c.5105delAT 
Novel 
Patient 
Ethnic Origin 
Nucleotide Change 
Position-
Gene Location 
Method of detection 
Predicted Effect 
Protein Domain 
c.DNA 
g.DNA 
Supporting Evidence -
Family Segregation Analysis 
Confirmatory nasay 
Yes 
A52.l 
Australian, British descent 
deletion AT 
5105 
29004 
Exon 15, duplicated region 
Direct sequencing 
Frameshift at codon T l632, addition of 24 novel 
amino acids followed by a premature tennination 
codon at position 1656 - truncation of polycystin-
1 by 2,646 aa 
PKD repeat domain nwnber 11 
Not possible 
PCR repeated and products cloned into Topo-TA 
PCR cloning vector and sequenced 
164 
Electrophoretograrn 
Upper row wild-type cloned product; lower row delAT cloned product 
T A T G T C C T G C A G C T C A T A G A G G 
5 
A T G T C C T G C A 6 C T G--A G A G G G 
i 
delAT 
165 
Mutation - c.S159de1G 
Novel 
Patient 
Ethnic Origin 
Nucleotide Change -
Position-
Gene Location 
Method of detection 
Predicted Effect 
Protein Domain 
c.DNA 
g.DNA 
Supporting Evidence -
Family Segregation Analysis 
Confirmatory assay 
Yes 
A36.I 
Australian, British descent 
deletion G 
5159 
29058 
Exon 15, duplicated region 
Direct sequencing 
Frameshift at codon Vl650, addition of 71 novel 
amino acids, followed by a premature tennination 
codon at position 172 I - truncation of polycystin-1 
by 2, 581 aa 
PKD repeat domain number 11 
Segregates in 5 affected family members (A36. l, 
A36.3, A36.6, A36. I 0, A36.20). No ur�'fected 
members available for analysis 
PCR repeated and products cloned into Topo-TA 
PCR cloning vector and sequenced 
166 
Pedigree 
---.--:D 
36.1 
36.3 36.6 36.10 36 .20 
EJectropboretogram 
Upper row delG cloned product and lower row wild-type cloned product. 
delG ! 
T T C CCC A C C AA C C A C A C G T A 
T T CC CC A C C A A t C A C A C G G T 
~>D.~~ 
delG i 
TT CCCC A C c ~ A C c .. C A C G T A C A N C T N 
A36.l 
2 
l CCCC A C C A A C C A C A C G N '- C N A N T N 
A36.3 
't CCC C A C C A A C C A- C A C G H A NN A 6 T N G 
A36.6 
TT CCCC A C C AA C C A C A C G NN C N A G TT 
A36.10 
T T CCCC A C C AA C c ... c .. t G N A C AAG T N A36.20 
167 
Mutation - c.9847delC 
Novel 
Patient 
Ethnic Origin 
Nucleotide Change -
Position-
Gene Location 
Method of detection 
Predicted Effect 
Protein Domain 
c.DNA 
g.DNA 
Supporting Evidence -
Family Segregation Analysis 
Confirmatory assay 
Yes 
AlO.l 
Australian, British descent 
deletion C 
9847 
41352 
Exon 28, duplicated region 
Direct sequencing 
/rameshift at codon V3213, addition of 102 novel 
amino acids, followed by a premature tennination 
codon at position 331 S - truncation of polycystin-1 
by 987 aa 
PLAT domein 
Not possible 
PCR repeated and products cloned into Topo-TA 
PCR cloning vector and sequenced 
168 
Electrophoretogram 
Upper row delC cloned product; lower row wild-type cloned product 
delC l 
C A G C G CC TT TT CC T G G T 
~ : ,'\r~;L\N~ 
lO 
C A G C G CC TT C T T C C T G G T 
::£::, ~ -~/)L)c 
169 
Mutation- c.10635del23 
Novel 
Patient 
Ethnic Origin 
Nucleotide Change 
Position- c.DNA 
Yes 
B22.l 
Bulgarian 
deletion 23 hp 
10635 
g.DNA 44374 
Gene Location Exon 34, unique region 
Method of detection SSCP and sequencing 
Predicted Effect Frameshift at codon 3475, addition of 42 novel amino 
acids, followed by a premature termination codon at 
position 3517 - truncation of polycystin-1 by 785 aa 
Protein Domain Helix between 5th & 6th TM domains 
Supporting Evidence -
Family Segregation Analysis 
Confirmatory assay 
Segregates in 5 affec\'ed family members (B22. J, 
B22.2, B22.3, B22.4, B22.5). No unaffected 
members available for analysis 
Ava II r'!striction enzyme assEiy (Restriction site 
abolished - 131 + 86 bp in mutant �Hele and 97, 
57 + 86 hp in wild-type) 
170 
Pedigree 
B22.4 B22.5 
Avall Restriction Digest Assay 
B22.3 
Family B22 (22.5-22.1), normal control (NC) Size standard (S) (JOObp ladder Gibco BRL) 
22.5 22.4 22.3 22.2 22. l NC S 
Only mutant allele produces band of 131 bp. 
... 13lbp 
... 97bp 
olll 86bp 
SSCP of B22. l in centre lane with normal controls in surrounding lanes 
171 
Sequencing Gel c.10635del23 
Normal 822.1 
Deletion in sequence begins 
above the arrow 
172 
Mutation - c.1 IS87delG 
Novel 
Patient 
Ethnic Origin 
Nucleotide Change 
Position-
Gene Location 
Method of detection 
Predicted Effect 
Protein Domain 
c.DNA 
g.DNA 
Supporting Evidence -
Family Segregation Analysis 
Confirmatory assay 
Yes 
B77.l 
Bulgarian 
deletion G 
11587 
49515 
Exon 40, unique region 
SSCP and sequencing 
Frameshift at codon 3792, addition of 32 novel 
amino acids, followed by premature tenninarion 
codon at position 3824- truncation of polycystin-1 
by 478 aa 
Loop between 6th and 71h TM domains 
Segregates in 6 affected family members (B77. l, 
B77.2, B77.3, B77.4, B77.S, B77.6), not found in 
the 2 unaffected spouses (B77.7, q77.8). 
SSCP and sequencing (no restriction enzyme 
assay possible) 
173 
Pedigree 
77.5 77.6 77.3 77.4 
SSCP 
77. l 77.2 77.3 77.4 77.5 77.6 77.7 77.8 
Sequencing change 
N M N: nonnal M: Mutant 
delG 
174 
M9tation-1vsu+1G>C 
Novel 
Patient 
Ethnic Origin 
SPLICE-SITE VARIATION 
Yes 
A22.l 
Australian, Spanish descent 
Nucleotide Change -
Position- c.DNA 
g.DNA 
G>C transversion 
3506+1 
26942 
Gene Location 
Method of detection 
Predicted Effect 
Protein Domain 
IVS 14, duplicated region 
Direct sequencing 
Canonical GT donor splice site abolished. Exact effect 
has not been confinned, as RNA was not available. 
However, the most likely effect is inactivation of the 
splice site leading to translation into intton 14 for a 
further 14 aa before truncation at g.26953. Another 
possibility is the activation of a cryptic splice site 16 
nucleotides beyond ihe canonical GT splice site at 
position g.26957-8; this would lead to the addition of 5 
novel aa to polycystin-1. 
PKD repeat domain 
Supporting Exidmse -
Family Segregation Analysis Segregates in 2 affected (A.22.1, A22.6), not 
found in I unaffected (A22.S) family members 
Confirmatory assay Sequencing (possible enzyme assay Alu I, 
restriction site created) 
175 
Pedigree 
Electrophoretogram 
D,-.---
22.s 
22.6 
C T G C C C c A 
22.1 
G>Cl 
G G T G A G 
C T G CCC C A G G T G A G 
C T G CCC C A G G T G A G 
G 
A22.l 
A22.5 
A22.6 
176 
Mutation - IVS16+1G>T 
Novel 
Patient 
Ethnic Origin 
Nucleotide Change 
Position-
Gene Location 
Method of detection 
Predicted Effect 
c.DNA 
g.DNA 
Yes 
AS.I 
Australian, British descent 
G>T transversion 
7276+1 
31394 
IVS 16, duplicated region 
Sequencing 
(actual change of protein) Canonical GT donor splice site aboiished. Exact effect 
has not been confirmed, as R�· .\ was not available. 
However, the most likely effect is inactivation of the 
splice site leading to translation into intron 16 for a 
further 25 aa before truncation at g.31468. Another 
possibility is the activation of a cryptic splice site 70 
nucleotides beyond the canonical GT splice site et 
position g.314563-4; this would lead to the addition of23 
novel aa to polycystin-1. 
Protein Domain RF J domain 
Supporting Evidence -
Family Segregation Amdysis 
Confirmatory assay 
Segregates in 3 affected (A5. l, AS.3, A5.5} family 
members. No sample of unaffected (AS.2) 
available for analysis. 
Sequencing (possible enzyme assay Mae II, 
restriction site created) 
Pedigree 
Pedigree 
Electrophoretogram 
~1 I ~2 
A5.3 A5.5 
Family A5 (from the top A5.l , A5.3 and A5.5) I 
Arrow indicates G>T transversion t 
CC A CC AA CC A G A C GG T GGG T G CC C: 
Nxm 
I() 
C C A C C A A C C A G A C G TT G GG T G C C 
00 
3 
G CC A C C A A C C A G A C G G T G G G T G CC 
~~
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Mutation - IVS37-10C>A 
Novel Yes 
Patient B57. l 
Ethnic Origin Bulgarian 
Nucleotide Change 
Position-
Gene Location 
Method of detectioa 
Predicted Effect 
Protein Domain 
c.DNA 
g.DNA 
Supporting Evidence -
Family Segregation Analysis 
Confirmatory assay 
C> A transversion 
11225-10 
48491 
IVS 37, unique region 
SSCP and sequencing 
Activation of cryptic acceptor splice site: 
predicted addition of 8 nucleotides to coding 
sequence resulting in frameshift and a premature 
termination signal at codon 3685 - truncation of 
polycystin-1 by 518 aa 
Loop between 5th and 6th TM domains 
Segregates in 3 affected (B57. l, B57.2, B57.3), no 
unaffected family members were available for 
analysis. 
Bsr I restriction enzyme assay (restriction site 
created - 52, 174 + 46 bp in mutant allele and 226 
+ 46 bp in wild-type) 
179 
Wild Type 48481 agggcccccc cgtccacc [ag] AGC CTC CTG ..... . 
S L L 
Mutant 48481 agggcccccc [ag] TCC ACC AGA GCC TCC TGG ..... . 
S T R A S W 
Figure V.3 Proposed effect of splice site mutation g.48491 C> A 
Pedigree 
~ 57.1 
1 2 3 4 
57.3 
SSCP Gel: PCR fragment IVS37-IVS 38 
Lanes 1-3 
Lane 4 
Normal controls 
857.1 
180 
Bsrl Restriction Digest 
57 .1 57 .2 57 .3 NC Family B57 with normal control (NC) 
Sequencing Gel 
B57.l 
ACGT 
,.__ 372bp 
·...- 226bp 
..__ 174bp 
Normal 
ACGT 
Arrow indicates C> A mutation 
181 
Mutation-G381C 
Novel 
Patient 
Ethnic Origin 
Nucleotide Change 
Position-
Gene Location 
Method of detection 
Predicted Effect 
Protein Domain 
c.DNA 
g.DNA 
Supporting Evidence -
Family Segregation Analysis 
Confirmatory assay 
MISSENSE VARIATION 
Yes 
A9.l 
Australian, British descent 
G>T transversion 
1352 
21430 
Exon 5, duplicated region 
Sequencing 
Non-polar glycine { conserved between mouse and 
human) is replaced by uncharged polar cysteine 
with a sulphydryl group. Loop & helix changes in 
protein topology predicted by PHDsec {Fig V.4 ). 
Between 1 st PKO domain and C-type lectin 
domain 
Segregates in 3 affected (A9. l, A9.3, A9.5), not 
found in I unaffected (A9.4) family members. 
Sequencing (possible Sac II restriction site 
abolished) 
182 
Pedigree 
~ 9.3 9.4 
9.1 9.5 ? 
Electrophoretogram G>T i 
• 32•PKD1-Ex5c-9.4F S95 of 243 • 
fCAGCATCCAG A AC C G c I I GTGGT TCAGGC C T G ( 
c ~ G C r c F ~ G ~lfL "' J C l ~ T IJ. JJ T ~ ~ G ~I ~ - rn ~ 
' ~ ~ A 
A " 
\ n ~ \ 
,, 
... l/ 
-
\... \ , _ .A ,_ ~ r • 
• - -
.. 
'CAGCATCCAGAAC CGC II GTGGTTCAGGC CTGC: 
· c G C r c .. ~ G fP "- ~ c , T 1di l~ C JI G1J ~- J 51~ 
, 
• 35•PKD1-ExSc-9 3R 97 of 245 • 
C A G C A T C C A G A A C C G C . -G T G G T T C A G G C C T G G 
J ~ J TT iJ J iJ i.1 fl ~ f 0iJ fl J 
fl ~ f 
t \ ~ \ 
~, .... ~ l/1 ~ rl. l ,1 1-._ I/' v -~ /J .) hi ,.,.J ,.. ~ ,A 
34•"KD1-Ex5c-9.1R '96 of 240 
CA G CAT CC AG A AC CG C P.l'J G T G GT TC AG G CC T G C: 
r ri ~ a I J TT J iJ R ~ ~a ll J 
L 1,... 1.t: ..,. 
A9.4 
A9.5 
A9.1F 
(forward 
reaction) 
A9.3 
A9.1R 
(reverse 
reaction) 
183 
G38!C 
Mouse 
LVCPSFVHSNESLELGIRHRGGSALEVTYSILALDKEPAQVVHPLCPLDT 
Human 
LVCPSSVQSDESLDLSIQNRGGSGLEAA YSIV ALGEEP ARAVHPLCPSDT 
G381 
AA 
ILVCPSSVQSDESLDLSIQNRGGSGLEAA YSIV ALGEEP ARA VHPLCPSDTI 
PHDsec 
subset: SUB sec 
P 3 ace 
subset: SUB ace 
C381 
AA 
I EE HHHHHHHHHH HHH I 
IL.LLLLLLLL ... L. ... LLLL. .. HHHH .. HH ... LL .... LLLLLLLLI 
lebbeeebebeebbcbbbeeeeeeebebbbbbbbbbee bebbbebbeeeel 
I ................ b ......... bb. bbbbb.e ..... b ..... e.el 
ILVCPSSVQSDESLDLSIQNRCGSGLEAA YSIV ALGEEP.'\R.A VHPLCPSDTI 
PHDsec I EE HHHHHHHHH HHH I 
subset: SUB sec IL.LLLLLLLL ........ LLLL ..... HH ..... L.LL. ... LLLLLLLLI 
P _3 ace lebbeeebebeebbebbbt.eeeeeebebbbbbbbbbee bebbbebbeeeel 
subset: SUB ace j .......................... bb.bbbbb.e ..... b ..... e.el 
Figure V.4 Evolutionruy conservation and topology prediction for mutation G381C. 
Amino acids at position 381 are shown in bold and underlined. The human and mouse 
protein sequences are aligned. Predicted protein topologies for the wild-type and 
variant alleles are shown. The abbreviations of E (extended sheet), H (helix)and L 
(loop), are in accordance with PHDsec. PHD predicted relative solvent accessibility 
(ace) in 3 states are represented by: b = 0-9%, i = 9-36%, e ::;: 36-100%. (Rost & Sander 
1994). 
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Mutation- Y2185D 
Novel 
Patient 
Ethnic Origin 
Nucleotide Change 
Position-
Gene Location 
Method or detection 
Predicted Effect 
Protein Domain 
c.DNA 
g.DNA 
Supporting Evidence -
Family Segregation Annlysis 
Confirmatory assay 
Yes 
A61.l 
Australian, British descent 
T>G transversion 
6764 
30662 
Exon 15, duplicated region 
Sequencing 
Non-polar ttyptophan ( conserved between 
pufferfish, mouse and human) is replaced by 
acidic aspartic acid. Loop lost in protein topology 
predicted by PHDsec (fig V.5). 
PKDdomain 
Not possible 
Sequencing (possible Ava II restriction site 
created) 
185 
Electrophoretogram 
G T C A CC T J\ CC A 
Y2185D 
N A CC G C T GGG • 
A61 .1 
Normal 
control 
Mouse QRNYLEAHVDLRNCVSYQTEYR WEIYRT ASCQRPGRMAQMVLPGVD 
HumanQRNYLEAHVDLRDCVTYQTEYRWEVYRTASCQRPGRPARVALPGVD 
Fugu L VEASVDLKGCLRYGAQYL WQILSAPSCDNDPHF ASGRVNGAT 
Y2185 
AA 
JQRNYLEAHVDLRDCVTYQTEYRWEVYRT ASCQRPGRP ARVALPGVDJ 
PHD sec I EE EE EE I 
subset: SUB sec JLLLE ... .. LL. .... LLLL. .. ... LLL.LLLLLLLLL. ... LLLI 
P 3 ace le ebbebbbebbebbeeeeeeebee eeee e ee ebebbbebhel 
Jsubset: SUB ace Je ... b .b.b.b ... b .... e ... e .. ........... b.b ..... eJ 
02185 
AA 
JQRNYLEAHVDLRDCVTYQTEDR WEVYRT ASCQRPGRP ARV ALPGVDI 
PHO sec I EEEE EEE EE HHHHEEEEEE E EEEE I 
subset: SUB sec ILL. ....................... ...... LLLLL .. E. .LLLLI 
P 3 ace Jeee beb bebeebbb ee bebb ebebe ee ebebbbeeeeJ 
Figure V.5 Evolutionary conservation and topology prediction for mutation Y2185D. 
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Mutation - G2785D 
Novel 
Patient 
Ethnic Origin 
Nucleotide Change 
Position-
Gene Location 
Method of detection 
Predicted Effect 
Protein Domain 
c.DNA 
g.DNA 
Supporting Evidence -
Family Segregation Analysis 
Confirmatory assay 
Yes 
A6. l 
Australian, British descent 
G> A transition 
8565 
37893 
Exon 23, duplicated region 
Sequencing 
Non-polar glycine (conserved between pufferfish, 
mouse and human) is replaced by acidic aspartic 
acid. Slight change, loop shortened, in protein 
topology predicted by PHDsec (fig V.6). 
Upstream of REJ domain in extracdlular region 
prior to TM domains 
Segregates in 4 affected (A6. l, A6.3, A6.8, A6. 7), 
not found in 2 unaffected (A6.4, A6.6) family 
members. 
Sequencing (restriction assay not possible) 
187 
Pedigree 
Jf6. l 
6.4 
6.6 6.7 6.8 
Electrophoretogram 
• 1 O•PKD1-EX23Af-6_ I •191 of ~04 • 
T C G T G G C C C A G G II C A A G C G C T C G 
T C G T 6 G C C R G NC R R G C G C T C G 
A6.l 
A6.3 
A6.6 
A6.8 
A6 .7 
A6.4 
188 
G2785D 
Mouse 
Human 
Fugu 
MRSRVLNEEPL TLAGEEIV ALGKRSDPLSLLCY 
MRSRVLN EEPL TLAGEEIV AQ!i.KRSDPRSLLCY 
MHARVLNEEPL VLKGAEIAATGKLADPQSLLCY 
G2785 
AA !MRSRVLNEEPL TLAGEEIVAQ!iKRSDPRSLLCYI 
PHDsec 
subset: SUB sec 
P 3 ace 
subset: SUB ace 
1 EE HHHHHHHHHHHH EEEE I 
ILL.. .. LLLL ... HHHHHHHHH.LLLLL. EEELI 
leebebbeeebbebbbeebbbebeeeeeebbbbel 
1 ....... e ......... b .... e ...... b .. I 
1)2785 
AA 
PHD sec 
!MRSR VLNEEPL TLAGEEIV AQJ!KRSDPRSLLCYI 
subset: SUB sec 
P 3 ace 
subset: SUB ace 
I EE HHHHHHHHHHH EEEE I 
ILLL ... LLLL. .. HHHHHHHHH. LLLLL.EEELI 
leebebbeeebbebbbeebbbeeeeeeeebbbbel 
1 ....... e ......... b .... e ...... b ... 1 
Figure V.6. Evolutionary conservation and topology prediction for mutation G2785D. 
189 
l\1utation - L4046F 
Novel 
Patient 
Ethnic Origin 
Nucleotide Change 
Position-
Gene Location 
Method of detection 
PrMlicted EfT�t 
Protein Domain 
c.DNA 
g.DNA 
SupnortintLEvidens;e 
Family Segregation Analysis 
Confirmatory assay 
Yes 
A54.l 
Australian, British descent 
C>A transversion 
l2347 
51003 
Exon 45, unique region 
Sequencing 
Non-polar leucine (conserved between mouse and 
human) is replaced by aromatic hydrocarbon -
containing phenylalanine. Changes in protein 
topology predicted by PHDsec 
91Ji TM domain 
Not possible 
Sequencing (po�sible Bbv I restriction site 
abolished). 
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4046F 
C>A 
C G C A G A T C G 
C G C A G C T C G 
U046F 
Mouse 
Human 
4046L 
A Y AQMAIL11SSGAD 
A Y AQL AIL1 VSSCVD 
A54.1 
Normal 
control 
AA ILGLVVLGV A Y AQLAIL1 VSSCVDSL WSV AQALL VLCPGTG! 
PHD sec I EE HHHHHHHHHHHHHH HHHHHHHHHHHHHHH I 
subset: SUB sec ILL. .... HHHHHHHHHHHH. .. HHHHHHHHHHHHH. .LLLI 
4046F 
AA !LGL VVLGV AY AQLAIL.[VSSCVDSL WSV AQALLVLCPGTG! 
PHD sec I EEEEHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHI 
subset: SUB sec !L.EEE .. HHHHHHHHHH.HH.HHHHHHHHHHHHHH.LLLLI 
Figure V. 7. Evolutionary conservation and topology prediction for mutation L4046F. 
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Mutation - R4227P 
Novel 
Patient 
Ethnic Origin 
Nucleotide Change 
Position -
Gene Location 
Method of detection 
Predicted Effect 
Protein Domain 
c.DNA 
g.DNA 
ruspporting Evidence 
Family Segregation Analysis 
Confirmatory assay 
Yes 
A38.l 
Australian, British descent 
G>C transversion 
12891 
51637 
Exon 46, unique region 
Sequencing 
Non-polar argmme (conserved between mouse 
and human) is replaced by charged basic proline. 
Changes in protein topology predicted by PHDsec 
Coiled-coil domain 
Segregates in 3 affected (A38.l, A38.3, A38.6), 
not found in 2 unaffected (A38.2, A38.4) family 
members. 
Sequencing (restriction assay not possible) 
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Pedigree: 
2t~~ 38.3 6 
38.4 38.6 
Electrophoretogram: 
2913. 
4 
CC C A G TTT G A C C G A C T C A A C C A G G C C A C A 
-~~'0~JS/Y~ 
From the top of the page these are A38.1, A38.2, A38.3, A38.4 and A38.6. 
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R4227P 
Mouse 
Human 
4227R 
LHAVFESLLVQFDRLNQATEDVYQLEQQLQSLRG 
LQAVFEALLTQFDRLNQATEDVYQLEQQLHSLQG 
AA: LGRLGTRCEPEPSRLQA VFEALL TQFDRLNQATEDVYQLEQQLHSLQGRRI 
Sec. structure I HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH I 
Prediction Subsets 
ILLLLLLLLLLLL..HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH.LLLLI 
SUB ace 1 ................ bbb.bbb ........ b ... b .. b ........... 1 
4227P 
AA:LGRLGTRCEPEPSRLQAVFEALLTQFDfLNQATEDVYQLEQQLHSLQGRRI 
Sec. structure I HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH I 
Prediction Subsets 
ILLLLLLLLLL.HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH.LLLLI 
SUB ace 1 ............ e.b .. bb .. bb .. b ..... b ...... b ... b ... e ... l 
Figure V.8 Evolutionary conservation and topology prediction for mutation R4227P. 
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NON-TRUNCATING INSERTIONS & DELETIONS 
Mutation - c. 7472d-el3 
Novel 
Patient 
Ethnic Origin 
Nucleotide Change 
Position-
Gene Location 
Method of detection 
Predicted Effect 
Protein Location 
c.DNA 
g.DNA 
Supporting Evidence -
Family Segregation Analysis 
Confirmatory assay 
Yes 
A46.l 
Australian, British descent 
deletion ACC 
7472 
32650 
Exon 18, duplicated region 
Sequencing 
Deletion of threonine residue at codon 2421 
( conserved between pufferfish, mouse and 
hwnan). Changes in protein topology predicted by 
PHDsec 
REJ domain 
Segregates in 2 affected (A46.1, A46.3), not found 
in 2 unaffected (A46.4, A46.8) family members. 
Sequencing (restriction assay not possible) 
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Pedigree 
46.8 
46.3 46.4 
Electrophoretogram del3 i 
T A G A C C A C NN C A T C 
A46.l 
G A G A C C A C A N C NN C 
A46.3 
f G A G A C C A C C A C A T C A46.4 
4 
f G A G A C C A C C A C A T C A46.8 
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c.7472de13 
Mouse 
Human 
Fugu 
Wild-type 
AA 
PHD sec 
AARTFSNKTLVLNE TTTSTGSTGMNLVVR 
AARTFSNKTL VLDE TTTSTGSAGMRL VLR 
SAVTLQNDTL VLDSSSTif GSGGMNL VLR 
IKRGRW AARTFSNKTL VLDETI'fSTGSAGMRL VLRRGVLRDI 
I EEEEEE EEEE HHHEEEEE EEE I 
subset: SUB sec 
P_3 ace 
ILL .. EEEE .. LL..EEE.LLLL.LL. ............. LI 
leeeeebb ebeeebbbbeeeeeeeb bbb bbbeebbbeel 
subset: SUB ace le .... bb ........ b.e .......... b.bbb ...... el 
delT2421 
AA IKRGRW AARTFSNKTLVLDET-TSTGSAGMRL VLRRGVLRDI 
PHD sec I EEEEEE EEEEE E EEEEE EEE I 
subset: SUB sec ILL.EEEEE..LL.EEEE .. LLLLL. ............. LI 
P _3 ace jeeeeebb ebeeebbbbeeeeeeb bbb bbbeebbbeel 
subset: SUB ace je .... bb ........ b ........... b.bbb ...... el 
Figure V.9. Evolutionary conservation and topology prediction for c.7472dell3. 
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Mutation - c.9289del39 
Novel 
Patient 
Ethnic Origin 
Change 
Position-
Gene Location 
Method of detection 
Predicted Effect 
Protein Location 
c.DNA 
g.DNA 
Supporting Evidence -
Family Segregation Analysis 
Confirmatory assays 
Yes 
A42.l 
Australian, British descent 
39 bp deletion 
gac aga ggg get get gee ect gga gga gac etc gee ccg 
9289 
39090 
Exon 25, duplicated region 
Sequencing 
Deletion of aa 3027-3039: delTEGLLPLEETSPR 
(domain conserved between mouse and human). 
Changes in protein topology predicted by PHDsec 
Extracellular region prior to the 1st TM domain 
Detected in 1 affected (A42.1), absent in 1 
unaffected (A42.3) family member. Linkage 
analysis in this family was perfonned on DNA 
from blood-spots. The yield was not sufficient for 
XL-PCR 
PCR repeated and products cloned into Topo-TA 
PCR cloning vector then sequenced. Agarose gel 
electrophoresis also showed both alleles. 
198 
Pedigree 
42.3 
Electrophoretogram 
AGGAGGACAT GGTGTGGCGG ACAGAGGGGC 'l'GCTGCCCCT GGAGGAGACC TCGCCCCGCC AGGCCGTCTG C( 
AGGAGGACAT GGTGTGGCG- --- ----- -- ----- ----- - - -------- -------·}-C AGGCCGTI'TG C< 
Start of 39bp deletion t 
A G C G A GG A GG A C A T G G T G T G G C G G A C 
2 
A G C G A G G A G G A C A T G G T G T G G cl G C C A 
c.9289del39 
Human 
Mouse 
GLYTSLCQYFSEEDMVWRTEGLLPLEETSPRQAVCLTRHLTA 
GL YTSLCQYFSEEMMMWRTEGIVPLEETSPSQA VCL TRHLT A 
Wild-type c.9289 
AA IGL YTSLCQYFSEEDMVWR-TEGLLPLEETSPR-QAVCLTRHLT Al 
PHD sec I EE HHHH EEEEE I 
subset: SUB sec IL.EE ...... LL.LL.H. .. LLLLLLLLLLLLL.L. .. .. . Lj 
P 3 ace lebbebbb bbbee eeeeeeebbebeeebeeebeebeeebeel 
subset: SUB ace le.b.bbb .. bb ...... .. e ...... e .. ee .......... ej 
c.9289del39 
AA jGL YTSLCQYFSEEDMVWR--QA VCL TRHLT Al 
PHD sec I EEEHHHH HHHHHHHHHHHHHHH I 
subset: SUB sec jL.EE.HH ... .. HHHHHHHHHHHHHHHLLI 
P 3 ace jebbbbbbe bbee bbb bbbbbbeebeel 
subset: SUB ace je ... bbb ....... ... .. bbbbb .. .. ej 
Figure V.10. Evolutionary conservation and topology prediction for c.9289del39. 
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Mutation - c.l 1669del6 
Novel 
Patient 
Ethnic Origin 
Nucleotide Change 
Position-
Gene Location 
Method of detection 
Predicted Effect 
Protein Domain 
c.DNA 
g.DNA 
SupportingEvidence -
Family Segregation Analysis 
Confirmatory assay 
Yes 
B25.l 
Bulgarian 
6 hp deletion CAGGAG 
11669-11674 
49737-49742 
Exon 41, unique region 
Agarose gel and sequencing 
Deletion of glu and gin at codons 3820-21 
(conserved between mouse and human). Changes 
in protein topology predicted by PHDsec 
Extracellular region between 61h-J1h TM domains 
Not possible 
Alu I restriction enzyme assay (restriction site 
abolished in mutant allele (resulting fragments are 
214 and 135bp. Fragments are l 72, 48,and 135bp 
in wild-type. 
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S N N 825.1 N N 
Agarose gel of Exon 41 
S- Size Standard 
N- Normal Control 
825.1- c.11669del6 (Agarose gel appeared to have normal and larger allele; 
when sequenced this proved to in fact be a 6 bp deletion). 
Sequencing Gel c.11669del6 
825.1 Normal 
ACGT ACGT 
Arrow indicates start of 6bp deletion 
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B25.1 Alul restriction assay 
B25.1 NC Only mutant allele has 214bp band 
NC normal control does not 
.- 349 bp (Incomplete digest -ID) 
._ 301 bp (ID 349 bp - 48 bp fragment) 
~ 214 bp (Mutant only) 
172 bp (Mutant and wild-type) 
._ 135bp (Mutant and wild-type) 
48bp Fragment not shown (ran off gel) 
c.11669del6 
Human 
Mouse 
DSGGYV.QE.LGLSLEESRDRLRFLQLHNWL 
DSGGY I .QE.LGLSLEESRARLGFLQLHNWL 
Wild-type c.11669 
AA I A WS WGSCA VYDSGGYV.QE.LGLSLEESRDRLRFLQLHNWLDN I 
sec. structure I EEE EEEEEE HHHHHHHHHHHHHHHH I 
prediction 
subset ILLLLL E LLL E HHHHHHHHH LLI 
c.11669del6 
AA 
sec. structure 
prediction 
subset 
IA WS WGSCA VYDSGGYVLGLSLEESRDRLRFLQLHNWLDNI 
I EEEE EEEE HHHHHHHHHHHHHHH I 
ILL L EEE LLL EEE HHHHHHHHHHHH LLI 
Figure V.11. Evolutionary conservation and topology prediction for c.11669del6. 
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Mutation - c.13069ins39 
Novel 
Patient 
Ethnic Origin 
Nucleotide Change 
Position-
Gene Location 
Method of detection 
Predicted Effect 
Protein Domain 
c.DNA 
g.DNA 
Supporting Evidence -
Family Segregation Analysis 
Confirmatory assay 
Yes 
841.1 
Bulgarian 
ins 39bp 
�cg cag gga cca ctt egg gee aag aac aag gtc cac ccc"' 
13069 
51815 
Exon 46, unique region 
SSCP and sequencing 
Insertion of 13 aa (TQGPLRAKNKVHP) between 
codons 4286-7 Changes in protein topology 
predicted by PHDsec 
Cytoplasmic terminal region 
Segregates in 2 affected (B41.l, B41.5) and 2 pre­
symptomatic (B41.4, B4l.7), shown to be carriers 
by linkage analysis, absent in 3 unaffected (B4 I .2, 
B4 l .3, B4 I .6) family members. 
Size-separation by agarose gel electrophoresis 
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Nucleotide Insertion 
(4286) CCC "acg cag gga cca ctt egg gee aag aac aag gtc cac ccc " AGC(4287) 
Additional Amino Acids 
(4286) Pro "Thr Gin Gly Pro Leu Arg Ala Lys Asn Lys Val His Pro" Ser(4287). 
Fig V.12. Nucleotide insertion and corresponding amino acids (c.13069ins39) 
Pedigree 
41.6 
41.4 41.2 41.7 
Individuals B41.4 and B41.7 both display the insertion; both children are asymptomatic 
at this time. 
Family B41 
S 41.1 41.2 41.3 41.4 41.5 41.6 41.7 
Agarose Gel 
Lane 1: 
Marker(S) 
Lanes 2-8: 
Family B41 
(S) size standard- lOObp ladder 
NB. Although 3 bands were seen on agarose gel in the affected individuals when this 
PCR product was sequenced only 2 alleles were detected, namely the normal wild type 
allele and the allele containing the 39 bp insertion as described. Future studies could 
include sequence analysis of individual bands to solve this anomaly. 
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Polycystin-1, pos. 4268- 4302 
ex. 46, normal sequence 
AA IALPSRLARASRGVDLATGPSRTPLRAKNKVHPSSTI 
sec. structure I HHHHHHH I 
prediction 
subset ILL HHHHH LL LLLLLLL LLLLLLLLJ 
ex. 46, c.13069-13070ins39 
AA JALPSRLARASRGVDLATGPTORPLRAKNKVHPSRTPLRAKNKVHPSSTJ 
sec. structure I HHHHHHH 
prediction 
subset ILL H HH LL LLLLLLL LLLLLLLL LLLLLLLLI 
Figure V.13. Evolutionary conservation and topology prediction for c.13069ins39. 
The 13 inserted aa residues are underlined. Repeated amino acids are shown in bold 
case. 
B41.1 Normal 
TGCA TGCA 
Arrow indicates position of insertion. 
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VI. Results - Polymorphisms 
VI.1. Introduction 
Alterations in the DNA sequence that have no apparent pathological significance and do 
not segregate with the disease phenotype in the affected families were classified as 
polymorphisms. Since the primary aim of this study was to identify the probable disease­
causing mutations in PKDJ, polymorphisms were detected as a "side product", using the 
same analytical methodology as that used for the detection of pathogenic mutations 
(outlined in Chapter III.4). 
When SSCP was used as a method for mutation screening, and several unrelated affected 
individuals produced identical aberrant banding patterns, they were assumed to share a 
common polymorphism. In such cases, sequencing analysis was performed on a small 
number of representative samples. After the sequencing identification of the variant 
causing the SSCP mobility shift, a confirmatory restriction assay was designed and 
performed on all DNA samples. 
A total of 50 sequence variants in P KD 1 that did not segregate with the disease phenotype 
were detected in the families investigated (Tables VI.I & VI.2). Nineteen of these variants 
have not been described previously. 
Eight polymorphisms were intronic and the remaining 42 occurred in the coding sequences. 
This ratio is not likely to represent the true proportion of intronic to exonic polymorphisms 
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in P KD I, as it reflects the biased design of the study. where only 50-100 bp of flanking 
intronic sequence were included in the analysis of each exon. 
All exonic polymorphisms were single nucleotide substitutions (SNPs). The overall length 
of the coding PKDJ sequence analysed in this study was 12,163 bp, with a total of 42 SNPs 
detected. This allows an approximate estimate of I SNP occurring per 290 nt in this part of 
the genome. 
Of the 42 exonic SNPs detected, 29 were silent, i.e. they did not result in an amino acid 
subsutution. These variants, together with the intronic polymorphisms, are shown in Table 
Vll. 
VI.2. Missense Polymorphisms 
A particularly interesting group of polymorphisms comprised 13 SNPs that resulted in 
missense variations in polycystin-1, yet did not segregate with the disease. These sequence 
variations are shown in Table VI.2. In general, missense changes present a challenge in 
mutation analysis. Their causative role in relation to the disease phenotype is difficult to 
establish, especialJy in cases such as ADPKD. where the role of the protein involved is 
complex and poorly understood, and in vitro functional assays are not available. In 
addition, even if unrelated to the disease phenotype, these variants may exert subtle 
functional effects and thus modify phenotypic severity - a hypothesis that is to be tested in 
future research. 
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Table VI.I. Silent mutations in the PKDI gene. 
Location Patients Sequence Amino Type of Previous Reference 
with Variation Acid Change 
cbane:e Posn. 
Exon 2 A7.I c.487G>A A92 Silent exonic Rossetti et al .• (200 I) 
g.19963G>A 
Exon5 A36.l c.1234C>T A341 Silent exonic l110mas tit al.. ( 1999) 
g.21312C>T 
Exon 5 AS.I c.1330T>C L373 Silent exonic Ross etti et al .. (200 I) 
A9.I g.21408T>C 
Al3.3 
Al5.l* 
A36.I 
A42.I 
IVS 6 A7.I g.22160G>A - lntronic Novel 
IVS 9 A9.I g.23307del7 - lntronic Novel 
A13.3 
A36.I (VNTR) 
Exon 11 AS.I c.290SA.C A898 Silent exonic Thomas et al .. ( 1999) 
g.249S2A>C g. 
Exon 11 A9.I c.291 IG>A P900 Silent exonic Thomas et al .• (1999} 
AJ3.3 g.249S8G>A 
A36.l 
Exon 11 A9.1 c.2941C>T D910 Silent exonic l110mas et al .• ( 1999) 
Al3.3 g.24988C>T 
A36.I 
Exon 13 A6.l c.3274T>C 01021 Silent exonic Thomas et al., (1999) 
A29.I g.26395T>C 
A46.I 
Exon 13 AS.I c.3319G>T TI036 Silent exonic Novel 
g.26440G>T 
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Exon 13 A7.l c.3322A>G Ll037 Silent exonic Thomas et al., (1999) 
AlO.l g.26443A>G 
A52.l 
A61.1 
Exon 15 A9.l c.3583C>T All24 Silent exonic Thomas et al., (1999) 
A46.l g.27483C>T 
Exon 15 A9.l c.3586C>T Sll25 Silent exonic Thomas et al., (1999) 
A46.l g.27486C>T 
Exon 15 A9.l c.4876A>C AI555 Silent exonic Watnick et al., (1999) 
Al3.3 g.28775A>C 
A29.l 
A36.l 
A46.l 
Exon 15 A7.1 c.4885G>A T1558 Silent exonic Watnick et al., (1999) 
AIO.l g.28784G>A 
Exon 15 A9.l c.5383C>T T1724 Silent exonic Watnick et al., (1999) 
Al3.3 g.29280C>T 
A29.l 
A36.1 
A46.l 
Exon 15 A9.l c.5974G>A Ll921 Silent exonic Thomas et al., (1999) 
A13.3 g.29872G>A 
A36.1 
Exon 16 A13.3 c.7I38C>T 02309 Silent exonic Perrichot et al., (2000b) 
g.31255C>T 
IVS 16 A42.1 g.31414 G>A - Intronic Novel 
Exon 17 A9.1 c.7376T>C L2389 Silent exonic Watnick et al., ( 1999) 
A13.3 g.32427T>C 
A36.1 
A46.l 
Exon 18 Al3.3 c.7652C>T L248I Silent exonic Perrichot et al., (2000b} 
A29.l g.32830C>T 
A36.1 
A46.l 
Exon 21 A61.1 c.8098G>A A2629 Silent exonic Novel 
g.33824G>A 
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Exon 26 A6.I c.9541T>C P3110 Silent exonic Peral et al., (1997) 
A9.1 g.39466T>C 
A29.l 
A36.l 
A46.l 
IVS 31 A61.l g.4 3740T>C - lntronic Novel 
Ex35 B71.1 c.10743C>A A351 l Silent exonic Novel 
g.47419C>A 
11/48 
Ex36 B62.4 c.1095IC>T P3580 Silent exonic Novel 
g.47705C>T 
8/48 
Ex36 A29.I. c.10976C>T L3589 Silent exonic Aguiari et al., (2000) 
Pl 13.1 g.47705C>T 
2/48 
IVS 38 A25.l, c.IVS38+ 13G>A - Intronic Perricho t et al., (1999) 
A34.1 g.48653G>A 
3/48 
Ex40 B23.l c.11554C>T D3781 Silent exonic Novel 
g.49482C>T 
1/48 
Ex40 A4.1, c.l 1584G>C S3i9I Silent exonic Peral et al., (1996a) 
A22.l g.49512G>C 
2/48 
IVS 41 B23.1 "* c.IVS4 I +5ins3 - lntronic Perricho t et al .• 
g.4981 SinsGGG (2000a) 
1/48 
IVS 44 PI07.l c.IVS44+ 12C>T - lntronic Novel 
g.5093IC>T 
1/50 
IVS 44 Pl 13.l, c.lVS44+ 23insA - Intronic Novel 
A29.1 g.50942insA 
2/50 
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Ex45 A4.1, c.12484A>G A4091 Silent exonic Aguiari et al., (2000) 
Bl.I, g.51140A>G 
B78.l * 
21/48 
Ex 46(a) B4.l c.12838T>C 4209P Silent exonic Peral et al., ( 1997) 
B78.1 * g.SI584T>C 
17/48 
Ex 46(a) B3.l c.12871C>T 4220A Silent exonic Novel 
g.516I7C>T 
1/48 
Ex 46(a) A3.1 c.12872C>T 422IL Silent e:rnnic Novel 
g.516I8C>T 
1/48 
*AI5.l homozygous for c.I330T>C. & *B78.l homozygous for c.12484A>G and 
c.12838T>C. All other individuals are heterozygotes for the polymorphisms listed. 
** IVS41 +5ins3 previously reported as disease-causing by Perrichot et al., (2000a) then as 
a rare neutral polymorphism by Koptides et al., (2000). 
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Table VI.2. Missense variations in PKDI that did not segregate with the disease 
Exon Patients with Sequence Amino Frequency Previous 
change Variation Acid (%) * Reference 
cbanee 
Ex 11 A42.l c.2427A ** Q739R 1/34 (2.9%) Novel 
g.24474G>A 
Exl4 A6. I, A29. I, c.3486T>C M1092T 3/34 (8.8%) Novel 
A46.l g.26921T>C 
Ex 15 A29.l, A46.l c.4406T>C W 1399R 2/34 (5.8%) Watnick et al., 
g.28306T>C (1999) 
Ex 15 A52.1 c.5157C>T T1649M 2/34 (5.8%) Novel 
g.29056C>T 
Ex21 A29.I, A46.I c.8124A>G H2638R 2/34 (5.8%) Watnick et al., 
g.33849A>G (1999) 
Ex 23 A42.1, A46. l c.8504C>T R2765C 2/34 (5.8%) Novel 
g.37844C>T 
Ex 25 A6. l, A9.l, c. 9406GT>CC F3066L 5/34 (14.7%) Peral et al., ( 1997) 
A29.l, A36.l, g.39207GT>CC 
A46.l 
Ex 35 B80. l PI08. I c.10737C>T TM3509 2/96 (2.1%) P eral et al., (l 997). 
g.47413C>T 
Ex36 BI.I A29.1 c.10986G>T S/13592 2/96 (2.1%) Novel 
g.47737G>T 
Ex 38 Pl09.I c.l 1295G>A G/Q3695 l/96 (1.0%) Novel 
g.4857IG>A 
Ex40 PI01.1 c.l l582T>A S/T3791 1/96 ( 1.0%) Novel 
g.49510T>A 
Ex44 22 p e ople c.1234 lA>G l/Y4044 23/100 Ross etti et al., 
B78. l *** g.50914A>G (23.0%) (i996) 
Ex45 B2.I c.12384C>T A/V4058 1/96 (1.0%) Constantinides 
I g.5 I040C>T et al., ( 1997) 
* Frequency calculated as affected alleles divided by number of chromosomes tested. 
**Genomic sequence lists G at nucleotide 24474, however cDNA has A at the 
corresponding position 2427 
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*** B78.1 was homozygous for I/\/4044 producing a different SSCP pattern compared to 
heterozygotes for this change. 
In this study, the non-pathogenic missense variations were investigated in greater detail in 
terms of their predicted effect on protein topology. The analysis was conducted using 
nnPredict, a secondary protein prediction tool (http://dot.imgen.bcm.tmc.c::du: 9331/seq­
search/struc-predict.html). To assess evolutionary conservation, the amino acid involved 
was compared between human and mouse and, when possible, the Japanese Pufferfish 
(http://www.sanger.ac.uJrJSoftware/Pfam/index.html). The type of amino acid change was 
also determined. The results are presented below. 
Q/R 739 
Glutamine, a polar amino acid with an amide side chain, is replaced by arginine, a basic 
amino acid. The glutamine residue is conserved betweer. human (Accession# L33242) and 
mouse (008852). however another published human polycystin-1 sequence (Accession# 
P98161) lists this residue as arginine. One can presume therefore that the variation 
between published sequences represents a non-disease causing polymorphism. The change 
occurs between the LDL-A domain and the second PKD repeat The Q/R 739 mutation 
causes a marked change in the predicted secondary protein structure. however it is in a 
region of the protein which does not correspond to any known functional domain. Q/R 739 
was detected in one Australian patient (A42.1) and subsequently in an ADPKD family from 
Bulgaria (personal communication, Dr. Nadja Bogdanova). 
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0739R 
Human (L33243) 
Human (P98161) 
Mouse (008852) 
AGPGALLHCSP APGHPGPQAPYLSANASSW 
AGPGALLHCSP APGHPGPRAPYLSANASSW 
LLQCPLASSC PG QAL YLSTNASDW 
0739 
AA 
PHD sec 
JAGPGALLHCSP APGHPGPQAPYLSANASSWJ 
subset: SUB sec 
P 3 ace 
subset: SUB ace 
R739 
I EEEE I 
JLLL.EEEE.LLLLLLLLLLLL. .. LLLLLLJ 
Jeeeebbbbbbebee eeeebe bbbebeeeJ 
Je ... bbb.b .... e ................ J 
AA JAGPGALLHCSP APGHPGPRAPYLSANASSWJ 
PHD sec I HRH I 
subset: SUB sec JLLL..LLLLLLLLLLLLL. ..... LLLLLLJ 
P 3 ace Je beebbee eeeeee eebbebeeeeeeel 
subset: SUB ace Je .... b ....... e ..... b .... ee .... J 
Fig VI.1. Evolutionary conservation and topology prediction for variation Q739R. 
Sequencing gel 
A42.1 
AJG 
Nonna! 
Control 
A 
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M/1'1092 
Methionine, a non-polar amino acid with a sulphur-containing side chain, is repiaced by 
threonine, a polar amino acid with an aliphatic hydroxyl side chain. This residue is not 
conserved between human and mouse, in fact the mouse has threonine at this homologous 
position. The change occurs in the fourth PKD repeat domain of polycystin-1 and results in 
predicted changes in secondary protein structure. The novel change was detected in the 
DNA of three from 17 screened Australian patients (A6. l, A29 .1, A46.1 ). In two of these 
families (A6. l and A46. l ), other sequence variants segregating with the disease phenotype 
have been detected (Chapter V). 
M1092T 
Human 
Mouse 
PDPSVAQVLVEHNVMHTYAA 
PDPTVAQVLVEHNTfHIYTT 
Ml092 
AA IPDPSVAQVL VEHNVMHTYAAI 
PHl) sec 
subset: SUB sec 
P_3 ace 
subset: SUB ace 
Tl092 
I HHHEEEEE EEEEEE I 
ILLL .. H..EE ....... E.LI 
jeeeebbebbbebbbebb bel 
lee ... b.bbb ... b ...... l 
AA IPDPSVAQVL VEHNVIHTY AAI 
PHD sec I EEEEEEEE EEEEE I 
subset: SUB sec ILLL ... EEEEEE ..... E.LI 
P 3 ace leeeebbebbbebbbebb bel 
subset: SUB ace lee ... b. bbb ... b ...... I 
Fig VI.2. Evolutionary conservation and topology prediction for variation MI092T. 
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Sequencing Gel Mff1092 
Normal 
Control 
A6.l 
A29.1 
A46.l 
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W/R 1399 
Tryptophan, a non-polar amino acid with an aromatic side chain, is replaced by arginine, a 
polar basic amino acid. This residue is not conserved between human and mouse, the 
mouse has arginine at this position. The substitution occurs in the PKD-repeat domain of 
polycystin-1. No effect is predict�d on secondary protein structure. The change was 
detected in two Australian patients (A29. l and A46. l) and has been detected previously in 
a family living in the USA (ethnicity not given) (Watnick et al., 1999). 
W1399R 
Human 
Mouse 
PEVGNVTLQPERQFVQLGDEA \VL VACA 
PEIRNITLQPERQFVKLGDEA,RLVAYS 
W1399 
AA IPEVGNVTLQPERQFVQLGDEA WL V ACAi 
PHDsec 
subset: SUB sec 
P 3 ace 
subset: SUB ace 
R1399 
I HHHHHHH EEEEEE I 
ILLLL.. LLL. H. I-Il-Il-LL. ... EEE. LI 
leebbeb b eeeebbebeeebbbbbbel 
lee ........... b ...... bbbbb .. I 
AA IPEVGNVTLQPERQFVQLGDEARL VACAI 
PHD sec I HHHHHE EEEEEE I 
subset: SUB sec IL.LLLLLLL. ... H ... L. ... EEEELI 
P _3 ace leebbeb b eeeebbebeeebbbbbbel 
subset: SUB ace lee ........... b ...... b.bbb .. j 
Fig VI.3. Evolutionary conservation and topology prediction for variation W1399R. 
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Sequencing Gel W/R1399 
Normal 
Control 
A46.1 
A29.1 
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TIM 1649 
Threonine, a polar amino acid with an aliphatic hydroxyl side chain, is replaced by 
methionine, a non-polar amino acid with a sulphur-containing side chain. This residue is 
conserved between human and mouse. The change occurs in the PKO-repeat domain of the 
protein. A slight change is predicted in protein secondary structure. The novel change was 
detected in one Australian patient (A52. l ), with no other family members available for 
segregation analysis. In the same patient, a deletion resulting in a frame-shift 
(c.5I05de1AT) was found in the same PCR fragment as the polymorphism (see Chapter V). 
This deletion was investigated in detail after cloning of the PCR fragments with the TA-
10 cloning kit (Invitrogen). Subsequent sequence analysis of the cloned fragments 
demonstrated that the TIM 1649 variation and the deletion occurred on different 
chromosomes. 
T1649M 
Hwnan 
Mouse 
T1649 
AA 
PHD sec 
P1NHTVQLQAVVRDGTNVSYSWTAWR 
PTNYTLQLQAAVRDGTNISYSWTAQQ 
IPTNHTVQLQA VVRDGTNVSYSWT A WR! 
subset: SUB sec 
I EEEEEEEE EEEEEEEEE I 
ILLLL.EEEEEE .. LLL.E.EE .. EELI 
leeeebbebbbbeeebeebbebbbbbel P 3 ace 
subset: SUB ace je .... b.b .. b ...... b .. b ..... j 
M1649 
AA IPTNHMVQLQAVVRDGTNVSYSWTAWRI 
PHD sec I EEEEEEEEE E EEEEEE I 
subset: SUB sec ILL. ... E.EEEE.LLL. .. EEE ... LI 
P _3 ace leee ebbbebbb ebeebbbbbbbbel 
subset: SUB ace lee ... b.b.bb ............... l 
Fig VI.4. Evolutionary conservation and topology prediction for variation Tl649M. 
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Electrophoretogram T/M1649 
i T nt trnnslMes to methionine 
CC AA CC A C A I GG T A C A G C T G C A G 
Ml649 
T1649 
t I C nt tr:mslMes to threonine 
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H/R2638 
Histidine, a basic amino acid which can be polar or non-polar. is replaced by arginine, a 
polar amino acid of the same group. This residue is not conserved between human and 
mouse. The mutation is located in the REJ domain of polycystin-1. It has no predicted 
effect on secondary protein structure. H/R2638 was detected in two Australian individuals 
(A29.l and A46.1) and has been described previously in a family living in the USA 
(ethnicity not given) (Watnick er al., 1999). 
H2638R 
Human 
Mouse 
EPKHERQHRAQIR.K.NITETL VSLRVHTVDDIQQIAAAL 
EPNVEQ�RAQiviRKNITETLISLR VNTVDDIQQIT AAL 
H2638 
AA IEPKHERQ!!RAQIRKNITETL VSLRVHTVDDIQQIAAALI 
PHD sec 
subset: SUB sec 
P 3 ace 
subset: SUB ace 
R2638 
I HHE HHHHHHHH I 
ILLL..HHHHHHHHHHH.HH.H. ....... HHHHHHH.LI 
leeeeeeebebebeeebeebbbbb bbbbeebebbbbbbl 
le.e ........ b.e.b ... bb.b ....... b .. bb ... l 
AA IEPKHERQRRAQIRKNITETLVSLRVHTVDDIQQIAAALI 
PHD sec I IHEE HHHHHHHH I 
subset: SUB sec ILLL.HHHHHHHHHHHH.HH. ......... HHHHHHH.LI 
P 3 ace leeeeeeeeebebeeebeebbbbb bbbbeebebbbbbbl 
subset: SUB ace le.e ........ b.e.b ... bb.b .... b .. b .. bb ... l 
Fig VI.5. Evolutionary conservation and topology prediction for variation H2638R. 
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Sequencing GeJ H/R2638 
C A C G A G C GG C A G C A C C G A G C CC A G A T 
A29.1 
A46.l 
Normal 
Control 
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R/C2765 
Arginine, a polar basic amino acid, is replaced by cysteine, a polar amino acid with a 
sulphydryl side chain. This ·residue is conserved in human and mouse but not in pufferfish. 
The change occurs in the extracellular region of the protein, between the REJ and the first 
transmembrane domain. No effect is predicted on secondary protein structure. The novel 
RIC 2765 variant was detected in two Australian patients (A42. l and A46. l ). In both 
families, probable disease-causing mutations in PKDJ have been detected (see Chapter V). 
R276SC 
Human 
Mouse 
Fugu 
VASQAYNLTSALNIRILMRSRVLNEEPLTL 
VASKAYNLSSALMRILMRSRVLNEEPLTL 
V AAKA YSLSSVLMLILMHARVLNEEPL VL 
R2765 
AA jVASQA YNLTSALMRIL.MRSRVLNEEPL TLI 
PHDsec 
subset: SUB sec 
P 3 ace 
subset: SUB ace 
I HHHHHHHHHHHHHHHHHHH I IL.L .. IIBHHHHHHHHHHHHHHH.LLLLLLI 
lebbeb ebbbbbb bbbeb bbeeeebeel 
1 .... b .. b .. bbb.bbb.b .... e ..... 1 
C2765 
AA IVASQA YNL TSALMCIL:MRSRVLNEEPLTLI 
PHD sec 
subset: SUB sec 
P 3 ace 
subset: SUB ace 
I HHHHHHHHHHHHHHHHHHH I IL .... Hffi-IHHHHHHHHHHHHHH.LLLLLLj 
lebbeb ebbbbbbebbb b bbeeeebeel 
1 .... b .. b .. bbb.bbb.b .... e ..... 1 
Fig VI.6. Evolutionary conservation and topology prediction for variation R276 l C. 
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Sequencing Gel R/C2765 
T G C G C A T C C T C A T G i G C T CCC G C G T 
T G c G c A T cc T C A t G I G c T c cc G c G T 
= 
2 
T G c G c A T cc T C A T G I G c T c cc G C G T 
4 
T G C G C A T C C T C A T G I G C T CC C G C G T 
Normal 
Control 
A29.1 
Normal 
Control 
A46.1 
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F/L3066 
Phenylalanine, a non-polar amino acid with an amm�tic side chain, is replaced by leucine, 
a non-polar amino acid with an aliphatic side chain. This residue is conserved between 
human and mouse. A slight change is predicted in secondary protein structJre. The 
variation occurs in the extracellular region of the protein, between the REJ and the first 
transmembrane domain, and was detected in the DNA of five individuals (A6.1, A9.1, 
A29. l, A36.l and A46. l). It had been detected previously in a British population at a 
frequency of 23.5% (Peral et al .. 1997). 
F3066L 
Human 
Mouse 
F3066 
AA 
PHDsec 
HVRFVFPEPT ADVNYIVMLTCAVCL VTYMVMAAILHKLDQLD 
HVQFI FPEPSA S I NYIV LLTCV ICL VTY VVMAMILRKLDQLD 
IHVRFVIPEPT ADVNYIVMLTCAVCL VTYMVMAAILHKLDQLDI 
I EEEEE EEEEEE EEEEHHHHI-IlIHHH I 
subset: SUB sec 
P 3 ace 
ILEEEE.LLLLLL .. EEEEEE.LLL.EE ... HHHHHHHH.LLLI 
leb bbbeebeeebebbbbbbbbeeebbbbbbbbbbeebeebel 
subset: SUB ace 1 ... bb .......... b.bbbbb .... b .. bbbbbb .. b .... 1 
l.3066 
AA IHVRFVLPEPT ADVNYIVMLTCA VCL VTYMVMAAILHKLDQLDI 
PHO sec I EEEE EEEEEE EEEHHHHHHHHHIIB I 
subset: SUB sec IL.EEE.LLLLLL. .EEEEEE.LL .. E ... HHHHHHHHH.LLLI 
P 3 ace jeb bbbeebeeebebbbbbbbbeebbbbbbbbbbbeebeebel 
subset: SUB ace l.b.bbb ..... e ... bbbb.bb .... b .. bbbbbb ....... j 
Fig VI.7. Evolutionary conservation and topology prediction for variation F3066L. 
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Sequencing Gel F/L3066 
C C A T G T CC G C TTT G T NN TT CC T G T GA G T 
£VX,.(' [Y::scA~f\-r'--AL\,:;~~x::/Y:Y::x: 
i CC A T G T CC: G C TT T G T N N T T C C T G T GAG T 
£'f )<::l'UC::cJ'v.x , (\A__1':-lh----£::x:,,[v\.rJW\x;;;LY,,~V::-£ 
C C A T G T cc G C Tl T G T NN T T C C 1 G T GAG l 
~Ad\CJ':~,j-v>'AL~>A£::C\r.--,/\f:J_~~'2~· 
.:=:J. 
C C A T G T C C G C TTT G T G TTT C C T G T (i A G T 
YX: 
A6.1 
A9.1 
A29.1 
A36.1 
A46.1 
Normal . 
control 
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T/M3509 
Threonine, a polar amino acid with an aliphatic hydroxy] side chain, is replaced by 
methionine. a non-po]ar amino acid with a sulphur-containing side chain. This iesidue is 
conserved in human and mouse but not in pufferfish. The mutation is located in a 
cytoplasmic loop between the 3rd and 4th transmembrane domains of polycystin-1. No 
change is predicted in secondary protein structure. The mutation was detected in 2 families 
(B80 and PI 08) out of 48 families screened for this part of the gene. 
T3509M 
Mouse 
Human 
Puffer fish 
SSVPGEKTETLILQTVGEE 
SSTPGEKTETLALQRLGEL 
SSIFEDQTEVILLQKHHEP 
T3509 
HMETDLLSSLSSTPGEKTETLALQRLGELGPPSPGLNWEQPQAARLSRTG 
Secondary structure prediction (H = helix, E = strand, - = no prediction): 
----I-II-II-I-----------1-If-IIIfIJillrl----------------lilflifiif----
M 3509 
HMETDLLSSLSSTPGEKTEMLALQRLGELGPPSPGLNWEQPQAARLSRTG 
Secondary structure prediction (H = he1ix, E = strand, - = no prediction): 
----I-II-II-I----------liJ-I1Il-ll1l-Il-ItI----------------tifil-IlII-l----
Fig VI.8. Evolutionary conservation and topology prediction for variation T3509M. 
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Exon 35 
SfNal Restriction digest 
1, 2, 3, 4, 5, 6, 7, 8, 9 ,10, 11, 12, 13 
~ ,)?"· 
~·::\H.; ·. 
Lanes 1-11 Families P108 & B80 
Lane 12 Normal Control (NC) 
Lane 13 Size Marker 
Pedigree B80 
B8T05 
880.p0.2 
B80.3 
SSCP gels arrows indicate B80. l & P 108 
1 2 3 4 
Lanes 1-3 NC 
Lane 4 B80.1 
1 2 3 
Lane 1 P108.1 
Lane2NC 
Lane 3 Size Marker 
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S/13592 
Serine, a polar amino acid with an aliphatic hydroxyl side chain, is replaced by isole1;1cine, 
a non-polar amino acid with an aliphatic side chain. This residue is conserved in hwnan 
and mouse but not in pufferfish. The mutation occurs in the 4th transmembrane domain of 
the protein. A slight change is predicted in secondary protein structure. Two families (B 1, 
A29). from 48 were detected to have this change. 
S3592! 
Mouse 
Human 
Pufferfish 
S3592 
WLLSS§SSFLASFLGWEP 
WLLSS§ASFLASFLGWEP 
WLLSCF ASFLCSCLLLEP 
PPGVSVA WLLSS§ASFLASFLGWEPLKVLLEALYFSLV AKRLHPDEDDTL 
Secondary structure prediction (H = helix. E = strand, - = no prediction): 
---EEEEEEH--HHHEEE------HHHHHHHHHHHHHH--------
13592 
PPGVSV A WLLSS}ASFLASFLGWEPLKVLLEAL YFSL V AKRLHPDEDDTL 
Secondary structure prediction (H = helix, E = strand, - = no prediction): 
---EEEEEHHHHHHHHH-------HHHHHHHHHHHHHH----
Fig VL9. Evolutionary conservation and topology prediction for variation S3592I. 
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Restriction Digests of Exon 36 (Hhal);Gel A, arrows indicate A29 .1 and B 1.1 
Pedigree Bl 
0 
Bl. I Bl.6 
Bl.9 Bl.2 BI.3 
Gel B Family B 1 with normal control (far right) 
SSCP Family B 1 
Exon36 
B 1.1 - B 1.10 ran in 
lanes left to right. 
Aberrant SSCP does 
not co-segregate with 
disease as seen in 
pedigree below 
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GiQ 36�5 
Glycine, a polar amino acid, with an aliphatic side chain consisting of a hydrogen atom, is 
replaced by glutamine, a polar amino acid with an amide group side chain. This residue i.:. 
conserved between human and mouse but not in pufferfish. The variation occurs in an 
extracellular loop of the protein, between the 6th and 7th transmembrane domains. A slight 
change is predicted in secondary protein structure. One family (Pl09) out of 48 was found 
to have this change. 
G36950 
Mouse 
Human 
Puffer fish 
G 3695 
DASCHGHA YRLQSAIKQEL 
DASCHGHA YRLQSAIKQEL 
DSDKDAHSLRLRTQLQRAL 
LL VTLLASYGDASCHGHA YRLQSAIKQELHSRAFLAITRS 
Secondary structure prediction (H = helix, E = strand, - = no prediction): 
--EEEI-II-I-----------
B3695 
LLVTLLASYGDASCHQJ!AYRLQSAIKQELHSRAFLAITRS 
Secondary structure prediction (H = helix, E = strand, - = no prediction): 
--EEEHH----HHHHHHHHHHHHHHHHHHHHHHHH---
Fig VI.10. Evolutionary conservation and topology prediction for variation G3695Q. 
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Lane 18 
Pedigree 
P109.8 P109.51 
.13 .14 .15 
P109.11 .10 .12 P109.16 P109 .. 2 P109.4 
Restriction Digest 
Family segregation 
PlOl 
Lanes 1-16 
FamilyPlOl 
Lane 17 
Normal Control 
Lane 18 
1 OOObp Marker 
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srr 3791 
Serine, a polar amino acid with an aliphatic hydroxyl side chain, is replaced by threonine, 
an amino acid of the same group. This residue is conserved between human and mouse and 
no infonnation is available on pufferfish. The sequence variation corresponds to an 
extracellular loop in the protein between the 6th and 7'11 transmembrane domains. No 
change is predicted in secondary protein structure. One family (Ptol) from 48 was 
detected to have this change. A disease-causing mutation (S3 770X) had been detected in 
this family in the same amplicon. 
S3791T 
Mouse 
Hu.man 
S 3791 
WQSVVQNG§ET 
WESP---HNG§GT 
YDVGWESPHNG§GTWA YSAPDLLGA WSWGSCAVYDSGGYV 
Secondary structure prediction (H = helix, E = strand, - = no prediction): 
-------------EE----H--------E.E:E------
D791 
YDVGWESPHNGTGTWA YSAPDLLGA WSWGSCAVYDSGGYV 
Secondary structure prediction (H = helix, E = strand, - = no prediction): 
--------EE---H--------EEE---
Fig VI.11. Evolutionary conservation and topology prediction for variation S3791T. 
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264bp 
182bp 
82bp 
Pedigree: 
,Jf 101. l 
1 2 3 
101.4 
101.2 101.7 
Ava I restriction digest Exon 40 
Lane 1 
Lane 2 
Lane3 
101.6 
PlOl. l 
Normal Control 
Size Standard (lOObp ladder) 
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I/V 4044 
Isoleucine, a non-polar amino acid with an aliphatic side chain, is repiaced by valine, an 
amino acid of the same group. This residue is conserved between human and mouse and 
no infonnation is available on pufferfish. The variation is located in the 9th transmembrane 
region of the protein. No change is predicted in secondary protein structure. Of 48 
families screened, 21 were detected with this polymorphism. Family analysis was not 
undertaken for this common change. 1/V 4044 has been described previously (Rossetti et 
al., 1996) as a non-pathogenic polymorphism in an Italian family. The 14044 variant was 
detected at a frequency of26% in the Spanish population (Badenas et al., 1999). 
14044V 
Mouse 
Human 
LGVA YAQMA!l,LISSGAD 
LGV A Y AQLA!LL VSSCVD 
14044 
LGLVVLGVAYAQLA!LLVSSCVDSLWSVAQALLVLCPGTGLSTLCPAESW 
Secondary structure prediction (H = helix, E = strand, - = no prediction): 
--EEEEHHHHHHHHHEEE----HHHHHHHHEEE-------E------
V 4044 
LGLVVLGVAYAQLAVLLVSSCVDSLWSVAQALLVLCPGTGLSTLCPAESW 
Secondary structure prediction (H = helix, E = strand, - = no prediction): 
-EEEEHHHHHHHHHHEE-HIDiHHIDilfEEE--E--
Fig VL12. Evolutionary conservation and topology prediction for variation I4044V. 
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Sequencing Gel 1/V 4044 
A>Gi 
G C CC A G C T GG C C N T C C T GG T A GG 
2 
G G C T G G C G T A G 
SSCP Exon 44 
This common polymorphism can be seen across the gel with its two distinct SSCP patterns. 
Lane marked 57.1 (far right) represents a sample that was homozygous for the less 
common allele. 
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A/V 4058 
Alanine, a non-polar amino acid with an aliphatic side chain, is replaced by valine, an 
amino acid of the same group. This residue is conserved between hwnan and mouse and 
no information is available on pufferfish. The variable residue is located in the 10th 
transmembrane region of the protein. No change is predicted in secondary protein 
structure. NV 4058 was detected in one family (B2) from 48 ADPKD families studied. 
A4058V 
Mouse 
Human 
TLYNMARAFLVLCPGARVPTL 
SLWSV AQALL VLCPGTGLSTL 
A4058 
LGLVVLGVAYAQLAVLLVSSCVDSLWSVAQALLVLCPGTGLSTLCPABSW 
Secondary structure prediction (H = helix, E = strand, - = no prediction): 
--EEEEHHl-IHHHI-Il-Il-il-IEE------�EE------E------
V 4058 
LGLVVLGVAYAQLAVLLVSSCVDSLWSVVQALLVLCPGTGLSTLCPAESW 
Secondary structure prediction (H = helix, E = strand, - = no prediction): 
--EEEEHHHHHHHHHHEE-----EHHHHHHEEEE-----E-----
Fig VL13. Evolutionary conservation and topology prediction for variation A4058V. 
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Restriction Digest for family B2 (Avail) Exon 45 
Lanes 1-8: Family 82 
Lane 9: Normal Control 
Lane 10: Size standard (cut off picture) 
l \~~ .. . kl , .. 
\ . \ . :'- .. SSCPExon 45 1. Normal control 
2. 82.1 
,. 
PedigreeB2 
0 
82.7 
82.2 82.8 
82.4 82.3 82.6 
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VI.3. A variant in the 3' Unique Region segregating with the disease phenotype 
An intronic insertion was found to segregate with the ADPKD phenotype in Bulgarian 
family B23, and was characterised using the TOPO-TA cloning kit (Invitrogen). Clones 
containing the PCR inserts from patient B23. l were subject to sequence analysis. The 
resulting electrophoretogram below (Fig VI.14) displays the sequence variation between 
the cloned PCR insert of the wild-type allele and the IVS4 l + 5 ins3 variant allele. 
insGGG ! 
C T GG A C A,!, C A GG T GGG t. G C T CCC T C CCC T 
C T G G f.. A G G T G G C T CCC T CC 
10229 
Fig VI.14. B23.1 Clones showing Wild-type allele and below the IVS4 l +5insggg 
The change was initially suspected to be pathogenic as it segregated with the disease in this 
family. The insertion of three nucleotides so close to the donor splice site could 
hypothetically interfere with normal splicing and thus represent a disease-causing mutation. 
This sequence change had been suggested previously to be the disease-causing mutation in 
a French family (Perrichot et al., 2000a). However, shortly after the publication of the 
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French report, Koptides et al. (2000) showed that the same DNA variation was detected in 
a Greek-Cypriot kindred, where it did not segregate with the disease. In this study, the 
mutatior1 occurred in all four affected subjects in family B23 and was not found in one 
unaffected family member. No disease-causing mutation has been identified in this family. 
The change was not detected in the other 47 families screened. RNA from this family was 
not available for analysis. It was therefore not possible to determine the sequence of the 
transcribed RNA to assess if the translated protein is affected by the sequence variation. 
VI.4. Linkage Disequilibrium in the PKDJ gene 
VI.4.i. Linkage Disequilibrium in the 5' Duplicated Region of PKDJ 
A number of polymorphisms in the duplicated region of PKDJ (shown in Table VI.3) 
appear to be in linkage disequilibrium. The physical distance between the polymorphisms 
is approximately 18 kb of genomic DNA, corresponding to a region in PKD 1 between exon 
5 and exon 26. Only a small number of families, mostly of the same ethnic background, 
have been studied. It will be interesting to ascertain if linkage disequilibrium occurs in all 
ethnic groups and whether this SNP haplotype can be used for investigating affinities 
between populations. 
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Table VI.3. Shared polymorphisms of the 5' Duplicated region of PKDI 
Patient A6 2<:) 1\46 A9 A13 A36 A7 AlO 
Seq. Change 
1373 na + + + 
IVS9del7 + + + 
P900 + + + 
P910 + + + 
1021 +- + + 
Ll037 + + 
1 n-'1092 + 4- + 
A1124 na +- + 
Sl 125 na + + 
W/Rl399 na ;- 4-
A1555 na + + + + + 
Tl558 na + + 
T1724 na + .... + + + 
Ll921 na + + + 
12389 na + + + + 
L2481 na + + + + 
I 'R2638 na + + 
F/L3066 t- + + + + 
P3110 +- + + + 
*na Patient A6 was not screened in the region from exon 1 to 5 and 15 to 21. 
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VI.4.ii. Linkage Disequilibrium in the 3' Unique Region of PKDJ 
An interesting observation on the inheritance of ancestral chromosomes was related to the 
co-existence of three common polymorphisms in the final three exons of P KD 1, over a 
physical distance of670 hp. These are I/V4044 in exon 44; c.12484A>G (A4091) in exon 
45 and c.12838T>C (in exon 46). Of 85 PKDJ-linked individuals from three ethnic groups 
screened in this study, 29 (34%) shared all three polymorphisms and one (B78.l) was 
homozygous for each. Patients who had the polymorphisms included 19 of 57 Australians 
(33%}, 2 of 7 Poles (29%), and 8 of 21 Bulgarians (29%), suggesting that this haplotype is 
common across Europe. 
Greater vruiation in linkage disequilibrium was observed in Bulgarian individuals, where 
five had a combination of one or two of the polymorphisms but not all three (see Table 
VI.4). Two additional polymorphisms in exon 45, namely (AN4058 and c.12617C>T 
4220A}, were noted to occur in addition to the other three polymorphisms. The sub-group 
of individuals with all five polymorphisms represents nine of the total of 55 patients (16%). 
This linkage disequilibrium had previously been noted in a Spanish population (Badenas et 
al., 1999): 26% of the Spanish population had all three common polymorphisms, and 8% 
of individuals also had the additional A/V4058 polymorphism. The ease of investigating 
the I/V4044/c.12484A>G/c.12838T>C haplotype located in the unique region of PKDJ, its 
high frequency in diverse ethnic groups, and the observed differences, suggest that these 
polymorphisms may be useful in population genetics research. 
243 
Table VI.4. The shared common polymorphisms of PKDI exons 44-46 
Individuals with Individuals with Individuals with 
Exon 44 IN 4044 Exon 45 c. l 2484A>G Exon 46 c.12838T>C 
4091A 4209P 
B2.l B2.l B2.l - - B3.l 
- B4.l B4.l 
BIS. I BIS.I BIS.I 
B23. l B2:J. l B23.l 
B41. l B4l.1 B41.1 
BS3. I BS3.I B53.I 
BS7.l B57.I -
B73.l B73.l B73.I 
B74.1 B74.1 B74.I 
B7S.3 B7S.3 -
B77.l B77.1 -
B78.l* B78.1 * B78.1 * 
A3.1 A3.l A3.l 
A6.I A6.l A6.l 
A9.J A9.l A9.I 
AI I. I Al 1.1 Al I.I 
Al4.l Al4. l AI4. l 
A2S.l A2S.l A2S.l 
A27.l A27.l A27.l 
A29.l A29.l A29.l 
A34.l A34.I A34.I 
A36.l A36.l A36.I 
A37.l A37.l A37.l 
A38.l A38.J A38.I 
A44.l A44.I A44.l 
A46.l A46.l A46.l 
A49.2 A49.2 A49.2 
ASS.I ASS. I ASS.I 
AS7.l AS7.l AS7.l 
AS9.l AS9.l AS9.l 
A72.I A72.I A72.l 
Pl09.l Pi09.l Pl09.l 
Pill.I Pill.I Pill.I 
*B78. l was homozygous for each polymorphism 
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VII. Disct�aion 
VIL Discussion 
During the eight years since the cloning of the PKDJ gene (The European PKD 
Consortiwn, 1994) there has been limited progress in understanding the mutational 
basis of ADPKD. The detection of mutations in PKDJ has been hindered by the 
existence of homologous genes interfering with PKDJ-specific PCR amplification, as 
well as by the nature of the PK.DJ gene. Its very high GC content, 62% overall (The 
European PKO Consortium, 1994), poses significant technical problems with 
requirements for high annealing temperatures and careful optimisation of PCR 
amplification conditions. By far the most significant obstacle, however, has been the 
co-amplification of PKDJ homologous genes (HGs), leading to a heavy bias of 
mutation detection studies toward the unique 3' region of PKDJ. 
During the cloning of PKDJ, three HG transcripts were identified (International PKD 
Consortiwn, 1995) whose sequences were not characterised. Since the sequence 
infonnation on this part of the genome is still incomplete, the structure of these genes 
and even their exact number have remained unknown. Loftus et al. ( 1999) 
characterised a BAC clone (GenBank AC002039) containing two PK.DJ homologues, 
referred to as HG 1 and HG2. This publication opened the way to mutation analysis of 
the entire PKDJ gene, with subsequent studies using the sequence of BAC clone 
AC002039 for their PCR primer design (Watnick er al., 1999; Thomas et al., 1999; 
Rossetti et al., 2001; Phakdeekitcharoen et al., 2000 & 2001). The high degree of 
homology (about 95%) between PKDJ and the HGs, has added the requirement for 
long-range PCR amplification of large DNA fragments to the existing problems of 
PKDJ analysis. The number of mutation detection studies in ADPKD has remained 
246 
small, therefore both the understanding of the molecular defects, and the possibilities 
for molecular diagnosis in affected families are still limited. 
The present study has added important new data on the PKDJ homologous genes. 
Using different experimental approaches, we have identified two new homologues (HG 
3 and 4 ), and detailed database searches have led to the detection of two more (HGs 5 
and 6 ). At this stage, the total number of human duplications remains unclear and will 
probably only be established after completion of the Human Genome Project when alJ 
of the presently existing ''gaps" are filled. This uncertainty has to be taken into account 
in the molecular diagnosis and counselling of ADPKD families. 
The known number of PKDJ homologous genes is large enough to raise questions 
about their role, and the molecular mechanisms leading to their appearance. Our 
analysis of the model glioblastoma cell line T98G showed that, although HG3 and HG4 
transcripts are produced, they are not present in the translationally active poJysomal 
fraction, i.e. they are most probably not translated (Bogdanova et al., 2001). However, 
suppression of ribosome binding to the HGs cannot be discounted under certain cell 
conditions, and additional work is required into the expression of the PKDJ HGs to 
investigate this possibility. Further support is added to the hypothesis that the HGs are 
transcribed, but not translated, by the abundance of premature termination signals in HG 
coding sequences. Thus, even if the HGs were translated they would generate short, 
most probably non-functional, polypeptides. We have therefore proposed that the 
PKDI homologous genes (HGs l to 6) are pseudogenes and should be referred to as 
PKD/PI to PKDIP6 (Bogdanova et al., 2001 ). 
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A pseudogene can be defined as "A DNA sequence which shows a high degree of 
sequence homology to a nonallelic functional gene but which is itself non-functional" 
(Strachan & Read, 1999, 2nd Ed. p553). There are several types of pseudogene, 
including those with introns and exons that are probably the result of tandem gene 
duplication events, and pseudogenes with exonic sequence only that originate from the 
integration of reverse transcribed cDNA into a new chromosomal location. These types 
of pseudogenes are conventionally non-processed, ie. they are non-functional copies of 
the functional gene. However, an intermediate class of expressed non-processed 
pseudogenes also exist which undergo transcription (Strachan & Read, 1999). 
Immediately after a gene duplication event, it is thought that both the original gene and 
its homologue have the capacity to be expressed and function if the correct regulatory 
elements are intact. Through time, the HG may undergo deleterious mutations which 
prevent translation but stilJ allow transcription of the pseudogenc (Strachan & Read, 
1999). 
The PKDJ pseudogenes are homologous to the genomic DNA of PKDJ (Loftus et al., 
1999, and this study), and therefore probably result from tandem gene duplication 
events. Given the fact that the mouse p/rdl gene is not �uplicated (Piontek & Oermino, 
1999), these events have to be recent in mammalian evolution. It would be interesting 
to discover what sequence changes have made this part of the hwnan genome 
particularly unstable. 
Some pseudogenes, such as the 8·globin gene (HBQ-1), are known to express a 
polypeptide product whose role is unknown, and the gene sequence suggests that it is 
non-functional (Clegg, 1987). One of the recent theories of gene duplication is the 
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duplication-degeneration-complementation (DOC) model (Force et al., 1999). Gene 
duplication events can lead to three outcomes. The first is non-functionalisation, where 
the duplicate becomes a true non-functioning pseudogene; the second outcome is neo­
funcrionalisation, where the duplicate produces a novel protein product; and the third is 
sub-functionalisation where the duplicate continues to be expressed at lower levels than 
normal. The DOC model suggests that the sub-functional copy may become essential 
for gene function and could account for a significant proportion of preserved duplicate 
genes (Force et al., 1999). 
If the PKDJ HGs are expressed in vivo they may interact with PKDJ or its protein 
partners to alter the function of polycystin-1. Even if the HGs are not translated, their 
transcripts may modi{)• PKDJ expression in various tissues at different stages of 
development and pathogenesis. These intriguing possibilities remain to be addressed in 
future studies. 
By using sequence information on all six identified PKDJ pseudogenes, the design of 
PCR primers for the specific amplification of the PKDJ gene has been improved. 
Screening for ADPKD mutations was performed on over 94% of the PKDJ coding 
sequence, spanning exons 2 to 2 1, 23 to 41 and 43 to 46. This represents 12 , 163 bp of 
the overall 12909 bp PKDJ message (Hughes et al., 1995). So far, only two published 
studies have reported screening a greater proportion of the entire PKDJ gene: Rossetti 
et al .. (2001) screened the gene between exons I to 8, l 5 to 17 and 22 to 26 by direct 
sequence analysis and exons 8 to 46 using PTT. Phakdeekitcharoen et al. (2000 & 
200 l) analysed the complete duplicated coding region ( exons l to 34) by SSCP 1U1alysis 
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of genomic DNA Both studies relied on the sequence of HG l and HG2 (GenBank 
AC002039) to design PKDJ-specific primers in the duplicated region of the gene. 
A total of 74 sequence variants in the PKDJ gene were detected during the course of 
this study. Fifty of these variants are probably non-pathogenic in nature. It is proposed 
that 24 sequence changes are likely to be disease-causing mutations, of which twenty­
one are novel and three have been previously reported. Of the 50 neutral 
polymorphisms, 31 have been published previously and 19 are described here for the 
first time. 
A two-stage strategy was employed for the detection of mutations in the unique region 
of PKDJ, including SSCP screening and the subsequent sequencing of samples with 
aberrant electrophoretic banding patterns. The efficiency of SSCP as a mutation 
screening technique was compared with direct sequence analysis, using DNA samples 
from 15 Australian patients who bad been screened previously for exons 44 and 45 in 
the unique region. As described previously, (Chapter V), exons 44 and 45 were chosen 
for this comparison because of their different sized PCR amplified fragments and the 
relatively high number of sequence variations, both neutral and pathogenic, reported in 
this area of the PKDJ gene. The failure of SSCP to distinguish between individuals 
with the A4091 polymorphism in exon 45, and those with A4091 plus the A/V4058 and 
L4136 polymorphisms, reflects the limitations of the technique, whose sensitivity is 
lower for PCR fragment lengths over 300-400bp (Hayashi & Yandell, 1993). Therefore 
the 396 bp exon 45 fragment was probably too long for efficient mutation detection by 
SSCP. ln contrast, no additional variation was detected in the shorter 292bp fragment 
that included exon 44 when it was re-screened by direct sequencing. 
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Sequence analysis of exons 2-21 and 23-33 in 17 Australian P KD }-linked patients 
identified 12 possible disease-causing mutations. This represents a mutation detection 
rate of approximately 71 % over 71 % of the coding region of the gene. In the unique 
region of the gene (exons 34-41 & 43-46), nine disease-causing mutations were 
observed in 48 PKDJ-linked individuals using SSCP analysis (detection rate 19% over 
approx. 24% of the coding region). As the area screened did not include the entire 
gene, and since different nwnbers of patients were analysed in the unique and the 
duplicated regions, it was difficult to estimate the overall mutation detection rate. 
However, as illustrated in Table Vll.l, the approximate figures provided here compare 
favourably to those reported in similar studies. 
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Table VII.I Efficiency of PKDJ screening 
-- -
Screening Reference Mutations Region covered 
method detected/tested (% ofcDNA) 
(Template) individuals 
SSCP Koptides et al., ( 1998) I patient only ex 23-34 (27%) 
(DNA) Watnick et al., (1999) 8/35 (23%) ex 11-21 (42%) 
Koptides et al, (2000) I patient only ex 23-34 (16%) 
Peral et al., (1996b) 2/45-6/150 (4%) ex 34-46 (25%) 
Peral et al., ( 1996a) 1 family only ex 34-46 (25%) 
Neophytou et al., ( 1996) 1/14 (7%) ex 45 (2%) 
Torra et al., (1997) 1 family only ex 43-46 (16%) 
Daniells et al., ( 1998a & b) 9/147 (6%) ex 44-45 (3%) 
Badenas et al .. ( 1999) 7/175 (4%) ex 43-46 (16%) 
Afzal et al., ( 1999) 4/90 (4%) ex 37-39,44-45 (6%) 
Kim el al., (2000b) 6/91 (7%) ex 34-46 (25%) 
Bouba et al .. (2001) 8/53 (15%) ex 16- 34 (23%) 
Phakdeekitcharoen (2000) 13/47 (28%) ex 13-21 (36%) 
Phakdeekitcharoean (2001) 6/41 (14%) ex 1-12, 22-34 (40%) 
Present study 9/48 (19%) ex 34-41, 43-46 (24%) 
SSCP& Mizoguchi et al. (200 I) 4/176 (2%) ex 23-46 (41%) 
DHPLC 
HDA Watmck et al., ( 1997) 8/80 (10%) ex 23-34 (16%) 
{DNA) Peral el al., (1995) 2/130 (I%) e,.; 43-46 (16%) 
T·Jrco et al, ( 1995) 1/20 (5%) ex44 (1%) 
Rossetti et al., ( 1996) 1/67 (I%) ex 44-45 (3%) 
Aguiari et al.. (2000) 3/40 (7%) ex 36-46 (23%) 
HDA& Turco et al .. ( 1997) 3/60 (5%) ex 38,40,45 (4%} 
SSCP 
DGGE Perrichot et al. (2000b) 8/146 (5%) ex l 5-21, 23-34 (50%) 
(DNA) Perrichot el al .. ( 1999) 8/146 (7%) ex 34-46 (25%) 
Perrichot et al., (2000a) 3/146 (2%) ex 34-46 (25%) 
(total "" 13%) 
PTT Roelfsema et al., ( 1997) 6/135 (4%) ex 15 & 23 (30%) 
(ill i•itro 
translated) Rossetti et al .. (2001 ) 27/33 (82%) ex 8-46 (87%) 
(511131 r (43%) 
PTT& 
NIRCA Peral et al .. ( 1997) 6/95 (6%) ex 22-46 (42%) 
Direct Thomas et al .. ( 1999) 7/24, (29%) ex 2-15 (47%) 
Sequence Rossetti et al .. (200 I ) 30/98 (31%) ex I -8, 15-17. (51%) 
Analysis (57/131 )" (43%) 22-26 
Present study 12/17(71%) ex 2-21, 23-34 (71%) 
Present study 4/42 (10%) 44-45 (3%) 
Thongnoppakhun et al., I patient only Full-length RNA 
(2000) (100%) 
* Rossetti et al (200 I) detected 57 novel mutations in 13 l patients ( exons 1-46 ). Of 
these, 27 were detected by the PIT, and 30 by direct sequence analysis. 
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Obviously a I 00% detection rate is to be ultimately desired, however, this is often 
impractical and it can be technically and financially challenging. In other studies of 
genes where a large number of private mutations occur. such as the NF/ gene 
associated with neurofibromatosis, detection rates over 50% are considered average 
across a number of screening methods (Fahsold er al., 2000). 
We were unable to detect the probabie disease-causing mutations m five of the 
Australian PKD/-linked families screened (A7, Al2. Al3. A29, ASS). The mutation 
detection study in these families was preceded by linkage analysis, however it should be 
noted that four of the five families had only a minimum number of four members. A 
positive lod score was obtained for the chromosoml.! 16 locus and. given the fact that 
approximately 85% of Caucasian ADPKD cases are due to mutations in PKDI (Hughes 
et al., 1995). it seems highly probable that they are linked to PK/JI (See Table Vll.2). 
However, with so few related individuals investigated. one cannot rule out the 
possibility that the low positive lod score was a chance tinding. 
Table Vll.2. Observed Lod Score Values for PK!JI families with undetec!·•d mutation 
Family (Number of Observed Lod Score Observed Lod Score Probability of 
Individuals tested) Maximum Minimum PKD / linkage"' 
A7 (4) 0.2993 0.2984 91% 
Al2 (4) 0.3009 0.3005 91% 
Al3 (4) 0.2780 0.27 79 91% 
A29 (5) 0.5568 0.5566 95% 
A55 (4) 0.5809 0.5809 95% 
"' Probability of linkage to PKD1 was calculated as previously described (Hateboer et 
al., 1999a). If probability was between 86-100% linkage to PKDI was inferred. 
Assuming linkage to PKDJ, our failure to detect the mutation may be technical in 
oribrin, in other words due to low sensitivity of the detection system. A more likely 
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possibility is that these families may have mutations in regions of the P KD J gene that 
were not scr�ned. As stated previously, exons l ,  22 and 42 were not analysed, and 
large areas of the untranslated region, including the promoter region, were also omitted. 
The presence of gross deletions in the ADPKD allele is another possible reason why 
disease-causing mutations were not detected. In this case, only the wild-type allele 
would be amplified for mutation screening. For example, cryptic splice-sites may be 
activated in an intronic region that had not been screened. This form of variation could 
lead to the truncation of polycystin-1 but the genomic variation in the screened 
fragments would remain undetected. To test for this possibility it would be necessary to 
amplify the full length RNA and exanune the size of the resulting transcriptional 
products. 
Analysis of the mutations that were detected in the present study showed that 15 of the 
24 possible pathogenic variants (62.5%) resulted from a single base; substitution and 9 
resulted from small deletions or insertions. The nucleotide substitutions comprised 9 
transversions and 6 transitions. Of the 50 neutral polymorphisms detected, 4 were the 
result of a small insertion or deletion and 46 were single base substitutions. This group 
sub-divided into 38 transitions and 8 transversions. 
Although a greater number of transversions throughout the genome would be 
anticipated to occur by chance (4 possible transversions compared with 2 possible 
tmnsitions), in reality this has not been reported. Wheil 337 pairs of human and rodent 
orthologues were compared, it was found that the transition rate exceeded the 
transversion rate by a ratio of 1.4 to I for missense mutations and greater than 2.0 to 1 
for silent polymorphisms (Collins & Jukes, 1994). Mor� recently work on the Huruan 
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Genome Project has determined a transition to transversion ratio of 1.89: l (Venter et al., 
200 I). A total of 31 transversions and 63 transitions have been reported in the literature 
as PKDJ mutations which result from a single base substitution. This represents a 
transition to transversion ratio of approximately 2.1: l for pathogenic variants, when 
neutral variants are considered this ratio changes to of 3.25:l (see Tables II.3, ll.4.a & 
11.4.b). 
When the single base substitutions detected in the present study (both pathogenic and 
silent) are combined with those reported in the literature, 72% were transitions and 28% 
transversions. This represents a transition to transversion ratio of 2.6 to l, more in 
accordance with that reported by Venter et al. (2001). 
In classifying DNA variants as possibly pathogenic or non-pathogenic the guidelines 
proposed by Cotton & Scriver ( 1998) generally were followed. Mutations were 
classified as disease-causing when they could be predicted to result in a truncated 
protein or, in the case of missense mutations, segregated with the disease phenotype and 
caused a change in the predicted secondary structure of the protein (Rost & Sander, 
i 994 ). For the non-truncating mutations, the evolutionary conservation of the affected 
protein sequence was also examined as another indication of the possible functional 
importance of the particular codon(s). One hundred nonnal chromosomes for all 
mutations in the duplicated region of the gene were not tested as recommended (C'"tton 
& Scriver, 1998), because the demanding nature of very long range amplification of 
PKDJ fragments made an extended analysis of this type impractical. 
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Twenty-four of the DNA variants deter.ted in the sn1dy were classified as probable 
disease-causing mutations. Twenty-one of these variants were novel and three had been 
published previously (Turco et al., 1995; Ros�tti et al., 1996; and Daniells et al., 
1998b ). Subdivision on the basis of the effect of the mutation on gene expression 
showed that between 50% to 62.5% were truncating, these included seven nonsense 
mutations, four small deletions and one large deletion {12/24}. A further three splice­
site mutations may also result in a truncation (3/24 ). The remaining 9/24 variants 
(37.5%) were missense or in-frame deletions or insertions. 
The frequency of tnmcating mutations in the unique region of PKDJ was 66%, and in 
the duplicated region of the gene it was 58%. Other studies (listed in Table II.3) have 
reported that around 70% of mutations in PKDJ were truncating. These reported values 
may be slightly biased towards an over-representation of truncating mutations, as a 
number of studies (Roelfsema et al., 1997; Peral et al., 1997; Rossetti et al .. 2001) 
favoured screening methods such as PTT and NIRCA which are specifically designed to 
detect truncating mutations. Taken together, the results of PKDJ mutation detection 
studies suggest that the exclusive use of techniques aimed at the identification of 
truncating mutations would miss a significant proportion (around 30%) of the 
pathogenic variants causing ADPKD. 
Nine of the probable disease-causing mutations detected in this study were predicted to 
result in an intact protein with an altered amino acid sequence. These include five 
missense mutations, three in-frame deletions and one in-frame insertion. These 
mutations were examined {Chapter V) in terms of evolutionmy conservation and 
predicted effect on the secondmy structure of the protein (Rost & Sander, 1994 ). If en 
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amino acid (or group of amino acids) within a protein is conserved between species 
during evolution, the conserved residue is more likely to be functionally important than 
a non-conserved amino acid. In addition to conservation during evolution, the predicted 
effect on protein topology was also analysed using the PHDsec program (Rost & 
Sander, 1994). This program is based on the combination of evolutionary information 
and neural networks and has a reported accuracy of over 72% (Rost & Sander, 1994). 
When the disease•segregating non-truncating variants detected in the PKDJ gene in this 
study were analysed using these two measurements, it was inferred that they were more 
likely to be pathogenic if they altered a conserved residue and significantly shanged the 
predicted topology of tl1e protein. 
A further three probable pathogenic mutations were the product of nucleotide 
substitutions in the canonical splice signals or near the splice site. The effect of these 
pos�ible splice site mutations has to be determined by RNA studies. Unfortunately, 
RNA samples were not available at the time of the project. Initial blood samples from 
Australian index patients were divided equally, DNA was extracted from one half of the 
sample, and immortalised lymphoblastoid cell lines were created from the other half 
Due to equipment malfunction these cell lines were accidentally thawed during the 
course of the study. Patients will therefore need to be re-bled in the future in order to 
allow RNA experiments to be performed. 
Two of the mutations, IVS14+1 G>C and IVS16+1 G>T, resulted in the replacement of 
guanine at the GT donor site. Tnis form of sequence alteration infers a loss of the 
donor site that is likely to result in th� activation of a cryptic donor splice-site in the 
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following intron, or in· the continuation of translation up to the beginning of the next 
exon. 
In the simplest prediction, the IVS 14+ 1 G>C mutation could cause the addition of five 
novel amino acids prior to the utilisation of a cryptic GT splice donor site at genomic 
position 26957-5814. Alternatively, if this cryptic splice site is not activated. 14 novel 
amino acids may be translated before the introduction of a novel stop codon at genomic 
position 26984-86. 
Likewjse, the IVS 16+ I G> T alteration may result in the addition of 23 novel amino 
acids prior to the introduction of a cryptic GT splice donor site at genomic position 
31463-64. Alternatively, 25 novel amino acids may be translated prior to the 
introduction of a novel stop codon at genomic position 31469-71. 
The third possible splicing mutation, IVS37-IO C>A, is more complex. The change is 
sited 1 Obp before the start of exon 38 in IVS37 and could constitute an acceptor site 
alteration, which in tum may lead to the activation of a cryptic AG splice acceptor site 
(see Fig V.3 for the proposed model). If this cryptic splice-site is activated, the 
resultant frame-shift could cause the addition of 13 residues to the protein prior to the 
introduction of a novel stop codon. As shown in Chapter V, of the six family members 
tested three were affected and had this mutation, and the three members who were 
phenotypically unaffe;ted did not. The change was not detected in 47 other unrelated 
PKDJ-linked jndividuals. On the basis of the family segregation and the possible 
acceptor site change, we presume that this could be the disease-causing mutation in this 
family, although only RN A studies could confirm/refute this speculation. 
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The early mutation detection studies were biased towards the unique region of the 
PKDJ gene (Turco et al., 1995; Peral et al., 1995; Rossetti et al., 1996; Neophytou et 
al.. 1996). Screening techniques in the duplicated region that favoured the detection of 
truncating mutations followed these studies (Roelfsema et al., 1997; Peral et al., 1997). 
Reports on analyses of the entire PKDI gene for all types of mutation have begun to 
appear in the scientific literature only recently (Thomas et al., 1999; Perrichot et al., 
1999, 2000a & b; Rossetti er al., 2001; Phakdeekitcharoen et al., 2000 & 2001). 
Truncating and in-frame pathogenic mutations have been detected across the PKDJ 
gene from exon I. which corresponds to the flanking region arowid the leucine-rich 
repeat domain, to exon 46 which translates into the coiled-coil domain in the 
cytoplasmic region prior to the carboxy-tenninus. 
When the type of mutation is considered in the context of its position, trends begin to 
emerge in the published data that point to the possible existence of mutation hot spots in 
PKDI which deserve special attention in mutation detection studies. It should be noted, 
however, that as the number of PKDJ mutations identified increases these trends may 
prove to be illusions. The location of the novel mutations detected in this study, and of 
previously reported mutations (see Table 11.3), indicate that in the populations tested a 
high proportion of pathogenic vHriants cluster in exons 15 to 18, 23 and 25, and in 
exons 44 to 46. At the protein level, these areas correspond to the PKO repeat motifs, 
the REJ domain, the final three transmembrane regions, the coiled-coil domain and the 
cytopJasmic carboxy terminus. 
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A clustering of truncating mutations appears to exist in two areas of the gene, one 
within the unique region and anothef one within the duplicated region. Within the 
unique region, most truncating mutations are located in the final three exons of the 
gene, corresponding to the loops in the extracellular and cytoplasmic domains, the final 
transmernbrane domains, the coiled-coil domain and the carboxyl-terminus of 
polycystin-!. With the exception of exon 42, the entire unique region was analysed in 
this study. Clustering was observed, with 29% (7/24) of mutations located in exons 44 
to 46, which accom1t for only 5.6% of the coding region. The majority (4/24) were 
nonsen� mutations in exon 44. Tnese four mutations constitute 9% of all truncating 
mutations observed in our study population and are clustered in just 1.1 % of the gene. 
In the duplicated region, truncating mutations clustered in exon 15, with 24 of the 29 
mutations identified so far in this exon resulting in premature truncation of the protein. 
Only one study (Roelfsema et al., 1997) used PIT to detect five mutations in this exon. 
The remaining 19 mutations have been identified using a variety of techniques (Watnick 
et al., 1999; Thomas el al., 1999; Perrichot et al., 2000b; Phakdeekitcharoen et al., 
2000; Rossetti et al .• 2001;), suggesting that the observed clustering may be real. Thus 
it appears that exons 15, 44. 45 and 46 of may be suitable candidates for PTI screening. 
Missense mutations predominate in exons 23 and 25 in the duplicated region of the 
gene. These two exons harbour 15% (26/168) of all mutations reported to-date (Peral et 
al., 1997; Watnick et al., 1997; Rossetti et al., 2001; Phakdeekitcharoen et al., 2001), 
and the majority of these mutations (76%) are missense changes. Exons 23 and 25 are 
adjacent to the polypyrimidine tracts in introns 21 and 22 (Van Raay et al., 1996). The 
high GC content of the tracts makes them particularly susceptible to SNP vanation, 
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since methylated cytosines in CpG dinucleotides are susceptible to forming thymine and 
account for a 10-fold increase in mutation rate when compared to other dinucleotides 
(Venter et al., 200 I). These tracts have been implicated in gene conversion events 
(Watnick et al .. I 998a), with the homologous genes acting as reservoirs for inter-locus 
gene conversion. 
The second area where mutations seem to cluster in the duplicated region corresponds 
to exons 16, 17 and 18 (Watnick et al .• 1999; Perrichot et al., 2000b; Phakdeekitcharoen 
et al.. 2000; Rossetti et al., 200 I; Bouba er al., 200 I). These exons, encoding the REJ 
domain of polycystin-1, nccow1t for 4.5% of the PKDJ coding sequence but harbour 
7.6% of all reported mutations. No particular type of mutation has been observed to 
predominate in this region. 
Like others to date (Krawczak & Cooper, 1997; AfLal et al., 2000; Aguiari et al., 2000: 
Kim et al., 2000b; Koptides et al., 2000; Perrichot et al., 2000 a & b; 
Phakdeekitcharoen et al., 2000 & 200 I; Rossetti et al., 200 I; Bouba er al., 200 i ), this 
study failed to identify pathogenic variants in exons 3, 6, 7, 9, 14, 26, 29, 30 and 33. 
This may be due to severa! reasons. Firstly, it could be that these regions of the gene 
are not essential for protein function, and so m•.Jtations would remain w1detected due to 
as�crtainment bias towards ADPKD-affected individuals. Only two neutral 
polymorphisms have been detected in these exons; a novel missense variation in exon 
14 (Mffl092) and a previously described silent exonic change (P3110) in exon 26 
(Peral et al., 1997). Conversely, pathogenic mutations in these regions may be so 
detrimental that they are not conducive to post-natal survival and so they would not be 
found in the adult population. As greater numbers of individuals are screened for PKDJ 
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mutations, it will become apparent if these regions are indeed devoid of disease-causing 
mutations in the adult population. 
Most mutation detection studies of the PKDI gene have been performed on the DNA of 
Caucasian individuals, primarily those of northern European descent. Two studies have 
focussed on the DNA of Asian individuals from Thailand and Korea respectively 
(Phakdeekitcharoen et al., 2000; Kirn, et al., 2000b ). The first mutations in exons 18 
and 19 of the gene (R2408C, R2430X. c.7535ins3, Q2558X) were reported exclusively 
in the Thai population (Phakdeekitcharoen et al., 2000). As yet, there are insufficient 
published data on ethnic background to establish whether ethnic differences do exist in 
the location and type of path,.;t{enic sequence variation present. For example, three 
recurrent mutations in exon 44 (Q40IOX, R4020X and Q404JX) have been recorded in 
Anglo-Irish, southern European and Asian families (Daniells et al., I998b; Kim et al., 
2000b; Rossetti et al., 1996; Torra et al., 1998), providing further evidence that exon 44 
is a hot spot for truncating mutations. A slipped-mispairing mode! has been suggested 
as the mutational mechanism for Q404 l X (Daniells et al., 1998b ). 
An interesting observation on disease-causing mutations in the P KD I gene is their 
private nature, i.e. their restriction to single affected families, which account for the 
large number of novel mutations discovered in mutation detection studies. In this 
project. 21/24 or 87. 5% of the probable pathogenic variants were novel, which is 
comparable to the 85.2% (69/81 mutations) published recently by Rossetti et al. (2001). 
262 
The high rate of private mutations in PKDJ seems to contradict the familial nature of 
ADPKD, where only 10% of all patients are reported to have de novo mutations 
(Gabow, 1993). One might expect a proportion of the remaining 90% of individuals 
with ADPKD of familial origin to perhaps share a few common founder mutations. For 
example, in this study we detected the same mutation (Q4003X) in two Australian 
patients (A 18. l & A4 l.l) of Macedonian origin. Although they did not �lieve 
themselves to be closely related, they shared common haplotypes and a founder 
mutation can be presumed. Peral et al., (1995} also reported a similar situation where 
two families shared the same mutation (E43IVS43 + 5-I 3del20) and haplotype analysis 
suggested identity by descent. 
The scarcity of founder mutations in the PKDJ gene may be related to the reduced 
reproductive fitness of afiected individuals. A phenomenon that could theoretically 
contribute to this effect is that of clinical anticipation in ADPKD (Geberth et al., 1995a; 
Peral el al., 1996a; Torra el al., l 997; Penichot et al., 200 I), where the age of onset of 
the disease, arid particularly the age at end-stage renal failure, tends to be earlier with 
each successive generation. If anticipation in ADPKD exists, it may result in declining 
reproductive fitness in the younger generations of affected families, and thus ultimately 
lead to the elimination of the familial mutation. 
The high mutation rate in PKDJ could be attributed, at least partly, to the high nwnber 
of potential gene conversion reservoirs. In addition to the homologous genes located on 
chromosome l 6p 13. l, four functional genes have been identified in the paralogous 
polycystin family, PKD2, PKD2l, PKD2L2 and PKDREJ (Veldhuisen et al., 1999). 
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All four paralogues share homology with the PKDJ gene between exons 38 to 45 in the 
transmembrane regions and the cytoplasmic tail prior to the coiled-coil domain 
{Veldhuisen et al., 1999). The high incidence of reported mutations in exons 44 and 45 
might therefore be directly correlated with the nwnber of paralogous genes available for 
gene conversion in this region. 
Other mutational mechanisms in the PKDJ gene have been proposed. As stated 
previously, a slipped-mispairing model for the Q4041 X mutation has been postulated 
(Daniells et al., 1998b). In that model a directly adjacent imperfect 5 nucleotide repeat 
exists. If there is slipped mispairing between the nucleotide repeats then T replaces Cat 
nucleotide 12332 and Q4041 X results {Daniells et al., 1998b). Other regions of the 
gene may also be susceptible to such mutational events and give rise to novel variations 
in the gene. By combining the mutational mechanism theories it is possible that gene 
conversion, the high GC content of the gene, and the slipped mispairing model may all 
contribute to the high level of private mutation. 
We have detected 50 polymorphic variants, including 31 that have been published 
previously and 19 novel changes. They represent 42 exonic ( 13 missense and 29 silent) 
and eight intronic variations. This should not be interpreted as suggesting the erustence 
of fewer polymorphic variants in the non-coding regions of the gene, but rather reflects 
an analytical bias since only 50 to lOObp of the intronic sequences surrowiding exons 
were screened in the study. 
As of February 2002 the total nwnber of reported non-disease causing polymorphisms 
in the PKDJ gene was 132 (Krawczak & Cooper, 1997; Afzal et al., 2000; Aguiari et 
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al., 2000; Bogdanova et al., 2000; Kim et al., 2000b; Koptides et al., 2000; Perrichot et 
al., 2000 a & b; Phakdeekitcharoen et al., 2000 & 2001; Rossetti et al., 2001; 
Mizoguchi et al., 200 J; Bouba et al., 200 I; Tsuchiya el al., 200 I). Of these, 96 are 
silent variations and 36 are missense variations. The localisation of polymorphisms 
replicates that of pathogenic mutations in some parts of the gene. For example, 16% 
(21/131) of polymorphisms occur in exons 23 to 25, around the polypyrimidine tracts 
where a clustering of pathogenic missense mutations has also been observed, thus 
providing further support to the gene conversion theory (Watnick er al., 1998a). 
However, there did not appear to be a clustering of polymorphisms in exons 15 or 44 to 
46 which, as discussed earlier in this chapter, harbour a large number of disease-causing 
truncating mutations. 
Particular attention in this study was given to polymorphisms that did not segregate 
with the disease phenotype, yet cause an amino acid substitution in polycystin-1. 
Missense changes present a serious interpretational problem in any mutation detection 
study where a functional assay is unavailable as direct proof of the pathogenic effect. 
As demonstrated in the study, computer modelling of secondary protein structures 
predicts changes in a significant proportion of the missense polymorphisms detected. In 
the case of ADPKD the substantial number of novel mutations compounds the problem, 
where possible functional effects need to be invoked in every new case. One of the 
conventional approaches used to detemrine whether a missense mutation is indeed 
associated with a given disease phenotype, is to screen 50-100 nonnal unrelated 
controls for the mutation and, if present in the controls, the mutation is classified as a 
non-pathogenic polymorphism. However, besides the prohibitive costs involved in 
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screening PKDJ in 50-100 normal controls, the rarity of individual variants in this gene 
would mean that lack of a mutation in the control subjects could still be inconclusive. 
Family segregation may also be insufficient evidence in favour of a pathogenic role. 
For example, an intronic variation in PKDJ (IVS41+S ins 3) was originally reported to 
be a likely disease-causing change (Perrichot et al., 2000a). It was presumed that the 
change was involved in aberrant splicing even though RNA analysis was not perfonned. 
This insertion mutation segregated with the disease in a French family and was not 
detected in l 00 normal chromosomes, nor had it been reported previously in the 
literature. Soon after the initial report, the same variant was described as a non-disease 
causing polymorphism in a large Greek-Cypriot kindred, where the mutation failed to 
segregate with the ADPKD phenotype (Koptides et al., 2000). Again, however, no 
RNA analysis was performed in this family. The same insertion mutation was d.:tected 
by this candidate in Bulgarian patient, B23. l .  Subsequent investigation revealed that it 
segregated with the disease in family B23 (personal communication Dr. Nadja 
Bogdanova, Munster, Germany). RNA was not available to further investigate if the 
change had any effect on transcription in family B23. Its role therefore remains to be 
assessed in future studies. 
The so-called "neutral" polymorphisms, especially missense mutations, may have subtle 
effects on protein function and thus act as modifiers of disease severity in cases where a 
drastic mutation is the obvious major cause of the disorder. Moreover, the 
accwnulation of such "neutral" polymorphisms may lead to a cooperative effect on 
protein function, through nwnerous changes in topology, even in the absence of an 
obvious pathogenic mutation. The existence of such .. hypermorphic" alleles has been 
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proposed by Watnick et al. (1998a). The polymorphisms detected in the present study 
of five families where no pathogenic mutation was found are summarised in Table 
VII.3. Four polymorphisms located between exons 2 and 15 of PKDJ were detected in 
Australian patient A 7 .1. Three of the variants were silent in the coding region and one 
was intronic. No variation was detected in patient Al2.3, which was unusual as 
variation was detected in almost all of the other patient DNA samples analysed in this 
study. Five common polymorphisms in linkage disequilibriwn were detected in patient 
ASS.I between exons 44 and 46. Ten polymorphisms were detected in patient AB.I 
between exons 5 and 18, nine of which were silent variants in the cocling region and one 
was intronic. One patient (A29. 1) is a likely canclidate for a hypermorphic a11ele, if 
such an allele exists. This patient had 15 polymorphisms from exons 13 to 46; of which 
6 were missense, 8 were silent changes in the cocliog region, and 1 was intronic. 
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Table Vll.3. Polymorphisms in PKD/-linked patients with an undetected mutation 
Patient Polymorphisms Type of Comments 
Clume:e --
A7. l c.48"/G>A, A92 ( l/15) Silent exonic ( 1/131) Rossetti et al., (2001) 
IVS6-68G>A (1/17) Silent intronic I 
c.3322G>A, LI037 (4/17) Silent exonic I c.4885G>A, i 558T (2/15) Silent exonic 
Al2.3 none dete.cted 
AIJ.I c.1330T>C. L373 (Sil 5) Silent exonic 
g.23307de17 (3/17) Silent intronic g23307rlel7, P900 and 0910 
c.291 IG>A, P900 (3/17) Silent exomc occur in LD in (3/1 ?) patients. 
c.2941C>T, D9!0(3/17} Silent exonic 
c.4876A>C', Al555 (5/15) Silent exonic 
1 
c.5383C>T, Tl724 (S/15) Silent exonic 
I 
c.5974G>A, Ll92l (3/15) Silent exonic 
c. 7 I 38C>T, 02309 { I /15) Silent exonic 
c.7376T>C. L2389 (4/15) Silent exonic 
c.7652C>T, L2481 (4/15) Silent e:<onic i 
A29.i c.3274T>C, 01021(3/17) , Silent exonic 
c.3486T>C, Ml092T (3/17) ! Missense 
c.4406T>C, Wl399R (2/15) Missense 
c.4876A>C, A I 555 (5/15) Silent exomc 
c 5183C>T. Tl 724 (5/15) Silent exonic 
c.7652C>T, L2481 (4/15) Silent exonic 
c.8124A>G, H2638R(2/15) Missense 
c 9406GT>CC, F3066L (5/15) Missense 
c.Cl541T>C, P3110(5/15) Silent exonic l c. l 0976C>T. L3589 (2/48) Silent exonic 
c. I 0986G>T. S3592I (2/48) M1ssense j L3589 & lVS44+23 in LD 
!VS44+2JinsA (2/48) Silent intronic 
c.12341 A>G 14044 V (32/88) Missense I 14044V, A4091, P4209, in LD 
c.12484A>G, A4091 (31!85) Silent exonic I 
c. I 2838T>C', P4209 01/89) I s;,en, .,o .. , 
ASS. I c I 2341A>G, 14044V (32/88) ?vtissense Again 14044V, A4091, P4209, 
c.12384C>T, A4058V t9/5 I) Mis!>ense tn LD with the subset of 
c 12484A>G. A4091 {Jl/85) Silent cxonic i\4058\l and L4136 
c 12617C>T. L4136 (9/51) Silent exonic 
c.12838T>C, P4209 t3 l /89) Silent exonic 
Table 1:.:xpl!!ini:d;. 
Please note that numbers listed in brackets after described polymorphi:m1s represent the 
number of indi\'iduals with the polymorphism from the total number screened. e.g. 
c.487G>A. A92 ( I /15) represents I individual with the c.487G>A from the. 15 tested. 
268 
ADPKD is a well known example of phenotype variability (Milutinovic et al .• 1992� 
Torra el al., 1995; Hateboer et al., 1999a), with marked differences in disease severity 
observed both between and within families. By analogy to other single gene disorders 
(eg. neurofibromatosis (NF! gene) Fahsold et al., 2000), mutation heterogeneity should 
be expected to accowit. at least partly, for the interfamilial variation. Again by analogy 
with other single gene disorders, such as those described in chapter II cg. 
phenylketonuria and cystic fibrosis, mutation detection studies should provide 
information on genotype-phenotype correlations. This will allow conclusions to be 
d.'1lwn on the functional importance of different protein domains, as well as predictions 
on disease severity in the preclinical testing of at-risk individuais. 
In the case of ADPKD, the study of genotype-phenotype correlations is rendered 
particularly difficult by different factors, some of which are biological in nature, while 
others are the product of incomplete research or publication design. Biological factors 
include the p1,vate nature of PK.DJ mutations, meaning that the number of individuals 
ca.-rying the same mutation will never be sufficient for statistically significant 
conclusions to be made. Another very important factor is related to the proposed two­
hit model of cystogenesis (Knudson, 1971; Qian et al., 1996), where the random nature 
of the second hit could have a major confounding effect on attempts to study the 
phenotypic consequences of any germline mutation. In addition, the pathogenesis of 
ADPKD is extremely complicated, with multifactorial traits such as hypertension, 
known to play a major role in disease severity. This would suggest that a large number 
of genetic and environmental variables need to be taken into account which, in 
combination with rhe rarity of individual mutations and the two-hit model of 
cystogenesis, makes genotype-phenotype correlations in ADPKD an impossible task. 
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While the above factors are biological in nature and may thus present insurmountable 
obstacles, the study of genotype-phenotype correlations in ADPKD is hampered further 
by the failure of most research groups to provide adequate clinical information in the 
mutation reports. To date only 16 of the 31 published articles on PKDJ mutations have 
accompanying phenotype information, and this is usually limited to the age at onset of 
end-stage renal failure (ESRF). The general paucity of detail on age at renal failure and 
associated symptoms could be resolved by increased communication between clinicians 
and diagnostic laboratories, and the introduction of a comprehensive ADPKD­
phenotype database. Such a project was commenced by the PKO Foundation and 
administered at Johns Hopkins University, USA. Unfortunately, due to lack of funding 
the database was not maintained and a comparable substitute project has yet to be 
initiated (personal communication Dr. Gregory Germino, Johns Hopkins University, 
USA). 
Even less information exists on phenotype severity as it relates to the occurrence of 
supposed neutral sequence variations in the PKDJ gene. In future, as greater emphasis 
is placed not only on the search for disease-causing mutations, but also on the variable 
phenotypes that accompany them, it will be of vital importance to collate these data 
from the expanding number of private mutations in the gene. 
This PhD project was part of a larger collaborative study, resulting in an extensive 
clinical database containing various measures of phenotype severity, which should 
allow future analysis of the effect of both pathogenic mutations and polymorphisms on 
the clinical manifestations of ADPKD. 
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Here phenotype trends as related to the type of mutation (tnmcating versus missense) i."l 
the patients included in the present study. and in other publications have been examined 
in detail. Age at onset of ESRF was used as a measure of phenotype severity. In the 
study, 12 individuals with truncating mutations and 4 with in-frame mutations had 
reached ESRF. Obviously the number of individuals was too small to attempt to test for 
significance. Those with a rruucating mutation developed ESRF at a mean age of 51.1 
years (range = 42-74 years) and those with an in-frame variation developed ESRF at 
65.7 years {range = '.19-73 years}. When truncating versus non-truncating mutations 
reported in the literature were compared with respect to age at onset of ESRF. 42 
individuals with truncating mutations had a mean age at onset of 50.1 years (range = 
29-70 years), while 15 inrlividuals with in-frame mutations had a mean age at onset of 
ESRF of 53.3 years (range = 43-68 years). The difference was not statistically 
significant in any of the comparisons. 
A similar comparison has been conducted by Watnick et al. (1999), who found 10 
fawilies out of 35 screened to have a clustering of truncating mutations between exons 
13 and 17 in the duplicated region of the PKDJ gene. They proposed that these 
mutations co-occured with a specific phenotype. including very early onset of the 
diseru.. · and/or the presence of intracranial aneurysms (W atnick et al., 1999). 
In a similar manner the clinical effects of gennline mutations in PKDJ that have been 
found to occur in more than one family were tested in the present study. The numbers 
of such mutations are very small and even fewer have been published with phenotype 
infonnation, see Table VII.4. 
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Table Vll.4. Shared pathogenic mutations in PKDJ 
Mutation Number of families (reference) Age at ESRF 
c.5224del2 3 
(\Vatnick et al., 1999) NIA 
(Watnick et al., 1999) NIA 
(Watnick et al., 1999) NIA 
Q4010X 3 
(Daniells et al., I998b) NIA 
(Kim et al., 2000b) NIA 
Present study 49 
R4020X 2 
(Rossetti et al., 1996} 58,51,49 
Present study NIA 
Q404IX 6 
(Turco et al.. 1995) 68,70,42 
( Peral et al., 1997) NIA 
(Torra et al., 1998) 42 
(Daniells et al.. 1998b) N/A 
I 
(Rossetti et al., 200 I) NIA 
Present study 42,57 
R4227X 
I tPeral et al., 1996b) 42.42 I ( Peral et al.. 1997) 57,54,53 
(Rossetti et al., 200 I) NiA 
NI A - no infon11at1on available. 
VEO - Very early onset of the disease (in utero to <30 years). 
ICA - Intra-cranial aneurysm. 
Other symptoms 
YEO& ICA 
ICA 
YEO 
NIA 
NIA 
Inguinal hernia 
ICA 
VEO 
Anticipation 
NIA 
NIA 
NIA 
NIA 
ICA 
NIA 
I NIA 
I NIA 
Given the modest amount of mformation available at this point in time, it is not possible 
to ascertain if a direct correlation between the age at onset of ESRF and the same 
gennline mutation exists in different families. However, there may be certain mutations 
which are associated with the occurrence of intracranial aneurysms and an unusually 
early age at onset (in u1ero to before 30 years) of cyst development leading to severe 
renal disease. An ADPKD phenotype with ICA or early onset of the disease with 
clinical anticipation has been associated with two mutations (R4020X, and Q4041 X) in 
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more than one family, as outlined in Table VIl.5. Three unrelated families in the 
Watnick et al. study (1999) shared the same frame-shift mutation in exon 15 of PKDJ, 
c.5224del2. 
Table VIII.5. Private mutations with a severe ADPKD phenotype 
Mutation IVS14+1G> 
IVS16+1G> 
Q3206X 
c. l I 284insT 
S3770X 
Y3818X 
c. ! 280 I del28 
Phenotype i ICA ICA 
Reference Present study 
Present study 
Anticipation. ESRF in generation I age 37, Perrichot et al., 2000b 38 & 39. Generation II ESRF age 26. 
Anticipation. ESRF in generation I age 40, Perrichot et al., 1999 generation II nonnal renal function age 25, generation III palpable cysts at birth. 
Aniicipation. ESRF in generation I age 70, and in generation II age 42. 
I Anticipation. ESRF not reached in affected father age 28 with de novo mutation. Renal cysts detected m one dizygotic twin daughter in 11/ero. 
Anticipation. ESRF in generation I age 50, generation II age 58, generation III ages 60, 58, 53, generation IV chronic renal failure at age 23. 
Present study 
Peral et al., 1996a 
Torra et al., 1997 
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Conclusions and Future Studies 
Much work remains to be undertaken on the mutational mechanisms and pathogenic 
pathways of ADPKD. It is now possible to screen the major disease gene (PKDJ) for 
mutations and polymorphisms. Each successive variant detected will contribute to a 
greater understanding of the PKDJ gene and its protein products. If phenotypic 
information is also published (or made publicly available in designated databases), it 
may be possible in the future to attempt genotype-phenotype correlation studies. 
The discovery and further characterisation of additional PKDJ ·ps·eudogenes in this 
study has lead to the amplification of a PKDJ-specific product for mutation detection 
screening. This will facilitate future studies that undertake molecular diagnosis of 
ADPKD linked to thePKDJ gene. 
The differences and similarities between the pseudogene and the PKDJ sequences will 
provide a basis for further research at a nwnber of levels. As sequence information 
increases, the accuracy of PKDJ-specific primers will improve. By comparing the 
pseudogene sequences to PKDJ and each other, the order of evolution of the 
pseudogenes may also be modelled. PKDJ pseudogene sequences and paralogous gene 
sequences from genes in the PKD family will provide evidence to strengthen or dispute 
the gene conversion theory. As genomic information on other species improves, 
searches for PKDJ homologous sequences could be applied to primate genomic 
libraries in order to assess the stage of molecular evolution at which PK.DJ duplications 
first occurred. 
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ln addition to providing molecular diagnostic strategies for the PKDJ gene, this study 
may benefit other groups investigating genes where co-amplification of homologous 
sequences presents an obstacle in mutation detection. Similar approaches to those 
outlined in this study, using BAC libraries, could be used for the unique amplification 
of other genes, and the study of the function of homologous genes. 
For ADPKD families pre-symptomatic diagnosis, preceded by informed consent, can be 
extremely beneficial for various reasons. For example, individuals who are at-risk can 
ascertain whether they are likely to develop renal cysts and thus be more likely to 
develop renal failure with advancing age. Individuals who are pre-symptomaticaHy 
diagnosed as affected can be monitored, and if necessary treated, for hypertension prior 
to the onset of renal deterioration. These people then have tb opportunity to make 
informed life-style and reproductive choices. At-risk individuals who are diagnosed as 
unaffected can be spared mmecessary anxiety about developing the disease and, if they 
wish, can volunteer as possible kidney donors for affected family members. 
As suggested by Prof. Arno Motulsky in his address to the American Society of Human 
Genetics (2000), in future it will be necessary to understand the pathways that lead from 
an altered gene sequence to the disease phenotype. A new discipline termed 
"phenogenetics" is e:nerging that deals with the study of genotypic expression and how 
it is influenced by modifying genes, somatic mutations and epigenetic factors 
(Motulsky, 2000). Given the strong possibility that somatic mutations and modifying 
factors greatly influence the variable phenotype associated with ADPKD, it will be 
necessaiy to understand what influence all of these factors exert on the overall clinical 
outcome of the disease. 
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Microarray analysis may provide information of how gene expression levels of other, 
possible modifying genes. are altered in varying PKDJ phenotypes both between and 
within families. Although this analysis would not assist in determining the influence of 
somatic mutations, it may reduce the number of variables in the overall question. It has 
been predicted that there are as few as 26,000 to 40,000 protein-coding genes in the 
hwnan genome (McPherson et al., 2001; Venter et al., 2001). Given the levels of 
species complexity, this relatively low number of genes highlights the underlyfog gene 
in�eractions as well as the pre- and post-natal environmental conditions which must 
exist in order to account for phenotypic diversity in humans. 
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Appendices 
Appendices 
Appendix A 
Al. PCR Optimisation with Differing buffers 
Table A.I. Enzvme Buffers for Optimisation of Mg 2+ Concentrations 
Series Buffer Mix Final fl\i2Cl1llll� 
SOmMKCL A=0.75 
10 mM Tris-HCI pH 8.4 B = 1.50 
0.01 gelatin C=2.25 
0.1% Triton X-1000 D= 3.00 
E = 3.75 
II 40mMNaCI F= 0.75 
lOmMKCI G = I.SO 
0.01 gelatin H=2.25 
0.1%Triton X-1000 I= 3.00 
J = 3.75 
m l O mM (Nl-1.hSO .. K=0.75 
lOmMKCI L = I.SO 
10 mM Tris-HCI pH 8.4 M= 2.25 
0.01 gelatin N =3.00 
0.1% Triton X-1000 0=3.75 
Al. OIAguick Spin Column Protocol 
1. Initial PCR product was run on an agarose gel and the band excised and placed in a 
microcentrifuge tube ( 1.5ml). 
2. 3 volumes of QXl (QG) buffer were added to I volume of gel and it was melted at 
50°C until dissolved. 
3. Mixtlll"e was briefly vortexd, if pH indicator was yellow, 1 gel volume of 
Isopropanol was added and mixed. 
4. Spin column was placed in 2ml collection tube and sample applied to column. 
5. Sample was bound to the column by spinning at 13,000 rpm for l minute at room 
temp. 
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6. Flow through was discarded and 500µ1 of QXI buffer applied to column, this was 
centrifuged again and flow through discarded. 
7. 750µ1 of PE buffer was applied and column stood at nn. temp. for 2-5 minutes. 
8. Column was centrifuged at 13,000 rpm for 1 minute, flow through discarded and 
centrifugation repeated. 
9. Column was placed in a clean 1.5ml microcentrifuge tube. 
10. DNA was eluted by the addition of 30µ1 of pure water to centre of membrane, this 
was allowed to stand for 1 minute and then centrifuged at 13,000rpm for I minute. 
A3. Centricon Filter Protocol 
1. The remaining 90µ1 of ssDNA PCR product was applied to a Centricon YM30 
column (cut off size approx 60 bo s�DNA) 
2. 2.5ml of ddH20 was added to the column and centrifuged at S,OOOg for 15 mins at 
room temp. 
3. Flow through was discarded and column rinsed with 2.5ml of ddH20, then 
centrifuged at 5,000g for 10 mins at room temp. 
4. Step 3 was repeated twice and column was remove.d from lower discard tube 
5. Column was inverted into a clean collecting tube and centrifuged at 3,S00g for 5 
minutes to collect concentrated ssDNA. 
A4, Cleaning of AB I Seqµepcing Reaction Prior to Electrophoresis 
1. 2.5 volumes (25µ1) of ice-cold 95% ethanol (EtOH) and 0.1 volumes (lµl) of 3M 
sodium acetate (pH 4.6) were added to the 10µ1 sequencing reaction. 
2. The microcentrifuge tube was vortexed and left on ice or at -20°C for 30 minutes. 
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3. Tubes were then centrifuged at 13,000 rpm for 15-30 minutes at 4°C. 
4. Supernatant was removed and care was taken not to disturb the pellet. 
5. The pellet was rinsed in 250µ1 of 75% EtOH and then centrifuged at 13,000 rpm for 
5 minutes at 4 °C. 
6. Supernatant was carefully removed and pellet dried to z.ero volume ( either air-dried 
or dried in a rotary vacuum at room temperature). 
7. Sequencing reactions were stored at -20°C prior to pellet being redissolved for 
electrophoresis. 
AS. Plasmid Purification Post BAC/PAC clone identification 
Purification of the culture was then performed using a modification of the Qiagen 
Plasmid Midi Kit protocol (personal communication Dr. Arseni Markoff, Muenster). 
Maxi Prep from BAC/PAC DNA 
1. Two days prior to isolation a single clone was picked from those grown on the LB 
Agar plate and used to inoculate 3-5ml of LB Media (containing chloramphenicol 
12.Sµg/ml) (LB/Cm) in a 15ml glass centrifuge tube. The culture was grown 
overnight at 37°C with vigorous shaking (-300rpm). 
2. After 24 hours the starter culture was used to inoculate one litre of LB/Cm in n five 
litre flask and again shaken vigorously at 37°C overnight. 
3. The following morning 500ml of the culture was transferred into 2 X IL Beckmann 
centrifuge tubes and spun at 3,500 rpm for 10 mins at 4°C (JS horizontal rotor). 
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4. Supernatant was discarded and cells were resuspended in I 0ml of Pl  resuspension 
buffer (5C:mM Tris-Cl (pH 8.0), 10 mM EDT A, lOOµg/ml RNase A, stored at 4°C) 
and vortexed. 
5. 20ml of P2 lysis buffer (200mM NaOH, 1 % SOS) was immediately added and the 
suspension was gently shaken then incubated at room temperature for 5 minutes. 
6. 20ml of ice-cold P3 neutralisation buffer (3M potassium acetate pH 5.5) was added 
and tubes were mixed by inverting several times. 
7. A Qiagen-tip 100 was equilibrated with 10ml of QBT equilibration buffer (750mM 
NaCl, 50 mM MOPS pH 7.0, 15% isopropanol, 0.15% Triton X-100). 
8. The DNA precipitate was filtered through a funnel overlayed with cheese-cloth. 
The clear filtrate was then passed through the Qiagen tip in 2-3 shots by the 
application of vacuwn. 
9. The tip was then washed with 3 X 20ml of QC washing buffer (I.OM NaCl, SO mM 
MOPS pH 7.0, 15% isopropanol) by applying vacuum. 
10. The DNA was then eluted from the tip by the application of 5 X 1ml of pre-heated 
(65°C) QF elution buffer (1.25M NaCl, SOmM Tris, Tris-Cl pH 8.5, 15% 
isopropanol) into a 30ml Corex tube. 
11. 0.7 X volumes (3.5ml) of isopropanol was then added and mixed well. 
12. The tube was centrifuged at 10,000 rpm for 30 minutes at 4°C (JA 12 Sorvall rotor). 
13. The supernatant was decanted and the pellet was washed with 10ml of 70% ethanol 
for S minutes at 10,000 rpm at 4°C. 
14. The ethanol was then carefully decanted and the pellet air-dried. The pellet was 
resuspended in 500µ1 of TE buffer pH 8.0. 
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A6. ABI 373 ON A Sequencer (Perkin Elmer). Sample Preparation 
1. A mixture of 5: 1 deionised formamide (pH >7.0) to 25mM EDTA (pH 8.0), with 
50mg/ml blue dextran was prepared. 
2. 4µ1 of this mixture was added to each sequencing reaction. 
3. Tubes were briefly vortexed, then centrifuged for 10 seconds. 
4. Samples were denatured at 94°C for 3 minutes and placed immediately on ice. 
Preoaration of Sequencing Gel 
These quantities make 60ml of 4% (19:1 acrylamide:bisacrylamide) gel with 8.3M urea 
in 1 X TBE, for a 48cm gel. 
1. In a glass flask 30g urea, 22ml of ddH20, 6ml of 40% acrylamide stock and 
approximately l g  of mixed bed resin were mixed. 
2. The solution was stirred on a magnetic stirrer over a slight heat until the urea 
crystals began to dissolve and the flask was warm to touch. Stirring continued for 
5-10 minutes without heating until all crystals were dissolved. 
3. The acrylamide solution was filtered through a 0.2µm filter and the solution was 
degassed under vacuum for 5 minutes. 
4. The gel mix was transferred to a iOOml cylinder and 6ml of 10 X TBE was added 
5. The mix was made up to a finai volume of 60ml with ddH20. 
6. Clean plates were clamped together ready for gel pouring. 
7. The gel solution was mixed in a beaker with 300µ1 of 10% ammonium persulphate 
and 30µ1 of TEMED. This was swirled gently to avoid air-bubbles being 
incorporated into the mix. 
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8. Plates were held at an angle, and gel was poured, when plates were full they were 
lowered to a horizontal position and an inverted sharks-tooth comb (48-well) was 
inserted to form the well trough. 
9. The gel was allowed to polymerise at room temperature for 1-2 hours. 
The comb was removed and the sequencing gel was assembled in the 373 DNA 
sequencer, the plate was scanned to ensure it was clean in the read-region with no 
fluorescent contamination. The sharks-tooth comb was re-inserted to form the wells. 
The upper and lower buffer chambers were then filled with 1 X TBE and pre­
electrophoresed for five minutes at 40W to ensure that al) connections were working 
prior to loading. Power was interrupted and the wells were rinsed with buffer using a 
syringe, 2µ1 of each denatured sample was loaded and the gel was electrophoresed at 
40W constant power for 12-15 hours. Sequencing data were then saved to disk for 
analysis by requestor. 
A7. Seguitherm Excel II Cycle Sequencing 
Cycle Sequencing Protocol 
Premix 
Primer 5pmol 
[a33P ]-dA TP 
5X SequiThenn EXCEL Buffer 
DNA Template (200 finales) 
ddH20 (to 16µ1) 
SU of SequiTherm EXCEL II enzyme 
lµl 
0.5µ1 (lOµCi) 
5µ1 
'.-µl 
4.5µ1 
1.0µ1 
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For each template four 600µ1 microcentrifuge tubes were labelled A, G, T and C and 
2µ1 of the appropriate SequiTherm EXCEL II Termination mix was placed into each 
tube on ice. 4µ1 of the premix solution was then pipetted into each tube and mixed 
thoroughly. The tubes were denattrred at 95°C for five minutes and the reactions were 
cycled 30 times at 95°C for 15 seconds, 65°C for 1 minute and 70°C for l minute. 
After 30 cycles 5µ1 of stop buffer (95% vol/vo! formamide, 20 mM EDTA, 1% 
xylenecyanol FF, l % bromophenol blue) was added to each reaction tube. 
Appendix B 
Journal articles resulting directly from this thesis. 
1 . Bogdanova & McCluskey et al. (2000). Screening the 3' region of the 
polycystic kidney disease 1 (PKO l )  gene in 41 Bulgarian and Australian 
kindreds reveals a prevalence of protein truncation mutations. Hum Mu tat. 
16(2): 166-174. 
2. Bogdanova et al. (2001). Homologues to the first gene for polycystic kidney 
disease are pseudogenes. Genomics. 74(3): 333-341. 
3. McCluskey et al. (2002). Mutation detection in the duplicated region of the 
polycystic kidney disease 1 (PKO I) gene in PKO I-linked Australian families. 
Hum Murat. 19(3): 240-250. 
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RESEARCH ARTICLE 
Screening the 1 Region of the Polycystic Kidney 
Disease 1 (PKDl) Gene in 41 Bulgarian an.d 
Australian. ·Kindreds Reveals a Prevalence ·of Protein 
Truncating Mutations 
Nadja Bogdanova, 1 Marie McCluskey, l.2 Karin Silanann, 1 Arseni Markoff, 1 Vassil Todorov,3 
Dimitar Dimitrakov, 4 Tma Schiavello, 2 Mark Thomas, 5 Luba Kalaydjieva, 2 Bernd Dworniczak, 1 
and Jurgen Horst10 
1Irutiatt [iir H� West[alische Wdhelms-Un.ivemtat Munster. Munster. German:, 
2Centre far Human Genttics, Edith Cowan Universit], Joondalup, Australia 
3Clinic of Nephrolog] and Haemodialysis, Medical Univernt:Y, Pleven, Bulgaria 
�Clinic ofNephrolog:, and Haemodialysis, � Unwmity, Ploudiv, Bulgaria 
'Department of Nephrology, Ro:,al Perth Hospital, Perth, Awtraiia 
Comnumiazrd,,, Michd Goossms 
Screening for disease�causing mutations in the unique region of the polycystic kidney diac:ase l 
(PKDl) gene was performed in 41 unrelated individuals with autosomal dominant polycyst:ic 
kidney disease. Exons 34-41 and 43-46 were illlsayed using PCR amplification and SSCP analysis 
followed by &rect sequencing of amplicons presenting variant SSCP patterns. We have identified 
seven discase,causing mutations of which pve are novel { c.1063+ 10656del; c.11587delG; IVS3 7-
10C> A; c.11669,11674del; c.13069,13070ins39] and two have �en reported p1-eviously 
{Q4010X; Q4041X]. Defects in this part of the gene thus account for 17% of cur group of pa, 
tient.s. Five of the seven sequence alterations detected are protein-truncating which is m agree, 
ment with mutation screening data for diis part of the gene by other group&. The two other mutatiom 
are in-� deletions or insertions which could destroy important functional properties of polycyatin 
I. These findings suggest that the first step toward cyst formation in PKO! patients is the lcoa of 
one functional copy of pocycy5tin 1, which indirectly support& the "two-hit" model of cystogenesis 
where a second somatic mutation inactivating the normal allele is necessary to occur for develop, 
ment of the disease condition. Hum Mutat 16:166-174, 2000. C zooo Wllc:y.Uu, ln.c. 
l<EYWORDS, PKDl; polycystic kidney clisea:e; autosomal dominant; polycystin 1; genotype-phenotype 
correlation 
DATABASBSt 
PKDl-OMIM:601313, 173900 (PKD); GDB:120293; GenBank:L39891; HGMD:PKDI 
INTRODUCTION 
Autosomal dominant polycystic kidney disease 
(ADPKD) is one of the most common Mendelian 
inherited disorders (MIM# 173900) with an inci­
dence of approximately one in 1,000 [Dalgard, 
1957). The main clinical manifestation of the dis­
ease is the develcpment of fluid-filled cysts in both 
kidneys which, in most affected individuals, results 
in kidney failure. Eight to 10% of all patients re­
quiring haemodialysis or renal transplantation have 
ADPKD fGabow, 1993). Additional symptoms 
may include hypertension, urinary tract infections, 
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haematuria, proteinuria, extra-renal cysts, cerebral 
aneurysms, hemiae, cardiac valve defects, renal 
caliculi, gastrointestinal diverticuli [Roscoe et al., 
1993], and spinal meningeal diverticula [Schie­
vink and Torres, 1997}. The clinical course of 
ADPKD varies in tenns of presenting symptoms 
and the rate of progression towards kidney fail­
ure. In some patients end-stage renal failure 
(ESRF) occurs in adolescence while in others 
ESRF does not occur at all [Choukroun et al., 
1995; Parfrey et al., 1990]. Among those who de­
velop ESRF the mean age at onset is approximately 
50 years [Milutinovic et al., 1984]. The wide range 
of clinical manifestations and the variation in se­
verity are most probably a compound product of 
the genetic heterogeneity, locus as well as allelic, 
within ADPKD itself and of the effects of modif,r-
ing genes and environment 
At least three different genes are currently im­
plicated in autosomal dominant polycystic kidney 
disease: PKDl (MIM# 601313), located on chro­
mosome 16pl3.3 {The European Polycystic Kid­
ney Disease 'Consortium, 1994], PKD2 (MIM# 
173910) on chromosome 4q21-23 [Mochizuki et 
al., 1996], and at least one more gene which is yet 
to be identified [Bogdanova et al., 1995; de 
Almeida et al., 1995; Daoust et al., 1995]. 
T he participation of additional environmental 
and genetic factors in the course of the disease is 
supported by the demonstration of a "two-hit" 
mechanism in renal- and hepatic-cyst formation. 
Germline and somatic inactivating mutations of 
the two characterized genes for ADPKD, PKDl, 
and PKD 2 have been identified in cyst-lining 
epithelial cells [Qian et al., 1996; Watnick et al ., 
1998; Koptides et al., 1999]. To study the geno­
type-phenotype correlation and address the func­
tional importance of predicted protein domains 
further efforts have been made to screen PKDl 
and PKD2 for disease-causing alterations of the 
nucleotide and amino acid sequence. 
In affected individuals of European descent, mu­
tations in P.KD1 are the most common cause for 
the disease and account for up to 85% of cases 
[Peters and Sandkuijl, 199 2]. The PKDl gene con,. 
sists of 46 exons sp8!U}ing-52 kb of genomic DNA 
[The lntemational!f'olycystic Kidney Disease Con­
sortium, 1995; The American PKDl Consortium, 
1995; Hughes et al., 1995]. A large part ol"'the gene 
is duplicated in at least three homologous genes, 
HG-A, HG-B, and HG-C, which are located on 
chromosome 16p13.1 and share approximately95-
97% homology with the PKDI .gene [Hughes et 
al., 1995]. Only 3.5 kb of the PKDl transcript (ap-
proximately 14 kb in length), located at the 3' end 
of the gene (exons 34 to 46), is unique to PKDl. 
The PKDl gene product, polycystin 1, consists of 
4,30 2 amino acids and is predicted to contain a 
large N,terminal extracellular domain of -2,500 
residues, several transmembrane domains, and a 
short cytoplasmic C-terminal region [The Inter­
national Polycystic Kidney Disease Consortium, 
1995; Hughes et al., 1995; Sandford et al., 1997]. 
It has been demonstrated recently that polycystin 
1 and the gene product of PKD2, polycystin 2, as, 
sociatc in vivo in a heterodimeric interaction [Qian 
et al., 1997] involving the carboxy-tennini of the 
two proteins. In polycystin 1, the proposed region 
of interaction is positioned in exon 46, the final 
exon of the gene (nucleotide positions 1 2854-
1 2955 ef the cDNA, acc. L33243). To date, a to, 
tal of 40 mutations in the 3' end of PKDI have 
been reported, mostly detected in patients from 
western European countries. 
Here we present the results of a collaborative 
study of mutations in the unique region of PKDl 
in 41 Bulgaru:.n and Australian ADPKD individu, 
als, which indicate predominant appearance of 
protein-truncating sequence alterations in this part 
1the gene. 
MATERIALS AND ME1H0DS 
Patients 
Twenty-six of the affected subjects are from 
Bulgaria and represent a mixed southeastern Eu­
ropean population. The Australian group consists 
of 15 affected individuals predominantly of Brit­
ish descent with one far-.ily of Spanish origin. In 
all patients, the diagnosis of ADPKD war; based 
on standard ultrasound criteria [Bear et al., 1992]. 
linkage studies have been conducted in 39 of the 
families. Two affected individuals, one from Aus­
tralia (A72.1) and one Bulgarian (B2S.l), were 
included in rhe study without prior linkage analy­
sis, based on the assumption that PKDI accounts 
for most cases of ADPKD. 
DNA Isolation and PCR Amplification 
DNA was extracted from peripheral whole 
blood using standard procedures [Miller et al., 
1988]. Polymerase chain reaction (PCR) was per­
formed on 50 ng of genomic DNA in a final vol­
ume of 25 µI using 1.5 units of Taq polymerase 
(Gibco BRL Life Technologies) and 1.5 mlvt MgClz. 
The optimised conditions for the PCR amplifica­
tion of individual exons are shown in Table 1. Prior 
to SSCP, the PCR products were electrophoresed 
in 1 % agarose gels and visualized with ethidium 
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'mBl£ 1. AmeUBc::itfon CondltJon.s for SSCP AnnJysb of the Unique � Region of PKI>l 
Ampllailion e!!mets 
Emn34 Fotward 5' gtgagctggggtgagngpg 3' Reve:me 5'acggct�3' 
Excn35 Fonwrd 5' a  S' .. Reveme.- 5' c:mgct:Cdcc.ctstgugd 3' 
&on36 Fotward 5' ctgtgagctgcddalcag S' Revcn.e 5' cf.lu.'aggcdca:ta,.cggg 3' 
&onS7 
fonwrd 5' ggtaggctacaggcdccat S' Reverse 5' c:acc:tccgtctcttgtdcc 3' 
Exon38 
forwru-d 5' C!ll!Dga:ctgctgtcactg 3' Reverse 5' tagtccagccZlgaccctagg 3' 
Exon 39 
fol"WZ!ro 5' gtctctggtggccgctcad S' Reverse 5' gcagcctttagcggagctct 3' 
Exon40 
forward S'ga�S' Reverse 5' tdacgccaaggaC81'.lgggag 3' 
Exon41 Forward 5' cgtdacgccaaggaca&gg 3' Rewra2 5' cttc:cac:agca:ctc:agcca 3' 
Exon43 
forward 5' cagcgtccctca:gccctcctga 3' R.everae 5' gcgcacaca.:a,gggdgcangc 3' 
Elton 44 Forwnrd 5' au:a:cagggctgcaegczg 3' Reverse 5' gtggactccctctggagc:gt 3' 
Exon45 Forward 5' cgtcttagctc:agctcagct 3' Reverse 5' agtggggggagagggacac 3' 
Exon 46 (fragment a) Forward 5' gtgcagccggadgndgag 3' Reuense 5' cgtctaccagdggagcagc 3' 
Exon 46 (fragment b) Forward S' gaccgnctcaaccaggcau: 3' 
Reveme 5' caggcagaatggctga!Cg 3' 
AmpUi:on 
n:! (bp) 
240 
220 
286 
299 
272 
259 
264 
355 
883 
292 ,. 
396 
318 
336 
•Aa:ordlng to Genbank accesslon number 1.39891. · 
bromide staining in order to confirm amplification 
and rule out large deletions or insertions. 
SSCP Analysis 
Single#strand conformation polymorphism 
(SSCP) .-nalysis was performed using 2µ1 of PCR 
product and an equal volume of fonnamide loading 
buffer (98% fonnamide, 0.025% xylene cyanol, 
0.025% bromophenol blue). The mix was heat-de­
natured and kept on ice prior to loading. We found 
that the optimal gel composition for electrophore­
sis was a 12% polyacrylamide gel with a cross-link­
ing ratio (%C) equal to 2.5 [Savov et al., 1992]. 
The gels (160 x 200 x 0.75 mm) were run at 25°C 
for varying lengths of time at different constant volt­
ages using a vertical gel apparatus, D Gene .u Sys-
Annealing and 
cydl!!!l cond.!tions 
30 cyae:s m 65"C 
2-step PCR of SO cycle.. 
flt 68": 
50 q,dea at 63°C 
2-step PCR of 35 cycles at 68°C 
30 cycles at 64"C 
2-step PCR cf 35 cycles at WC 
2-step PCR of 35 cyda lit 68°C 
2-step PCR of 35 cycles at 68°C 
40 cycles st 60°C 
2-aep PCR of 35 cycles at 6S°C 
30 cycles at 68"C 
2-ctep PCR of 35 cydes at6WC 
35 cycles at 66°C 
... 
Nu=:leotide Additives position• 
BSA (0.5%) gelatine 44276-295 (2'£) 44496-515 
Non-
473S0-349 ......... .  47630-549 
Non 
47541..s60 
47807-826 
Non 
47801-820 48080-099 
Non 
48489-458 
48691-710 
Non 48929-948 
49167-187 
Non 
49330-349 
49573-593 
Non 
4957Ui90 
49906-925 
DMS0(2%) SOS81-403 50741-763 
Non 
50746-765 
51018-037 
Non 50946-965 
51322-341 
Non 
51361-380 
51659-678 
DMS0(2%) 
51688-652 
51950-968 
tern (Biorad), in 1 x T AE buffer without glycerol 
and in 1 x TBE with 5% glycerol [Kuldta et al., 
1997]. The single strand separation was visualized 
by a silver-staining procedure [Budowle et al., 1991]. 
The gels were dried and stored for documentation. 
DNA Sequencing and Restriction Analyafa 
All samples where an aberrant banding pattern 
had been detected by SSCP analysis were subjected 
t!) manual sequencing using internal labelling with 
[a)3P]-dATP {Hartmann Analytics). Products fur 
the sequencing reactions were obtained by PCR on 
genomic DNA with the amplification primers listed 
in Table 1. Cycle sequencing in fmward and reverse 
directions using the same or internal primers was 
performed with the SeqmTherm.,,. Cycle Sequenc-
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ing Kit according to the manufacturer's protorol 
{Epicentre Technologies). The products of these­
quencing reactions were electrophoresed in 6% de­
naturing polyacrylamide gels (C'%= 5; 6M urea; 350 
x 400 x 0.4mm), at 68W constant power for 2-3 
lu: Gels were dried under vacuum prior to autorad­
iographic exposure on Biomax ni films (Kodak). 
Restriction digestion of gel purified PCR prod­
ucts was performed in a total volume of 20 µI with 
10 units of the appropriate enzyme (Gibco BRL; 
New England Biolabs), in conditions specified by 
the manufacturer. Reaction products were sepa­
rated on a 2.5% agarose gel and visualized by 
ethidium bromide staining. 
All sequence changes were subject to family seg­
regation analysis using SSCP or, where possible, 
restriction fragment length polymorphism anal�. 
RESULTS 
Using the techniques outlined above, we have 
identified disease-causing mutations in the unique 
3' region of the PKDl gene in seven of the 41 
ADPKD patients screened (summarized in Tables 
2 and 3). Five novel and two previously reported 
mutations were detected. The results are presented 
according to the type of molecular change. 
Protein Truncating Mutations 
� Two nonsense mutations were detected in this 
study, both of which have been reported previously. 
Q4041X. 
1bis is a C to T substitution at nucleotide c.12332 
(Genbank acc. 133243) which changes a Glutamine 
to a Stop codon and is predicted to truncate 
polycystin 1 b-1 262 amino acids. It was first identi­
fied by Turco et al. [1995} in an Italian patient and 
subsequently reported in one Spanish and two Brit­
ish families [Torra et al., 1998; Daniells et al., 1998}. 
In our study, Q4041X was found in individual 
A3.1, the index patient from a large Australian fam­
ily of British origin, and was also detected in all six 
affected family members participating in the study. 
Hepatic cysts have been detected in 3/6 affected 
individuals. Apart from that, the clinical course of 
ADPKD, including rate of progression towards re­
nal failure, appears variable, as shown in Table 2. 
Q4010X. 
T his is a C co T substitution at nucleotide 
c.12239 which changes a Glutamine to a Stop 
codon and is predicted to truncate polycystln 1 by 
293 amino acids. It has been reported previously in ., 
TABl.E z. Clln!cal Data of Patients From 5 Bulgarian and 2 Australlan PK01 Families With Disease-Causing 
Mutations In the Unique Part of the PKDl Gen2 ldenttfled In the Present Study 
Mutation 
(exon'lntron) 
c.10634-10656del 
(&on34) 
IVS 37-lOC>A (lntron S7) 
c.11S87de1G 
(Exon40) 
c.11669-U674del 
(Exon 41) Q4010X (Exo .. 44) Q4041X 
(Exon44) 
c.51815-5181ins39 
(Exon 46) 
"CRF. c:hronk: renal £anare. 
Fam.lJv& 
patient ID 
B22.1 B22.2 
B22.S B22.4 
822.5 B57.1 B57.2 B57.3 877.1 B77.2 877.3 877.4 B77.5 B77.6 
B25.1 
A72.1 
AS.1 AS.11 AS.13 AS.18 A3.19 
A8.38 B41.1 B41.2 
�RF. ei>d stage renal fa!Jum. 
Current Sex age (ye.ms) 
M 6S F 61 
F 26 
F S8 
F 34 
F 64 
F 64 M 42 
F 55 
F 55 M 81 M 29 
M 28 M 25 
M -· 45 
M 58 
M 60 
F 66 M 45· 
M 41 F 39 
M 51 
F 35 M 39 
CRF" ESRP' lJver lntraa.mlaJ �) (years) Hypertensron ststs anewy:ms 
42 49 Yes No No 54 57 Yes No No No No No No No 
No No No No No 
No No No No No 
54 55 Yes Yea No 55 No No Yeo No 89 No Yes No No 45 No )es Ye.a No 49 No Yes Yea No 
No No Yes Yes No 
No No Yes No No 
No No No No No 
No No No No No 
44 No Yes No No 
45 49 Yes No No 
? 42 Yes ? ? 50 57 Yes Yes Yes 
No No Yes Yes No 
No No No No No 
No No No No No 
No No No No M:, 
No No Yes Yes No 
No No No No No 
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TABJ.£ s. Disease-Causing Mutations In the Unique Part of the PKDJ Gn>e ldentffled In the Present Sh$' 
Exon/ lntron Site of nucleotkie .A.mino add Restrk:tton changeO change stte dw1ge 
F.xon34 IVS37 Exon 40 Exon41 Exoo44 
c.10634-10656de.1 P3457rsx3617 -Awll Present study Present study Preseit study Present study 
IVS37-10C>A Splice site +Bsrl c.l 1587delG R3793fsX3824 c.11669-11674dd QE3820-3821de! c.12239C>T Q4010X c.12382C>T Q4M1X F.xon 4fj .. c:.l3069�13070in'°�9. - . . .. .4286-42871nsl3a& 
... Turco et al., 1995 Dnnlells et al.. 1998 Preseid study . .. -
•Accordlng to Gatlwlh ecce£Slon num� 1.33243. 
an ADPKD patient of British descent [DanieUs et 
al., 1998] and in a Korean patient [Kim et al., 2000]. 
In our study, the mutation was found in Aus­
tralian patient A72.l. No other family members 
were available for this study. The family has lived 
in Australia for the past three generations and 
originates from Britain. Patient A72.l was diag­
nosed at 15 years of age due to positive family his­
tory. He deveioped hypertension at age 27 and reached ESRF at 49 years (fable 2). His other 
symptoms include umbilical hernia and gout 
Three of the novel mutations identified in this 
study are predicted to result in a frameshift and 
subsequent introduction of a preliminary stop 
codon. Two of these changes are deletions and one 
is a possible splice mutation likely to have a frame-, 
shift effect 
c.11587delG. 
A single base pair deletion in exon 40 was found 
in Bulgarian patient B77.l. The mutation is pre­
dicted to result in termination of translation at 
codon 3824 and to truncate polycystin 1 by 478 
amino acids. 
The presence of this mutation was tested by the 
use of SSCP analysis in eight other family mem­
bers, of whom six are known to have ADPKD. 
Analysis of the other family members showed that the c.11587delG mutation segregated with the dis­
ease. The clinical features of ADPKD in this fam. 
ily are shown in Table 2. 
c.10634-10656dul. 
This novel 23 hp deletion in exon 34 results in 
a stop codon at position 3617 thus truncating the 
protein by 685 amino acids. The mutation was 
found in Bulgarian patient B22.l and in all five 
affected members of the family. Their phenotypic 
features are shown in Table 2. 
Splice-Site Mmatlon (IVS37-10C>A) 
A transVersion of C to A at position g.48491 
(Genbank accession number Ll9891) in intron 37 
of PKDl was detected in Bulgarian patient B57. l. 
This change could create a new acceptor splice 
site eight nucleotides upstream of the end ofIVS37 
as shown below. 
Wild Type 48481 agggcccccc cgtccac [cag] AGCCTCCTG ...• 
Mutant 48481 agggccccc [cag] TCC ACC 
AGA GCC TCC TOG . . .. 
The new acceptor site produces a fram.eshift with 
a transiation stop at codon 3684 thus resulting in 
truncation of polycystin 1 by 618 amino acids. 
The nucleotide substitution creates a Bsr I re­
striction site and restriction fragment length poly­
morphism analysis was used to screen additional 
family members and 50 unrelated normal subjects 
for the presence of the mutation. It was found that 
the mutation co-segregates with the disease in this 
family and it is not present in the nonnal controls 
(data not shown). Thus, we presume that this could 
indeed be a disease-causing mutation, although no 
RNA from this patient was available to verify that. 
The disease manifestation in the affected family 
members is summarized in Table 2. 
In-frame Deletions and ln&erilons 
c.11669-11674del. 
This 6 bp deletion in exon 41, resulting in the 
loss of glutamine and glutamic acid at ccdons 38� 
3821, was observed in Bulgarian index patient 
B25. l. Overview of rhe disease phenotype in the 
affected patient is shown in Table 2. 
There were no other familv members available 
so no segregation analysis has been performed. 
However, 50 unrelated norm.al individuals were 
tested for the presence of this deletion. using ge­
nomic amplification and subsequent separation of 
the PCR products on a 3% agarose gel. No earner 
of the mutation was detected in the control group 
(data not shown), thus sugge3ting that this could 
be a disease-causing mutation. 
In order to relate this mutation to an eventual 
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function distortion of polycystin 1, the protein seg­
ment encoded by exon 41 was subjected to a sec­
ondary structure prediction analysis, PHDsec [Rost 
and Sandei; 1994], with and without the deletion 
change. Figure 1 shows the comparison between 
both variants; the deletion of glutamine and 
glutamic acid at positions 3820 and 3821 modifies 
the topology of this portion of the protein, which 
is a predicted part of a loop exposed on the exter­
nal cell surface [Hughes et al., 1�95). 
c.13069-130701ns39. 
An in-frame insertion in exon 46 of 39 hp was 
detected in patient B41.1. T he insertion begins at 
nucleotide 13069, between codons 4286 (Pro) and 
4287 (Ser) as detailed below. 
(c.13067)CCC "acg cag gga cca ctt egg gee 
aag aac aag gtc cac ccc "' AGC(c.13072). 
These 39 nucleotides encode the following ad­
ditional amino acids: 
( 4286) Pro "Tur Gin Gly Pro Leu Arg Ala Lys 
Asn Lys Val His Pro "' Ser(4287). 
Ten of the 13 insened amino acids represent 2 
repeated segment further downstream in the se­
quence (positions 4290-4299). Titls insertion cre­
ates a third additional loop at the very C-terminus 
of the protein, as shown by using the PHDsec al­
gorithm (Fig. 2). 
The insertion was detected L"l the two mem­
bers of the family who are known to be affected 
and in two young individuals (born in 1987 and 
1986) who are predicted to be carriers of a PKDl 
a.41.---- ,-�, 
-· � I m a::zm .,, • I 
- 1=..s ... uz..:s ........... lmlZ!m!D ••• u.1 
... 1. .. 1110-11� 
-- ,� , 
-· .=-e J rm rm cuu 1#44 I 
. � •. pnd.ir:Uca - 1u.,_.i..c:1 •. i.u..:n .... aa .. :m,., ::tlll:IIIIIZ:I ... u.1 
FIGURE L Alignment of polycystfn I, exon 41. and excn 
41, c.11669-11674dcl mnlno add sequences and uecond­
ary structure prediction using the PHDsec algorithm. The 
deleted amino adds are underlined m the wild type se­
quence. E means extended sheet, H means helix l!IJY.I L 
means loop."The prediction subset fn both figures ls mean­
tngfu) for all residues with an expected awmge correla­
tion gn!lSler th.ml 0.69. 
... "---
- Ju..mmi .. 1.1. ••• u.uw. ..... =1 
1u..a.11a .•• u. •.• u.u.i.u. ••••• u.u.u.u. ..... u.u.u.u.1 
AGURE.2.. Alignment of the C-tennbml 35 amino adds of 
polyc:ystln 1, ex. 46 and the CtennlnaJ 48 amino adds of 
ex. 46, c.13069-13070lns39 and secondary Gtruc:ture pre­
diction using the PHDsec algorithm. The 13 Inserted resi­
dues are underlined. Repeated llilllno adds are shown fn 
ttaUc cuse. The symbols for secondary s:lructme are the 
same as· In Figure I. 
mut&tion on the basis of the linkage analysis with 
polymorphic markers flanking the PKDl gene. An 
outline of die clinical findings in this family is pro­
vided in Table 2. 
DISCUSSION 
Mutation detection in the PKDl gene is com­
pticated by the high GC content of the gene 
(around 62%) and, most of all, by the interference 
of the homologous genes. Predictably, most mu­
tation detection srudies have therefore focused on 
the unique 3' region of PKDl. Of the 82 muta­
tions reponed to date [Human Genome Mutation 
Dai:abase], 45 (55% of all mutations detected) are 
in the 3' unique region which, howevet; accounts 
for only 19% of the coding sequence. When these 
data are viewed as a true proportion of all indi­
viduals te.sted (approx 970 to date) [500 (British, 
Italian and Spanish) Daniells et al., 1998; 175 
(Spanish) Badenas et al., 1999; 15 (Cypriots} 
Neophytou et al., 1996; 146 (French) Perrichot 
et al., 1999; 90 (British) A&al et al., 1999; 41 (Aus­
tralian and Bulgarian) present paper], only 5-6% 
of individuals have mutations in this region. In 
the present srudy, we have detected mutations in 
16% of the ADPKD individuals investigated 
(125% Australian and 18.5% Bulgarian) overthe 
same region. Both sets of data suggest that there 
is no clustering of mutations in the unique part of 
the PKDI gene. Expressed as a percentage of pa­
tients investigated, the number of disease,caus­
ing mutations in the 3' end of the gene is roughly 
proportional to its length, therefore die majority 
of PKDl mutations should remain located in the 
duplicated region. 
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Given the sequence characteristics of PKDl and 
its complex genomic structure, designing a muta· 
tion screening strategy is not easy. Our experimen­
tal protocol, using SSCP as the screening technique, 
has been successful in identifying seven disease­
causing mutations in 41 individuals tested. Thus, 
the proportion of identified mutations in our study 
is at least asJJigh as iliat i.µ Qth.� s_tµ.d,ie.s Qf this part 
· of the gene. Five out of the seven sequence alter­
ations detected would lead to a premature termi­
nation of cranslation. They were all identified 
through SSCP analysis, which is clearly not a 
method biased towards this type of mutation. 
The exons analyzed here in the 3' region did 
not include exon 42 of the gene. Despite repeated 
attempts at amplification, using two different sets 
of oligonucleotide primers, we failed to obtain a 
specific product. No mutations have been reported 
to date in this exon, suggesting that other groups 
may also experience similar difficulties with spe­
cific amplification. This could be due to the pres• 
ence of a non-disease-causing polymorphism in 
IVS 42. It includes a 34 hp repeat region and pro, 
duces an intron size variation of -325 hp to -130 
hp [Peral et al., 1996a]. This variation may explain 
the problems we encountered in the amplification 
of this part of the gene. ,. Out of the total of 50 mutations identified in 
the unique part of P:KD 1 so far (including the 
present study), only five, namely Q4041X [Turco 
et al., 1995;Daniellset al., 1998:Torra et al., 1998; 
Badenas et al., 1999], Q40IOX [Daniells et al., 
1998; Kim et al., 2000), R4020X [Rossetti et al., 
1996; Neophytou et al., 1998], R4227X [Peral et 
al., 1996a; Peral et al., 1997], and R4275W 
[Badenas et al., 1999] have been reported to oc­
cur in more than one family. Two of these, ·namely 
Q4041X and Q4010X, were also detected in �lie 
present study. Comparison of polymorphic 
haplotypes of the Q4041X-bearing chromosomes 
in the Italian, British, and Spanish families with 
this mutation [Torra et al., 1998], revealed no iden­
tity by descent A slipped-mispairing model ex­
plaining the recurrence of this mutation was 
subsequently proposed by Daniells et al. [1998]. 
We cannot rule out identity by descent for either 
Q4041X or Q4010X. The two mutations have 
been identified previously in British patients 
[Daniells et al., 1998] and in our study were de­
tected in Australian individuals of British ances­
try. Whatever the mechanism of origin, the most 
common PKDl mutation known to date, Q4041X, 
accounts for less than 1 % (five out of 877) of dis­
ease alleles. The emerging pattern is that of a large 
multitude of private mutations confined to indi­
vidual families, thus complicating further the study 
of molecular d�fects and of genotype-phenotype 
correlations in ADPKD. 
Regardless of the variety of mutations detected, 
preliminary conclusions are already possible on the 
predominating type of defects. Of the reported 
mutations in the 3' end of PICT) 1 {Human C'-renome 
Mutation Database, Cardiff], approximately 80% 
are protein truncating. 1bis is.in contrast with the 
findings in the 5' part of the gene, where 37% (13/ 
35) of the defects so far reported are missense 
mutations resulting in amino acid substitutions 
[Human Genome Mutation Database, Cardiff]. 
The same trend was observed in our study, where 
five of the seven disease-causing mutations de­
tected in the unique part of the PKDl gene would 
lead to a truncated protein. Moreovei; missense 
mutations were identified in our studies but failed 
to segregate with the disease and were thus con­
sidered to be polymorphic variations (manuscript 
in preparation}. It should be noted, howevei; that 
our study was performed on multiplex families 
where the disease penetrance is high and linkage 
analysis indicating PKDl as the gene involved in 
ADPKD was possible. The spectrum of mutations 
could be different in the whole disease population 
which contains many isolated families with too few 
cases to make linkage analysis possible and where 
the disease penctrance may be low. Nevertheless, 
the protein-truncating mutations identified in our 
study cause C-terminal disruption of polycystin 1 
prior to the last 113 amino acids, which would ren­
der the protein incapable of interaction with 
polycystin 2 [Tsiokas et al., 1997; Qian et al., 1997]. 
These findings suggest that the fust step toward 
cyst formation in PKD 1 patients is the loss of one 
functional copy of polycystin l, which indirectly 
supports the "two-hit" model of cystogenesis where 
a second somatic mutation inactivating the nor­
mal allele is necessary to occur for development of 
the disease condition. 
The novel in-frame deletion and insertion we 
found in this study seem to be pathological muta­
tions, not only as judged by their non-occurrence 
in healthy subjects. Tne secondary structure pre­
diction data for the relevant segments of the pro­
tein do show a potential functional interference 
caused by these changes. c.11669-11674del is per­
haps distorting a possible interaction of polycystin 
1 with an extracellular ligand by changing the to­
pology of the second large extracellular loop, ac­
co"rding to the protein model proposed by Hughes 
et al. [ 1995]. c.13069-13070ins39 is clearly chang-
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ing the spatial organization of the very C-termi­
nus of the protein by introducing an additional 
loop. This mutation causes an early onset of 
ADPKD in the assayed family. The last 115 amino 
acids of the cytoplasmic C-tenninus of polycystin 
1 seem to be essential for modulation of Wnt sig, 
naling during renal development [Kim et al., 1999] 
but the proposed potential ligand(s) for cytoplas, mic-signalling cascades have not yet been identi­
fied. A conformation change as gross as the one induced by this insertion could definitely influence 
the interacting properties of this portion of the 
protein. The inserted repeated stretch of 10 amino acids, on the other hand, could be a consequence 
of a more general slipped,mispai.ring mutation gen­
erating mechanism. 
An assessment of the phenotypic effects of mu­
tations in PKDl is rendered difficult by the lim .. 
ited clinical data provided in mutation reports. We 
have been able to find information on the age.at onset of ESRF for 21 families with 19 different 
mutations in the unique region of PKDl, includ­
ing this study [Peral et al., 1996a, .1.!196b, 1997; 
Turco et al., 1995; Neophytou et al., 1996; Torra 
et al., 1998; The European Polycystic Kidney Dis­
ease Consortium, 1994]. The total number of af, 
fected individuals in these families was 39. The 
mean age at onset ofESRF in patients with muta­
tions in the rransmem.brane domain (N=28) was 
53.8 years and for patients with mutations in the cytoplasmic region (N= 11) it was 52. 7 years. No 
significant differences ce,uld be detected when 
mean age at onset ofESRF was compared between 
groups of patients with different typeS of muta­tion. It was 53.2 years for patients with truncating 
mutations (N=30) and 54.5 years for non-tnm­
cating mutations (N=9). A meaningful assess­ment of the clinical effect of mutations in different 
exons is not possible because of the very small 
numbers of patients with mutations in the same 
exon. Al;, already suggested by the comparison be­
tween individuals with mutations in the traru­
membrane domain and those with mutations in 
the cytoplasmic part of polycystin 1, most reach 
ESRF about age 55 regardless of the specific exon 
·affected. - - ··- . -Since the causes of clinical variation in ADPKD 
are of great interest :and since allelic variation may 
be one such cause, it is of interest to compare the 
phenotype characteristics of individuals with the 
same molecular defect. We have therefore exam­
ined the information on ADPKD patienu; with 
Q4041X. Hepatic cysts appear �o be commonly 
associated with this mutation and have been re-
ported to occur in eight of 12 individuals on whom 
clinical information is available (including this 
study). The rate of deterioration of kidney funr.­
tion is variable, with 2/5 individuals developing 
ESRF before age 45 a.11d 3/5 after 55 years. The 
presence of hypertension has been reported in 
seven of 10 individuals over the age of 30. This 
variation points further to the complexity of the 
disorder and supports again the "two hit" model 
suggesting that gennline mutations in the PKO 
genes are only one of many determinants in the 
development and clinical spectrum of ADPKD. 
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PKDI is the first gene identified to be causative for 
the condition of autosomal dominant polycystic kid­
ney djsease. There are sev.aral genes homologous to 
PKDl that are located proximal to the master gene on 
the same chromosome, Two of these genes have been 
recently covered in a Jorge sequencing work on chro­
mosome 16, and their structure has been broad.Jy ans• 
lyzed. However, the major question whether homolo­
gous genes (HG) code for functionally active 
polypeptides has not been resolved so far. The current 
study identifies and partially characterizes four more 
homologues of PKDl, different from the previously 
published sequence, two of which were found by 
screening of a BAC library and the other two con• 
tained in available databases. Analysis of HG tran• 
scripts shows that they are not tranolated in the model 
cell line T98G. Taken together, these findings suggest 
that homologues to PKDl form 2 family of 
pseudogenes. o scot kcd=>!c p...,.. 
INTR0DUCI10N 
Germ-line and somatic inactivating mutations of the 
two characterized genes for ADPKD, PKDl and PKD2, 
have been identified in cyst-lining epithelial cells (Qian 
et al., 1996; Watnick et al., 1998; Koptides et al., 1999), 
providing evidence for a "two hit" mechanism causing 
cyst formation. 
In affected individuals of European descent, muta­
tions in PKDl are the most common cause for the 
disease and account for up to 85.6% of cases (Peters 
and Sandkuijl, 1992). The PKDl gene extends over 
-52 kb of genomic DNA and contains 46 exons encoded 
by a 14-kb transcript (The International Polycystic 
Kidney Disease Consortium, 1995; The American 
PKDl Consortium, 1995; Hughes et al., 1995). The 
PKDl gene product, polycystin 1, consists of 4302 
amino acids and is predicted to contain a large N­
terminal extracellular domain of -2500 residues, sev­
eral transmembrane d1>mains, and a short cytoplasmfr 
C-terminal region (The International Polycystic Kid· 
ney Disease Consortium, 1995; Hughes et al., 1995; 
Sandford et al., 1997). It has been demonstrated that 
polycystin 1 and the gene product of PKD2, polycysti.n 
2, associate in vivo in a heterodimeric interaction ( Qian 
et al., 1997; Tsiokas et al., 1997) involving the carboxy· 
termini of the two proteins. This interaction of both 
po!ycystines results in the formation of a new calcium­
permeable nonselective cation channel recently de­
scribed (Hanaoka et al., 2000). The complexly orga­
nized extracellular N-terminus of polycystin 1 is 
thought to be involved in cell-cell or cell-matrix inter­
actions. 
PKDl is the first gene found to be impaired in auto­
somal dominant polycystic kidney disease (ADPKD). 
This condition is one of the most common monogenic 
inherited disorders with an incidence of approximately 
1 in 1000 (Dalgaard, 1957). Genetic linkage studies in 
affected families show that at least three different 
genes are implicated in ADPKD: PKDl, located on 
chromosome 16p13.3 (The European Polycystic Kidney 
Disease Consortium, 1994); PKD2 on chromosome 
4q21-q23 (Mochizuki et al., 1996); and at least one 
more gene, which is yet to be identified (Bogdanova et 
al., 1995; De Almeida et al., 1995; Daowit et al., 1995). 
Sequence data from tJtls article have been deposited with the 
GenBank Data Library under Accession Nos. AF320593 and 
AF320594. 1 Both first authors contributed equally to this work. 
2 To whom correspondence should be addressed at the Institut fi1r 
Humangenetik, WWU MOnster, Vesalliusweg 12-14, D-48149 Miln· 
ster, f'..ermany. Telephone: +49 251 836-5401. Fu: +49 251 835-
5431. E-mail: honrtj@uni•muenster.de. 
A large part of the PKDl gene is duplicated in an 
unknown number of homologous genes (HG), which an? 
located on chromosome 16p13.l and share approxi­
mately 95-97% homology with the PKDl gene (Hughes 
et al., 1995). Only 3.5 kb of the PKDl transcript, lo­
cated at the 3' end of the gene, is unique to PKDl. The 
exact number of the HG as well as their structure is yet 
unknown. More important, although published data 
indicate that these genes produce large transcripts 
(The European Polycystic Kidney Disease Consortium, 
1994), it is still unknown whether they would code for 
functional polypeptides. An answer to this question is 
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TABLE 1 
Primers and Annealing Temperatures for Second Round Amplification of Exons 6-14 of the PKDl Gene 
Exon Primer sequence Genomic position Annealing temperature c·c> Product. size (bp) 
6 6F 5' gtgagtgtctgr:tgccc 3' 21491-21508 
6R 6' ccu:cttcctcctgaact 3' 21868-21886 58 896 
7 7F 5' ggctctgagcctcagttt 3' 22104-22121 
7R 6' taaccacagccngcgtct 8' 22476-22493 65 391 
8 SF 5' gtctgttcgtc:ctg 3' 22676-22592 
8R 5' ccatcttcactgggcaca 3' 22863-22880 68 306 
9 9F 6' gttcgggtaggggga 3' 28090-23108 
9R 5' gtgaaagctcagagaggcca 3' 23341-23860 so 271 
10 lOF 5' ggtggi.-ctgtgggcaat1� 3' 23608-23627 
lOR 6' gcctgaggAgBtgcaggga 3' 23929-23947 61 340 
11-lla llaF 6' gggtccacgggccatgaccgt 3' 24300-24320 
llaR 6' cgcagt.ccagggttgggc 3' 24610-24680 66 331 
11-llb llbF 5' ncggaac:agctet.11:cgtgct 3' 24581-24600 
llbR 6' aeggtggccaccagggcaggg 8' 24880-24900 66 320 
11-llc llbF 5' gcagtgtcagcgc:ccgcttig 3' 24849-24869 
llbR 5' agcaccctgtctgcnggcacc 3' 25150-25170 66 821 
12 12F 5' ccaggaggcgacaggcta 3' 25923-25940 
12R 5' ggcagnggtgaaggtggn 3' 26178-26196 61 273 
13 13F 5' tcacctgccacctgggc:tcac 3' 26279-26299 
13R 6' gecaagagcctggtgc:ccacc 3' 26519-26589 68 261 
14 14F 6' ctgtcccggttcac:tcac:tgc 3' 26769--26789 
14R 5' cagcttgactggggagctggg 3' 26998-27018 68 250 
of substantial int.cirest regarding the gene function and 
the gene evolution in particular, because it has been 
shown that there are no Pkdl homologues in mouse 
(Olsson et al., 1996). 
Up to now mutation screens of PKDl have been 
heavily obstructed by the presence of these highly ho­
mologous copies of the gene extending from exon 1 to 
the first 87 hp of exon 33. Although different selective 
straregies for analysis of the duplicated part of the 
PKDl gene have been employed successfully by several 
groups, methods used, such as the long-range amplifi­
cation-based approacht:a, present a serious challenge 
for routine mutation detection. Therefore, the accumu­
lation of precise sequence information on the HG is 
desperately required to design PKDl-specific reagents 
that would serve more conventional scanning tech­
niques. 
By screening a bacterial artificial chromosome (BAC) 
DNA library, we have identified clones that contain 
exclusively PKDl-homologous genes. Further analysis 
of these clones allowed us to characterize the near 6' 
region of homo1ogues and to design primers for specific 
amplification of exons 6-14 of the PKDl gene. Differ­
ences identified by comparing the sequences of these 
HG with the PKDl master gene allowed us also to 
amplify specifically segments of PKDl and of the 
PKDl-like genes from total and translated cDNA 
pools. Results obtained clearly indicated that PKD! 
homologues are transcribed but not translated in the 
glioblastoma cell line T98G. In addition, detailed anal­
ysis of the HG coding sequences demonstrates the pres­
ence of premature stop codons and thus, if translated, 
they would generate only short, most probably non­
functional polypeptides. Our conclusion from this com-
parison is that these genes are pseudogenes, dupli­
cated in the course of molecular evolution. 
MATERIALS AND METHODS 
BAC anc. PAC library screening and characterization. Primer 
pain! from the PKDl unique and duplicated regions were used for 
identification of PKDl or PKDl-homolcgoua genes contwning BAC 
and PAC clones. The BAC (Human BAC DNA Pools, Release ll; 
Research Genetics, Inc., Huntsville, AL) and PAC (Genome Syatema) 
librarie!I were acreened through PCR according to the manufactur­
ers' instructions. Positive BAC and PAC clones were grown o.nd DNA 
was isolated as previously described (Pennekamp ct al., 1998). 
Clones were sequenced for genomic regions covering e::on 3 through 
to intron 14 in direct or amplicon sequencing reactions using PKDl 
exon-apecific primers in both direct.i01l8. Sequencing reactions were 
performed with the Applied Biosystems CABD Bigl)ye Terminator 
Cycle Sequencing Ready Reaction Kit according to the manufactur• 
cr'a guidelines and annlyzed on an ABI 310 automated GOqUencer. 
Obtained sequences were compared with each other and w¥..b the 
PKDl genomic sequence. 
PCR amplification on genomic DNk PKDl-specific templates 
were generated for exons 6 -11 and 12-14 by amplification from 
genomic DN, with the following primers: for exons 6 -11, Fl primer 
6' GGCCGCCTACAGCATCGTGGCCC S', position 21447-21470 
CPKDl genomic sequence, GenBo.nk Accession No. I..39891), end Rl 
primer 5' CAGTGAGGGGAGGCACCTACACTG S', position 25622-
25€44, end for <?Xons 12-14, F2 primer 5' CAGTGTAGGTGCCTC­
CCCl'CACTGCT S', position 25621-25644, and R2 primer 5' 
CCAGCGGTCAGGAGGTACACTC S', position 27410-27430. PCR 
was 36 cycles of deneturation at 94•c for 1 min, annealing et 62"C 
for l min, end extension at 12•c for 4 min. Reactions were performed 
in a total volume of25 µ) end the reaction mix contained the follow­
ing: 50 mM Tris-Cl, pH 9.5, 20 mM CNH,>.SO •• l mM DTT, 0.005'1> 
NP-40, 1.6 mM MgCI,, 0.5 M betaine, 5% DMSO, 20 pM each primer, 
600 µM dNTP, 100-21}(} ng DNA, and 1.25 U Taq polymcn111e pro­
duced end purified as previoualy described (Pluthcro, 1993). PCR 
products of 4.2 and 1.8 kb accordingly were obtained and after 
dilution of 10-• they were used in second rounds of amplificatiODD 
with primers specific for each exon to be nnalyzed (Table 1). Reaction 
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conditions were 30 cycles of denaturotion at 94'C for l min, anneal­
ing (see Table l) for 1 min, and extension at 72'C for l min. 
showed that both BAC clones contain different PKDl­
homologous gene sequences. These clones were com­
pletely sequenced for the region corresponding to posi­
tion 19866 through position 27596 (exon 2 to IVS 14) of 
the PKDl gene. The sequences obtained (7.7 kb) were 
queried against the GenBank and EMBL databases 
and four more BAC clones showing high degrees of 
homology to the queried segment were identified. Fur­
ther analysis showed that two of those clones (Gen­
Bank Accession Nos. AC009066 and AC012171) con­
tain the PKDl gene or a part thereof Coverall sequence 
identity 99.6 and 99.8%) and two other clones contain 
PKDl-homologous genes. 
To answer the question whether the PKDl homolo­
gous genes we identified are the same genes found in 
the BAC clone A-13F4 described by Loftus et al. (1999), 
we performed a eequence alignment of those genes 
with the genes contained in our BAC clones, as well as 
with the homologous gene sequences identified 
through our BLAST search, on regions correaponcling 
to position 19866-27595 of the PKDl genomic se­
quence (Fig. 1). Overall sequence identity for each of 
the homologous gen�ntaining BACs with the PKDl 
genomic sequence was 95.4-96. 7% for the Sequenced 
regions. There were, however, several bigger deletions/ 
insertions (5-21 hp) identified in intrans 9, 11, 12, and 
13. 
Reverse ,ranscription and PCR {RT-PCR). Total RNA was iso­
lated from confluent glioblnstoms. T98G cell cultures by using the 
Triiol CGibw BRI.. Life Teclmologiea) reagent. Translationii1ly active 
RNA was prepared from a polyaomal fraction (membrane-bound 
polyaomes) as previoW1ly described (Mechler, 1987). Briefly, the mi­
crosomal fraction was obtained through sucrose gradient centrifuga­
tion of a T98G cytoplasmic extract and mRNA was separated and 
purified from the bound polyaomes. Total RNA and mRNA (0.3-
0.5p.g) were subjected to reverse tr8.Dl!cription 1.111ing the SuperScript 
II reverse tran.scriptase and reaction conditions specified by the 
manufactww (Gibco BRL Life Teclmologies). Reactions were primed 
with 100 pM random hexamer and 10 pM 3' oligonucleot.ide primer 
common for PKDl and homologous genes, 6' GCCATCCCCGAAAG­
GTCCAGTCGAA 3', position 4187-4230 <PKDl cDNA sequence, 
GenBank Accession No. L33243), located in exon 16 of the PKDl 
gene. First round of PCR amplification was performed on 1-µ1 ali­
quots ofUie RT reaction, with oligonucleotides RT-Fl, 6' GTGTGC­
CCGTCCTCGGTGCAGA 3', poeition 1294-1316 (exon 6), and RT­
Rl, 5' CCGAAGTCCCACGTGTAAAGAA 3', position 3681-3702 
(eion 16). Cycling conditions were denaturation at 941C for 46 2, 
nnne.aling at 661C for 1 min, and extension at 12·c for 4 min in 40 
cycles. Aliquots (l µI) of the finrt PCR were used in a second ampli­
fication round with "nested- oligonucleotide primei-s specific for 
PKDl and for HG. PKDl reactions were primed with oligonucleo­
tides RT-F2-PKD1, 6' CTI'GAGGC,'CCAACCCTGGAC'l' 3', position 
2660-2780 Cexon 11), and RT-R2-PKD1, 6' CCGGCACTGTG­
GAGACCTGCAGA 3', position 3274-3296 (emn 13). HG reactions 
were performed with primers RT-R2-HG, 6' C.Q'l'GAGGCC_AAC­
CCTGGQCT 3', end 6' CTGCACTGTAGAGACC�AGQ 3' (differ­
ences with the PKDl sequence are underlined). PCR waa 40 cyc]es of 
denaturation nt 94"C for 46 s, annealing at 681C for l min, and 
extension at 72'C for l min. React.ion products were resolved on 
EtBr-stained 1% agaroae gel.a. 
The result of this sequence comparison of every pos­
sible homologous gene couple, including the PKDl se­
quence, is summarized in Table 2. The comparison 
clearly indicates that we have identified in our BAC 
clones two more different homologous genes, which we 
term PKD1P3 and PKDIP4 (PKDl pseudogenes 8 and 
4), and another two homologous genes contained in 
publicly available BAC clone sequences (GenBank Ac­
cession Nos. AC010488 and AC040168). The latter 
genes we term PKD1P6 and PKD1P6 accordingly. 
PKD1P3 (CknBank Accession No. AF320593) is con­
tained in BAC clone 204_o_15, and clone 267_d_9 har­
bors the PKD1P4 gene (GenBank Accession No. 
AF320594). Preliminary data on those clones show 
that PKD1P3 and PKD1P4 begin to share homology 
with the PKDl genomic sequence in the first third of 
intron 1, in the PKD1P5 sequence this is position 4150, 
and in PKD1P6, position 6566. Both genomic positions 
land at potential splice acceptor sites. PKD1P8 and 
PKD1P4 seem to end their PKDl-homologous region 
with exon 31, PKDl homology in PKD1P5 ends at 
position 34285, in the beginning of the polypyrimidine 
tract found in intron 21. The PKD1P6 homology with 
PKDl ext.ends over only 2530 bp after position 19866, 
before it ends with position .l2893 in exon 7 at a poten­
tial splice acceptor site. That is why we exclude this 
_gene from quantitative comparisons in the above de. 
Sequencing of PCR procwcts. The sequence of RT-PCR ampliCODS 
from PKDl and bomologou.o genes was determined with the ampli­
fication primers lillted above. 
First- and �d-round amplicons from human genomic DNA 
were sequenced and compared with the PKDl genomic sequence. All 
sequencing reaction.II were performed by using amplification primers 
and the Sequitberm Exeel ll DNA Sequencing Kit as described by 
the manufacturer (Epicent.re Technologies), and labeling was with 
[cr-"P)dATP (Hart.mann Analytics). The products of the sequencing 
reactions were electrophore,ed in 6% denaturing polyacrylamide 
gels (0% "' 6; 6 M urea; 360 x 400 x 0.4 mm}, at 70 W constant 
power for 2-3 h. Gels were dried under vacuum prior to autorndio­
graphic e%Jl()8ure on Biomax films (Kodak). 
Computer analysi.8. Additional BAC clones containing other 
PKDl homologous genes were found by using BLAST eearch on the 
GenBank and EMBL databaaes. The 7.7-kb region sequenced from 
our HG-cont.'lining BAC clones was used for the query. Sequence 
alignments and degree of homology estimates were accomplished by 
wiing the GENESTREAM global alignment tool. Sequenced regions 
were anal� for repeats and low-complexity DNA at the Repeat­
Masker Web Server. 
RESULTS 
Structural Analysis of Homologous Genes 
Two positive BAC clones (204_o_15 and 267 _d_9) 
containing PKDl-homologous genes and a third clone, 
containing a part of PKDl as shown later by sequenc­
ing, amplified with primers from the repeated region 
and did not amplify with the primers located in the 
PKDl unique region. The sequence comparison with 
the PKDl genomic sequence and with each other for 
intron regions in introrts 3, 4, 7, 8, 11, 12, 13, and 14 
fined 7. 7-kb region. 
The sequence homology levels with PKO! show that 
PKD1P2 (p:reviously HG2, Loftus et al., 1999) is next to 
identical with PKDl, whereas PKD!Pl (previously 
HG!) and PKD1P5 are farthest distant and PKD1P3 
and PKD1P4 are in the middle, but closer to PKDIP2. 
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TABLE 2 1 2 3 4 M 
Degi-ees of Homology between PKDI and HG in the 
Implicated Region of PKDl • 
Ident PKDlPl PKD1P2 PKDlPS PKD1P4 PKD1P5 
PKDl 95.4% 96.7% 96.4% 96.5% 95.5% 
PKDlPl 97.4% 97.6% 96.5% 99.9% 
PKD1P2 97.49& 98.2% 98.0% 97.5% 
PKDlPS 9,'.6% 98.2% 97.6% 97.6% 
PKD1P4 96.5% 98.0% 97.6% 96.5'ii, 
PKD1P5 99.9% 97.5% 97.6% 96.69& 
• Genomic position 19866-27595. 
HGl and HG5 possess the highest degree of identity 
(99.9%), followed by PKD1P2 and PKD1P3 (98.2%), 
whereas PKDlPl and PKD1P4 (or PKD1P5 and 
PKD1P4) share only 96.5% identical sequence over the 
examined region. On a first glance one might remain 
with the impression that PKDlPl and PKD1P5 are the 
same gene; however, when looking closer into sequence 
details (Fig. 1) it is visible that these are two different 
genes. PKDlPl for example should have a different 
splicing at the exon 11 to exon 12 junction, and 
PKD1P5 has other than the PKDlPl-specific deletions/ 
insertions in intron 12, by wh,ch PKD1P5 looks more 
like the other HG. Overall for the region examined, 
PIIDl exons 2 through 14, the splicing pattern seems 
to be conserved for the homologous genes, with small 
exceptions: exon 8 for PIID1P3 and PKD1P4, the afore­
mentioned exon 11 in PKDlPl, and exon 15 in 
PKDlP3. PKDlPl and PKD1P5 share another pecu­
liarity, 91 bp from the beginning of exon 15, there is a 
4.3-kb deletion first described by Loftus et al. (1999), 
which contains most of PKDl exon 15 and exon 16. 
PKD1P2, PKD1P3, and PKD1P4 do not have this fea­
ture, the PKDl homologous sequence in PKD1P6 ex­
tends until the last 55 bp of exon 7. Most of the se­
quence variations are common for the HG; there are, 
however, many specific differences in the coding and 
noncoding sequences. Interestingly, exons 2, 3, and 4 
and the adjacent intronic regions contain a very few 
variations from the PKDl sequence. This is true for 
exon 9, for example, whereas exon 8 is a hot spot for 
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FIG. 8, RT-PCR on total RNA and tnmslationally active mRNA 
(polysomal fraction) from the T9BG glioblaatoma cell line. Lanes 1 
and 2, t.otal RNA; lanes 3 and 4, mRNA. Lanes l and 8, PKDI­
specific amplification; lanes 2 3Dd 4, HG-apecific amplification. M, I 
kb ladder. 
such differences, six on a homologous gene on average, 
in a segment of 116 bp. Almost all HG, with the 
exception of PKD1P2, have a stop codon in exon 8 
(CAGPJCDJ -TAGHo) with C -Tat position 22690 of 
the PKDl genomic sequence. 
In the 7.7-kb sequenced region, two mammalian 
wide interspersed repeats were identified in all homol­
ogous genes and in PKDl in matching locations (PKDl 
positions 22068-22176 and 26717-25816) and 
PKD1P2 and PKDl contain an additional simple re­
peat of a slightly different length in a matching posi­
tion (PKDl position 26133-26172). The level of re­
peated sequence for all genes but PKDl and PKD1P2 is 
2. 7% over the analyzed segment; for PKD1P2 it is 3. 7% 
and PKDl has 3.2% due to a shorter simple repeat. 
We used some of the identified clustered basepair 
differences with HG (Fig. 1) to design PKDl-specific 
primers for amplification of the genomic region con­
taining exons 6 to 14 in two overlapping PCR for.:nat.s 
and for differential amplification of exon 12 from PKDl 
or HG from cDNA (eee Materials and Methods). First­
and second-round amplicons from human genomic 
DNA and T98G cDNA were also sequenced and com­
pared with the PKDl and HG sequences for the ampli­
fied segments. We showed that an input of a 10-& mini­
mal dilution of the first-round PCR product into the 
second (nested) PCR yields a PKDl-specific product, 
whereas a dilution of 10-3 or lower gives rise to a 
coamplification of the homologous genes (Fig. 2). 
Analysis of HG Transcripts FJG. 2. Coamplification of the homologous genes, by lower dilu­
tions of the first-round PCR. Intron 8 of PKDI is specifically ampli­
fied in the 1:101 panel. The observed differences with HG are in 
position 22770 of the PKDI genomic sequence. Note that only 
PKD1P2 has an ·An at this position (sequence is of the opposite 
strand), which disappears in the 10-s dilution, whereas the 'T" (A in 
the opposite strl!-]ld) present in four of the HG at matching location 
is still visible. 
To analyze HG transcripts further, we used RT-PCR 
on total RNA and translationally active mRNA from 
the cell line T98G with primers specific for PKDl or for 
homologous genes (see Materials and Methods). We 
were able to amplify exon 12 of PKDl and HG from 
PKDl HOMOLOGUES ARE PSEUDOGEJl,'ES 339 
total RNA, as is shown on Fig. 3, lanes 1 and 2, and of 
PKDl only from translationally active mRNA Oane 3). 
The expected PCR product of 739 bp is detected in the 
first three lanes, indicating that there is no genomic 
DNA contamination in the cDNA preparations that 
would result in coamplification of the abridging introns 
and hence in an additional band of larger size (1.8 kb). 
The EtBr staining of the HG amplification product is at 
least twice as intensive as the staining of the PJ�l 
amplification product by equal aliquots of the PCR 
reactions loaded on the gel. This could be indicative of 
at least two homologous genes, provided their trrn­
scription rates do not differ significantly. PKDl and 
HG amplicons were confirmed by direct sequencing 
and it was demonstrated that HG amplicons contain 
all specific sequence changes characteristic for both 
PKD1P3 and PKD1P4 in the amplified region (results 
not shown). 
In contrast, there is no amplification of HG from 
translationally active mRNA (see Materials and Meth­
ods), whereas PKDl is amplified (Fig. 3, lanes 3 and 4). 
In lane 4 (HG amplification) the primers not. utilized in 
the course of the PCR can be seen as a "primer cloud," 
a diffuse band of a very low size, and there is no 739-bp 
specific product. This failure to amplify HG from trans­
lationally active mRNA shows that HG transcripts are 
not bound on polysomes but rather segregated by pro­
teins comprising the translation machinery. In addi­
tion, translation of the HG sequences we obtained in 
the three open reading frames (ORF) shows the pres­
ence of multiple early stop codons; in the reading frame 
matching the PKDl ORF they occur already in exon 8. 
DISCUSSION 
somes, some SOS ribosomes and 608 subunits, as well 
as mitochondrial ribosomes. The mRNA species ob­
tained from this fraction are only those which are 
bound on polysomes, i.e., this is the translationally 
active mRNA. Homologues to PKDl seem to produce 
nontranslatable mRNA species t'bat are segregated by 
polysome complexes. The finding that certain mRNAs 
are not used as protein templates is not unusual. For 
example, genes in the Prader-Willi Angelman locus, 
PAR-SN, PAR-5, PAR-7, IPW, PAR-1, and PAR-4, pro­
duce processed but not translated mRNA species. It 
could as well be that the only function of those non­
protein--coding transcripts is to host multiple snoRNA 
copies (Cavaille et al., 2000). For the PKDlP locus 
there are no snoRNAs identified in introns. Neverthe­
less, translation seems not to be favored for PKDl 
pseudogenes. From our analysis, almost all of them 
may lack the PKDl exon 1 carrying the firstATG codon 
(in PKDlPl there is a sequence gap in this region). 
According to the proposed scanning mechanism of 
translation initiation, the 40S ribosome subunit scans 
the transcript for an AUG codon that is in the optimal 
sequence context (Kozak, 1999). Downstream ATG 
codons in exons 6 and 9 could perhaps also make good 
initiation sites, since they conform to the -3 A, +4 G 
rule. It is, however, being demonstrated that highly 
structured sequences preceding a downstream AUG in 
the mRNA can block the advance of 40S ribosomal 
subunits and prevent them from reaching the start 
codon (Kozak, 1998). The 5' end of PKDl and PKDlP 
transcripts is very rich in highly structured sequences, 
and it should be expected that initiation of translation 
cannot occur downstream of the first AUG codon in 
exon 1. The absence of an optimal start codon in PKDl 
homologues supports the conclusion that HG are pseu­
dogenes. Since the discovery of genes homologous to PKDl in 
1994, many ADPKD researchers have raised the ques­
tion about the possible number of HG and their even­
tual functional importance. The possibility that HG 
might code for polycystin I-related proteins has been a 
major concern in localization studies on cells and tis­
sues for the past years. Since the availability of se­
quence information on at least two of the homologues 
(Loftus et al., 1999) it became evident that if trans­
lated, those genes should produce much shorter 
polypeptide chains of unknown functional importance 
compared to intact polycyatin 1. The structural fea­
tures of the two new HG we identified in the current 
study conform to this rule, indicating that premature 
stop codons can occur already in exon 8. 
Our work confirms transcription of the homologous 
genes shown by others (The European Polycystic Kid­
ney Disease Consortium, 1994). However, the new 
finding that HG are not translated in the model cell 
line T98G, in which polycystines are well expressed, 
guides us to the conclusion that this is the case in other 
cells and tissues as well, since translation of functional 
mRNA is a universal biological process. The polysomal 
fraction that we used as a source for mRNA in our 
RT-PCR experiments contains membrane-bound poly-
In the course of molec1.. la.,. evolution these sequences 
seem to have arisen at d• ,,,,t the same time, judging 
from repeats distribution l'his should be a com­
paratively recent event, sin, transcription is a very 
energy-demanding process, which if not bound on func­
tional entities might not be tolerated just for pseudo­
gene divers: y. On the other hand, HG transcription 
could additionally regulate the level of PKDl mRNA 
through recruitment and titration of transcription fac­
tors. It could : ie speculated that PKDlPl and PKD1P5 
are the oldest and PKD1P2 the youngest member of 
this pseudogene family, but additional sequencing 
work is necessary to support such conclusion. The ex­
act HG number is still unknown; these genes should 
have arisen in a divergent fashion as paralogues to 
PKDl. Their repeat abundance and high GC content 
suggest that these pseudogenes might have emerged as 
a consequence of retroposition and/or nonhomologous 
recombination (Jurka, 1998). It is more likely that HG 
have resulted from recombination/duplication events, 
however, since they carry their intrans, and the splice 
pattern in the PKDl homologous regions seems to be 
overall conserved for these genes. Most of Llie retro­
posed sequences found in eukaryote genomes are al-
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ready processed transcripts, for example the G-coupled 
receptor gene family and other genes resulting from 
retroposition of mRNA sequences (Brosius, 1999). One 
cannot exclude, however, even the marginal possibility 
that pre-mRNA sequences flanked by autonomous 
transposable elements could be "moved around" in the 
genome (Jurka, 1998). This scenario could put the ac­
cent on PKDl and its pseudogenes as "patchworks" of 
minigene evolution, i.e., many small genes with de­
fined functions assemble together to result in a new, 
different function. Although very attractive, such hy­
pothesis is not confirmed by PKDl evolutionary com­
parisons with the fugu fish orthologue (Sandford et al., 
1997}. The comparative analysis has demonstrated an 
evolutionarily conserved sequence and an unchanged 
domain structure across 400 million years of verte­
brate evolution. In PKDl pseudogenes certain pre­
dicted extracellular domains of PKDl, like the leucine­
rich repeat encoded by exons 2 to 4, or the e.'Con 9 
module, show extremely hi1;h degrees of conservation, 
in contrast to other neighboring exons. Most probably 
PKDl homologues have emerged in higher primates by 
duplications of relevant genomic regions, since such 
duplicons were already identified in corresponding hu­
man chromosome 16 loci (Loftus et al., 1999). Searches 
for PKDl-homologous sequences similar to our strat­
egy could be applied to primate genomic libraries to 
find at which stage of evolution HG appeared. 
The sequencing data on HG should allow for con­
struction of better reagents for mutation analysis of 
PKDl using more conventional approaches, which in 
turn can be applied to routine diagnosis. This informa­
tion should be instructive for development of a com­
plete PKDl analytic system, and it can be used for a 
critical review of the mutation data on the duplicated 
part of the gene obtained by other groups. 
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Screening for disease-causing mutations in the duplicated region of thePKDI gene wa5 perfonntd 
in 17 unrelated Australian individuals with PKDl-linked autosomal dominant polycyi;tic kidney 
disease. Exons 2-21 and 23-34 were assayed using PKDI-apecific PCR amplification and direct 
sequencing. We have identified 12 novel probably pathogenic DNA variants, including five trun• 
eating mutations (Q563X, c.S lOSdelA'I; c.5159delG, S2269X, c.9847delC}, two in,frame dele­
tions (c.7472del3, c.9292del39), and two splice-site mutations (IVS14+ 1G>C, 1VS16+ lG>T). 
Three of the mutations (G3S1C, Y2I85D, G278SD) were predicted to lead to the replncement of 
conserved amino acid residues, with en.suing changes in protein c:cnformation. Defects in the 
duplicnted region of PKDl thus account for 63% of our patients. Together with the previously 
detected mutations tQ4041X, R4227P) in the 3' region of the gene, the study bas achieved an 
overall mutition detection rate of74%.1n addition, we have detected 31 variants (nine novel and 
22 previously published) that did not segregate with the disease and were considered to be neutral 
polymorphisms. Three of the nine novel polymorphisms were misscnse mutations with a pre• 
dieted effect on protein conformation, emphasizing the problems of interpretation in PKDl muta­
tion screening. Hum Mutat 19:240-250, 2002. c 2002 Wiley,Liss, Inc. 
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INIRODUCTION 
Autosomal dominant polycystic kidney dis• 
ease (ADPI<D; MIM# 173900) is a common 
monogenic disorder with an incidence of ap­
proximately one in 1,000 [Dalgaard, 1957]. The 
disease manifests with the development ofbilat· 
eral kidney cysts followed by renal failure in most 
affected individuajs. Eight to 10% of all patients 
requiring hemodialysis or renal transplantation 
haveADPKD [Gabow, 1993].Additional symp­
toms, such as hypertension, urinary tract infec­
tions, hematuria, proteinuria, extra•renal cysts, 
C2002 Wlley-l.lsa. Inc. 
cerebral aneurysms, hemiae, cardiac valve de­
fects, renal calculi, and gastrointestinal diver· 
ticula, vary both between and within famtlies 
[Roscoe et al., 1993; Schievink and Torres, 
1997]. The rate of progression toward kidney 
failure is also variable: end-stage renal failure 
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(ESRF} occurs most commonly in the fifth de­
cade [Milutinovic et al., 1984]. However, it can 
present as early as in utero, while some individu­
als may never progress to renal failure [Chou­
kroun et al., 1995; Parfrey et al., 1990; Perrichot 
et al., 2001]� T he wide range of clinical mani­
festations and severity is probably a compound 
product of heterogeneous germline mutations, 
and of the random nature of the "second hit," 
namely soma.tic mutations in die two character­
ize.cl genes for ADPKD, PKDl (MIM# 601313), 
and PI<D2 (MIM# 173910) [Qian et al., 1996; 
Wamick et al., 1998; Koptides et al., 1999]. 
Up to..85% of germline mutations in Cauca• 
sian ADPKD individuals affect the PKD 1 gene 
[Peters and Sandkuijl, 1992], located on chro­
mosome 16p13.3 [T he European Polycystic Kid­
ney Disease Consortium, 1994]. The PKD 1 gene 
consists of 46 e.,cons spanning-52 kb of genomic 
DNA [The International Polycystic Kidney Dis­
ease Consortium, 1995; The American PKDI 
Consortium, 1995; Hughes et al., 1995].A large 
part of the gene is duplicated in at least six ho­
mologous genes (HGs), which show > 95% ho­
mology with the PKD 1 gene [Hughes et al., 
1995; Bogdanova et al., 2001). The homologous 
genes cause problems of co-amplification, thus 
creating major obstacles to the mutation analy, 
sis of patients and families with the most com­
mon form of ADPKD. 
Here we present the results of a screening for 
mutations in the duplicated region of PKDI in 
17 Western Australian ADPKD families. Using 
PKDl-specifit oligonucleotide primers and di­
rect automated DNA sequencing, we have iden­
tified 12 putative pathogenic mutations and 
achieved a.., overall PKDl mutation detection 
rate of74%. 
SUBJECTS AND METHODS 
Subjects 
Nineteen ADPKD families, 18 of British and 
one of Spanish descent, were recruited through 
index patients at the Department of Nephrol­
ogy, Royal Perth Hospital, Western Australia, as 
part of a large collaborative study of ADPKD. 
The diagnosis was based on standard ultrasound 
criteria [Bear et al., 1992]. Preliminary analysis 
of these families had shown linkage to thcPKD 1 
gene. Two families had mutations in the unique 
part of the PKD 1 gene [Bogdanova et al., 2000]. 
The scree1ting for mutations in the duplicated 
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region of PKDI included the remaining 17 af­
fected individuals. 
DNA Isolation and PCH Amplification 
DNA was extracted from whole blood using 
standard procedures [Miller et al., 1988] . Prim­
ers for long-range amplification were chosen to 
be specific to PKD1 when compared with its 
homologous genes. All long�range polymerase 
chain reaction (XL-PCR) primers are specific to 
PKDl when compared to HGl and HG2 [Loftus 
et al., 1999]. The PKDl sequence between ex­
ans 2 to 14 was compared also to HG3, HG4, 
and HGS [Bogdanova et al., 2001]. All primers 
in this region are specific to PKDl when com­
pared to HG3 and HGS. Our XL-PCR products 
are not specific to PKDl when compared with 
HG4 between exons 6 arid 11 ,  due to the iden­
tity between the two sequences. However, the 
nested primers used for amplification of exons 
6, 9, 10, and i 1 (fragment A) are specific to PKD 1 
when compared to HG4. 
XL-PCR was performed on 400 ng cf genomic 
DNA in a final volume of 100 µl using 4 units of 
Applied Biosystems XL-rTth Taq polymerase 
with 200 µM of each dNTP, 120ng each of for­
ward and reverse primer, 1.5 mM Mg()Ac, and 
1 x buffer (Applied Biosystems, Foster City, CA). 
The optimized conditions for XL-PCR are listed 
in Table 1. 
XL-PCR products (5µ1 aliquots) were elec­
trophoresed in 1 % agarose gels :md visualized 
with erhidium bromide staining in order to 
confirm an amplification product of the ex­
pected length and to rule out large deletions 
or insertions. 
Nested PCR reactions utilized lµl ofXL-PCR 
template diluted by a factor of at least 1 x lo-4 to 
prevent co-amplification of the PKDl homolo­
gous genes [Watnick et aL, 1997; Bogdanova et 
al., 2001]. Nested PCR was performed in a fin2l 
volume of 25 µI with 0.2 units of QIAGENe Taq 
DNA polymerase with 200µM of each dNTP, 
60ng each of forward and teverse prime� 20% Q­
solution (QIAGEN, Hilden, Germany), 1.5 mM 
MgCh, and 1 x buffer (QIAGEN). The optimized 
conditions and specific oligonucleotide primers 
for nested PCR amplification of individual frag, 
ments are listed in Table 2. 
DNA Sequencing 
All samples were subjected to-cycle �equenc­
ing in both directions with the BigDye,.. Termi-
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Exons 
Ex2.S 
XIA 
Ex6-ll 
Xl..2 
Ex 12-14 
XL-3 
Ex 15 
XL4 
Ex 15-21 
XL,.5 
Ex23-24 
XL,.6 
Primer S!:!juence 
JVSlF 5' cccagcgtdcatdgtctgg 3,. 
IVS5R 5' ggtgggaacgagggtgtcaac 3' 
2927 5' gccgcctacagcatcgtggca: 3' 
1 lR 5' cagtgaggggaggcacdacact 3' 
12F 5' cagtgtaggtgcdcccctcactg 3' 
31SO 5' ccagcacggtccgg11ggmct 3' 
IVS13F 5' ctgtcccggttcadcactgc 3' 
ExlSXLR 5' caacgtgggcdccangtagttg 3' 
Ex15XI.F 5' gcaactacttggagga:cacg 3' 
IVS2IR 5' gcasggtgagcaggtg�c 3' &23F 5' ctgcactgacdcacgcatgt 
Ex34R 5' atgtgggtgtcttgggtagg 3' 
a(VS1F used by Thomiw et al. [1999] designated l7EXT. 
bEx23F U$ed by Watnldc et Ill. (1997] designated lWFl. 
nator Cycle Sequencing Ready Reaction Kit 
(Applied Biosystems), using the nested PCR 
primers listed in Table 2. The products were elec­
trophoresed on an automated 377 DNA Ana• 
lyzer (Applied Biosystems). 
Deletions and· insertions were characterized 
by oerforming a fresh PCR reaction, cloning the 
products using the TOPO"' TA Cloning� Kits 
with the pCR2.1-TOPO"' vector (lnvitrogen, 
San Diego, CA);and subsequent sequencing. 
Data AnalY11ls 
Sequences were analyzed using Sequence 
Navigator 1.0.r (Applied Biosystems} and 
Sequencher 3.0 (Gene Codes C.Orporation, Ann 
Arbor, MI). Missense mutations were analyzed 
further for the conservation of the amino acid 
residue in the mquse and pufferfish protein se­
quences, using Pfam (www.sanger.ac.uk/Soft­
ware/Pfam/). PHDsec [Rost and Sander, 1994] 
was used to predict the effect of the mutation 
on secondary protein sttucture. 
Confinnation of putative pathogenic se­
quence variants was achieved through repeated 
analysis of the index patient and a segregation 
study including affected and unaffected family 
members. Segregation analysis was not possible 
in one out of 12 families, where linkage analysis 
had been performed on DNA extracted from 
blood spots collected on Guthrie cards. 
Mutations are .named following the recom­
mendations of Cotton and Scriver (1998], 
whereas nucleotide positions are numbered in 
the traditional way, where the first coding nucle­
otide of the cDNA is at position 212 for genomic 
sequence Accession# !33243 and position 3648 
for Accession# 139891. 
Cycling Genomic Product 
condttlons �lilon me Cb2> 
68°C(X40) 17049-69 4,542 
2-step (0.5'/5') 21579-90 
68°C (X40) 21447-470 4,198 
2-step (0.5'/4') 25622-644 
68°C (X 40) 2562i-644 1,810 
2-step (O.S'tl') 27410-430 
68°C (X40) 26769-89 3,861 
2-step (0.5'/4') 30607-29 
68°C (X40) 30606-26 3,375 
2-step (0.5'/4') 33957-80 
6f>OC (X40) 37674-694 6,749 
2-step (0.5'/6') 44403-422 
RESULlS 
Using the techniques outlined above, we have 
identified a total of 43 DNA sequence variations 
in the duplicated region of the PKD 1 gene in 
the 17 unrelated affected individuals. The de­
' tected variants include 12 probable pathogenic 
mutations, all of which are reported for the first 
time (Table 3 and Fig. 1), and 31 neutral poly­
morphisms, including nine novel and 22 previ• 
ously reported (fable 4). 
Probable Disease-Causing Mutathms 
Protein mmcating mutations. Two nonsense 
and three frameshift mutations were detected 
in the study. 
Q563X. The C> T transition at c.1898 
(g.22716) in exon 8 is predicted to truncate 
polycystin-1 by 31739 amino acids, correspond­
ing to the loss of most of the protein. 
S2269X. S2269X results from a C>G trans• 
version at c. 7017 (g.30915) in exon 15. It is pre­
dicted to ttuncate polycystin-1 by 2,033 amino 
acids, spanning the REJ domain and all of the 
transmembrane and cytoplasmic regiOT"..; of the 
protein. 
c.5105-5I06de1AT. A 2 bp deletion, c.5105-
5106delAT (g.29004-29005deIA1), was found 
in exon 15 of the PKD 1 gene. The mutation 
causes a fram .. shift at amino acid position 1632 
and a premature termination signal at codon 
1656, corresponding to the ioss of most of the 
PKD repeats, the REJ domain, the transmem• 
brane domains, and the entire cytoplasmic re­
gion of the protein. 
c.5159delG. A SU".gle hp deletion, c.5159delG 
(g.29058delG), was detected in exon 15 of the 
gene, !eading to a shift in the reading frame at 
Exons 
Ex2 
XL-1 
Ex3 
XL-1 
Ex4 
XL-1 
Ex 5(a) 
XL-1 
Ex5(b) 
XL-I 
Ex S(c) 
XL-1 
Ex6 
XL-2 
Ex7 
XL-2 
Ex8 
XL-2 
Ex9 
XL-2 
Ex 10 
x.t..2 
Ex 11-118 
XL-2 
Ex 11-llb 
XL-2 
Ex 11-llc 
XL-2 
Ex 12 
XL-3 
Ex 13 
XL-3 
Ex14 
XL-3 
Ex l5 
Ex 15-15(r.,} 
fil,.5 
Ex 15- lS{b} 
XL-5 
Ex 16 
XL-5 
Ex 17 
XL-5 
Ex18 
XL-5 
Ex19 
Xf...5 
Ex20 
XL-5 
Elt2I 
Xl..5 
Ex23-2Sa 
Ex23-23b 
XL-6 
Ex24 
xu; 
Ex25 
XL-6 
Ex26 
XL-6 
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TABLE 2. Primers and Conditions for Nested PCR Ame!lflcation of PKDl 
Primer !:;guence 
Ex2F 5' ggaaggcddggcctncto 3' 
Ex2R 5' ggggattcggcaaagdgat 3' 
Ex3F 5' dcagctgtgggggattcca 3' 
OOR 5' ggcagaagggatmtggggg 3' 
Ex4F 5' ggdggcatcgacccttccc S' 
Ex4R 5' cctggdgggaaggacagag 3' 
Ex5oF 5' gtggagccaggaggagca 3' 
Ex5aR 5' gggaagacgtgctggagg 3' 
Ex5bF 5' tctccagc:acgtcttccc 3' 
ExSbR 5' ccgctta::acdgcacgt 3' 
Ex5cF 5' dcagccdgctggggacaga S' 
IVS5 R 5' ggtgggaacgagggtgtcaac 3' 
4349 5' gtgagtgtctgdgccca 3' 
4350 5' cctccttcctcctgagltd 3' 
435] 5' ggdctgag«tcagttt 3' 
4352 5' tztAa:acagccagcgtct 3' 
4353 5' gtclgttcgtcctggtgt 3' 
4354 5' ccalcttcactgggcaca 3' 
4345 5' gttcgggtagggggagtct 3' 
4346 5' gtgaaagctcagagaggcca 3' 
4347 5' ggtggcagtgggcaaatca 3' 
4348 5' gcctgAggagmgcagggo 3' 
l lAF 5' ggg:ccacgggcaitgaccgt 3' 
1 lAR 5' cgcagtcaigggttgggcctc 3' 
l 1 e:= 5' acggaacagc:tcaccgtgct 3' 
IIBR 5' aziggtggccaccagggcaggg 3' 
UCF 5' gcegtgtcagcgcccgctttg 3' 
l lCR 5' agcaccctgtctgcagg::acc 3' 
4355 5' ccaggaggcgacaggctn 3' 
5135 5' cdggccdgattggcgtc 3' 
5228 5' tcacctg.:cacctgggctcac 3' 
5136 5' ccg11ggctcagaaaagca 3' 
5002 5' ctgtcccggttcactcactgc 3' 
4140 5' gagggctgttggggaggaagg 3' 
Amplified as 16 fragments using primers and 
conditions described previously by Watnlck 
et al. [1999] 
Ex15Xl.F 5'gcaactacttggaggcccacg 3' 
Ex15aR 5' ctcaatgatgggcaa:aggcg 3' 
Ex15bF 5' catccaggca11rtgtga� 3' 
Exl5bR 5' cctggtggcaagctggg:gU s· 
Exl6F 5' ctggatggggctdcagg 3' 
Ex16R 5' cctggtggcaagctgggtgtt 3' 
Ex17F 5' gggtcccccagtccttccag 3' 
Ex17R 5' cattccccagcccgcccaca 3' 
Ex1SF 5' gccccctcaccaccccttd 3' 
Ex18R 5' gatcccgctgcacccca:a S' 
Exl 9F 5' gtg11tgccgtggggaccgtc S' 
Exl 9R 5' gtgngcaggt!l9('21gtctcg 3' 
Ex20F 5' ctgctcaccaccccctc:tg 3' 
F.x20R 5' ggtcccaagcacgcatgca 3' 
Ex21F 5' cgctgctgacagcttgdgtgccc 3' 
IVS21R 5' gcagggtgagtllggtggggccmc S' 
23aF 5' dgcactgacclcacgcatgt S' 
23aR 5' caccagaaagatgggctgai.c 3' 
23bF 5' ggggccctggccaacctcag 3' 
23bR 5' cgtgtgccccacccgctgca 3' 
24F 5' tgtgacctgcgcgttdg S' 
24R 5' ccaggctggcccgcagag 3' 
25F .5' dgggctcacgtccgctacc 3' 
25R 5' cctcgadctgcagaggctc 3' 
26F 5' cggctctatcctg119Mggc 3' 
26R 5' cagcacasccagtgagagca 3' 
Cycling Gcnamtc 
cGndlUons 22s1t1on 
64°C (X35) 19845-64 
(0.5'/0.5'/1') 20064--74 
SS°C (X 35) 20045-64 
(0.5'/1 '/1 ') 20211-30 
64°C(X35) 20378-97 
(0.5'/0,5'/ l ') 20630-50 
58°C(X35) 20770-87 
(0.6'/1'/1') 21081-98 
64°C{X35) 21081-98 
(0.5'/0,5'/1') 21335-52 
64°C (X35) 21315-35 
(0.5'/0.5'/ l') 21579-89 
SS°C (XSO) 21491-508 
(1',1'/1') 21868-886 
5S°C (X30) 22104-121 
(1'/1'/ l'J 22476-493 
S8°C(X30) 22575-592 
(I'/1'/1') 22863-880 
60"C(XS5) 23090-108 
(0.8'/0.8'/0.8') 23341-360 
61°c (X30l 23608-627 
(1'/1'/1') 23929-947 
66°C (X25) 24300-320 
(0.5'/1 '/11 24610-630 
66°C(X25) 24581-600 
(0.5'/I '/1 ') 24880-900 
66°C(X25) 24849-869 
(0.5'/1'/ 11 25150-170 
61°C(X30) 25923-940 
(0.8'/0.6'/0.8') 26256-74 
68°C (X35) 26279-299 
2-step {0.5'/21 26581-598 
6S°C(X35) 26769-789 
2"6t2p (0.5'/2') 27023-043 
66°C (X35) 30606-26 
(0.5'/0.5'/l') 30872-92 
64°C (X 35) 30841-61 
(0.5'/0.5'/1 '} S1086-106 
56°C (X30) 31197-214 
(0.5'/0.5'/11 31468-85 
66°C (X35) 32262-81 
(0.510.5'/11 3241i9-508 
66°C(X35) 3257!-90 
(0,5'/0.5'/1') 32895-914 
66°C(X35) 32946-65 
(0.5'/0.5'/ 1 ') 33213-32 
64°C(X35) 33225-43 
(0.5'/0.5'/1 ') 33445-68 
66°C (XSOJ 33763-86 
0.5'l0.5'/I ') 33957-80 
S8°C(X30) 37674-694 
(0.5'/0.5'1 ') 38006-026 
6S°C(X35) 37979-998 
2-step {0.5'l2') 38336-355 
68°C (X 35) 38600-617 
2-step (0.5'/2') 38786-803 
6S°C(XS5) 38927-946 
2-step (0.5'/2') 39236-255 
68�C(X35) 39272-291 
2-st!:E (0.5'/2') 39567-586 
Prodl.ld 
size !b2) 
230 
186 
273 
329 
272 
275 
396 
391 
306 
271 
340 
331 
320 
321 
352 
320 
275 
287 
266 
289 
247 
344 
287 
239 
218 
377 
204 
329 
315 
(Continued) 
244 MCCWSKEY ET AL 
TAB!£ 2. Continued. 
Exons Primer �uence 
Ex27 27F 5' cctcccacccctccctcttg 3' 
Xl-6 21R 5' cagagcttggcagggtccgc 3' 
Ex28 28F 5' cgzigcctgzicctccctcctg 3' 
X1,.6 28R 5' cggagtggg11ccatggaacg 3' 
Ex29 29F 5' cgtggcctcctgcagtgcgg 3' 
Xlr6 29R 5' ggcaggaagaggctgccccg 3' 
Ex30 3-0F 5' cacctgtgtggcdcctctc 3' 
X1,.6 3-0R 5' ggctcarttcccagtadcc 3' 
Ex31 31F 5' gctgaccactgccacgtc 3' 
X1,.6 31R 5' agtccaagctgcgc:aagg 3' 
Ex32 32F 5' ttggcgcagcttggactc 3' 
XL-6 32R 5' cagggctcgaggtttdc 3' 
Ex33 33F 5' taccttgctgacccgcgc 3' 
XL-6 33R 5' ggtgzigcttcagagcccc 3' 
codon 1650 and a termination signal at position 
1721. The mutation is predicted to truncate 
polycystin-1 by 2;581 amino acids, including the 
domains described in the above paragraph. 
c.9847delC. A single bp deletion in exon 28, 
c.9847delC (g.41352delC), causes a frameshift 
at position 3213 and generates a premature stop 
codon at residue 3315. Polycystin-1 is truncated 
by 987 amino acids, corresponding to most of its 
cytoplasmic region. 
Splicing mutations. We have identified two 
nucleotide substitutions affecting donor splice 
sites and therefore predicted to result in aber, 
rant RNA splicing. 
IVS14+1G>C. A G>C transversion at 
g.26942, 1 hp downstream of exon 14, abolishes 
the consensus donor splice signal in IVS 14. 
Cycling Genomic Product 
condHlons IY.ls!tlon slu (be) 
68°C (X35) 41000-019 225 
2-step (0.5'/l') 41205-224 
5S°C(X30) 41254-273 204 
(0.S'/0.S'/1') 41438-457 
68°C (X35) 41486-505 285 
2-step (0.5'/l') 41751-770 
68°C(X35) 41794-813 199 
2-step (0.5'/21 4191s.m 
68°C (X35) 43585-603 207 
2-step (0.5'/21 4377S.791 
58°C (X30) 43775-792 123 
(0.5'/0.5'/1 ') 43879.896 
6S°C(X35) 44064-081 250 
2-step (0.5'/21 44296-313 
IVS16+1G>T. A G>T transversion at 
g3I394G>T. lbp downstream of exon 16, af. 
fee ts the consensus sequence of the donor splice 
site in IVS 16. 
In-frame deletions and missense mutations. 
These mutations were classified as probably 
pathogenic on the basis of family segregation 
analysis, the evolutionary conservation of the 
amino acid residues involved and/or the pre• 
dieted changes in the secondary structure of 
the protein. 
c.7472-7474de13. A three base pair deletion in 
exon 18,c.7472-7474delACC(g.32650-32652del), 
results in the deletion of threonine at ccxlon 2421 
in the REJ domain of polycystin• l. This is the sec, 
ond· threonine in a group of three that are con• 
served in the mouse and Fugu proteins. 
TABLE 3. Sulnm!:!J! of Novel, Probable Disease-Causing Mutations In the 5' Duplicated Region of PKDI 
Amino add change 
(and protein region Predicted effect Affected FamUy 
LocmJon S�uence wrlatfon ordomnln) on�ein fam1ly segregrrtron 
Ex6 c.1898C> T g.22716C> T Q563X (Extracellular) Truncation (non.sense) A4 Yes 
Ex 15 c.7017C>G g.30915C>G S2269X (RE.I domain) Truncation (non.sense) Al5 Yes 
Ex 15 c.5105-5106deJ (An Jl 632EsX1656 T ru ncatlon (frame-shift A52 Not 
g.29004de!AT (PKO domain) deletJon) possible 
Ex 15 c.5159delG g.29058delG VI 650fsXI 721 Truncation (fuune-&hlft A36 Yes 
(PKD domain) deletion) 
Ex28 c.9847delC g.41352deJC F32lfsX33I5(PLAT Truncation (Emme-shift AlO Yes 
domain) deletion) 
IVS 14 IVS14+1G>C g.26942G>C lntronlc Aberrant splicing A22 Yes 
IVS 16 IV516+1G>T g.31394G>T lntnmlc AbemmtGplldng A5 Yes 
Ex5 c.1352G> T g.21430G> T G381C (Extmcellular) Mlssense (loop and A9 Yes 
Exl5 c.6764T>G g.30662T>G 
hellx shortt:ned) 
Y2J85D (PKO domain) Mlssense (loop lo::t) A6l Yes 
Ex23 c.8565G>A g.37893G>A G2785D (Extracellular) Mt=mse (loop slightly A6 Yu 
shortened) 
Exl8 c.7472-74del (ACC) 242ldelT (REJ domain) In-frame deletion (hell: A46 Yen 
g.32650-52del replaced by extended 
sheet) 
Ex25 c.9292-9331dcl 3027del1S 11a ln-frnme deletion A42 Yes 
g.39090delS9 (Extracellular) (loop lost) 
' 
6 
7 
I 
10 
II 
12 
ll 
u 
15 
18 
19 
20 
21 
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f1Glm 1. Scliematlc representation o( polycystln-1 [adapted from PhakdeekJtcharoen et AL, 2000]. The locatlolll of 
mutmlons detected In th1a study are marhed with an arrow. 
c.9292-933IdeL This 39 base pair deletion in 
exon 25 is expected to result in the deletion of 
13 highly conserved amino acid residues (�i­
tions 3027 to 3039) preceding the first trans· 
membrane domain of polycystin- .. An example 
of the predicted topology change for this dele­
tion is shown in Figure 2. 
G381C. A G>T transversion at c.1352 
(g.Z 1430) in cxon 5 leads to the replacement of 
a conserved glycine by a cysteine residue at po· 
sition 381. between the first PKD domain and 
the c-type lectin domain. 
Y2185D. A T>O transversion at c.6764 
(g.30662) in exon 15 results in the substitution 
of histidine for tryptophan at the conserved po· 
sicion 2185 in the PKO repeat region of 
polycystin-1. An example of the evolutionary 
conservation and topology prediction for this 
missense change is shown in Figure 2. 
G2785D. A G>A transition at c.8565 
(g.37893) in exon 23 is predicted co result in a 
histidine for glycine substitution at conserved 
position 2785, immediately downstream of the 
REJ domain. 
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TABLE 4. Polymo!J!hlsms In the 5' Dufllcated R!:1!lon of PKOl 
Nu mber 
of patients Amino 
with add 
Loc.atlon chan!:!!: S!:9uence variation E•!Uon T�'J?! of change Previous reference 
Exon2 1 c.487G>A g.19963G>A A92A Sllent exoolc Rossetti et al. (2001] 
Exon5 1 c.1234C>T g.21312C>T A341A Silent exon!c ThomM et a1. (1999] 
Exon5 6 (A15 .t)· c.1330T>C g.21408T>C L373L Silent exon1c Rossetti et al. {2001] 
IVS6 1 g.22160G>A lntronlc Novel 
IVS9 3 g.23307del7 lntronlc Novel 
(VNlR) 
Exon 11 1 c.2427A g.24474G>A Q739R M!ssense Novel 
Exon 11 1 c.2905A>C g.24952A>C AB98A Silen! exoclc Thomas et al. (1999] 
Exon 11 3 c.2911G>A g.24958G>A P900P Silent e:xon1c Thomas et al. (1999) 
Exon 11 3 c.2941C>T g.2'1988C>T D910D Silent�nlc Thomes et al . [1999) 
Exoa 13 3 c.3274T>C g.26395T>C Gl021G Silent e:xonk Tnomns et al. (1999) 
Exon 13 1 c.3319G>T g.26440G>T TI036T SllMt exonlc Novel 
Exon 13 4 c.3322A>G g.26443A>G L1037L SUent exontc Thomas et al. [1999] 
Exon 14 3 c.3486T>C g.26921T>C Ml092T M1saense Novel 
Exon 15 2 c.3583C>T g.27483C>T Al124A Silent exonlc Thomas et al. (1999) 
Exon 15 2 c.3586C>T g.27486C>T S1125S Silent exonlc Thomas e:t al. (1999) 
Exon 15 2 c.4406T>C g.28306T>C W1399R Mlssense Watnk:k et al. (1999) 
Exon 15 5 c.4876A>C g.28775A>C Al555A Silent exonlc Watnldl d a1. (1999) 
Exon 15 2 c.4885G>A g.28784G>A TI558T Silent cxoruc P/;:rtnlck et el. {1999) 
Exon 15 1 c.5157C>T g.29056C>T TI649M Mlrlseme NOVCII 
Exon 15 5 c.S383C>T g.29280C>T TI724T Silent exonlc Watnk:k et al. (1999) 
Exon 15 3 c.5974G>A g.29872G>A L1921L Silent exonlc Thomas et aJ. (1999] 
Exon 16 1 c.713SC>T g.31255C>T G2309G Sl!ent exonlc Pen1chot et a1. [2000b] 
IVS 16 1 g.31414G>A lntronlc Novel 
Exon 17 4 c.7376T>C g.32427T>C L2389L SIient exonlc Wntnlck et al. (1999) 
&on 18 4 c.7652C>T g.32830C>T L2481L SIient e:xonlc Pmk:hot et a1. (2000b) 
Exon21 1 c.8098G>A g.33824G>A A2629A Silent exonlc Novel 
Exon21 2 c.8124A>G g.33849A>G H2638R Mmense Watnlck et a1. [1999) 
Exon 23 2 c.8504C> T g.37854C> T R2765C MlsGenae Rouettl et al. (2001] 
Exoo 25 5 c.9406GT>CC F3066L Mbsense Peml et a1. (J 997] 
g.39207GT>CC 
Exon 26 5 c.9541T>C g.39466T>C P3110P SUent exonlc Penil et al . [1997] 
IVS 31 l g.43740T>C lntroolc Novd 
•AJs.l II homozyoote for c.1330T>C. All other lndMdual.t ere hetero.iygotes for polymorpt,{sms llmd. 
Probable Neutral PolymoJJJhlsms 
The 31 polymorphic variants detected dur• 
ing our analysis of the duplicated region of PI<Dl 
are shown in Table 4. Here we present in more 
detail the novel missense variants. 
Q739R. A G to A transition (c.2427, 
g.24474) in exon 11 was predicted to result in 
an amino acid substitution at codon 739. Hu­
man sequence Accession # L33242 and mouse 
Pkdl Accession # 008852 suggest a conserved 
glutamine at that position. However; another pub· 
lished human sequence, Accession #P98161, lists 
the same residue as arginine, suggesting a poly• 
morphic variant. Computer prediction models 
show a marked difference in protein secondary 
structure (Fig. 2). In this study, the glutamine 
to arginine change was detected in a single af. 
fected subject (A42.l). The same substitution 
has been found subsequently in an ADPKD 
family from Bulgaria, where it did not scgre-
gate with the disease (N. Bogdanova, unpuh• 
lished results). 
Ml092T. AT co C substitution (c. 3486, 
g.26921) in exon 14 was found to occur in duce 
unrelated affected subjects. Published human sc• 
quences have a methionine residue, while the 
mouse protein contains threonine. Again, a dif. 
fercnce in secondary protein structure, albeit less 
pronounced, is predicted by computer analysis. 
TI649M. A C to T substitution (c.S157, 
g.29056) in exon 15 results in the replacement 
of the conserved threonine at position 1649 
by methionine. Computer models predict a 
slight change in secondary structure. This 
variant was detected in patient A52.l, where 
family segregation analysis was not possible. 
However, the cloning experiment performed 
to characterize the frameshift deletion 
(c.5105delAT) of the same subject demon• 
strated that the mwense variant was carried 
on the other chromosome. 
� 
Mouse 
Human 
Fugu 
nm 
AA 
PHO sec 
wtr..at: SUB sec 
P 3acc 
tstihcet: SUB ace 
p21es (Mutlrtl<>nl 
AA 
PHO sec 
subset SUB MC 
P_3aa: 
�t:SUSacc 
e,9292.S331del 
Human 
Mouse 
Wild-typo c,92112 
AA 
PHO IIOC 
subset SUB sec 
P 311cc 
�SUB:icc 
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QRNYLEAHVDLRNCVSYQTE!RViEIYRTASCQRPGRMAQMVLPGVD 
QRNYlEAHVOLROCVTYQTeyRWEVYRTASCQR?GRPARVALPGVD 
LVEASVDLKGCLRYGAOXLWOiLSAPSCDNOPHFASGRVNGAT 
IORNYlEAHVOLROCVTYO'f'EXRWEVYRTASCORPGRPARVALPGVDJ 
I EE EE EE I 
ILLLE. ..•. LL ..... LLLL. .... LLLLLLLLLLLL.LLLJ 
Jo ebbob:X>ebbebbeooacoebee oeec e ee ebSbllbebbel 
ie ... b.b.b.b ... b ... e. .. e. ........... b.b ..... ej 
fQRNYLEA.'iVDLRDCVTYOTEQRWEVYRTASCQRPGRPARVALPGVOf 
f EEEE EEE EE HHHHEEEEEE E EEEE I 
ILL ............................. LLLLL.E •• Lll.LI 
fGee beb bebeebbb oe bebb abebe ee ebebbbeeffl 
10 ... b.b ... b •. b ......... b ... b .... a .. .b.bb .... of 
GLYTSLCOYFSEED�OAVCLTRHLTA 
GLYTSLCQYFSEEMMMWRTEGIVpLEETSPSOAVCLTRHLTA 
fGLYTSL �QYFSEEDMVVVR-TEGlLPLEETSf'B-<lAVCLTRHLTA/ 
I EE HHHH EEEEE I 
fLEE ....•. LL LLH ... LLLWJ.U.lllLL ..... 4 
iet,bebbbbbboe I 
fo.b.bbb .. bb ........ o ...... a .. aa ......... ef 
c,929:Jd!\39 (r,lutp1i2f)) 
AA (Gl YTSLCOYFSEEOMVWR-OAVCL TRHLTA! 
PHO ace I EEEHHHH HHHHHHHHHHHHHHH I 
cubaot: SUS sec ll.EE.HH .•••• HHHHHHHHHHHHHHHL t I 
P _3 ace lebbtltbbe bb9G bbb llbbbbbeabeel 
subs.at SUB ace /o ... bbb ............ bbbbb .... ej 
QillB 
Human (L33243) 
Hum.m(P98161) 
Mou.so (00i!852) 
AGPGALLHCSPAPGHPGpgAPYLSANASSW 
AGPGALLHCSPAPGHPGP.BAPYLSANASSVV 
LLQCPLASSC PG gAI. YlSTNASOW 
.Qlli 
AA !AGflGALLHCSPAPGHPGPQAPYI.SANASSWJ 
I EEEE I PHO sec 
IUbsot· SUS we 
P_3acc 
lllLEEEE.LLLllllilllL .. LlLLLLl 
I� oeeobo bbbebellel 
subset SUB ace fo ... bcb.b .... e. ............... J 
BI3¥ 1ec1vmomhJc vanaon 
AA IAGPGAl.ll-lCSPAPGHPGPBAJlYl.SANASSWJ 
PHO l8C I HHH I 
subset: SUB sec: ILLL.LLLLLLLl.lllll.. .... l.lllll/ 
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FIGtmE 2. Evolutionary conservation and topology predldlon for mutations \'21850, and.c.9292-93Sldel; and for 
polymorphism MIT 1092. Variable amino aclrls are shown In bold and underlined. The human and mouse (and where 
possible the Fugu) protein setiuences are aligned. Predicted protein topologies for the wlld-type and variant alleles are 
shown for each eiaunple. The abbreviations of E (extended sheet), H (helix), and L (loop) me In accordance with 
PHDsec [Rcwl: and Sander, 1994). 
DiSCUSSJON 
Mutation detection in the duplicated region 
of the PKO 1 gene has been hindered by the high 
(>95%) sequence identity with the homologous 
genes, raising concerns about PCR primer speci­
ficity and hence the reliability of the analysis. 
Most studies have therefore focused on a lim­
ited area of the gene. Only a few have screened 
most or the entire coding region of PKO I 
[Watnick et al., 1999; Thomas et al., 1999; 
Rossetti et al., 2001; Phalcdeelcitcharoen et al., 
2001]. ln this study, we have used infonnation 
published previously on the sequence of HGl 
and HG2 [Loftus et al., 1999], as well as our 
own data on additional homologous genes 
[Bogdanova et al., 2001], to design amplifica­
tion primers that were specific to the duplicated 
region of PKDI. The analytical prorocol in-
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eluded long-range amplification, followed by 
nested PCR and direct sequencing. 
We have tested 17 affected subjects for mu­
tations in exons 2-21 and 23-34, which account 
for about 69% of the PI<Dl coding sequence. A 
total of 12 possible disease-causing mutations 
were identified, spread from exon 5 to exon 28. 
The results of this study and others [Krawczak 
and Cooper, 1997; Afaal et al., 2000; Aguiarl et 
al., 2000; Bogdanova et al., 2000; Kirn et al., 
2000; Koptides et al., 2000; Perrichot et al., 
2000a,b; Phakdeekitcharoen et al., 2000, 2001; 
Rossetti et al., 2001) suggest that mutations are 
dispersed across the entire PKD 1 gene, without 
any apparent clustering in mutation "hot spots." 
Similar to previous studies [Krawczak and 
Cooper, 1997; Afzal et al., 2000; Aguiari et al., 
2000; Phakdeekitcharoen et al., 2000, 2001), all 
mutations that we have identified were private, 
i.e. confined to individual families. 
Our analytical procedure is not problem-free: 
it is relatively costly and includes sequential 
amplification steP.5 that can introduce sequence 
errors and therefore should be avoided in diag­
nostic p rotocols. However, in the case of 
ADPKD, the choice is limited by the character­
istics of the PKDl gene and of the pathogenic 
mutations. The a.sic of non-specific PCR ampli­
fication, due to the homologous genes, imposes 
the need of consecutive amplification steps. The 
spread of mutations across the PKD I gene, their 
diversity (with truncating defects accounting for 
a little over 50% of our patients), and their pri­
vate nature, all interfere with designing a hier­
archical diagnostic procedure, prioritizing 
common defects and mutation hot S{Xlts, 
The large number of private ADPKD muta­
tions, together with the proposed random sec­
ond-hit mechanism [Qian ct al., 19961, rnalce 
phenotype-genotype correlatior.s difficult to as­
sess. The analysis of such correlations will have 
to be limited to comparing the general effects of 
the nature of mutations ( truncating vs. nrisscnse) 
and localization in specific protein domains. In 
our small group of patients, there was no signifi­
cant difference between the age at onset ofESRF 
as related to the type of gennline mutation (data 
not shown). 
In view of the lack of functional assays and 
the prohibitively high costs of analyzing the 
PKDJ gene in a sufficient number of control 
chromosomes, the distinction between disease-
causing missense mutations, and "neutral vari• 
ants" resulting in amino acid substitutions, has 
to rely on family segregation studies, assessment 
of the evolutionary conservation of the amino 
acid residue involved, the nature of the substi­
tution, and the predicted effect on protein con­
formation. The predictive value of segregation 
analysis is limited in small families, as co-inher­
itance can be due to chance. As for evolution­
ary conservation and conformational changes, 
all three novel missense mutations, classified as 
non-pathogenic in our study due to lack of co• 
segregation, were predicted to result in confor­
mational changes and one of the three (f / 
Ml649) was conserved between mouse and hu­
man, emphasizing the problems of interpretation 
in PKDl mutation analysis. Moreover, while in­
dependent segregation of missense mutations 
and the ADPKD phenotype indicates a lack of 
drastic effect on protein function, modifying ef­
fects on disease severity remain a possibility and 
:nerit further studies. In addition, the accumu­
lation of "neutral" polymorphisms may affect 
protein function through numerous changes in 
topology even in the absence of an obvious 
pathogenic mutation. The existence of such "hy­
permorphic" alleles has been proposed by 
Watnick et al. [1998]. 
Differences between the PKDl nucleotide 
sequence and those of the homologous genes can 
provide an indication of the age of single nucle­
otide polymorphisms (SNPs) and the order of 
duplication events. In the case ofM/Tl092, the 
mouse seauence encodes threonine, while both 
puhlished
°
human PKDl sequences, as well as 
all homologous genes, code for methionine at 
that amino acid position. The current data would 
suggest a very recent origin, subsequent to the 
duplication events, of the back mutation result­
ing in the human M/f1092 polymorphism. 
At po.,;tion 1649, threonine is conserved be­
tween the mouse and human PKO! orthologs 
and in HG2t while the other HGs encode me­
thionine. The findings may indicate that the 
origin ofT /M1649 variant preceded some of the 
dupllcation events and that HGs l, 3, 4, and 5 
were derived from the Ml649 allele. 
The Q/R.739 {Xllymorphism is evident in the 
two published human PKDl sequences, with 
Q739 encoded by sequence #U3242, and R739 
encoded by #P98161. The homologous genes 
show differences. Based on the mouse PKO! 
sequence (Accession # 008852), one could ar• 
gue that Q739 is the ancestral allele, which gave 
rise to HG3 and HG4, whereas HGs 1,2, and 5 
appear to be the products of duplication events 
involving the derived R739 allele. 
Reliable conclusions on PKO 1 gene genealogy 
and the origins and age of the HGs have to await 
the accumulation of SNP frequency data in hu, 
mans, i:i.s well as information on other mamma• 
lian species. Such data will also allow conclusions 
· on the role of the homologues genes as reservoirs 
of mutations in gene conversion events. 
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